インスリン イコデク（遺伝子組換え）

2.7.4.7. 付録
4. 低血糖

ノボ ノルディスク ファーマ株式会社

Table of contents

Page

7.4.1 Hypoglycaemic episodes by trial and classification - on-treatment/main-on-treatment - summary - safety analysis set 3
7.4.2 Nocturnal hypoglycaemic episodes by trial and classification - on-treatment/main-on-treatment - summary - safety analysis set 5
7.4.3 Hypoglycaemic episodes by trial, classification and month since randomisation - on-treatment/main- on-treatment - summary - safety analysis set 7
7.4.4 Nocturnal hypoglycaemic episodes by trial, classification and month since randomisation - on-treatment/main-on-treatment - summary - safety analysis set 15
7.4.5 Hypoglycaemic episodes by trial, classification and phase - on-treatment/main-on-treatment - summary - safety analysis set 23
7.4.6 Nocturnal hypoglycaemic episodes by trial, classification and phase - on-treatment/main-on-treatment - summary - safety analysis set 26
7.4.7 Severe (level 3) or clinically significant hypoglycaemia (level 2) by trial - on-treatment/main-on-treatment - dot plot - safety analysis set 29
7.4.8 Nocturnal severe (level 3) or clinically significant hypoglycaemia (level 2) by trial - on-treatment/main-on-treatment - dot plot - safety analysis set 30
7.4.9 Hypoglycaemic episodes by trial - on-treatment/main-on-treatment - supportive statistical analysis - full analysis set 31
7.4.10 Nocturnal hypoglycaemic episodes by trial - on-treatment/main-on-treatment - supportive statistical analysis - full analysis set 34
7.4.11 Severe (level 3) or clinically significant hypoglycaemia (level 2) by trial - ONWARDS 1-5 - on-treatment/main-on-treatment - mean cumulative function - safety analysis set 36
7.4.12 Severe (level 3) or clinically significant hypoglycaemia (level 2) - ONWARDS 6 - main-on-treatment - mean cumulative function - safety analysis set 37
7.4.13 Nocturnal severe (level 3) or clinically significant hypoglycaemia (level 2) by trial - ONWARDS 1-5 - on-treatment/main-on-treatment - mean cumulative function - safety analysis set 38
7.4.14 Nocturnal severe (level 3) or clinically significant hypoglycaemia (level 2) - ONWARDS 6 - main-on-treatment - mean cumulative function - safety analysis set 39
7.4.15 Hypoglycaemic episodes by trial, classification and baseline renal function - on-treatment/main-on- treatment - summary - safety analysis set 40
7.4.16 Hypoglycaemic episodes by trial, classification and baseline BMI group - on-treatment/main-on-treatment - summary - safety analysis set 46
7.4.17 Hypoglycaemic episodes by trial, classification and age group - on-treatment/main-on-treatment - summary - safety analysis set 52
7.4.18 Hypoglycaemic episodes by trial, classification and treatment day - on-treatment/main-on-treatment - summary - safety analysis set 58
7.4.19 Severe (level 3) or clinically significant hypoglycaemia (level 2) by trial and treatment day - ONWARDS 1-5 - on-treatment/main-on-treatment - bar plot - safety analysis set 64
7.4.20 Severe (level 3) or clinically significant hypoglycaemia (level 2) by treatment day - ONWARDS 6 - main-on-treatment - bar plot - safety analysis set 65
7.4.21 Severe (level 3) or clinically significant hypoglycaemia (level 2) by treatment day and phase - ONWARDS 6 - main-on-treatment - bar plot - safety analysis set 66

7.4.22 Duration of hypoglycaemic episodes in 30-minute intervals by trial and classification based on hypoglycaemic episodes form - on-treatment/main-on-treatment - summary - safety analysis set 67
7.4.23 Duration of hypoglycaemic episodes by trial and classification - on-treatment/main-on-treatment - summary - safety analysis set 76
7.4.24 Severe (level 3) or clinically significant hypoglycaemia (level 2) by trial - on-treatment/main-on-treatment - summary of categories of total number of episodes - safety analysis set 82
7.4.25 Severe (level 3) or clinically significant hypoglycaemia (level 2) by trial - ONWARDS 1-5 - on-treatment/main-on-treatment - bar plot of total number of episodes - safety analysis set.....84
7.4.26 Severe (level 3) or clinically significant hypoglycaemia (level 2) - ONWARDS 6 - main-on-treatment - bar plot of total number of episodes - safety analysis set 85
7.4.27 Demographics and baseline characteristics by categories of total number of severe (level 3) or clinically significant hypoglycaemia (level 2) in insulin icodec arm - ONWARDS 6 - summary of categorical variables - safety analysis set.....86
7.4.28 Demographics and baseline characteristics by categories of total number of severe (level 3) or clinically significant hypoglycaemia (level 2) in insulin degludec arm - ONWARDS 6 - summary of categorical variables - safety analysis set 88
7.4.29 Demographics and baseline characteristics by categories of total number of severe (level 3) or clinically significant hypoglycaemia (level 2) in insulin icodec arm - ONWARDS 6 - summary of continuous variables - safety analysis set.....90
7.4.30 Demographics and baseline characteristics by categories of total number of severe (level 3) or clinically significant hypoglycaemia (level 2) in insulin degludec arm - ONWARDS 6 - summary of continuous variables - safety analysis set 91

7.4 Hypoglycaemic episodes

7.4.1 Hypoglycaemic episodes by trial and classification - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
ONWARDS 1								
Number of subjects	492				492			
PYE (years)	485.88				485.03			
Hypoglycaemia alert value (level 1)	232	(47.2)	1447	297.81	191	(38.8)	631	130.09
Clinically significant hypoglycaemia (level 2)	48	(9.8)	143	29.43	49	(10.0)	75	15.46
Severe hypoglycaemia (level 3)	1	(0.2)	1	0.21	3	(0.6)	3	0.62
Severe (level 3) or clinically significant (level 2) hypoglycaemia	48	(9.8)	144	29.64	52	(10.6)	78	16.08
ONWARDS 2								
Number of subjects	262				263			
PYE (years)	155.25				152.77			
Hypoglycaemia alert value (level 1)	145	(55.3)	1209	778.76	118	(44.9)	589	385.54
Clinically significant hypoglycaemia (level 2)	37	(14.1)	113	72.79	19	(7.2)	41	26.84
Severe hypoglycaemia (level 3)	0				1	(0.4)	1	0.65
Severe (level 3) or clinically significant (level 2) hypoglycaemia	37	(14.1)	113	72.79	19	(7.2)	42	27.49
ONWARDS 3								
Number of subjects	293				294			
PYE (years)	170.90				171.13			
Hypoglycaemia alert value (level 1)	91	(31.1)	400	234.06	65	(22.1)	185	108.10
Clinically significant hypoglycaemia (level 2)	26	(8.9)	53	31.01	17	(5.8)	23	13.44
Severe hypoglycaemia (level 3)	0				2	(0.7)	2	1.17
Severe (level 3) or clinically significant (level 2) hypoglycaemia	26	(8.9)	53	31.01	18	(6.1)	25	14.61
ONWARDS 4								
Number of subjects	291				291			
PYE (years)	167.36				166.80			
Hypoglycaemia alert value (level 1)	244	(83.8)	5264	3145.28	251	(86.3)	4145	2485.04
Clinically significant hypoglycaemia (level 2)	148	(50.9)	937	559.86	160	(55.0)	935	560.56
Severe hypoglycaemia (level 3)	4	(1.4)	7	4.18	2	(0.7)	3	1.80
Severe (level 3) or clinically significant (level 2) hypoglycaemia	150	(51.5)	944	564.05	162	(55.7)	938	562.36

%: Percentage of subjects with one or more events, BG: Blood glucose, E: Number of events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. A hypoglycaemia alert value (level 1) was excluded from each of ONWARDS 1 and 6 as these had been erroneously included in trial clinical trial reports. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Hypoglycaemic episodes by trial and classification - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
ONWARDS 5								
Number of subjects	542				538			
PYE (years)	559.54				560.72			
Hypoglycaemia alert value (level 1)	200	(36.9)	1028	183.72	153	(28.4)	851	151.77
Clinically significant hypoglycaemia (level 2)	64	(11.8)	104	18.59	42	(7.8)	76	13.55
Severe hypoglycaemia (level 3)	0				4	(0.7)	5	0.89
Severe (level 3) or clinically significant (level 2) hypoglycaemia	64	(11.8)	104	18.59	45	(8.4)	81	14.45
ONWARDS 6								
Number of subjects	290				292			
PYE (years)	142.31				144.12			
Hypoglycaemia alert value (level 1)	288	(99.3)	10799	7588.47	287	(98.3)	7401	5135.29
Clinically significant hypoglycaemia (level 2)	246	(84.8)	2789	1959.83	223	(76.4)	1478	1025.53
Severe hypoglycaemia (level 3)	9	(3.1)	47	33.03	9	(3.1)	17	11.80
Severe (level 3) or clinically significant (level 2) hypoglycaemia	247	(85.2)	2836	1992.86	223	(76.4)	1495	1037.33

%: Percentage of subjects with one or more events, BG: Blood glucose, E: Number of events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. A hypoglycaemia alert value (level 1) was excluded from each of ONWARDS 1 and 6 as these had been erroneously included in trial clinical trial reports. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

adsl.xpt; variable(s): STDNM OTMTDURY; criteria: SAFFL == "Y"
adhypo.xpt; variable(s): STDNM ACAT4; criteria: SAFFL == "Y" & ANL06FL == "Y" & ANELFL == "Y"
nn1436/nn1436-iss/submission_20221024_er
05DEC2022:12:56:56 - thyposum/thyposumontsas.txt

7.4.2 Nocturnal hypoglycaemic episodes by trial and classification - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
ONWARDS 1								
Number of subjects	492				492			
PYE (years)	485.88				485.03			
Hypoglycaemia alert value (level 1)	67	(13.6)	190	39.10	58	(11.8)	95	19.59
Clinically significant hypoglycaemia (level 2)	9	(1.8)	20	4.12	10	(2.0)	14	2.89
Severe hypoglycaemia (level 3)	0				1	(0.2)	1	0.21
Severe (level 3) or clinically significant (level 2) hypoglycaemia	9	(1.8)	20	4.12	11	(2.2)	15	3.09
ONWARDS 2								
Number of subjects	262				263			
PYE (years)	155.25				152.77			
Hypoglycaemia alert value (level 1)	60	(22.9)	144	92.76	35	(13.3)	102	66.77
Clinically significant hypoglycaemia (level 2)	16	(6.1)	32	20.61	9	(3.4)	13	8.51
Severe hypoglycaemia (level 3)	0				0			
Severe (level 3) or clinically significant (level 2) hypoglycaemia	16	(6.1)	32	20.61	9	(3.4)	13	8.51
ONWARDS 3								
Number of subjects	293				294			
PYE (years)	170.90				171.13			
Hypoglycaemia alert value (level 1)	24	(8.2)	40	23.41	23	(7.8)	37	21.62
Clinically significant hypoglycaemia (level 2)	1	(0.3)	2	1.17	4	(1.4)	5	2.92
Severe hypoglycaemia (level 3)	0				0			
Severe (level 3) or clinically significant (level 2) hypoglycaemia	1	(0.3)	2	1.17	4	(1.4)	5	2.92
ONWARDS 4								
Number of subjects	291				291			
PYE (years)	167.36				166.80			
Hypoglycaemia alert value (level 1)	108	(37.1)	380	227.05	132	(45.4)	440	263.79
Clinically significant hypoglycaemia (level 2)	54	(18.6)	131	78.27	71	(24.4)	171	102.52
Severe hypoglycaemia (level 3)	0				1	(0.3)	2	1.20
Severe (level 3) or clinically significant (level 2) hypoglycaemia	54	(18.6)	131	78.27	72	(24.7)	173	103.72

%: Percentage of subjects with one or more events, BG: Blood glucose, E: Number of events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6. Nocturnal: The period between 00:01 and 05:59 (both included).

Nocturnal hypoglycaemic episodes by trial and classification - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
ONWARDS 5								
Number of subjects	542				538			
PYE (years)	559.54				560.72			
Hypoglycaemia alert value (level 1)	48	(8.9)	107	19.12	46	(8.6)	213	37.99
Clinically significant hypoglycaemia (level 2)	11	(2.0)	13	2.32	11	(2.0)	18	3.21
Severe hypoglycaemia (level 3)	0				1	(0.2)	1	0.18
Severe (level 3) or clinically significant (level 2) hypoglycaemia	11	(2.0)	13	2.32	12	(2.2)	19	3.39
ONWARDS 6								
Number of subjects	290				292			
PYE (years)	142.31				144.12			
Hypoglycaemia alert value (level 1)	214	(73.8)	980	688.65	171	(58.6)	734	509.30
Clinically significant hypoglycaemia (level 2)	135	(46.6)	476	334.49	98	(33.6)	224	155.43
Severe hypoglycaemia (level 3)	2	(0.7)	5	3.51	3	(1.0)	3	2.08
Severe (level 3) or clinically significant (level 2) hypoglycaemia	135	(46.6)	481	338.00	98	(33.6)	227	157.51

%: Percentage of subjects with one or more events, BG: Blood glucose, E: Number of events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6. Nocturnal: The period between 00:01 and 05:59 (both included).

7.4.3 Hypoglycaemic episodes by trial, classification and month since randomisation - on-treatment/main- on-treatment - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
ONWARDS 1								
Number of subjects	492				492			
PYE (years)	485.88				485.03			
Hypoglycaemia alert value (level 1)	232	(47.2)	1447	297.81	191	(38.8)	631	130.09
0 < to <= 1 month	29	(5.9)	54	131.44	15	(3.0)	17	41.51
1 < to <= 2 months	38	(7.7)	71	172.82	21	(4.3)	29	71.18
2 < to <= 3 months	58	(11.8)	95	231.23	33	(6.8)	52	127.87
3 < to <= 4 months	49	(10.0)	90	219.25	35	(7.2)	47	115.62
4 < to <= 5 months	56	(11.5)	104	255.06	23	(4.7)	35	86.39
5 < to <= 6 months	69	(14.1)	163	400.46	46	(9.5)	69	170.72
6 < to <= 7 months	69	(14.2)	126	310.97	42	(8.7)	63	155.92
7 < to <= 8 months	74	(15.3)	174	432.18	42	(8.7)	57	141.35
8 < to <= 9 months	68	(14.2)	130	324.33	41	(8.5)	65	161.49
9 < to <= 10 months	70	(14.6)	144	359.73	36	(7.5)	55	136.65
10 < to <= 11 months	69	(14.4)	136	340.01	43	(8.9)	67	166.46
11 < to <= 12 months	82	(17.1)	158	408.14	53	(11.0)	74	190.07
> 12 months	2	(2.9)	2	403.59	1	(1.2)	1	145.52
Clinically significant hypoglycaemia (level 2)	48	(9.8)	143	29.43	49	(10.0)	75	15.46
0 < to <= 1 month	2	(0.4)	2	4.87	4	(0.8)	4	9.77
1 < to <= 2 months	5	(1.0)	10	24.34	3	(0.6)	4	9.82
2 < to <= 3 months	5	(1.0)	8	19.47	3	(0.6)	3	7.38
3 < to <= 4 months	5	(1.0)	8	19.49	4	(0.8)	5	12.30
4 < to <= 5 months	9	(1.8)	17	41.69	7	(1.4)	9	22.21
5 < to <= 6 months	12	(2.5)	17	41.77	9	(1.9)	11	27.22
6 < to <= 7 months	7	(1.4)	12	29.62	9	(1.9)	11	27.22
7 < to <= 8 months	11	(2.3)	19	47.19	10	(2.1)	11	27.28
8 < to <= 9 months	14	(2.9)	18	44.91	7	(1.5)	7	17.39
9 < to <= 10 months	7	(1.5)	11	27.48	2	(0.4)	2	4.97
10 < to <= 11 months	9	(1.9)	13	32.50	4	(0.8)	5	12.42
11 < to <= 12 months	7	(1.5)	8	20.67	3	(0.6)	3	7.71
> 12 months	0				0			
Severe hypoglycaemia (level 3)	1	(0.2)	1	0.21	3	(0.6)	3	0.62
0 < to <= 1 month	0				0			
1 < to <= 2 months	0				0			
2 < to <= 3 months	0				0			
3 < to <= 4 months	0				0			
4 < to <= 5 months	0				0			
5 < to <= 6 months	0				0			
6 < to <= 7 months	0				0			
7 < to <= 8 months	0				0			
8 < to <= 9 months	0				2	(0.4)	2	4.97
9 < to <= 10 months	1	(0.2)	1	2.50	0			
10 < to <= 11 months	0				0			
11 < to <= 12 months	0				1	(0.2)	1	2.57
> 12 months	0				0			

%: Percentage of subjects with one or more events, BG: Blood glucose, E: Number of events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. 1 month = 30.5 days. A hypoglycaemia alert value (level 1) was excluded from each of ONWARDS 1 and 6 as these had been erroneously included in trial clinical trial reports. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

adsl.xpt; variable(s): STDNM RANDDT OTMTDURY OMTMXXDM(XX=01 to 13); criteria: SAFFL == "Y"
adhypo.xpt; variable(s): STDNM ACAT4 ASTDT; criteria: SAFFL == "Y" & ANELFL == "Y" & ANL06FL == "Y"
nn1436/nn1436-iss/submission_20221024_er
05DEC2022:12:58:46 - thypomth/thypomonthsumontsas.txt

Hypoglycaemic episodes by trial, classification and month since randomisation - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
Severe (level 3) or clinically significant (level 2) hypoglycaemia	48	(9.8)	144	29.64	52	(10.6)	78	16.08
0 < to <= 1 month	2	(0.4)	2	4.87	4	(0.8)	4	9.77
1 < to <= 2 months	5	(1.0)	10	24.34	3	(0.6)	4	9.82
2 < to <= 3 months	5	(1.0)	8	19.47	3	(0.6)	3	7.38
3 < to <= 4 months	5	(1.0)	8	19.49	4	(0.8)	5	12.30
4 < to <= 5 months	9	(1.8)	17	41.69	7	(1.4)	9	22.21
5 < to <= 6 months	12	(2.5)	17	41.77	9	(1.9)	11	27.22
6 < to <= 7 months	7	(1.4)	12	29.62	9	(1.9)	11	27.22
7 < to <= 8 months	11	(2.3)	19	47.19	10	(2.1)	11	27.28
8 < to <= 9 months	14	(2.9)	18	44.91	9	(1.9)	9	22.36
9 < to <= 10 months	8	(1.7)	12	29.98	2	(0.4)	2	4.97
10 < to <= 11 months	9	(1.9)	13	32.50	4	(0.8)	5	12.42
11 < to <= 12 months	7	(1.5)	8	20.67	4	(0.8)	4	10.27
> 12 months	0				0			

%: Percentage of subjects with one or more events, BG: Blood glucose, E: Number of events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. 1 month = 30.5 days. A hypoglycaemia alert value (level 1) was excluded from each of ONWARDS 1 and 6 as these had been erroneously included in trial clinical trial reports. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

adsl.xpt; variable(s): STDNM RANDDT OTMTDURY OMTMXXDM(XX=01 to 13); criteria: SAFFL == "Y"
adhypo.xpt; variable(s): STDNM ACAT4 ASTDT; criteria: SAFFL == "Y" & ANELFL == "Y" & ANL06FL == "Y"

Hypoglycaemic episodes by trial, classification and month since randomisation - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
ONWARDS 2								
Number of subjects	262				263			
PYE (years)	155.25				152.77			
Hypoglycaemia alert value (level 1)	145	(55.3)	1209	778.76	118	(44.9)	589	385.54
0 < to <= 1 month	42	(16.0)	161	735.89	50	(19.0)	126	575.70
1 < to <= 2 months	51	(19.5)	161	737.55	42	(16.0)	100	461.47
2 < to <= 3 months	62	(23.8)	160	734.72	40	(15.5)	61	283.73
3 < to <= 4 months	60	(23.1)	159	733.45	35	(13.6)	61	284.60
4 < to <= 5 months	78	(30.1)	219	1013.17	45	(17.6)	74	346.76
5 < to <= 6 months	79	(30.6)	193	898.69	48	(18.8)	96	453.46
> 6 months	56	(21.8)	156	624.15	40	(15.8)	71	298.66
Clinically significant hypoglycaemia (level 2)	37	(14.1)	113	72.79	19	(7.2)	41	26.84
0 < to <= 1 month	5	(1.9)	25	114.27	8	(3.0)	15	68.54
1 < to <= 2 months	10	(3.8)	25	114.53	6	(2.3)	7	32.30
2 < to <= 3 months	9	(3.4)	12	55.10	4	(1.6)	4	18.61
3 < to <= 4 months	10	(3.8)	14	64.58	1	(0.4)	1	4.67
4 < to <= 5 months	5	(1.9)	7	32.38	3	(1.2)	3	14.06
5 < to <= 6 months	9	(3.5)	15	69.85	5	(2.0)	6	28.34
> 6 months	9	(3.5)	15	60.01	4	(1.6)	5	21.03
Severe hypoglycaemia (level 3)	0				1	(0.4)	1	0.65
0 < to <= 1 month	0				1	(0.4)	1	4.57
1 < to <= 2 months	0				0			
2 < to <= 3 months	0				0			
3 < to <= 4 months	0				0			
4 < to <= 5 months	0				0			
5 < to <= 6 months	0				0			
> 6 months	0				0			
Severe (level 3) or clinically significant (level 2) hypoglycaemia	37	(14.1)	113	72.79	19	(7.2)	42	27.49
0 < to <= 1 month	5	(1.9)	25	114.27	8	(3.0)	16	73.10
1 < to <= 2 months	10	(3.8)	25	114.53	6	(2.3)	7	32.30
2 < to <= 3 months	9	(3.4)	12	55.10	4	(1.6)	4	18.61
3 < to <= 4 months	10	(3.8)	14	64.58	1	(0.4)	1	4.67
4 < to <= 5 months	5	(1.9)	7	32.38	3	(1.2)	3	14.06
5 < to <= 6 months	9	(3.5)	15	69.85	5	(2.0)	6	28.34
> 6 months	9	(3.5)	15	60.01	4	(1.6)	5	21.03

%: Percentage of subjects with one or more events, BG: Blood glucose, E: Number of events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. 1 month = 30.5 days. A hypoglycaemia alert value (level 1) was excluded from each of ONWARDS 1 and 6 as these had been erroneously included in trial clinical trial reports. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

adsl.xpt; variable(s): STDNM RANDDT OTMTDURY OMTMXXDM(XX=01 to 13); criteria: SAFFL == "Y"
adhypo.xpt; variable(s): STDNM ACAT4 ASTDT; criteria: SAFFL == "Y" & ANELFL == "Y" & ANL06FL == "Y"

Hypoglycaemic episodes by trial, classification and month since randomisation - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
ONWARDS 3								
Number of subjects	293				294			
PYE (years)	170.90				171.13			
Hypoglycaemia alert value (level 1)	91	(31.1)	400	234.06	65	(22.1)	185	108.10
0 < to <= 1 month	17	(5.8)	21	86.38	11	(3.7)	18	73.32
1 < to <= 2 months	28	(9.7)	58	240.00	16	(5.4)	23	94.64
2 < to <= 3 months	37	(12.8)	73	303.60	15	(5.2)	21	86.99
3 < to <= 4 months	29	(10.1)	68	285.07	19	(6.6)	28	116.59
4 < to <= 5 months	36	(12.7)	73	307.82	23	(8.0)	36	150.83
5 < to <= 6 months	31	(10.9)	67	282.62	22	(7.7)	35	147.73
> 6 months	22	(7.8)	40	147.61	19	(6.7)	24	90.34
Clinically significant hypoglycaemia (level 2)	26	(8.9)	53	31.01	17	(5.8)	23	13.44
0 < to <= 1 month	2	(0.7)	2	8.23	4	(1.4)	5	20.37
1 < to <= 2 months	3	(1.0)	5	20.69	2	(0.7)	2	8.23
2 < to <= 3 months	8	(2.8)	16	66.54	3	(1.0)	3	12.43
3 < to <= 4 months	8	(2.8)	10	41.92	1	(0.3)	1	4.16
4 < to <= 5 months	6	(2.1)	8	33.73	1	(0.3)	1	4.19
5 < to <= 6 months	6	(2.1)	9	37.96	3	(1.1)	4	16.88
> 6 months	3	(1.1)	3	11.07	5	(1.8)	7	26.35
Severe hypoglycaemia (level 3)	0				2	(0.7)	2	1.17
0 < to <= 1 month	0				0			
1 < to <= 2 months	0				0			
2 < to <= 3 months	0				0			
3 < to <= 4 months	0				0			
4 < to <= 5 months	0				0			
5 < to <= 6 months	0				0			
> 6 months	0				2	(0.7)	2	7.53
Severe (level 3) or clinically significant (level 2) hypoglycaemia	26	(8.9)	53	31.01	18	(6.1)	25	14.61
0 < to <= 1 month	2	(0.7)	2	8.23	4	(1.4)	5	20.37
1 < to <= 2 months	3	(1.0)	5	20.69	2	(0.7)	2	8.23
2 < to <= 3 months	8	(2.8)	16	66.54	3	(1.0)	3	12.43
3 < to <= 4 months	8	(2.8)	10	41.92	1	(0.3)	1	4.16
4 < to <= 5 months	6	(2.1)	8	33.73	1	(0.3)	1	4.19
5 < to <= 6 months	6	(2.1)	9	37.96	3	(1.1)	4	16.88
> 6 months	3	(1.1)	3	11.07	6	(2.1)	9	33.88

%: Percentage of subjects with one or more events, BG: Blood glucose, E: Number of events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. 1 month = 30.5 days. A hypoglycaemia alert value (level 1) was excluded from each of ONWARDS 1 and 6 as these had been erroneously included in trial clinical trial reports. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

adsl.xpt; variable(s): STDNM RANDDT OTMTDURY OMTMXXDM(XX=01 to 13); criteria: SAFFL == "Y"
adhypo.xpt; variable(s): STDNM ACAT4 ASTDT; criteria: SAFFL == "Y" & ANELFL == "Y" & ANL06FL == "Y"

Hypoglycaemic episodes by trial, classification and month since randomisation - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
ONWARDS 4								
Number of subjects	291				291			
PYE (years)	167.36				166.80			
Hypoglycaemia alert value (level 1)	244	(83.8)	5264	3145.28	251	(86.3)	4145	2485.04
0 < to <= 1 month	138	(47.4)	659	2726.55	142	(48.8)	527	2187.97
1 < to <= 2 months	160	(55.6)	743	3109.31	153	(53.3)	558	2350.34
2 < to <= 3 months	172	(60.6)	765	3239.23	167	(59.0)	550	2339.71
3 < to <= 4 months	187	(66.3)	907	3863.79	175	(62.5)	631	2698.74
4 < to <= 5 months	184	(65.7)	854	3666.45	179	(63.9)	619	2659.88
5 < to <= 6 months	195	(70.4)	883	3841.99	189	(68.0)	727	3138.73
> 6 months	134	(48.9)	453	1747.00	159	(57.6)	533	2078.12
Clinically significant hypoglycaemia (level 2)	148	(50.9)	937	559.86	160	(55.0)	935	560.56
0 < to <= 1 month	46	(15.8)	108	446.84	46	(15.8)	129	535.58
1 < to <= 2 months	61	(21.2)	145	606.80	55	(19.2)	121	509.66
2 < to <= 3 months	53	(18.7)	141	597.04	60	(21.2)	118	501.97
3 < to <= 4 months	64	(22.7)	156	664.56	67	(23.9)	135	577.39
4 < to <= 5 months	61	(21.8)	118	506.61	73	(26.1)	138	592.99
5 < to <= 6 months	72	(26.0)	174	757.08	82	(29.5)	178	768.49
> 6 months	52	(19.0)	95	366.37	64	(23.2)	116	452.27
Severe hypoglycaemia (level 3)	4	(1.4)	7	4.18	2	(0.7)	3	1.80
0 < to <= 1 month	1	(0.3)	3	12.41	1	(0.3)	1	4.15
1 < to <= 2 months	1	(0.3)	1	4.18	0			
2 < to <= 3 months	1	(0.4)	1	4.23	0			
3 < to <= 4 months	0				0			
4 < to <= 5 months	2	(0.7)	2	8.59	0			
5 < to <= 6 months	0				1	(0.4)	2	8.63
> 6 months	0				0			
Severe (level 3) or clinically significant (level 2) hypoglycaemia	150	(51.5)	944	564.05	162	(55.7)	938	562.36
0 < to <= 1 month	47	(16.2)	111	459.25	47	(16.2)	130	539.73
1 < to <= 2 months	62	(21.5)	146	610.98	55	(19.2)	121	509.66
2 < to <= 3 months	54	(19.0)	142	601.27	60	(21.2)	118	501.97
3 < to <= 4 months	64	(22.7)	156	664.56	67	(23.9)	135	577.39
4 < to <= 5 months	62	(22.1)	120	515.19	73	(26.1)	138	592.99
5 < to <= 6 months	72	(26.0)	174	757.08	83	(29.9)	180	777.13
> 6 months	52	(19.0)	95	366.37	64	(23.2)	116	452.27
ONWARDS 5								
Number of subjects	542				538			
PYE (years)	559.54				560.72			

%: Percentage of subjects with one or more events, BG: Blood glucose, E: Number of events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. 1 month = 30.5 days. A hypoglycaemia alert value (level 1) was excluded from each of ONWARDS 1 and 6 as these had been erroneously included in trial clinical trial reports. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

adsl.xpt; variable(s): STDNM RANDDT OTMTDURY OMTMXXDM(XX=01 to 13); criteria: SAFFL == "Y"
adhypo.xpt; variable(s): STDNM ACAT4 ASTDT; criteria: SAFFL == "Y" & ANELFL == "Y" & ANL06FL == "Y"

Hypoglycaemic episodes by trial, classification and month since randomisation - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
Hypoglycaemia alert value (level 1)	200	(36.9)	1028	183.72	153	(28.4)	851	151.77
0 < to <= 1 month	17	(3.1)	22	48.89	18	(3.3)	54	120.65
1 < to <= 2 months	20	(3.7)	33	73.86	22	(4.1)	47	106.17
2 < to <= 3 months	29	(5.4)	56	126.30	31	(5.9)	44	100.33
3 < to <= 4 months	36	(6.8)	69	156.84	32	(6.1)	62	142.51
4 < to <= 5 months	39	(7.4)	68	155.64	32	(6.2)	54	125.02
5 < to <= 6 months	35	(6.7)	72	167.60	41	(7.9)	63	146.57
6 < to <= 7 months	47	(9.2)	82	192.97	39	(7.6)	64	149.98
7 < to <= 8 months	45	(8.9)	82	194.17	42	(8.2)	83	195.45
8 < to <= 9 months	45	(8.9)	80	190.49	30	(5.9)	68	160.64
9 < to <= 10 months	54	(10.8)	122	293.73	35	(6.9)	83	197.14
10 < to <= 11 months	63	(12.7)	135	327.19	32	(6.3)	84	200.07
11 < to <= 12 months	65	(13.2)	142	346.91	38	(7.6)	78	188.10
> 12 months	34	(7.0)	65	146.29	38	(7.7)	67	148.44
Clinically significant hypoglycaemia (level 2)	64	(11.8)	104	18.59	42	(7.8)	76	13.55
0 < to <= 1 month	9	(1.7)	9	20.00	5	(0.9)	8	17.87
1 < to <= 2 months	8	(1.5)	8	17.91	2	(0.4)	2	4.52
2 < to <= 3 months	6	(1.1)	7	15.79	4	(0.8)	5	11.40
3 < to <= 4 months	5	(0.9)	5	11.37	4	(0.8)	5	11.49
4 < to <= 5 months	5	(1.0)	7	16.02	5	(1.0)	5	11.58
5 < to <= 6 months	4	(0.8)	8	18.62	4	(0.8)	4	9.31
6 < to <= 7 months	10	(2.0)	12	28.24	7	(1.4)	7	16.40
7 < to <= 8 months	6	(1.2)	7	16.58	3	(0.6)	3	7.06
8 < to <= 9 months	5	(1.0)	5	11.91	5	(1.0)	5	11.81
9 < to <= 10 months	4	(0.8)	10	24.08	4	(0.8)	6	14.25
10 < to <= 11 months	8	(1.6)	10	24.24	9	(1.8)	11	26.20
11 < to <= 12 months	7	(1.4)	8	19.54	6	(1.2)	9	21.70
> 12 months	8	(1.6)	8	18.00	5	(1.0)	6	13.29
Severe hypoglycaemia (level 3)	0				4	(0.7)	5	0.89
0 < to <= 1 month	0				0			
1 < to <= 2 months	0				0			
2 < to <= 3 months	0				2	(0.4)	2	4.56
3 < to <= 4 months	0				2	(0.4)	2	4.60
4 < to <= 5 months	0				0			
5 < to <= 6 months	0				0			
6 < to <= 7 months	0				0			
7 < to <= 8 months	0				0			
8 < to <= 9 months	0				0			
9 < to <= 10 months	0				1	(0.2)	1	2.38
10 < to <= 11 months	0				0			
11 < to <= 12 months	0				0			
> 12 months	0				0			

%: Percentage of subjects with one or more events, BG: Blood glucose, E: Number of events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. 1 month = 30.5 days. A hypoglycaemia alert value (level 1) was excluded from each of ONWARDS 1 and 6 as these had been erroneously included in trial clinical trial reports. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

adsl.xpt; variable(s): STDNM RANDDT OTMTDURY OMTMXXDM(XX=01 to 13); criteria: SAFFL == "Y"
adhypo.xpt; variable(s): STDNM ACAT4 ASTDT; criteria: SAFFL == "Y" & ANELFL == "Y" & ANL06FL == "Y"

Hypoglycaemic episodes by trial, classification and month since randomisation - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
Severe (level 3) or clinically significant (level 2) hypoglycaemia	64	(11.8)	104	18.59	45	(8.4)	81	14.45
0 < to <= 1 month	9	(1.7)	9	20.00	5	(0.9)	8	17.87
1 < to <= 2 months	8	(1.5)	8	17.91	2	(0.4)	2	4.52
2 < to <= 3 months	6	(1.1)	7	15.79	6	(1.1)	7	15.96
3 < to <= 4 months	5	(0.9)	5	11.37	6	(1.1)	7	16.09
4 < to <= 5 months	5	(1.0)	7	16.02	5	(1.0)	5	11.58
5 < to <= 6 months	4	(0.8)	8	18.62	4	(0.8)	4	9.31
6 < to <= 7 months	10	(2.0)	12	28.24	7	(1.4)	7	16.40
7 < to <= 8 months	6	(1.2)	7	16.58	3	(0.6)	3	7.06
8 < to <= 9 months	5	(1.0)	5	11.91	5	(1.0)	5	11.81
9 < to <= 10 months	4	(0.8)	10	24.08	5	(1.0)	7	16.63
10 < to <= 11 months	8	(1.6)	10	24.24	9	(1.8)	11	26.20
11 < to <= 12 months	7	(1.4)	8	19.54	6	(1.2)	9	21.70
> 12 months	8	(1.6)	8	18.00	5	(1.0)	6	13.29

%: Percentage of subjects with one or more events, BG: Blood glucose, E: Number of events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. 1 month = 30.5 days. A hypoglycaemia alert value (level 1) was excluded from each of ONWARDS 1 and 6 as these had been erroneously included in trial clinical trial reports. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Hypoglycaemic episodes by trial, classification and month since randomisation - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
ONWARDS 6								
Number of subjects	290				292			
PYE (years)	142.31				144.12			
Hypoglycaemia alert value (level 1)	288	(99.3)	10799	7588.47	287	(98.3)	7401	5135.29
0 < to <= 1 month	263	(90.7)	1984	8234.73	255	(87.3)	1600	6563.71
1 < to <= 2 months	263	(91.3)	2053	8542.47	254	(87.3)	1324	5497.54
2 < to <= 3 months	265	(92.3)	1776	7465.58	245	(85.4)	1151	4802.68
3 < to <= 4 months	262	(92.3)	1745	7393.12	245	(85.4)	1207	5058.89
4 < to <= 5 months	259	(92.2)	1617	6926.75	244	(85.6)	1058	4452.52
5 < to <= 6 months	249	(89.9)	1604	7019.24	241	(84.9)	1050	4478.72
> 6 months	11	(14.1)	20	3366.36	10	(11.6)	11	1746.85
Clinically significant hypoglycaemia (level 2)	246	(84.8)	2789	1959.83	223	(76.4)	1478	1025.53
0 < to <= 1 month	162	(55.9)	488	2025.48	138	(47.3)	364	1493.24
1 < to <= 2 months	169	(58.7)	538	2238.60	126	(43.3)	293	1216.60
2 < to <= 3 months	156	(54.4)	488	2051.35	97	(33.8)	212	884.59
3 < to <= 4 months	148	(52.1)	451	1910.77	114	(39.7)	217	909.51
4 < to <= 5 months	134	(47.7)	377	1614.96	96	(33.7)	182	765.94
5 < to <= 6 months	144	(52.0)	434	1899.22	94	(33.1)	205	874.42
> 6 months	8	(10.3)	13	2188.13	5	(5.8)	5	794.02
Severe hypoglycaemia (level 3)	9	(3.1)	47	33.03	9	(3.1)	17	11.80
0 < to <= 1 month	3	(1.0)	15	62.26	5	(1.7)	7	28.72
1 < to <= 2 months	2	(0.7)	17	70.74	2	(0.7)	3	12.46
2 < to <= 3 months	2	(0.7)	4	16.81	1	(0.3)	1	4.17
3 < to <= 4 months	3	(1.1)	5	21.18	1	(0.3)	1	4.19
4 < to <= 5 months	1	(0.4)	1	4.28	1	(0.4)	1	4.21
5 < to <= 6 months	4	(1.4)	5	21.88	3	(1.1)	4	17.06
> 6 months	0				0			
Severe (level 3) or clinically significant (level 2) hypoglycaemia	247	(85.2)	2836	1992.86	223	(76.4)	1495	1037.33
0 < to <= 1 month	163	(56.2)	503	2087.74	138	(47.3)	371	1521.96
1 < to <= 2 months	170	(59.0)	555	2309.34	126	(43.3)	296	1229.06
2 < to <= 3 months	157	(54.7)	492	2068.17	97	(33.8)	213	888.77
3 < to <= 4 months	148	(52.1)	456	1931.96	114	(39.7)	218	913.70
4 < to <= 5 months	134	(47.7)	378	1619.24	97	(34.0)	183	770.14
5 < to <= 6 months	145	(52.3)	439	1921.10	95	(33.5)	209	891.48
> 6 months	8	(10.3)	13	2188.13	5	(5.8)	5	794.02

%: Percentage of subjects with one or more events, BG: Blood glucose, E: Number of events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. 1 month = 30.5 days. A hypoglycaemia alert value (level 1) was excluded from each of ONWARDS 1 and 6 as these had been erroneously included in trial clinical trial reports. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

7.4.4 Nocturnal hypoglycaemic episodes by trial, classification and month since randomisation - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
ONWARDS 1								
Number of subjects	492				492			
PYE (years)	485.88				485.03			
Hypoglycaemia alert value (level 1)	67	(13.6)	190	39.10	58	(11.8)	95	19.59
0 < to <= 1 month	3	(0.6)	3	7.30	4	(0.8)	4	9.77
1 < to <= 2 months	7	(1.4)	11	26.77	6	(1.2)	7	17.18
2 < to <= 3 months	12	(2.4)	15	36.51	8	(1.6)	9	22.13
3 < to <= 4 months	12	(2.4)	14	34.11	6	(1.2)	6	14.76
4 < to <= 5 months	9	(1.8)	9	22.07	5	(1.0)	5	12.34
5 < to <= 6 months	12	(2.5)	15	36.85	12	(2.5)	14	34.64
6 < to <= 7 months	9	(1.9)	9	22.21	9	(1.9)	10	24.75
7 < to <= 8 months	14	(2.9)	25	62.09	3	(0.6)	6	14.88
8 < to <= 9 months	11	(2.3)	22	54.89	6	(1.2)	6	14.91
9 < to <= 10 months	14	(2.9)	22	54.96	9	(1.9)	9	22.36
10 < to <= 11 months	13	(2.7)	20	50.00	6	(1.2)	8	19.88
11 < to <= 12 months	14	(2.9)	25	64.58	10	(2.1)	11	28.25
> 12 months	0				0			
Clinically significant hypoglycaemia (level 2)	9	(1.8)	20	4.12	10	(2.0)	14	2.89
0 < to <= 1 month	0				1	(0.2)	1	2.44
1 < to <= 2 months	1	(0.2)	1	2.43	0			
2 < to <= 3 months	0				0			
3 < to <= 4 months	2	(0.4)	2	4.87	2	(0.4)	2	4.92
4 < to <= 5 months	2	(0.4)	2	4.90	0			
5 < to <= 6 months	2	(0.4)	2	4.91	3	(0.6)	4	9.90
6 < to <= 7 months	0				3	(0.6)	4	9.90
7 < to <= 8 months	2	(0.4)	5	12.42	2	(0.4)	2	4.96
8 < to <= 9 months	2	(0.4)	2	4.99	0			
9 < to <= 10 months	1	(0.2)	2	5.00	0			
10 < to <= 11 months	2	(0.4)	3	7.50	1	(0.2)	1	2.48
11 < to <= 12 months	1	(0.2)	1	2.58	0			
> 12 months	0				0			
Severe hypoglycaemia (level 3)	0				1	(0.2)	1	0.21
0 < to <= 1 month	0				0			
1 < to <= 2 months	0				0			
2 < to <= 3 months	0				0			
3 < to <= 4 months	0				0			
4 < to <= 5 months	0				0			
5 < to <= 6 months	0				0			
6 < to <= 7 months	0				0			
7 < to <= 8 months	0				0			
8 < to <= 9 months	0				1	(0.2)	1	2.48
9 < to <= 10 months	0				0			
10 < to <= 11 months	0				0			
11 < to <= 12 months	0				0			
> 12 months	0				0			

%: Percentage of subjects with one or more events, BG: Blood glucose, E: Number of events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. 1 month = 30.5 days. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6. Nocturnal: The period between 00:01 and 05:59 (both included).

Nocturnal hypoglycaemic episodes by trial, classification and month since randomisation - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
Severe (level 3) or clinically significant (level 2) hypoglycaemia	9	(1.8)	20	4.12	11	(2.2)	15	3.09
0 < to <= 1 month	0				1	(0.2)	1	2.44
1 < to <= 2 months	1	(0.2)	1	2.43	0			
2 < to <= 3 months	0				0			
3 < to <= 4 months	2	(0.4)	2	4.87	2	(0.4)	2	4.92
4 < to <= 5 months	2	(0.4)	2	4.90	0			
5 < to <= 6 months	2	(0.4)	2	4.91	3	(0.6)	4	9.90
6 < to <= 7 months	0				3	(0.6)	4	9.90
7 < to <= 8 months	2	(0.4)	5	12.42	2	(0.4)	2	4.96
8 < to <= 9 months	2	(0.4)	2	4.99	1	(0.2)	1	2.48
9 < to <= 10 months	1	(0.2)	2	5.00	0			
10 < to <= 11 months	2	(0.4)	3	7.50	1	(0.2)	1	2.48
11 < to <= 12 months	1	(0.2)	1	2.58	0			
> 12 months	0				0			

%: Percentage of subjects with one or more events, BG: Blood glucose, E: Number of events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. 1 month = 30.5 days. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6. Nocturnal: The period between 00:01 and 05:59 (both included).

Nocturnal hypoglycaemic episodes by trial, classification and month since randomisation - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
ONWARDS 2								
Number of subjects	262				263			
PYE (years)	155.25				152.77			
Hypoglycaemia alert value (level 1)	60	(22.9)	144	92.76	35	(13.3)	102	66.77
0 < to <= 1 month	11	(4.2)	16	73.13	15	(5.7)	25	114.23
1 < to <= 2 months	15	(5.7)	18	82.46	12	(4.6)	20	92.29
2 < to <= 3 months	12	(4.6)	17	78.06	8	(3.1)	8	37.21
3 < to <= 4 months	16	(6.2)	24	110.71	8	(3.1)	12	55.99
4 < to <= 5 months	12	(4.6)	14	64.77	9	(3.5)	10	46.86
5 < to <= 6 months	14	(5.4)	25	116.41	11	(4.3)	14	66.13
> 6 months	18	(7.0)	30	120.03	10	(4.0)	13	54.68
Clinically significant hypoglycaemia (level 2)	16	(6.1)	32	20.61	9	(3.4)	13	8.51
0 < to <= 1 month	3	(1.1)	6	27.42	5	(1.9)	6	27.41
1 < to <= 2 months	2	(0.8)	3	13.74	2	(0.8)	2	9.23
2 < to <= 3 months	5	(1.9)	6	27.55	1	(0.4)	1	4.65
3 < to <= 4 months	3	(1.2)	4	18.45	0			
4 < to <= 5 months	1	(0.4)	1	4.63	1	(0.4)	1	4.69
5 < to <= 6 months	5	(1.9)	6	27.94	1	(0.4)	2	9.45
> 6 months	4	(1.6)	6	24.01	1	(0.4)	1	4.21
Severe hypoglycaemia (level 3)	0				0			
0 < to <= 1 month	0				0			
1 < to <= 2 months	0				0			
2 < to <= 3 months	0				0			
3 < to <= 4 months	0				0			
4 < to <= 5 months	0				0			
5 < to <= 6 months	0				0			
> 6 months	0				0			
Severe (level 3) or clinically significant (level 2) hypoglycaemia	16	(6.1)	32	20.61	9	(3.4)	13	8.51
0 < to <= 1 month	3	(1.1)	6	27.42	5	(1.9)	6	27.41
1 < to <= 2 months	2	(0.8)	3	13.74	2	(0.8)	2	9.23
2 < to <= 3 months	5	(1.9)	6	27.55	1	(0.4)	1	4.65
3 < to <= 4 months	3	(1.2)	4	18.45	0			
4 < to <= 5 months	1	(0.4)	1	4.63	1	(0.4)	1	4.69
5 < to <= 6 months	5	(1.9)	6	27.94	1	(0.4)	2	9.45
> 6 months	4	(1.6)	6	24.01	1	(0.4)	1	4.21

%: Percentage of subjects with one or more events, BG: Blood glucose, E: Number of events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. 1 month = 30.5 days. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6. Nocturnal: The period between 00:01 and 05:59 (both included).

Nocturnal hypoglycaemic episodes by trial, classification and month since randomisation - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
ONWARDS 3								
Number of subjects	293				294			
PYE (years)	170.90				171.13			
Hypoglycaemia alert value (level 1)	24	(8.2)	40	23.41	23	(7.8)	37	21.62
0 < to <= 1 month	0				3	(1.0)	3	12.22
1 < to <= 2 months	6	(2.1)	6	24.83	4	(1.4)	4	16.46
2 < to <= 3 months	4	(1.4)	6	24.95	4	(1.4)	5	20.71
3 < to <= 4 months	5	(1.7)	5	20.96	2	(0.7)	2	8.33
4 < to <= 5 months	7	(2.5)	10	42.17	7	(2.4)	7	29.33
5 < to <= 6 months	7	(2.5)	8	33.75	7	(2.5)	12	50.65
> 6 months	5	(1.8)	5	18.45	4	(1.4)	4	15.06
Clinically significant hypoglycaemia (level 2)	1	(0.3)	2	1.17	4	(1.4)	5	2.92
0 < to <= 1 month	0				0			
1 < to <= 2 months	0				1	(0.3)	1	4.11
2 < to <= 3 months	0				2	(0.7)	2	8.28
3 < to <= 4 months	0				0			
4 < to <= 5 months	1	(0.4)	1	4.22	0			
5 < to <= 6 months	0				1	(0.4)	1	4.22
> 6 months	1	(0.4)	1	3.69	1	(0.4)	1	3.76
Severe hypoglycaemia (level 3)	0				0			
0 < to <= 1 month	0				0			
1 < to <= 2 months	0				0			
2 < to <= 3 months	0				0			
3 < to <= 4 months	0				0			
4 < to <= 5 months	0				0			
5 < to <= 6 months	0				0			
> 6 months	0				0			
Severe (level 3) or clinically significant (level 2) hypoglycaemia	1	(0.3)	2	1.17	4	(1.4)	5	2.92
0 < to <= 1 month	0				0			
1 < to <= 2 months	0				1	(0.3)	1	4.11
2 < to <= 3 months	0				2	(0.7)	2	8.28
3 < to <= 4 months	0				0			
4 < to <= 5 months	1	(0.4)	1	4.22	0			
5 < to <= 6 months	0				1	(0.4)	1	4.22
> 6 months	1	(0.4)	1	3.69	1	(0.4)	1	3.76

%: Percentage of subjects with one or more events, BG: Blood glucose, E: Number of events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. 1 month = 30.5 days. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6. Nocturnal: The period between 00:01 and 05:59 (both included).

Nocturnal hypoglycaemic episodes by trial, classification and month since randomisation - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
ONWARDS 4								
Number of subjects	291				291			
PYE (years)	167.36				166.80			
Hypoglycaemia alert value (level 1)	108	(37.1)	380	227.05	132	(45.4)	440	263.79
0 < to <= 1 month	28	(9.6)	46	190.32	39	(13.4)	60	249.10
1 < to <= 2 months	31	(10.8)	39	163.21	40	(13.9)	59	248.51
2 < to <= 3 months	36	(12.7)	55	232.89	36	(12.7)	45	191.43
3 < to <= 4 months	41	(14.5)	61	259.86	56	(20.0)	71	303.66
4 < to <= 5 months	36	(12.9)	57	244.72	34	(12.1)	60	257.82
5 < to <= 6 months	36	(13.0)	56	243.66	56	(20.1)	87	375.61
> 6 months	38	(13.9)	66	254.53	41	(14.9)	58	226.14
Clinically significant hypoglycaemia (level 2)	54	(18.6)	131	78.27	71	(24.4)	171	102.52
0 < to <= 1 month	6	(2.1)	7	28.96	16	(5.5)	24	99.64
1 < to <= 2 months	14	(4.9)	20	83.70	13	(4.5)	20	84.24
2 < to <= 3 months	12	(4.2)	17	71.98	16	(5.7)	22	93.59
3 < to <= 4 months	18	(6.4)	27	115.02	18	(6.4)	19	81.26
4 < to <= 5 months	13	(4.6)	15	64.40	20	(7.1)	24	103.13
5 < to <= 6 months	14	(5.1)	21	91.37	29	(10.4)	43	185.65
> 6 months	17	(6.2)	24	92.56	15	(5.4)	19	74.08
Severe hypoglycaemia (level 3)	0				1	(0.3)	2	1.20
0 < to <= 1 month	0				0			
1 < to <= 2 months	0				0			
2 < to <= 3 months	0				0			
3 < to <= 4 months	0				0			
4 < to <= 5 months	0				0			
5 < to <= 6 months	0				1	(0.4)	2	8.63
> 6 months	0				0			
Severe (level 3) or clinically significant (level 2) hypoglycaemia	54	(18.6)	131	78.27	72	(24.7)	173	103.72
0 < to <= 1 month	6	(2.1)	7	28.96	16	(5.5)	24	99.64
1 < to <= 2 months	14	(4.9)	20	83.70	13	(4.5)	20	84.24
2 < to <= 3 months	12	(4.2)	17	71.98	16	(5.7)	22	93.59
3 < to <= 4 months	18	(6.4)	27	115.02	18	(6.4)	19	81.26
4 < to <= 5 months	13	(4.6)	15	64.40	20	(7.1)	24	103.13
5 < to <= 6 months	14	(5.1)	21	91.37	30	(10.8)	45	194.28
> 6 months	17	(6.2)	24	92.56	15	(5.4)	19	74.08
ONWARDS 5								
Number of subjects	542				538			
PYE (years)	559.54				560.72			

%: Percentage of subjects with one or more events, BG: Blood glucose, E: Number of events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. 1 month = 30.5 days. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6. Nocturnal: The period between 00:01 and 05:59 (both included).

Nocturnal hypoglycaemic episodes by trial, classification and month since randomisation - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
Hypoglycaemia alert value (level 1)	48	(8.9)	107	19.12	46	(8.6)	213	37.99
0 < to <= 1 month	4	(0.7)	5	11.11	4	(0.7)	6	13.41
1 < to <= 2 months	1	(0.2)	1	2.24	6	(1.1)	10	22.59
2 < to <= 3 months	5	(0.9)	6	13.53	8	(1.5)	12	27.36
3 < to <= 4 months	8	(1.5)	12	27.28	9	(1.7)	17	39.07
4 < to <= 5 months	6	(1.1)	11	25.18	8	(1.5)	16	37.04
5 < to <= 6 months	10	(1.9)	12	27.93	9	(1.7)	13	30.25
6 < to <= 7 months	8	(1.6)	12	28.24	9	(1.8)	16	37.50
7 < to <= 8 months	3	(0.6)	4	9.47	6	(1.2)	16	37.68
8 < to <= 9 months	4	(0.8)	4	9.52	11	(2.2)	26	61.42
9 < to <= 10 months	11	(2.2)	17	40.93	6	(1.2)	16	38.00
10 < to <= 11 months	4	(0.8)	4	9.69	8	(1.6)	23	54.78
11 < to <= 12 months	10	(2.0)	13	31.76	10	(2.0)	22	53.05
> 12 months	4	(0.8)	6	13.50	14	(2.8)	20	44.31
Clinically significant hypoglycaemia (level 2)	11	(2.0)	13	2.32	11	(2.0)	18	3.21
0 < to <= 1 month	1	(0.2)	1	2.22	0			
1 < to <= 2 months	1	(0.2)	1	2.24	0			
2 < to <= 3 months	0				2	(0.4)	3	6.84
3 < to <= 4 months	2	(0.4)	2	4.55	2	(0.4)	2	4.60
4 < to <= 5 months	0				1	(0.2)	1	2.32
5 < to <= 6 months	0				2	(0.4)	2	4.65
6 < to <= 7 months	1	(0.2)	1	2.35	2	(0.4)	2	4.69
7 < to <= 8 months	2	(0.4)	2	4.74	0			
8 < to <= 9 months	1	(0.2)	1	2.38	2	(0.4)	2	4.72
9 < to <= 10 months	0				1	(0.2)	1	2.38
10 < to <= 11 months	0				2	(0.4)	2	4.76
11 < to <= 12 months	2	(0.4)	2	4.89	2	(0.4)	3	7.23
> 12 months	3	(0.6)	3	6.75	0			
Severe hypoglycaemia (level 3)	0				1	(0.2)	1	0.18
0 < to <= 1 month	0				0			
1 < to <= 2 months	0				0			
2 < to <= 3 months	0				0			
3 < to <= 4 months	0				1	(0.2)	1	2.30
4 < to <= 5 months	0				0			
5 < to <= 6 months	0				0			
6 < to <= 7 months	0				0			
7 < to <= 8 months	0				0			
8 < to <= 9 months	0				0			
9 < to <= 10 months	0				0			
10 < to <= 11 months	0				0			
11 < to <= 12 months	0				0			
> 12 months	0				0			

%: Percentage of subjects with one or more events, BG: Blood glucose, E: Number of events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. 1 month = 30.5 days. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6. Nocturnal: The period between 00:01 and 05:59 (both included).

Nocturnal hypoglycaemic episodes by trial, classification and month since randomisation - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
Severe (level 3) or clinically significant (level 2) hypoglycaemia	11	(2.0)	13	2.32	12	(2.2)	19	3.39
0 < to <= 1 month	1	(0.2)	1	2.22	0			
1 < to <= 2 months	1	(0.2)	1	2.24	0			
2 < to <= 3 months	0				2	(0.4)	3	6.84
3 < to <= 4 months	2	(0.4)	2	4.55	3	(0.6)	3	6.90
4 < to <= 5 months	0				1	(0.2)	1	2.32
5 < to <= 6 months	0				2	(0.4)	2	4.65
6 < to <= 7 months	1	(0.2)	1	2.35	2	(0.4)	2	4.69
7 < to <= 8 months	2	(0.4)	2	4.74	0			
8 < to <= 9 months	1	(0.2)	1	2.38	2	(0.4)	2	4.72
9 < to <= 10 months	0				1	(0.2)	1	2.38
10 < to <= 11 months	0				2	(0.4)	2	4.76
11 < to <= 12 months	2	(0.4)	2	4.89	2	(0.4)	3	7.23
> 12 months	3	(0.6)	3	6.75	0			

%: Percentage of subjects with one or more events, BG: Blood glucose, E: Number of events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. 1 month = 30.5 days. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6. Nocturnal: The period between 00:01 and 05:59 (both included).

Nocturnal hypoglycaemic episodes by trial, classification and month since randomisation - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
ONWARDS 6								
Number of subjects	290				292			
PYE (years)	142.31				144.12			
Hypoglycaemia alert value (level 1)	214	(73.8)	980	688.65	171	(58.6)	734	509.30
0 < to <= 1 month	101	(34.8)	174	722.20	78	(26.7)	141	578.43
1 < to <= 2 months	107	(37.2)	191	794.75	71	(24.4)	128	531.48
2 < to <= 3 months	98	(34.1)	156	655.76	68	(23.7)	112	467.33
3 < to <= 4 months	97	(34.2)	177	749.90	74	(25.8)	134	561.63
4 < to <= 5 months	86	(30.6)	138	591.15	60	(21.1)	96	404.01
5 < to <= 6 months	88	(31.8)	143	625.78	74	(26.1)	122	520.38
> 6 months	1	(1.3)	1	168.32	1	(1.2)	1	158.80
Clinically significant hypoglycaemia (level 2)	135	(46.6)	476	334.49	98	(33.6)	224	155.43
0 < to <= 1 month	51	(17.6)	88	365.25	30	(10.3)	45	184.60
1 < to <= 2 months	50	(17.4)	89	370.33	29	(10.0)	37	153.63
2 < to <= 3 months	45	(15.7)	70	294.25	29	(10.1)	40	166.90
3 < to <= 4 months	55	(19.4)	86	364.36	27	(9.4)	30	125.74
4 < to <= 5 months	44	(15.7)	56	239.89	20	(7.0)	26	109.42
5 < to <= 6 months	47	(17.0)	86	376.34	34	(12.0)	46	196.21
> 6 months	1	(1.3)	1	168.32	0			
Severe hypoglycaemia (level 3)	2	(0.7)	5	3.51	3	(1.0)	3	2.08
0 < to <= 1 month	1	(0.3)	1	4.15	3	(1.0)	3	12.31
1 < to <= 2 months	1	(0.3)	1	4.16	0			
2 < to <= 3 months	1	(0.3)	2	8.41	0			
3 < to <= 4 months	0				0			
4 < to <= 5 months	0				0			
5 < to <= 6 months	1	(0.4)	1	4.38	0			
> 6 months	0				0			
Severe (level 3) or clinically significant (level 2) hypoglycaemia	135	(46.6)	481	338.00	98	(33.6)	227	157.51
0 < to <= 1 month	52	(17.9)	89	369.40	31	(10.6)	48	196.91
1 < to <= 2 months	51	(17.7)	90	374.49	29	(10.0)	37	153.63
2 < to <= 3 months	46	(16.0)	72	302.66	29	(10.1)	40	166.90
3 < to <= 4 months	55	(19.4)	86	364.36	27	(9.4)	30	125.74
4 < to <= 5 months	44	(15.7)	56	239.89	20	(7.0)	26	109.42
5 < to <= 6 months	47	(17.0)	87	380.72	34	(12.0)	46	196.21
> 6 months	1	(1.3)	1	168.32	0			

%: Percentage of subjects with one or more events, BG: Blood glucose, E: Number of events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. 1 month = 30.5 days. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6. Nocturnal: The period between 00:01 and 05:59 (both included).

adsl.xpt; variable(s): STDNM RANDDT OTMTDURY OMTMXXDM(XX=01 to 13); criteria: SAFFL == "Y"
adhypo.xpt; variable(s): STDNM ACAT4 ASTDT; criteria: SAFFL == "Y" & NOCTFL == "Y" & ANELFL == "Y" & ANL06FL == "Y"

7.4.5 Hypoglycaemic episodes by trial, classification and phase - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
ONWARDS 1								
Number of subjects	492				492			
PYE (years)	485.88				485.03			
PYE in titration (years)	113.24				112.36			
PYE in maintenance (years)	371.75				372.18			
Hypoglycaemia alert value (level 1)	232	(47.2)	1447	297.81	191	(38.8)	631	130.09
Titration	79	(16.1)	197	173.97	47	(9.6)	80	71.20
Maintenance	214	(43.6)	1250	336.25	171	(35.1)	550	147.78
Clinically significant hypoglycaemia (level 2)	48	(9.8)	143	29.43	49	(10.0)	75	15.46
Titration	10	(2.0)	17	15.01	9	(1.8)	10	8.90
Maintenance	42	(8.6)	126	33.89	42	(8.6)	65	17.46
Severe hypoglycaemia (level 3)	1	(0.2)	1	0.21	3	(0.6)	3	0.62
Titration	0				0			
Maintenance	1	(0.2)	1	0.27	3	(0.6)	3	0.81
Severe (level 3) or clinically significant (level 2) hypoglycaemia	48	(9.8)	144	29.64	52	(10.6)	78	16.08
Titration	10	(2.0)	17	15.01	9	(1.8)	10	8.90
Maintenance	42	(8.6)	127	34.16	45	(9.2)	68	18.27
ONWARDS 2								
Number of subjects	262				263			
PYE (years)	155.25				152.77			
PYE in titration (years)	59.89				59.37			
PYE in maintenance (years)	70.14				68.73			
Hypoglycaemia alert value (level 1)	145	(55.3)	1209	778.76	118	(44.9)	589	385.54
Titration	78	(29.8)	431	719.65	74	(28.1)	267	449.74
Maintenance	123	(47.3)	619	882.51	88	(34.2)	242	352.11
Clinically significant hypoglycaemia (level 2)	37	(14.1)	113	72.79	19	(7.2)	41	26.84
Titration	15	(5.7)	58	96.84	13	(4.9)	24	40.43
Maintenance	23	(8.8)	39	55.60	9	(3.5)	11	16.01
Severe hypoglycaemia (level 3)	0				1	(0.4)	1	0.65
Titration	0				1	(0.4)	1	1.68
Maintenance	0				0			
Severe (level 3) or clinically significant (level 2) hypoglycaemia	37	(14.1)	113	72.79	19	(7.2)	42	27.49
Titration	15	(5.7)	58	96.84	13	(4.9)	25	42.11
Maintenance	23	(8.8)	39	55.60	9	(3.5)	11	16.01

%: Percentage of subjects with one or more events, BG: Blood glucose, E: Number of events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. Titration phase is defined as from date of first dose of trial product up until week 12 or at the date of the end of treatment visit, whichever comes first. Maintenance phase is defined as from week 12 to date of the end of treatment visit or date of the last visit within the main part, if applicable, whichever comes first. If the end of treatment visit is prior to week 12, then there will be no maintenance phase. A hypoglycaemia alert value (level 1) was excluded from each of ONWARDS 1 and 6 as these had been erroneously included in trial clinical trial reports. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Hypoglycaemic episodes by trial, classification and phase - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
ONWARDS 3								
Number of subjects	293				294			
PYE (years)	170.90				171.13			
PYE in titration (years)	66.28				66.72			
PYE in maintenance (years)	77.14				76.87			
Hypoglycaemia alert value (level 1)	91	(31.1)	400	234.06	65	(22.1)	185	108.10
Titration	48	(16.4)	132	199.17	30	(10.2)	55	82.44
Maintenance	65	(22.7)	226	292.99	46	(15.9)	103	134.00
Clinically significant hypoglycaemia (level 2)	26	(8.9)	53	31.01	17	(5.8)	23	13.44
Titration	9	(3.1)	19	28.67	8	(2.7)	9	13.49
Maintenance	18	(6.3)	31	40.19	6	(2.1)	8	10.41
Severe hypoglycaemia (level 3)	0				2	(0.7)	2	1.17
Titration	0				0			
Maintenance	0				0			
Severe (level 3) or clinically significant (level 2) hypoglycaemia	26	(8.9)	53	31.01	18	(6.1)	25	14.61
Titration	9	(3.1)	19	28.67	8	(2.7)	9	13.49
Maintenance	18	(6.3)	31	40.19	6	(2.1)	8	10.41
ONWARDS 4								
Number of subjects	291				291			
PYE (years)	167.36				166.80			
PYE in titration (years)	65.56				65.37			
PYE in maintenance (years)	75.14				74.99			
Hypoglycaemia alert value (level 1)	244	(83.8)	5264	3145.28	251	(86.3)	4145	2485.04
Titration	206	(70.8)	1943	2963.92	203	(69.8)	1498	2291.51
Maintenance	224	(80.0)	2846	3787.58	230	(81.9)	2086	2781.71
Clinically significant hypoglycaemia (level 2)	148	(50.9)	937	559.86	160	(55.0)	935	560.56
Titration	92	(31.6)	353	538.48	91	(31.3)	336	513.98
Maintenance	111	(39.6)	485	645.46	127	(45.2)	473	630.75
Severe hypoglycaemia (level 3)	4	(1.4)	7	4.18	2	(0.7)	3	1.80
Titration	2	(0.7)	5	7.63	0			
Maintenance	2	(0.7)	2	2.66	1	(0.4)	2	2.67
Severe (level 3) or clinically significant (level 2) hypoglycaemia	150	(51.5)	944	564.05	162	(55.7)	938	562.36
Titration	93	(32.0)	358	546.11	91	(31.3)	336	513.98
Maintenance	112	(40.0)	487	648.12	128	(45.6)	475	633.42

%: Percentage of subjects with one or more events, BG: Blood glucose, E: Number of events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. Titration phase is defined as from date of first dose of trial product up until week 12 or at the date of the end of treatment visit, whichever comes first. Maintenance phase is defined as from week 12 to date of the end of treatment visit or date of the last visit within the main part, if applicable, whichever comes first. If the end of treatment visit is prior to week 12, then there will be no maintenance phase. A hypoglycaemia alert value (level 1) was excluded from each of ONWARDS 1 and 6 as these had been erroneously included in trial clinical trial reports. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Hypoglycaemic episodes by trial, classification and phase - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
ONWARDS 5								
Number of subjects	542				538			
PYE (years)	559.54				560.72			
PYE in titration (years)	122.50				121.28			
PYE in maintenance (years)	387.52				391.58			
Hypoglycaemia alert value (level 1)	200	(36.9)	1028	183.72	153	(28.4)	851	151.77
Titration	45	(8.3)	96	78.37	47	(8.7)	133	109.66
Maintenance	181	(34.4)	869	224.24	135	(25.9)	652	166.51
Clinically significant hypoglycaemia (level 2)	64	(11.8)	104	18.59	42	(7.8)	76	13.55
Titration	19	(3.5)	22	17.96	8	(1.5)	13	10.72
Maintenance	42	(8.0)	74	19.10	32	(6.1)	57	14.56
Severe hypoglycaemia (level 3)	0				4	(0.7)	5	0.89
Titration	0				1	(0.2)	1	0.82
Maintenance	0				4	(0.8)	4	1.02
Severe (level 3) or clinically significant (level 2) hypoglycaemia	64	(11.8)	104	18.59	45	(8.4)	81	14.45
Titration	19	(3.5)	22	17.96	9	(1.7)	14	11.54
Maintenance	42	(8.0)	74	19.10	35	(6.7)	61	15.58
ONWARDS 6								
Number of subjects	290				292			
PYE (years)	142.31				144.12			
PYE in titration (years)	65.94				66.55			
PYE in maintenance (years)	75.33				77.16			
Hypoglycaemia alert value (level 1)	288	(99.3)	10799	7588.47	287	(98.3)	7401	5135.29
Titration	283	(97.6)	5373	8148.85	278	(95.2)	3774	5671.25
Maintenance	279	(99.3)	5400	7168.27	278	(96.9)	3621	4692.79
Clinically significant hypoglycaemia (level 2)	246	(84.8)	2789	1959.83	223	(76.4)	1478	1025.53
Titration	220	(75.9)	1409	2136.93	186	(63.7)	820	1232.23
Maintenance	209	(74.4)	1376	1826.58	177	(61.7)	657	851.47
Severe hypoglycaemia (level 3)	9	(3.1)	47	33.03	9	(3.1)	17	11.80
Titration	5	(1.7)	36	54.60	6	(2.1)	10	15.03
Maintenance	8	(2.8)	11	14.60	5	(1.7)	7	9.07
Severe (level 3) or clinically significant (level 2) hypoglycaemia	247	(85.2)	2836	1992.86	223	(76.4)	1495	1037.33
Titration	221	(76.2)	1445	2191.53	186	(63.7)	830	1247.25
Maintenance	210	(74.7)	1387	1841.18	178	(62.0)	664	860.54

%: Percentage of subjects with one or more events, BG: Blood glucose, E: Number of events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. Titration phase is defined as from date of first dose of trial product up until week 12 or at the date of the end of treatment visit, whichever comes first. Maintenance phase is defined as from week 12 to date of the end of treatment visit or date of the last visit within the main part, if applicable, whichever comes first. If the end of treatment visit is prior to week 12, then there will be no maintenance phase. A hypoglycaemia alert value (level 1) was excluded from each of ONWARDS 1 and 6 as these had been erroneously included in trial clinical trial reports. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

7.4.6 Nocturnal hypoglycaemic episodes by trial, classification and phase - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
ONWARDS 1								
Number of subjects	492				492			
PYE (years)	485.88				485.03			
PYE in titration (years)	113.24				112.36			
PYE in maintenance (years)	371.75				372.18			
Hypoglycaemia alert value (level 1)	67	(13.6)	190	39.10	58	(11.8)	95	19.59
Titration	14	(2.8)	25	22.08	14	(2.8)	18	16.02
Maintenance	58	(11.8)	165	44.39	48	(9.9)	77	20.69
Clinically significant hypoglycaemia (level 2)	9	(1.8)	20	4.12	10	(2.0)	14	2.89
Titration	1	(0.2)	1	0.88	1	(0.2)	1	0.89
Maintenance	8	(1.6)	19	5.11	9	(1.8)	13	3.49
Severe hypoglycaemia (level 3)	0				1	(0.2)	1	0.21
Titration	0				0			
Maintenance	0				1	(0.2)	1	0.27
Severe (level 3) or clinically significant (level 2) hypoglycaemia	9	(1.8)	20	4.12	11	(2.2)	15	3.09
Titration	1	(0.2)	1	0.88	1	(0.2)	1	0.89
Maintenance	8	(1.6)	19	5.11	10	(2.1)	14	3.76
ONWARDS 2								
Number of subjects	262				263			
PYE (years)	155.25				152.77			
PYE in titration (years)	59.89				59.37			
PYE in maintenance (years)	70.14				68.73			
Hypoglycaemia alert value (level 1)	60	(22.9)	144	92.76	35	(13.3)	102	66.77
Titration	27	(10.3)	47	78.48	22	(8.4)	50	84.22
Maintenance	36	(13.8)	66	94.10	22	(8.6)	37	53.84
Clinically significant hypoglycaemia (level 2)	16	(6.1)	32	20.61	9	(3.4)	13	8.51
Titration	7	(2.7)	13	21.71	7	(2.7)	9	15.16
Maintenance	9	(3.5)	12	17.11	2	(0.8)	3	4.37
Severe hypoglycaemia (level 3)	0				0			
Titration	0				0			
Maintenance	0				0			
Severe (level 3) or clinically significant (level 2) hypoglycaemia	16	(6.1)	32	20.61	9	(3.4)	13	8.51
Titration	7	(2.7)	13	21.71	7	(2.7)	9	15.16
Maintenance	9	(3.5)	12	17.11	2	(0.8)	3	4.37

%: Percentage of subjects with one or more events, BG: Blood glucose, E: Number of events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. Titration phase is defined as from date of first dose of trial product up until week 12 or at the date of the end of treatment visit, whichever comes first. Maintenance phase is defined as from week 12 to date of the end of treatment visit or date of the last visit within the main part, if applicable, whichever comes first. If the end of treatment visit is prior to week 12, then there will be no maintenance phase. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6. Nocturnal: The period between 00:01 and 05:59 (both included).

Nocturnal hypoglycaemic episodes by trial, classification and phase - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
ONWARDS 3								
Number of subjects	293				294			
PYE (years)	170.90				171.13			
PYE in titration (years)	66.28				66.72			
PYE in maintenance (years)	77.14				76.87			
Hypoglycaemia alert value (level 1)	24	(8.2)	40	23.41	23	(7.8)	37	21.62
Titration	10	(3.4)	12	18.11	9	(3.1)	11	16.49
Maintenance	18	(6.3)	24	31.11	13	(4.5)	20	26.02
Clinically significant hypoglycaemia (level 2)	1	(0.3)	2	1.17	4	(1.4)	5	2.92
Titration	0				3	(1.0)	3	4.50
Maintenance	1	(0.3)	1	1.30	2	(0.7)	2	2.60
Severe hypoglycaemia (level 3)	0				0			
Titration	0				0			
Maintenance	0				0			
Severe (level 3) or clinically significant (level 2) hypoglycaemia	1	(0.3)	2	1.17	4	(1.4)	5	2.92
Titration	0				3	(1.0)	3	4.50
Maintenance	1	(0.3)	1	1.30	2	(0.7)	2	2.60
ONWARDS 4								
Number of subjects	291				291			
PYE (years)	167.36				166.80			
PYE in titration (years)	65.56				65.37			
PYE in maintenance (years)	75.14				74.99			
Hypoglycaemia alert value (level 1)	108	(37.1)	380	227.05	132	(45.4)	440	263.79
Titration	61	(21.0)	122	186.10	79	(27.1)	151	230.99
Maintenance	76	(27.1)	189	251.53	94	(33.5)	230	306.71
Clinically significant hypoglycaemia (level 2)	54	(18.6)	131	78.27	71	(24.4)	171	102.52
Titration	22	(7.6)	39	59.49	34	(11.7)	61	93.31
Maintenance	34	(12.1)	68	90.50	43	(15.3)	87	116.02
Severe hypoglycaemia (level 3)	0				1	(0.3)	2	1.20
Titration	0				0			
Maintenance	0				1	(0.4)	2	2.67
Severe (level 3) or clinically significant (level 2) hypoglycaemia	54	(18.6)	131	78.27	72	(24.7)	173	103.72
Titration	22	(7.6)	39	59.49	34	(11.7)	61	93.31
Maintenance	34	(12.1)	68	90.50	44	(15.7)	89	118.68


%: Percentage of subjects with one or more events, BG: Blood glucose, E: Number of events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. Titration phase is defined as from date of first dose of trial product up until week 12 or at the date of the end of treatment visit, whichever comes first. Maintenance phase is defined as from week 12 to date of the end of treatment visit or date of the last visit within the main part, if applicable, whichever comes first. If the end of treatment visit is prior to week 12, then there will be no maintenance phase. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6. Nocturnal: The period between 00:01 and 05:59 (both included).

Nocturnal hypoglycaemic episodes by trial, classification and phase - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
ONWARDS 5								
Number of subjects	542				538			
PYE (years)	559.54				560.72			
PYE in titration (years)	122.50				121.28			
PYE in maintenance (years)	387.52				391.58			
Hypoglycaemia alert value (level 1)	48	(8.9)	107	19.12	46	(8.6)	213	37.99
Titration	8	(1.5)	10	8.16	13	(2.4)	26	21.44
Maintenance	41	(7.8)	86	22.19	38	(7.3)	167	42.65
Clinically significant hypoglycaemia (level 2)	11	(2.0)	13	2.32	11	(2.0)	18	3.21
Titration	2	(0.4)	2	1.63	2	(0.4)	3	2.47
Maintenance	7	(1.3)	8	2.06	9	(1.7)	15	3.83
Severe hypoglycaemia (level 3)	0				1	(0.2)	1	0.18
Titration	0				0			
Maintenance	0				1	(0.2)	1	0.26
Severe (level 3) or clinically significant (level 2) hypoglycaemia	11	(2.0)	13	2.32	12	(2.2)	19	3.39
Titration	2	(0.4)	2	1.63	2	(0.4)	3	2.47
Maintenance	7	(1.3)	8	2.06	10	(1.9)	16	4.09
ONWARDS 6								
Number of subjects	290				292			
PYE (years)	142.31				144.12			
PYE in titration (years)	65.94				66.55			
PYE in maintenance (years)	75.33				77.16			
Hypoglycaemia alert value (level 1)	214	(73.8)	980	688.65	171	(58.6)	734	509.30
Titration	172	(59.3)	482	731.02	131	(44.9)	353	530.46
Maintenance	165	(58.7)	493	654.44	126	(43.9)	376	487.29
Clinically significant hypoglycaemia (level 2)	135	(46.6)	476	334.49	98	(33.6)	224	155.43
Titration	92	(31.7)	226	342.76	64	(21.9)	112	168.30
Maintenance	100	(35.6)	248	329.21	63	(22.0)	111	143.86
Severe hypoglycaemia (level 3)	2	(0.7)	5	3.51	3	(1.0)	3	2.08
Titration	2	(0.7)	4	6.07	3	(1.0)	3	4.51
Maintenance	1	(0.4)	1	1.33	0			
Severe (level 3) or clinically significant (level 2) hypoglycaemia	135	(46.6)	481	338.00	98	(33.6)	227	157.51
Titration	93	(32.1)	230	348.82	64	(21.9)	115	172.81
Maintenance	100	(35.6)	249	330.54	63	(22.0)	111	143.86

%: Percentage of subjects with one or more events, BG: Blood glucose, E: Number of events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. Titration phase is defined as from date of first dose of trial product up until week 12 or at the date of the end of treatment visit, whichever comes first. Maintenance phase is defined as from week 12 to date of the end of treatment visit or date of the last visit within the main part, if applicable, whichever comes first. If the end of treatment visit is prior to week 12, then there will be no maintenance phase. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6. Nocturnal: The period between 00:01 and 05:59 (both included).

7.4.7 Severe (level 3) or clinically significant hypoglycaemia (level 2) by trial - on-treatment/main-on-treatment - dot plot - safety analysis set




BG: Blood glucose, PYE: Patient years of exposure (1 PYE = 365.25 days), T1D: Type 1 diabetes, T2D: Type 2 diabetes. Safety analysis set. Observed data. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. OD analogues: Once-daily basal insulin analogues (IDeg, IGlar U100, IGlar U300). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

adsl.xpt; variable(s): STDNM PRINSTR OTMTDURY; criteria: SAFFL == "Y"
adhypo.xpt; variable(s): STDNM ACAT4 ACAT4N; criteria: SAFFL == "Y" & ACAT4N %in% (2:3) & ANELFL == "Y" & ANL06FL == "Y"

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:12:59:09 - fhypodot/fhypolev23dotontsas.png

7.4.8 Nocturnal severe (level 3) or clinically significant hypoglycaemia (level 2) by trial - on-treatment/main-on-treatment - dot plot - safety analysis set



BG: Blood glucose, PYE: Patient years of exposure (1 PYE = 365.25 days), T1D: Type 1 diabetes, T2D: Type 2 diabetes. Safety analysis set. Observed data. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. OD analogues: Once-daily basal insulin analogues (IDeg, IGlar U100, IGlar U300). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6. Nocturnal: The period between 00:01 and 05:59 (both included).

adsl.xpt; variable(s): STDNM PRINSTR OTMTDURY; criteria: SAFFL == "Y"
adhypo.xpt; variable(s): STDNM ACAT4 ACAT4N; criteria: SAFFL == "Y" & ACAT4N %in% (2:3) & ANELFL == "Y" & ANL06FL == "Y" & NOCTFL == "Y"

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:12:59:12 - fhypodot/fhypolev23noctdotontsas.png

7.4.9 Hypoglycaemic episodes by trial - on-treatment/main-on-treatment - supportive statistical analysis - full analysis set

	FAS	N	Estimate	95% CI	p-value
ONWARDS 1					
Clinically significant hypoglycaemia (level 2)					
Treatment					
Insulin icodec	492	492			
Daily basal insulin	492	492			
Treatment rate ratio					
Insulin icodec / Daily basal insulin			1.67	[0.99 ; 2.84]	0.0561
Severe (level 3) or clinically significant (level 2) hypoglycaemia					
Treatment					
Insulin icodec	492	492			
Daily basal insulin	492	492			
Treatment rate ratio					
Insulin icodec / Daily basal insulin			1.64	[0.98 ; 2.75]	0.0611
ONWARDS 2					
Clinically significant hypoglycaemia (level 2)					
Treatment					
Insulin icodec	263	263			
Daily basal insulin	263	263			
Treatment rate ratio					
Insulin icodec / Daily basal insulin			1.98	[0.95 ; 4.12]	0.0677
Severe (level 3) or clinically significant (level 2) hypoglycaemia					
Treatment					
Insulin icodec	263	263			
Daily basal insulin	263	263			
Treatment rate ratio					
Insulin icodec / Daily basal insulin			1.93	[0.93 ; 4.02]	0.0782

BG: Blood glucose, CI: Confidence interval, FAS: Number of subjects in full analysis set, N: Number of subjects contributing to the analysis. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. P-value: Two-sided p-value for test of no treatment difference. No correction for multiplicity. The number of events is analysed using a negative binomial regression model (log link) with treatment, region and, if applicable, additional relevant factors as fixed factors, and the logarithm of the time period for which the events are considered as an offset. Missing data are imputed using multiple imputation, assuming that event rate before follow-up 2 visit follows the respective treatment group's rate while the event rate after follow-up 2 visit is the rate of the comparator group. Each imputed dataset is analysed separately and estimates are combined using Rubin's rules. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Hypoglycaemic episodes by trial - on-treatment/main-on-treatment - supportive statistical analysis - full analysis set

	FAS	N	Estimate	95% CI	p-value
ONWARDS 3					
Clinically significant hypoglycaemia (level 2)					
Treatment					
Insulin icodec	294	294			
Daily basal insulin	294	294			
Treatment rate ratio					
Insulin icodec / Daily basal insulin			2.09	[0.99 ; 4.41]	0.0536
Severe (level 3) or clinically significant (level 2) hypoglycaemia					
Treatment					
Insulin icodec	294	294			
Daily basal insulin	294	294			
Treatment rate ratio					
Insulin icodec / Daily basal insulin			1.82	[0.87 ; 3.80]	0.1091
ONWARDS 4					
Clinically significant hypoglycaemia (level 2)					
Treatment					
Insulin icodec	291	291			
Daily basal insulin	291	291			
Treatment rate ratio					
Insulin icodec / Daily basal insulin			0.99	[0.73 ; 1.34]	0.9274
Severe hypoglycaemia (level 3)					
Treatment					
Insulin icodec	291	291			
Daily basal insulin	291	291			
Treatment rate ratio					
Insulin icodec / Daily basal insulin			2.19	[0.20 ; 24.44]	0.5251
Severe (level 3) or clinically significant (level 2) hypoglycaemia					
Treatment					
Insulin icodec	291	291			
Daily basal insulin	291	291			
Treatment rate ratio					
Insulin icodec / Daily basal insulin			0.99	[0.73 ; 1.33]	0.9290

BG: Blood glucose, CI: Confidence interval, FAS: Number of subjects in full analysis set, N: Number of subjects contributing to the analysis. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. P-value: Two-sided p-value for test of no treatment difference. No correction for multiplicity. The number of events is analysed using a negative binomial regression model (log link) with treatment, region and, if applicable, additional relevant factors as fixed factors, and the logarithm of the time period for which the events are considered as an offset. Missing data are imputed using multiple imputation, assuming that event rate before follow-up 2 visit follows the respective treatment group's rate while the event rate after follow-up 2 visit is the rate of the comparator group. Each imputed dataset is analysed separately and estimates are combined using Rubin's rules. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Hypoglycaemic episodes by trial - on-treatment/main-on-treatment - supportive statistical analysis - full analysis set

	FAS	N	Estimate	95% CI	p-value
ONWARDS 5					
Clinically significant hypoglycaemia (level 2)					
Treatment					
Insulin icodec	542	542			
Daily basal insulin	543	543			
Treatment rate ratio					
Insulin icodec / Daily basal insulin			1.23	[0.77 ; 1.98]	0.3928
Severe (level 3) or clinically significant (level 2) hypoglycaemia					
Treatment					
Insulin icodec	542	542			
Daily basal insulin	543	543			
Treatment rate ratio					
Insulin icodec / Daily basal insulin			1.17	[0.73 ; 1.86]	0.5153
ONWARDS 6					
Clinically significant hypoglycaemia (level 2)					
Treatment					
Insulin icodec	290	290			
Daily basal insulin	292	292			
Treatment rate ratio					
Insulin icodec / Daily basal insulin			1.88	[1.53 ; 2.32]	<0.0001
Severe hypoglycaemia (level 3)					
Treatment					
Insulin icodec	290	290			
Daily basal insulin	292	292			
Treatment rate ratio					
Insulin icodec / Daily basal insulin			2.08	[0.39 ; 10.96]	0.3889
Severe (level 3) or clinically significant (level 2) hypoglycaemia					
Treatment					
Insulin icodec	290	290			
Daily basal insulin	292	292			
Treatment rate ratio					
Insulin icodec / Daily basal insulin			1.89	[1.54 ; 2.33]	<0.0001

BG: Blood glucose, CI: Confidence interval, FAS: Number of subjects in full analysis set, N: Number of subjects contributing to the analysis. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. P-value: Two-sided p-value for test of no treatment difference. No correction for multiplicity. The number of events is analysed using a negative binomial regression model (log link) with treatment, region and, if applicable, additional relevant factors as fixed factors, and the logarithm of the time period for which the events are considered as an offset. Missing data are imputed using multiple imputation, assuming that event rate before follow-up 2 visit follows the respective treatment group's rate while the event rate after follow-up 2 visit is the rate of the comparator group. Each imputed dataset is analysed separately and estimates are combined using Rubin's rules. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

7.4.10 Nocturnal hypoglycaemic episodes by trial - on-treatment/main-on-treatment - supportive statistical analysis - full analysis set

	FAS	N	Estimate	95% CI	p-value
ONWARDS 1					
Clinically significant hypoglycaemia (level 2)					
Treatment					
Insulin icodec	492	492			
Daily basal insulin	492	492			
Treatment rate ratio					
Insulin icodec / Daily basal insulin			0.92	[0.29 ; 2.86]	0.8816
Severe (level 3) or clinically significant (level 2) hypoglycaemia					
Treatment					
Insulin icodec	492	492			
Daily basal insulin	492	492			
Treatment rate ratio					
Insulin icodec / Daily basal insulin			0.88	[0.29 ; 2.64]	0.8189
ONWARDS 2					
Clinically significant hypoglycaemia (level 2)					
Treatment					
Insulin icodec	263	263			
Daily basal insulin	263	263			
Treatment rate ratio					
Insulin icodec / Daily basal insulin			2.38	[0.87 ; 6.51]	0.0900
Severe (level 3) or clinically significant (level 2) hypoglycaemia					
Treatment					
Insulin icodec	263	263			
Daily basal insulin	263	263			
Treatment rate ratio					
Insulin icodec / Daily basal insulin			2.38	[0.87 ; 6.51]	0.0900


BG: Blood glucose, CI: Confidence interval, FAS: Number of subjects in full analysis set, N: Number of subjects contributing to the analysis. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. P-value: Two-sided p-value for test of no treatment difference. No correction for multiplicity. The number of events is analysed using a negative binomial regression model (log link) with treatment, region and, if applicable, additional relevant factors as fixed factors, and the logarithm of the time period for which the events are considered as an offset. Missing data are imputed using multiple imputation, assuming that event rate before follow-up 2 visit follows the respective treatment group's rate while the event rate after follow-up 2 visit is the rate of the comparator group. Each imputed dataset is analysed separately and estimates are combined using Rubin's rules. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6. Nocturnal: The period between 00:01 and 05:59 (both included).

Nocturnal hypoglycaemic episodes by trial - on-treatment/main-on-treatment - supportive statistical analysis - full analysis set

	FAS	N	Estimate	95% CI	p-value
ONWARDS 4					
Clinically significant hypoglycaemia (level 2)					
Treatment					
Insulin icodec	291	291			
Daily basal insulin	291	291			
Treatment rate ratio					
Insulin icodec / Daily basal insulin			0.74	[0.47 ; 1.15]	0.1818
Severe (level 3) or clinically significant (level 2) hypoglycaemia					
Treatment					
Insulin icodec	291	291			
Daily basal insulin	291	291			
Treatment rate ratio					
Insulin icodec / Daily basal insulin			0.73	[0.47 ; 1.14]	0.1694
ONWARDS 6					
Clinically significant hypoglycaemia (level 2)					
Treatment					
Insulin icodec	290	290			
Daily basal insulin	292	292			
Treatment rate ratio					
Insulin icodec / Daily basal insulin			2.13	[1.56 ; 2.91]	<0.0001
Severe (level 3) or clinically significant (level 2) hypoglycaemia					
Treatment					
Insulin icodec	290	290			
Daily basal insulin	292	292			
Treatment rate ratio					
Insulin icodec / Daily basal insulin			2.13	[1.56 ; 2.91]	<0.0001

BG: Blood glucose, CI: Confidence interval, FAS: Number of subjects in full analysis set, N: Number of subjects contributing to the analysis. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. P-value: Two-sided p-value for test of no treatment difference. No correction for multiplicity. The number of events is analysed using a negative binomial regression model (log link) with treatment, region and, if applicable, additional relevant factors as fixed factors, and the logarithm of the time period for which the events are considered as an offset. Missing data are imputed using multiple imputation, assuming that event rate before follow-up 2 visit follows the respective treatment group's rate while the event rate after follow-up 2 visit is the rate of the comparator group. Each imputed dataset is analysed separately and estimates are combined using Rubin's rules. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6. Nocturnal: The period between 00:01 and 05:59 (both included).

7.4.11 Severe (level 3) or clinically significant hypoglycaemia (level 2) by trial - ONWARDS 1-5 - on-treatment/main-on-treatment - mean cumulative function - safety analysis set




BG: Blood glucose. Safety analysis set. Observed data. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. OD analogues: Once-daily basal insulin analogues (IDeg, IGlar U100, IGlar U300). Data from ONWARDS 1-5, only main part of ONWARDS 1.

adsl.xpt; variable(s): TRTA TRTAN OTMTDURD SAFFL STDNM STDNMN USUBJID; criteria: SAFFL == "Y"
adhypo.xpt; variable(s): TRTA TRTAN ANL06FL ANELFL SAFFL NOCTFL ACAT4N STDNM STDNMN ASTDY USUBJID; criteria: SAFFL == "Y" & ACAT4N %in% (2:3) & ANELFL == "Y" & ANL06FL == "Y" & STDNMN %in% c(1, 2, 3, 4, 5)

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:12:59:32 - fhypomcfow15/fhypolev23mcfow15ontsas.png

7.4.12 Severe (level 3) or clinically significant hypoglycaemia (level 2) - ONWARDS 6 - main-on-treatment - mean cumulative function - safety analysis set




BG: Blood glucose. Safety analysis set. Observed data. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. Data from main part of ONWARDS 6.

adsl.xpt; variable(s): TRTA TRTAN STDNM STDNMN MONTDURD USUBJID; criteria: SAFFL == "Y"
adhypo.xpt; variable(s): TRTA TRTAN ANL06FL ANELFL SAFFL NOCTFL ACAT4N STDNM STDNMN ASTDY USUBJID; criteria: SAFFL == "Y" & ACAT4N %in% (2:3) & ANELFL == "Y" & ANL06FL == "Y" & STDNMN == 6

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:12:59:54 - fhypomcfow6/fhypolev23mcfow6ontsas.png

7.4.13 Nocturnal severe (level 3) or clinically significant hypoglycaemia (level 2) by trial - ONWARDS 1-5 - on-treatment/main-on-treatment - mean cumulative function - safety analysis set




BG: Blood glucose. Safety analysis set. Observed data. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. OD analogues: Once-daily basal insulin analogues (IDeg, IGlar U100, IGlar U300). Data from ONWARDS 1-5, only main part of ONWARDS 1. Nocturnal: The period between 00:01 and 05:59 (both included).

adsl.xpt; variable(s): TRTA TRTAN OTMTDURD SAFFL STDNM STDNMN USUBJID; criteria: SAFFL == "Y"
adhypo.xpt; variable(s): TRTA TRTAN ANL06FL ANELFL SAFFL NOCTFL ACAT4N STDNM STDNMN ASTDY USUBJID; criteria: SAFFL == "Y" & ACAT4N %in% (2:3) & ANELFL == "Y" & ANL06FL == "Y" & NOCTFL == "Y" & STDNMN %in% c(1, 2, 3, 4, 5)

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:12:59:35 - fhypomcfow15/fhyponoctlev23mcfow15ontsas.png

7.4.14 Nocturnal severe (level 3) or clinically significant hypoglycaemia (level 2) - ONWARDS 6 - main-on-treatment - mean cumulative function - safety analysis set



BG: Blood glucose. Safety analysis set. Observed data. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. Data from main part of ONWARDS 6. Nocturnal: The period between 00:01 and 05:59 (both included).

adsl.xpt; variable(s): TRTA TRTAN STDNM STDNMN MONTDURD USUBJID; criteria: SAFFL == "Y"
adhypo.xpt; variable(s): TRTA TRTAN ANL06FL ANELFL SAFFL NOCTFL ACAT4N STDNM STDNMN ASTDY USUBJID; criteria: SAFFL == "Y" & ACAT4N %in% (2:3) & ANELFL == "Y" & ANL06FL == "Y" & NOCTFL == "Y" & STDNMN == 6

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:12:59:57 - fhypomcfow6/fhyponoctlev23mcfow6ontsas.png

7.4.15 Hypoglycaemic episodes by trial, classification and baseline renal function - on-treatment/main-on- treatment - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
ONWARDS 1								
Number of subjects	492				492			
Number of subjects (Normal)	224				222			
Number of subjects (Mild)	223				213			
Number of subjects (Moderate)	45				56			
Number of subjects (Severe)	0				1			
Number of subjects (Missing)	0				0			
PYE	485.88				485.03			
PYE (Normal)	221.46				220.19			
PYE (Mild)	220.61				210.98			
PYE (Moderate)	43.81				52.87			
PYE (Severe)	0				1.00			
PYE (Missing)	0				0			
Hypoglycaemia alert value (level 1)	232	(47.2)	1447	297.81	191	(38.8)	631	130.09
Normal	101	(45.1)	590	266.41	84	(37.8)	299	135.79
Mild impairment	107	(48.0)	723	327.73	86	(40.4)	271	128.45
Moderate impairment	24	(53.3)	134	305.88	21	(37.5)	61	115.38
Severe impairment	0				0			
Missing	0				0			
Clinically significant hypoglycaemia (level 2)	48	(9.8)	143	29.43	49	(10.0)	75	15.46
Normal	22	(9.8)	33	14.90	26	(11.7)	41	18.62
Mild impairment	21	(9.4)	98	44.42	17	(8.0)	28	13.27
Moderate impairment	5	(11.1)	12	27.39	6	(10.7)	6	11.35
Severe impairment	0				0			
Missing	0				0			
Severe hypoglycaemia (level 3)	1	(0.2)	1	0.21	3	(0.6)	3	0.62
Normal	1	(0.4)	1	0.45	1	(0.5)	1	0.45
Mild impairment	0				1	(0.5)	1	0.47
Moderate impairment	0				1	(1.8)	1	1.89
Severe impairment	0				0			
Missing	0				0			
Severe (level 3) or clinically significant (level 2) hypoglycaemia	48	(9.8)	144	29.64	52	(10.6)	78	16.08
Normal	22	(9.8)	34	15.35	27	(12.2)	42	19.07
Mild impairment	21	(9.4)	98	44.42	18	(8.5)	29	13.75
Moderate impairment	5	(11.1)	12	27.39	7	(12.5)	7	13.24
Severe impairment	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, BG: Blood glucose, E: Number of events, eGFR: Estimated glomerular filtration rate (mL/min/1.73m^2), N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Renal function categories are based on eGFR derived using the 2009 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation. Categories are coded as normal (eGFR>=90), mild impairment (60<=eGFR<90), moderate impairment (30<=eGFR<60), and severe impairment (eGFR<30). Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. A hypoglycaemia alert value (level 1) was excluded from each of ONWARDS 1 and 6 as these had been erroneously included in trial clinical trial reports. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

adsl.xpt; variable(s): STDNM OTMTDURY GFRGR1; criteria: SAFFL == "Y"
adhypo.xpt; variable(s): STDNM ACAT4; criteria: SAFFL == "Y" & ANL06FL == "Y" & ANELFL == "Y"
nn1436/nn1436-iss/submission_20221024_er
05DEC2022:12:57:33 - thypogrp/thyporenalsumontsas.txt

Hypoglycaemic episodes by trial, classification and baseline renal function - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
ONWARDS 2								
Number of subjects	262				263			
Number of subjects (Normal)	94				109			
Number of subjects (Mild)	134				108			
Number of subjects (Moderate)	34				46			
Number of subjects (Severe)	0				0			
Number of subjects (Missing)	0				0			
PYE	155.25				152.77			
PYE (Normal)	55.36				62.74			
PYE (Mild)	80.04				63.33			
PYE (Moderate)	19.84				26.70			
PYE (Severe)	0				0			
PYE (Missing)	0				0			
Hypoglycaemia alert value (level 1)	145	(55.3)	1209	778.76	118	(44.9)	589	385.54
Normal	50	(53.2)	454	820.10	44	(40.4)	217	345.90
Mild impairment	74	(55.2)	548	684.63	46	(42.6)	214	337.90
Moderate impairment	21	(61.8)	207	1043.14	28	(60.9)	158	591.65
Severe impairment	0				0			
Missing	0				0			
Clinically significant hypoglycaemia (level 2)	37	(14.1)	113	72.79	19	(7.2)	41	26.84
Normal	13	(13.8)	42	75.87	8	(7.3)	18	28.69
Mild impairment	15	(11.2)	53	66.21	7	(6.5)	12	18.95
Moderate impairment	9	(26.5)	18	90.71	4	(8.7)	11	41.19
Severe impairment	0				0			
Missing	0				0			
Severe hypoglycaemia (level 3)	0				1	(0.4)	1	0.65
Normal	0				0			
Mild impairment	0				0			
Moderate impairment	0				1	(2.2)	1	3.74
Severe impairment	0				0			
Missing	0				0			
Severe (level 3) or clinically significant (level 2) hypoglycaemia	37	(14.1)	113	72.79	19	(7.2)	42	27.49
Normal	13	(13.8)	42	75.87	8	(7.3)	18	28.69
Mild impairment	15	(11.2)	53	66.21	7	(6.5)	12	18.95
Moderate impairment	9	(26.5)	18	90.71	4	(8.7)	12	44.94
Severe impairment	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, BG: Blood glucose, E: Number of events, eGFR: Estimated glomerular filtration rate (mL/min/1.73m^2), N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Renal function categories are based on eGFR derived using the 2009 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation. Categories are coded as normal (eGFR>=90), mild impairment (60<=eGFR<90), moderate impairment (30<=eGFR<60), and severe impairment (eGFR<30). Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. A hypoglycaemia alert value (level 1) was excluded from each of ONWARDS 1 and 6 as these had been erroneously included in trial clinical trial reports. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Hypoglycaemic episodes by trial, classification and baseline renal function - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
ONWARDS 3								
Number of subjects	293				294			
Number of subjects (Normal)	172				185			
Number of subjects (Mild)	97				88			
Number of subjects (Moderate)	23				21			
Number of subjects (Severe)	0				0			
Number of subjects (Missing)	1				0			
PYE	170.90				171.13			
PYE (Normal)	100.31				107.95			
PYE (Mild)	57.25				51.32			
PYE (Moderate)	12.77				11.87			
PYE (Severe)	0				0			
PYE (Missing)	0.58				0			
Hypoglycaemia alert value (level 1)	91	(31.1)	400	234.06	65	(22.1)	185	108.10
Normal	54	(31.4)	259	258.20	38	(20.5)	107	99.12
Mild impairment	27	(27.8)	87	151.98	18	(20.5)	49	95.48
Moderate impairment	10	(43.5)	54	422.98	9	(42.9)	29	244.34
Severe impairment	0				0			
Missing	0				0			
Clinically significant hypoglycaemia (level 2)	26	(8.9)	53	31.01	17	(5.8)	23	13.44
Normal	14	(8.1)	35	34.89	10	(5.4)	15	13.90
Mild impairment	5	(5.2)	10	17.47	6	(6.8)	7	13.64
Moderate impairment	7	(30.4)	8	62.66	1	(4.8)	1	8.43
Severe impairment	0				0			
Missing	0				0			
Severe hypoglycaemia (level 3)	0				2	(0.7)	2	1.17
Normal	0				1	(0.5)	1	0.93
Mild impairment	0				0			
Moderate impairment	0				1	(4.8)	1	8.43
Severe impairment	0				0			
Missing	0				0			
Severe (level 3) or clinically significant (level 2) hypoglycaemia	26	(8.9)	53	31.01	18	(6.1)	25	14.61
Normal	14	(8.1)	35	34.89	10	(5.4)	16	14.82
Mild impairment	5	(5.2)	10	17.47	6	(6.8)	7	13.64
Moderate impairment	7	(30.4)	8	62.66	2	(9.5)	2	16.85
Severe impairment	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, BG: Blood glucose, E: Number of events, eGFR: Estimated glomerular filtration rate (mL/min/1.73m^2), N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Renal function categories are based on eGFR derived using the 2009 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation. Categories are coded as normal (eGFR>=90), mild impairment (60<=eGFR<90), moderate impairment (30<=eGFR<60), and severe impairment (eGFR<30). Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. A hypoglycaemia alert value (level 1) was excluded from each of ONWARDS 1 and 6 as these had been erroneously included in trial clinical trial reports. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

adsl.xpt; variable(s): STDNM OTMTDURY GFRGR1; criteria: SAFFL == "Y"
adhypo.xpt; variable(s): STDNM ACAT4; criteria: SAFFL == "Y" & ANL06FL == "Y" & ANELFL == "Y"
nn1436/nn1436-iss/submission_20221024_er
05DEC2022:12:57:33 - thypogrp/thyporenalsumontsas.txt

Hypoglycaemic episodes by trial, classification and baseline renal function - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
ONWARDS 4								
Number of subjects	291				291			
Number of subjects (Normal)	123				127			
Number of subjects (Mild)	121				120			
Number of subjects (Moderate)	47				44			
Number of subjects (Severe)	0				0			
Number of subjects (Missing)	0				0			
PYE	167.36				166.80			
PYE (Normal)	70.74				72.58			
PYE (Mild)	69.79				70.23			
PYE (Moderate)	26.83				23.99			
PYE (Severe)	0				0			
PYE (Missing)	0				0			
Hypoglycaemia alert value (level 1)	244	(83.8)	5264	3145.28	251	(86.3)	4145	2485.04
Normal	97	(78.9)	2074	2931.73	111	(87.4)	1896	2612.37
Mild impairment	104	(86.0)	2269	3251.28	107	(89.2)	1631	2322.32
Moderate impairment	43	(91.5)	921	3432.60	33	(75.0)	618	2576.18
Severe impairment	0				0			
Missing	0				0			
Clinically significant hypoglycaemia (level 2)	148	(50.9)	937	559.86	160	(55.0)	935	560.56
Normal	57	(46.3)	409	578.15	67	(52.8)	368	507.04
Mild impairment	64	(52.9)	379	543.07	70	(58.3)	384	546.76
Moderate impairment	27	(57.4)	149	555.33	23	(52.3)	183	762.85
Severe impairment	0				0			
Missing	0				0			
Severe hypoglycaemia (level 3)	4	(1.4)	7	4.18	2	(0.7)	3	1.80
Normal	2	(1.6)	5	7.07	1	(0.8)	2	2.76
Mild impairment	2	(1.7)	2	2.87	0			
Moderate impairment	0				1	(2.3)	1	4.17
Severe impairment	0				0			
Missing	0				0			
Severe (level 3) or clinically significant (level 2) hypoglycaemia	150	(51.5)	944	564.05	162	(55.7)	938	562.36
Normal	58	(47.2)	414	585.21	68	(53.5)	370	509.80
Mild impairment	65	(53.7)	381	545.94	70	(58.3)	384	546.76
Moderate impairment	27	(57.4)	149	555.33	24	(54.5)	184	767.02
Severe impairment	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, BG: Blood glucose, E: Number of events, eGFR: Estimated glomerular filtration rate (mL/min/1.73m^2), N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Renal function categories are based on eGFR derived using the 2009 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation. Categories are coded as normal (eGFR>=90), mild impairment (60<=eGFR<90), moderate impairment (30<=eGFR<60), and severe impairment (eGFR<30). Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. A hypoglycaemia alert value (level 1) was excluded from each of ONWARDS 1 and 6 as these had been erroneously included in trial clinical trial reports. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Hypoglycaemic episodes by trial, classification and baseline renal function - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
ONWARDS 5								
Number of subjects	542				538			
Number of subjects (Normal)	311				304			
Number of subjects (Mild)	174				169			
Number of subjects (Moderate)	52				61			
Number of subjects (Severe)	5				3			
Number of subjects (Missing)	0				1			
PYE	559.54				560.72			
PYE (Normal)	322.96				320.02			
PYE (Mild)	178.95				173.75			
PYE (Moderate)	52.57				63.33			
PYE (Severe)	5.06				3.29			
PYE (Missing)	0				0.33			
Hypoglycaemia alert value (level 1)	200	(36.9)	1028	183.72	153	(28.4)	851	151.77
Normal	112	(36.0)	535	165.65	80	(26.3)	439	137.18
Mild impairment	63	(36.2)	357	199.50	48	(28.4)	313	180.14
Moderate impairment	23	(44.2)	120	228.28	25	(41.0)	99	156.32
Severe impairment	2	(40.0)	16	316.06	0			
Missing	0				0			
Clinically significant hypoglycaemia (level 2)	64	(11.8)	104	18.59	42	(7.8)	76	13.55
Normal	35	(11.3)	47	14.55	23	(7.6)	35	10.94
Mild impairment	20	(11.5)	45	25.15	12	(7.1)	32	18.42
Moderate impairment	8	(15.4)	11	20.93	7	(11.5)	9	14.21
Severe impairment	1	(20.0)	1	19.75	0			
Missing	0				0			
Severe hypoglycaemia (level 3)	0				4	(0.7)	5	0.89
Normal	0				3	(1.0)	4	1.25
Mild impairment	0				0			
Moderate impairment	0				1	(1.6)	1	1.58
Severe impairment	0				0			
Missing	0				0			
Severe (level 3) or clinically significant (level 2) hypoglycaemia	64	(11.8)	104	18.59	45	(8.4)	81	14.45
Normal	35	(11.3)	47	14.55	25	(8.2)	39	12.19
Mild impairment	20	(11.5)	45	25.15	12	(7.1)	32	18.42
Moderate impairment	8	(15.4)	11	20.93	8	(13.1)	10	15.79
Severe impairment	1	(20.0)	1	19.75	0			
Missing	0				0			

%: Percentage of subjects with one or more events, BG: Blood glucose, E: Number of events, eGFR: Estimated glomerular filtration rate (mL/min/1.73m^2), N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Renal function categories are based on eGFR derived using the 2009 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation. Categories are coded as normal (eGFR>=90), mild impairment (60<=eGFR<90), moderate impairment (30<=eGFR<60), and severe impairment (eGFR<30). Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. A hypoglycaemia alert value (level 1) was excluded from each of ONWARDS 1 and 6 as these had been erroneously included in trial clinical trial reports. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Hypoglycaemic episodes by trial, classification and baseline renal function - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
ONWARDS 6								
Number of subjects	290				292			
Number of subjects (Normal)	197				190			
Number of subjects (Mild)	88				93			
Number of subjects (Moderate)	5				9			
Number of subjects (Severe)	0				0			
Number of subjects (Missing)	0				0			
PYE	142.31				144.12			
PYE (Normal)	97.36				93.48			
PYE (Mild)	42.42				46.13			
PYE (Moderate)	2.54				4.51			
PYE (Severe)	0				0			
PYE (Missing)	0				0			
Hypoglycaemia alert value (level 1)	288	(99.3)	10799	7588.47	287	(98.3)	7401	5135.29
Normal	197	(100.0)	7370	7570.21	187	(98.4)	4881	5221.22
Mild impairment	87	(98.9)	3188	7515.76	91	(97.8)	2346	5085.92
Moderate impairment	4	(80.0)	241	9505.97	9	(100.0)	174	3858.74
Severe impairment	0				0			
Missing	0				0			
Clinically significant hypoglycaemia (level 2)	246	(84.8)	2789	1959.83	223	(76.4)	1478	1025.53
Normal	169	(85.8)	1878	1929.02	151	(79.5)	963	1030.12
Mild impairment	75	(85.2)	873	2058.11	66	(71.0)	488	1057.94
Moderate impairment	2	(40.0)	38	1498.87	6	(66.7)	27	598.77
Severe impairment	0				0			
Missing	0				0			
Severe hypoglycaemia (level 3)	9	(3.1)	47	33.03	9	(3.1)	17	11.80
Normal	6	(3.0)	41	42.11	8	(4.2)	16	17.12
Mild impairment	3	(3.4)	6	14.15	1	(1.1)	1	2.17
Moderate impairment	0				0			
Severe impairment	0				0			
Missing	0				0			
Severe (level 3) or clinically significant (level 2) hypoglycaemia	247	(85.2)	2836	1992.86	223	(76.4)	1495	1037.33
Normal	170	(86.3)	1919	1971.13	151	(79.5)	979	1047.24
Mild impairment	75	(85.2)	879	2072.26	66	(71.0)	489	1060.11
Moderate impairment	2	(40.0)	38	1498.87	6	(66.7)	27	598.77
Severe impairment	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, BG: Blood glucose, E: Number of events, eGFR: Estimated glomerular filtration rate (mL/min/1.73m^2), N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Renal function categories are based on eGFR derived using the 2009 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation. Categories are coded as normal (eGFR>=90), mild impairment (60<=eGFR<90), moderate impairment (30<=eGFR<60), and severe impairment (eGFR<30). Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. A hypoglycaemia alert value (level 1) was excluded from each of ONWARDS 1 and 6 as these had been erroneously included in trial clinical trial reports. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

7.4.16 Hypoglycaemic episodes by trial, classification and baseline BMI group - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
ONWARDS 1								
Number of subjects	492				492			
Number of subjects (<25)	87				80			
Number of subjects (>=25 - <30)	164				171			
Number of subjects (>=30 - <35)	162				146			
Number of subjects (>=35)	79				95			
Number of subjects (Missing)	0				0			
PYE	485.88				485.03			
PYE (<25)	86.05				77.29			
PYE (>=25 - <30)	162.45				170.12			
PYE (>=30 - <35)	160.04				144.48			
PYE (>=35)	77.33				93.15			
PYE (Missing)	0				0			
Hypoglycaemia alert value (level 1)	232	(47.2)	1447	297.81	191	(38.8)	631	130.09
<25	58	(66.7)	515	598.47	46	(57.5)	194	251.01
>=25 - <30	84	(51.2)	405	249.30	70	(40.9)	217	127.56
>=30 - <35	58	(35.8)	305	190.58	49	(33.6)	154	106.59
>=35	32	(40.5)	222	287.07	26	(27.4)	66	70.86
Missing	0				0			
Clinically significant hypoglycaemia (level 2)	48	(9.8)	143	29.43	49	(10.0)	75	15.46
<25	6	(6.9)	50	58.10	12	(15.0)	21	27.17
>=25 - <30	20	(12.2)	32	19.70	16	(9.4)	22	12.93
>=30 - <35	16	(9.9)	28	17.50	11	(7.5)	16	11.07
>=35	6	(7.6)	33	42.67	10	(10.5)	16	17.18
Missing	0				0			
Severe hypoglycaemia (level 3)	1	(0.2)	1	0.21	3	(0.6)	3	0.62
<25	1	(1.1)	1	1.16	0			
>=25 - <30	0				1	(0.6)	1	0.59
>=30 - <35	0				1	(0.7)	1	0.69
>=35	0				1	(1.1)	1	1.07
Missing	0				0			
Severe (level 3) or clinically significant (level 2) hypoglycaemia	48	(9.8)	144	29.64	52	(10.6)	78	16.08
<25	6	(6.9)	51	59.27	12	(15.0)	21	27.17
>=25 - <30	20	(12.2)	32	19.70	17	(9.9)	23	13.52
>=30 - <35	16	(9.9)	28	17.50	12	(8.2)	17	11.77
>=35	6	(7.6)	33	42.67	11	(11.6)	17	18.25
Missing	0				0			

%: Percentage of subjects with one or more events, BG: Blood glucose, BMI: Body mass index (kg/m^2), E: Number of events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. A hypoglycaemia alert value (level 1) was excluded from each of ONWARDS 1 and 6 as these had been erroneously included in trial clinical trial reports. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Hypoglycaemic episodes by trial, classification and baseline BMI group - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
ONWARDS 2								
Number of subjects	262				263			
Number of subjects (<25)	54				56			
Number of subjects (>=25 - <30)	92				104			
Number of subjects (>=30 - <35)	69				63			
Number of subjects (>=35)	47				40			
Number of subjects (Missing)	0				0			
PYE	155.25				152.77			
PYE (<25)	31.79				31.52			
PYE (>=25 - <30)	54.34				60.73			
PYE (>=30 - <35)	40.99				37.01			
PYE (>=35)	28.12				23.50			
PYE (Missing)	0				0			
Hypoglycaemia alert value (level 1)	145	(55.3)	1209	778.76	118	(44.9)	589	385.54
<25	32	(59.3)	219	688.85	25	(44.6)	139	440.94
>=25 - <30	56	(60.9)	524	964.28	40	(38.5)	187	307.92
>=30 - <35	33	(47.8)	229	558.62	33	(52.4)	160	432.28
>=35	24	(51.1)	237	842.80	20	(50.0)	103	438.21
Missing	0				0			
Clinically significant hypoglycaemia (level 2)	37	(14.1)	113	72.79	19	(7.2)	41	26.84
<25	5	(9.3)	6	18.87	7	(12.5)	14	44.41
>=25 - <30	19	(20.7)	54	99.37	7	(6.7)	15	24.70
>=30 - <35	7	(10.1)	10	24.39	3	(4.8)	3	8.11
>=35	6	(12.8)	43	152.91	2	(5.0)	9	38.29
Missing	0				0			
Severe hypoglycaemia (level 3)	0				1	(0.4)	1	0.65
<25	0				0			
>=25 - <30	0				0			
>=30 - <35	0				0			
>=35	0				1	(2.5)	1	4.25
Missing	0				0			
Severe (level 3) or clinically significant (level 2) hypoglycaemia	37	(14.1)	113	72.79	19	(7.2)	42	27.49
<25	5	(9.3)	6	18.87	7	(12.5)	14	44.41
>=25 - <30	19	(20.7)	54	99.37	7	(6.7)	15	24.70
>=30 - <35	7	(10.1)	10	24.39	3	(4.8)	3	8.11
>=35	6	(12.8)	43	152.91	2	(5.0)	10	42.55
Missing	0				0			

%: Percentage of subjects with one or more events, BG: Blood glucose, BMI: Body mass index (kg/m^2), E: Number of events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. A hypoglycaemia alert value (level 1) was excluded from each of ONWARDS 1 and 6 as these had been erroneously included in trial clinical trial reports. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Hypoglycaemic episodes by trial, classification and baseline BMI group - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
ONWARDS 3								
Number of subjects	293				294			
Number of subjects (<25)	52				58			
Number of subjects (>=25 - <30)	108				121			
Number of subjects (>=30 - <35)	76				70			
Number of subjects (>=35)	57				45			
Number of subjects (Missing)	0				0			
PYE	170.90				171.13			
PYE (<25)	29.47				33.79			
PYE (>=25 - <30)	63.50				70.01			
PYE (>=30 - <35)	43.93				40.51			
PYE (>=35)	34.00				26.82			
PYE (Missing)	0				0			
Hypoglycaemia alert value (level 1)	91	(31.1)	400	234.06	65	(22.1)	185	108.10
<25	22	(42.3)	114	386.87	20	(34.5)	68	201.24
>=25 - <30	41	(38.0)	209	329.15	27	(22.3)	71	101.41
>=30 - <35	16	(21.1)	30	68.28	8	(11.4)	26	64.18
>=35	12	(21.1)	47	138.23	10	(22.2)	20	74.56
Missing	0				0			
Clinically significant hypoglycaemia (level 2)	26	(8.9)	53	31.01	17	(5.8)	23	13.44
<25	5	(9.6)	20	67.87	6	(10.3)	8	23.68
>=25 - <30	13	(12.0)	23	36.22	6	(5.0)	9	12.85
>=30 - <35	3	(3.9)	5	11.38	3	(4.3)	3	7.41
>=35	5	(8.8)	5	14.71	2	(4.4)	3	11.18
Missing	0				0			
Severe hypoglycaemia (level 3)	0				2	(0.7)	2	1.17
<25	0				0			
>=25 - <30	0				1	(0.8)	1	1.43
>=30 - <35	0				1	(1.4)	1	2.47
>=35	0				0			
Missing	0				0			
Severe (level 3) or clinically significant (level 2) hypoglycaemia	26	(8.9)	53	31.01	18	(6.1)	25	14.61
<25	5	(9.6)	20	67.87	6	(10.3)	8	23.68
>=25 - <30	13	(12.0)	23	36.22	6	(5.0)	10	14.28
>=30 - <35	3	(3.9)	5	11.38	4	(5.7)	4	9.87
>=35	5	(8.8)	5	14.71	2	(4.4)	3	11.18
Missing	0				0			

%: Percentage of subjects with one or more events, BG: Blood glucose, BMI: Body mass index (kg/m^2), E: Number of events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. A hypoglycaemia alert value (level 1) was excluded from each of ONWARDS 1 and 6 as these had been erroneously included in trial clinical trial reports. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Hypoglycaemic episodes by trial, classification and baseline BMI group - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
ONWARDS 4								
Number of subjects	291				291			
Number of subjects (<25)	42				49			
Number of subjects (>=25 - <30)	95				96			
Number of subjects (>=30 - <35)	93				99			
Number of subjects (>=35)	61				47			
Number of subjects (Missing)	0				0			
PYE	167.36				166.80			
PYE (<25)	23.95				28.37			
PYE (>=25 - <30)	55.61				54.86			
PYE (>=30 - <35)	53.13				56.58			
PYE (>=35)	34.67				26.99			
PYE (Missing)	0				0			
Hypoglycaemia alert value (level 1)	244	(83.8)	5264	3145.28	251	(86.3)	4145	2485.04
<25	39	(92.9)	1053	4397.03	47	(95.9)	884	3116.01
>=25 - <30	81	(85.3)	1899	3414.95	79	(82.3)	1559	2841.87
>=30 - <35	74	(79.6)	1397	2629.36	83	(83.8)	1246	2202.28
>=35	50	(82.0)	915	2638.80	42	(89.4)	456	1689.36
Missing	0				0			
Clinically significant hypoglycaemia (level 2)	148	(50.9)	937	559.86	160	(55.0)	935	560.56
<25	30	(71.4)	243	1014.70	33	(67.3)	243	856.55
>=25 - <30	52	(54.7)	336	604.22	55	(57.3)	345	628.89
>=30 - <35	44	(47.3)	215	404.66	49	(49.5)	274	484.29
>=35	22	(36.1)	143	412.40	23	(48.9)	73	270.45
Missing	0				0			
Severe hypoglycaemia (level 3)	4	(1.4)	7	4.18	2	(0.7)	3	1.80
<25	1	(2.4)	1	4.18	0			
>=25 - <30	0				0			
>=30 - <35	1	(1.1)	3	5.65	2	(2.0)	3	5.30
>=35	2	(3.3)	3	8.65	0			
Missing	0				0			
Severe (level 3) or clinically significant (level 2) hypoglycaemia	150	(51.5)	944	564.05	162	(55.7)	938	562.36
<25	30	(71.4)	244	1018.88	33	(67.3)	243	856.55
>=25 - <30	52	(54.7)	336	604.22	55	(57.3)	345	628.89
>=30 - <35	44	(47.3)	218	410.31	51	(51.5)	277	489.59
>=35	24	(39.3)	146	421.05	23	(48.9)	73	270.45
Missing	0				0			

%: Percentage of subjects with one or more events, BG: Blood glucose, BMI: Body mass index (kg/m^2), E: Number of events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. A hypoglycaemia alert value (level 1) was excluded from each of ONWARDS 1 and 6 as these had been erroneously included in trial clinical trial reports. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Hypoglycaemic episodes by trial, classification and baseline BMI group - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
ONWARDS 5								
Number of subjects	542				538			
Number of subjects (<25)	54				51			
Number of subjects (>=25 - <30)	159				153			
Number of subjects (>=30 - <35)	154				153			
Number of subjects (>=35)	175				180			
Number of subjects (Missing)	0				1			
PYE	559.54				560.72			
PYE (<25)	55.46				53.66			
PYE (>=25 - <30)	166.46				162.08			
PYE (>=30 - <35)	157.27				159.61			
PYE (>=35)	180.35				184.26			
PYE (Missing)	0				1.11			
Hypoglycaemia alert value (level 1)	200	(36.9)	1028	183.72	153	(28.4)	851	151.77
<25	24	(44.4)	135	243.44	26	(51.0)	187	348.48
>=25 - <30	71	(44.7)	365	219.27	42	(27.5)	282	173.99
>=30 - <35	53	(34.4)	272	172.95	41	(26.8)	206	129.06
>=35	52	(29.7)	256	141.94	43	(23.9)	174	94.43
Missing	0				1	(100.0)	2	179.93
Clinically significant hypoglycaemia (level 2)	64	(11.8)	104	18.59	42	(7.8)	76	13.55
<25	11	(20.4)	15	27.05	5	(9.8)	5	9.32
>=25 - <30	20	(12.6)	31	18.62	12	(7.8)	29	17.89
>=30 - <35	15	(9.7)	29	18.44	9	(5.9)	15	9.40
>=35	18	(10.3)	29	16.08	16	(8.9)	27	14.65
Missing	0				0			
Severe hypoglycaemia (level 3)	0				4	(0.7)	5	0.89
<25	0				0			
>=25 - <30	0				0			
>=30 - <35	0				2	(1.3)	2	1.25
>=35	0				2	(1.1)	3	1.63
Missing	0				0			
Severe (level 3) or clinically significant (level 2) hypoglycaemia	64	(11.8)	104	18.59	45	(8.4)	81	14.45
<25	11	(20.4)	15	27.05	5	(9.8)	5	9.32
>=25 - <30	20	(12.6)	31	18.62	12	(7.8)	29	17.89
>=30 - <35	15	(9.7)	29	18.44	11	(7.2)	17	10.65
>=35	18	(10.3)	29	16.08	17	(9.4)	30	16.28
Missing	0				0			

%: Percentage of subjects with one or more events, BG: Blood glucose, BMI: Body mass index (kg/m^2), E: Number of events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. A hypoglycaemia alert value (level 1) was excluded from each of ONWARDS 1 and 6 as these had been erroneously included in trial clinical trial reports. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Hypoglycaemic episodes by trial, classification and baseline BMI group - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
ONWARDS 6								
Number of subjects	290				292			
Number of subjects (<25)	105				135			
Number of subjects (>=25 - <30)	118				102			
Number of subjects (>=30 - <35)	46				41			
Number of subjects (>=35)	21				14			
Number of subjects (Missing)	0				0			
PYE	142.31				144.12			
PYE (<25)	50.77				67.45			
PYE (>=25 - <30)	58.04				49.72			
PYE (>=30 - <35)	23.14				19.93			
PYE (>=35)	10.36				7.01			
PYE (Missing)	0				0			
Hypoglycaemia alert value (level 1)	288	(99.3)	10799	7588.47	287	(98.3)	7401	5135.29
<25	105	(100.0)	4308	8485.21	134	(99.3)	3570	5292.62
>=25 - <30	116	(98.3)	4301	7410.45	99	(97.1)	2692	5414.09
>=30 - <35	46	(100.0)	1416	6119.19	40	(97.6)	828	4154.22
>=35	21	(100.0)	774	7473.00	14	(100.0)	311	4433.75
Missing	0				0			
Clinically significant hypoglycaemia (level 2)	246	(84.8)	2789	1959.83	223	(76.4)	1478	1025.53
<25	95	(90.5)	1069	2105.54	109	(80.7)	703	1042.22
>=25 - <30	97	(82.2)	1213	2089.95	78	(76.5)	540	1086.04
>=30 - <35	36	(78.3)	368	1590.30	26	(63.4)	194	973.33
>=35	18	(85.7)	139	1342.05	10	(71.4)	41	584.51
Missing	0				0			
Severe hypoglycaemia (level 3)	9	(3.1)	47	33.03	9	(3.1)	17	11.80
<25	3	(2.9)	3	5.91	5	(3.7)	13	19.27
>=25 - <30	4	(3.4)	9	15.51	3	(2.9)	3	6.03
>=30 - <35	0				1	(2.4)	1	5.02
>=35	2	(9.5)	35	337.93	0			
Missing	0				0			
Severe (level 3) or clinically significant (level 2) hypoglycaemia	247	(85.2)	2836	1992.86	223	(76.4)	1495	1037.33
<25	95	(90.5)	1072	2111.45	109	(80.7)	716	1061.49
>=25 - <30	98	(83.1)	1222	2105.46	78	(76.5)	543	1092.07
>=30 - <35	36	(78.3)	368	1590.30	26	(63.4)	195	978.35
>=35	18	(85.7)	174	1679.98	10	(71.4)	41	584.51
Missing	0				0			

%: Percentage of subjects with one or more events, BG: Blood glucose, BMI: Body mass index (kg/m^2), E: Number of events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. A hypoglycaemia alert value (level 1) was excluded from each of ONWARDS 1 and 6 as these had been erroneously included in trial clinical trial reports. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

7.4.17 Hypoglycaemic episodes by trial, classification and age group - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
ONWARDS 1								
Number of subjects	492				492			
Number of subjects (>=18 - <65 years)	333				332			
Number of subjects (>=65 - <75 years)	134				144			
Number of subjects (>=75 years)	25				16			
PYE	485.88				485.03			
PYE (>=18 - <65 years)	329.13				329.36			
PYE (>=65 - <75 years)	132.08				140.33			
PYE (>=75 years)	24.67				15.35			
Hypoglycaemia alert value (level 1)	232	(47.2)	1447	297.81	191	(38.8)	631	130.09
>=18 - <65 years	148	(44.4)	961	291.98	129	(38.9)	444	134.81
>=65 - <75 years	71	(53.0)	427	323.29	58	(40.3)	173	123.28
>=75 years	13	(52.0)	59	239.18	4	(25.0)	14	91.21
Clinically significant hypoglycaemia (level 2)	48	(9.8)	143	29.43	49	(10.0)	75	15.46
>=18 - <65 years	32	(9.6)	86	26.13	37	(11.1)	59	17.91
>=65 - <75 years	15	(11.2)	53	40.13	11	(7.6)	14	9.98
>=75 years	1	(4.0)	4	16.22	1	(6.2)	2	13.03
Severe hypoglycaemia (level 3)	1	(0.2)	1	0.21	3	(0.6)	3	0.62
>=18 - <65 years	1	(0.3)	1	0.30	2	(0.6)	2	0.61
>=65 - <75 years	0				1	(0.7)	1	0.71
>=75 years	0				0			
Severe (level 3) or clinically significant (level 2) hypoglycaemia	48	(9.8)	144	29.64	52	(10.6)	78	16.08
>=18 - <65 years	32	(9.6)	87	26.43	39	(11.7)	61	18.52
>=65 - <75 years	15	(11.2)	53	40.13	12	(8.3)	15	10.69
>=75 years	1	(4.0)	4	16.22	1	(6.2)	2	13.03

%: Percentage of subjects with one or more events, BG: Blood glucose, E: Number of events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. A hypoglycaemia alert value (level 1) was excluded from each of ONWARDS 1 and 6 as these had been erroneously included in trial clinical trial reports. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Hypoglycaemic episodes by trial, classification and age group - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
ONWARDS 2								
Number of subjects	262				263			
Number of subjects (>=18 - <65 years)	144				149			
Number of subjects (>=65 - <75 years)	99				99			
Number of subjects (>=75 years)	19				15			
PYE	155.25				152.77			
PYE (>=18 - <65 years)	85.31				87.79			
PYE (>=65 - <75 years)	58.97				56.04			
PYE (>=75 years)	10.97				8.94			
Hypoglycaemia alert value (level 1)	145	(55.3)	1209	778.76	118	(44.9)	589	385.54
>=18 - <65 years	71	(49.3)	571	669.31	67	(45.0)	349	397.53
>=65 - <75 years	60	(60.6)	508	861.53	45	(45.5)	212	378.31
>=75 years	14	(73.7)	130	1184.99	6	(40.0)	28	313.14
Clinically significant hypoglycaemia (level 2)	37	(14.1)	113	72.79	19	(7.2)	41	26.84
>=18 - <65 years	19	(13.2)	75	87.91	10	(6.7)	21	23.92
>=65 - <75 years	15	(15.2)	33	55.97	9	(9.1)	20	35.69
>=75 years	3	(15.8)	5	45.58	0			
Severe hypoglycaemia (level 3)	0				1	(0.4)	1	0.65
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(1.0)	1	1.78
>=75 years	0				0			
Severe (level 3) or clinically significant (level 2) hypoglycaemia	37	(14.1)	113	72.79	19	(7.2)	42	27.49
>=18 - <65 years	19	(13.2)	75	87.91	10	(6.7)	21	23.92
>=65 - <75 years	15	(15.2)	33	55.97	9	(9.1)	21	37.47
>=75 years	3	(15.8)	5	45.58	0			

%: Percentage of subjects with one or more events, BG: Blood glucose, E: Number of events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. A hypoglycaemia alert value (level 1) was excluded from each of ONWARDS 1 and 6 as these had been erroneously included in trial clinical trial reports. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Hypoglycaemic episodes by trial, classification and age group - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
ONWARDS 3								
Number of subjects	293				294			
Number of subjects (>=18 - <65 years)	209				201			
Number of subjects (>=65 - <75 years)	74				84			
Number of subjects (>=75 years)	10				9			
PYE	170.90				171.13			
PYE (>=18 - <65 years)	122.00				116.74			
PYE (>=65 - <75 years)	42.91				49.06			
PYE (>=75 years)	5.99				5.33			
Hypoglycaemia alert value (level 1)	91	(31.1)	400	234.06	65	(22.1)	185	108.10
>=18 - <65 years	63	(30.1)	297	243.44	37	(18.4)	108	92.51
>=65 - <75 years	23	(31.1)	79	184.12	24	(28.6)	68	138.61
>=75 years	5	(50.0)	24	400.64	4	(44.4)	9	168.84
Clinically significant hypoglycaemia (level 2)	26	(8.9)	53	31.01	17	(5.8)	23	13.44
>=18 - <65 years	17	(8.1)	38	31.15	10	(5.0)	16	13.71
>=65 - <75 years	6	(8.1)	8	18.64	6	(7.1)	6	12.23
>=75 years	3	(30.0)	7	116.85	1	(11.1)	1	18.76
Severe hypoglycaemia (level 3)	0				2	(0.7)	2	1.17
>=18 - <65 years	0				1	(0.5)	1	0.86
>=65 - <75 years	0				0			
>=75 years	0				1	(11.1)	1	18.76
Severe (level 3) or clinically significant (level 2) hypoglycaemia	26	(8.9)	53	31.01	18	(6.1)	25	14.61
>=18 - <65 years	17	(8.1)	38	31.15	11	(5.5)	17	14.56
>=65 - <75 years	6	(8.1)	8	18.64	6	(7.1)	6	12.23
>=75 years	3	(30.0)	7	116.85	1	(11.1)	2	37.52

%: Percentage of subjects with one or more events, BG: Blood glucose, E: Number of events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. A hypoglycaemia alert value (level 1) was excluded from each of ONWARDS 1 and 6 as these had been erroneously included in trial clinical trial reports. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Hypoglycaemic episodes by trial, classification and age group - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
ONWARDS 4								
Number of subjects	291				291			
Number of subjects (>=18 - <65 years)	189				184			
Number of subjects (>=65 - <75 years)	92				96			
Number of subjects (>=75 years)	10				11			
PYE	167.36				166.80			
PYE (>=18 - <65 years)	108.79				105.57			
PYE (>=65 - <75 years)	53.20				54.69			
PYE (>=75 years)	5.37				6.54			
Hypoglycaemia alert value (level 1)	244	(83.8)	5264	3145.28	251	(86.3)	4145	2485.04
>=18 - <65 years	151	(79.9)	3225	2964.54	155	(84.2)	2544	2409.80
>=65 - <75 years	85	(92.4)	1824	3428.45	86	(89.6)	1478	2702.31
>=75 years	8	(80.0)	215	4000.45	10	(90.9)	123	1882.10
Clinically significant hypoglycaemia (level 2)	148	(50.9)	937	559.86	160	(55.0)	935	560.56
>=18 - <65 years	89	(47.1)	552	507.42	99	(53.8)	596	564.56
>=65 - <75 years	54	(58.7)	346	650.35	54	(56.2)	319	583.24
>=75 years	5	(50.0)	39	725.66	7	(63.6)	20	306.03
Severe hypoglycaemia (level 3)	4	(1.4)	7	4.18	2	(0.7)	3	1.80
>=18 - <65 years	3	(1.6)	6	5.52	1	(0.5)	2	1.89
>=65 - <75 years	1	(1.1)	1	1.88	1	(1.0)	1	1.83
>=75 years	0				0			
Severe (level 3) or clinically significant (level 2) hypoglycaemia	150	(51.5)	944	564.05	162	(55.7)	938	562.36
>=18 - <65 years	90	(47.6)	558	512.93	100	(54.3)	598	566.46
>=65 - <75 years	55	(59.8)	347	652.23	55	(57.3)	320	585.07
>=75 years	5	(50.0)	39	725.66	7	(63.6)	20	306.03

%: Percentage of subjects with one or more events, BG: Blood glucose, E: Number of events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. A hypoglycaemia alert value (level 1) was excluded from each of ONWARDS 1 and 6 as these had been erroneously included in trial clinical trial reports. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Hypoglycaemic episodes by trial, classification and age group - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
ONWARDS 5								
Number of subjects	542				538			
Number of subjects (>=18 - <65 years)	359				361			
Number of subjects (>=65 - <75 years)	150				151			
Number of subjects (>=75 years)	33				26			
PYE	559.54				560.72			
PYE (>=18 - <65 years)	369.87				379.93			
PYE (>=65 - <75 years)	155.99				153.23			
PYE (>=75 years)	33.68				27.56			
Hypoglycaemia alert value (level 1)	200	(36.9)	1028	183.72	153	(28.4)	851	151.77
>=18 - <65 years	125	(34.8)	610	164.92	92	(25.5)	521	137.13
>=65 - <75 years	61	(40.7)	289	185.26	53	(35.1)	286	186.64
>=75 years	14	(42.4)	129	383.07	8	(30.8)	44	159.67
Clinically significant hypoglycaemia (level 2)	64	(11.8)	104	18.59	42	(7.8)	76	13.55
>=18 - <65 years	38	(10.6)	57	15.41	31	(8.6)	46	12.11
>=65 - <75 years	22	(14.7)	41	26.28	9	(6.0)	28	18.27
>=75 years	4	(12.1)	6	17.82	2	(7.7)	2	7.26
Severe hypoglycaemia (level 3)	0				4	(0.7)	5	0.89
>=18 - <65 years	0				3	(0.8)	4	1.05
>=65 - <75 years	0				1	(0.7)	1	0.65
>=75 years	0				0			
Severe (level 3) or clinically significant (level 2) hypoglycaemia	64	(11.8)	104	18.59	45	(8.4)	81	14.45
>=18 - <65 years	38	(10.6)	57	15.41	33	(9.1)	50	13.16
>=65 - <75 years	22	(14.7)	41	26.28	10	(6.6)	29	18.93
>=75 years	4	(12.1)	6	17.82	2	(7.7)	2	7.26

%: Percentage of subjects with one or more events, BG: Blood glucose, E: Number of events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. A hypoglycaemia alert value (level 1) was excluded from each of ONWARDS 1 and 6 as these had been erroneously included in trial clinical trial reports. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Hypoglycaemic episodes by trial, classification and age group - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
ONWARDS 6								
Number of subjects	290				292			
Number of subjects (>=18 - <65 years)	267				271			
Number of subjects (>=65 - <75 years)	20				18			
Number of subjects (>=75 years)	3				3			
PYE	142.31				144.12			
PYE (>=18 - <65 years)	131.27				133.59			
PYE (>=65 - <75 years)	9.58				9.02			
PYE (>=75 years)	1.46				1.52			
Hypoglycaemia alert value (level 1)	288	(99.3)	10799	7588.47	287	(98.3)	7401	5135.29
>=18 - <65 years	266	(99.6)	10132	7718.66	266	(98.2)	6863	5137.54
>=65 - <75 years	19	(95.0)	583	6085.76	18	(100.0)	430	4767.99
>=75 years	3	(100.0)	84	5745.51	3	(100.0)	108	7120.40
Clinically significant hypoglycaemia (level 2)	246	(84.8)	2789	1959.83	223	(76.4)	1478	1025.53
>=18 - <65 years	227	(85.0)	2627	2001.28	210	(77.5)	1363	1020.32
>=65 - <75 years	17	(85.0)	155	1618.00	11	(61.1)	100	1108.83
>=75 years	2	(66.7)	7	478.79	2	(66.7)	15	988.94
Severe hypoglycaemia (level 3)	9	(3.1)	47	33.03	9	(3.1)	17	11.80
>=18 - <65 years	9	(3.4)	47	35.81	8	(3.0)	16	11.98
>=65 - <75 years	0				1	(5.6)	1	11.09
>=75 years	0				0			
Severe (level 3) or clinically significant (level 2) hypoglycaemia	247	(85.2)	2836	1992.86	223	(76.4)	1495	1037.33
>=18 - <65 years	228	(85.4)	2674	2037.08	210	(77.5)	1379	1032.30
>=65 - <75 years	17	(85.0)	155	1618.00	11	(61.1)	101	1119.92
>=75 years	2	(66.7)	7	478.79	2	(66.7)	15	988.94

%: Percentage of subjects with one or more events, BG: Blood glucose, E: Number of events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. A hypoglycaemia alert value (level 1) was excluded from each of ONWARDS 1 and 6 as these had been erroneously included in trial clinical trial reports. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

7.4.18 Hypoglycaemic episodes by trial, classification and treatment day - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
ONWARDS 1								
Number of subjects	492				492			
PYE (years)	485.88				485.03			
Hypoglycaemia alert value (level 1)								
Day 1	68	(13.8)	122	173.52	67	(13.6)	97	138.26
Day 2	120	(24.4)	305	438.78	59	(12.0)	79	113.76
Day 3	149	(30.3)	362	522.03	61	(12.4)	83	119.86
Day 4	117	(23.8)	265	382.65	55	(11.2)	76	109.91
Day 5	85	(17.3)	168	242.80	62	(12.6)	108	156.35
Day 6	75	(15.2)	123	177.85	62	(12.6)	95	137.63
Day 7	52	(10.6)	102	147.60	65	(13.2)	93	134.90
Clinically significant hypoglycaemia (level 2)								
Day 1	10	(2.0)	13	18.49	8	(1.6)	10	14.25
Day 2	17	(3.5)	25	35.97	8	(1.6)	10	14.40
Day 3	14	(2.8)	31	44.70	8	(1.6)	8	11.55
Day 4	18	(3.7)	31	44.76	11	(2.2)	13	18.80
Day 5	12	(2.4)	17	24.57	10	(2.0)	12	17.37
Day 6	10	(2.0)	12	17.35	11	(2.2)	11	15.94
Day 7	9	(1.8)	14	20.26	11	(2.2)	11	15.96
Severe hypoglycaemia (level 3)								
Day 1	0				1	(0.2)	1	1.43
Day 6	0				1	(0.2)	1	1.45
Day 7	1	(0.2)	1	1.45	1	(0.2)	1	1.45
Severe (level 3) or clinically significant (level 2) hypoglycaemia								
Day 1	10	(2.0)	13	18.49	9	(1.8)	11	15.68
Day 2	17	(3.5)	25	35.97	8	(1.6)	10	14.40
Day 3	14	(2.8)	31	44.70	8	(1.6)	8	11.55
Day 4	18	(3.7)	31	44.76	11	(2.2)	13	18.80
Day 5	12	(2.4)	17	24.57	10	(2.0)	12	17.37
Day 6	10	(2.0)	12	17.35	12	(2.4)	12	17.39
Day 7	10	(2.0)	15	21.71	12	(2.4)	12	17.41

%: Percentage of subjects with one or more events, BG: Blood glucose, E: Number of events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Day represents the relative weekdays with day of start of treatment defined as day 1. Day 1 therefore includes day 1, 8, 15, etc., where day 8 is the day of the 2nd dose of insulin icodec for the insulin icodec arm and day of the 8th dose for the daily basal insulin arm etc. Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. A hypoglycaemia alert value (level 1) was excluded from each of ONWARDS 1 and 6 as these had been erroneously included in trial clinical trial reports. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

adsl.xpt; variable(s): TRAG1 TRAG1N OTMTDURW OTMTDURD SAFFL STDNM USUBJID; criteria: SAFFL == "Y"
adhypo.xpt; variable(s): TRAG1 TRAG1N ANL06FL ANELFL SAFFL ACAT4 ACAT4N ASTDY ASTWK STDNM USUBJID; criteria: SAFFL == "Y" & ANL06FL == "Y" & ANELFL == "Y"
nn1436/nn1436-iss/submission_20221024_er
05DEC2022:12:57:18 - thypotrtweek/thypodaysumontsas.txt

Hypoglycaemic episodes by trial, classification and treatment day - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
ONWARDS 2								
Number of subjects	262				263			
PYE (years)	155.25				152.77			
Hypoglycaemia alert value (level 1)								
Day 1	48	(18.3)	91	401.03	48	(18.3)	74	334.93
Day 2	95	(36.3)	283	1276.12	54	(20.5)	84	384.18
Day 3	96	(36.6)	298	1347.75	55	(20.9)	97	444.31
Day 4	88	(33.6)	225	1018.36	47	(17.9)	89	407.97
Day 5	64	(24.4)	138	624.90	50	(19.0)	86	394.62
Day 6	51	(19.5)	99	448.91	54	(20.5)	84	386.51
Day 7	45	(17.2)	75	340.34	44	(16.7)	75	346.58
Clinically significant hypoglycaemia (level 2)								
Day 1	7	(2.7)	7	30.85	6	(2.3)	7	31.68
Day 2	13	(5.0)	23	103.71	5	(1.9)	6	27.44
Day 3	14	(5.3)	24	108.54	4	(1.5)	5	22.90
Day 4	16	(6.1)	26	117.68	4	(1.5)	6	27.50
Day 5	10	(3.8)	16	72.45	8	(3.0)	9	41.30
Day 6	7	(2.7)	12	54.41	4	(1.5)	4	18.41
Day 7	5	(1.9)	5	22.69	3	(1.1)	4	18.48
Severe hypoglycaemia (level 3)								
Day 4	0				1	(0.4)	1	4.58
Severe (level 3) or clinically significant (level 2) hypoglycaemia								
Day 1	7	(2.7)	7	30.85	6	(2.3)	7	31.68
Day 2	13	(5.0)	23	103.71	5	(1.9)	6	27.44
Day 3	14	(5.3)	24	108.54	4	(1.5)	5	22.90
Day 4	16	(6.1)	26	117.68	4	(1.5)	7	32.09
Day 5	10	(3.8)	16	72.45	8	(3.0)	9	41.30
Day 6	7	(2.7)	12	54.41	4	(1.5)	4	18.41
Day 7	5	(1.9)	5	22.69	3	(1.1)	4	18.48

%: Percentage of subjects with one or more events, BG: Blood glucose, E: Number of events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Day represents the relative weekdays with day of start of treatment defined as day 1. Day 1 therefore includes day 1, 8, 15, etc., where day 8 is the day of the 2nd dose of insulin icodec for the insulin icodec arm and day of the 8th dose for the daily basal insulin arm etc. Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. A hypoglycaemia alert value (level 1) was excluded from each of ONWARDS 1 and 6 as these had been erroneously included in trial clinical trial reports. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Hypoglycaemic episodes by trial, classification and treatment day - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
ONWARDS 3								
Number of subjects	293				294			
PYE (years)	170.90				171.13			
Hypoglycaemia alert value (level 1)								
Day 1	26	(8.9)	38	152.00	24	(8.2)	31	125.59
Day 2	35	(11.9)	66	270.31	14	(4.8)	18	73.51
Day 3	41	(14.0)	80	328.83	17	(5.8)	26	106.31
Day 4	49	(16.7)	71	292.07	18	(6.1)	23	94.15
Day 5	35	(11.9)	58	238.67	20	(6.8)	28	114.73
Day 6	33	(11.3)	44	181.12	21	(7.1)	29	119.01
Day 7	27	(9.2)	43	177.31	26	(8.8)	30	123.44
Clinically significant hypoglycaemia (level 2)								
Day 1	8	(2.7)	8	32.00	2	(0.7)	2	8.10
Day 2	8	(2.7)	10	40.96	2	(0.7)	2	8.17
Day 3	7	(2.4)	11	45.21	2	(0.7)	3	12.27
Day 4	7	(2.4)	9	37.02	4	(1.4)	4	16.37
Day 5	4	(1.4)	5	20.58	4	(1.4)	5	20.49
Day 6	4	(1.4)	4	16.47	2	(0.7)	2	8.21
Day 7	6	(2.0)	6	24.74	5	(1.7)	5	20.57
Severe hypoglycaemia (level 3)								
Day 1	0				2	(0.7)	2	8.10
Severe (level 3) or clinically significant (level 2) hypoglycaemia								
Day 1	8	(2.7)	8	32.00	4	(1.4)	4	16.20
Day 2	8	(2.7)	10	40.96	2	(0.7)	2	8.17
Day 3	7	(2.4)	11	45.21	2	(0.7)	3	12.27
Day 4	7	(2.4)	9	37.02	4	(1.4)	4	16.37
Day 5	4	(1.4)	5	20.58	4	(1.4)	5	20.49
Day 6	4	(1.4)	4	16.47	2	(0.7)	2	8.21
Day 7	6	(2.0)	6	24.74	5	(1.7)	5	20.57

%: Percentage of subjects with one or more events, BG: Blood glucose, E: Number of events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Day represents the relative weekdays with day of start of treatment defined as day 1. Day 1 therefore includes day 1, 8, 15, etc., where day 8 is the day of the 2nd dose of insulin icodec for the insulin icodec arm and day of the 8th dose for the daily basal insulin arm etc. Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. A hypoglycaemia alert value (level 1) was excluded from each of ONWARDS 1 and 6 as these had been erroneously included in trial clinical trial reports. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Hypoglycaemic episodes by trial, classification and treatment day - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
ONWARDS 4								
Number of subjects	291				291			
PYE (years)	167.36				166.80			
Hypoglycaemia alert value (level 1)								
Day 1	166	(57.0)	520	2124.73	190	(65.3)	632	2620.48
Day 2	193	(66.3)	1050	4392.04	185	(63.6)	627	2621.47
Day 3	202	(69.4)	1029	4314.57	182	(62.5)	611	2562.50
Day 4	202	(69.4)	911	3825.95	175	(60.1)	590	2478.69
Day 5	183	(62.9)	717	3014.32	179	(61.5)	564	2374.10
Day 6	173	(59.5)	544	2288.33	173	(59.5)	551	2323.93
Day 7	162	(55.7)	493	2074.76	183	(62.9)	570	2410.19
Clinically significant hypoglycaemia (level 2)								
Day 1	62	(21.3)	108	441.29	68	(23.4)	128	530.73
Day 2	74	(25.4)	169	706.91	73	(25.1)	134	560.25
Day 3	74	(25.4)	180	754.74	68	(23.4)	138	578.76
Day 4	67	(23.0)	139	583.76	62	(21.3)	122	512.54
Day 5	57	(19.6)	121	508.69	70	(24.1)	136	572.48
Day 6	60	(20.6)	110	462.71	76	(26.1)	131	552.51
Day 7	59	(20.3)	110	462.93	68	(23.4)	146	617.35
Severe hypoglycaemia (level 3)								
Day 3	2	(0.7)	2	8.39	0			
Day 4	2	(0.7)	2	8.40	1	(0.3)	1	4.20
Day 5	0				1	(0.3)	1	4.21
Day 6	1	(0.3)	1	4.21	1	(0.3)	1	4.22
Day 7	2	(0.7)	2	8.42	0			
Severe (level 3) or clinically significant (level 2) hypoglycaemia								
Day 1	62	(21.3)	108	441.29	68	(23.4)	128	530.73
Day 2	74	(25.4)	169	706.91	73	(25.1)	134	560.25
Day 3	75	(25.8)	182	763.12	68	(23.4)	138	578.76
Day 4	69	(23.7)	141	592.16	63	(21.6)	123	516.74
Day 5	57	(19.6)	121	508.69	71	(24.4)	137	576.69
Day 6	61	(21.0)	111	466.92	77	(26.5)	132	556.73
Day 7	61	(21.0)	112	471.34	68	(23.4)	146	617.35

%: Percentage of subjects with one or more events, BG: Blood glucose, E: Number of events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Day represents the relative weekdays with day of start of treatment defined as day 1. Day 1 therefore includes day 1, 8, 15, etc., where day 8 is the day of the 2nd dose of insulin icodec for the insulin icodec arm and day of the 8th dose for the daily basal insulin arm etc. Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. A hypoglycaemia alert value (level 1) was excluded from each of ONWARDS 1 and 6 as these had been erroneously included in trial clinical trial reports. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Hypoglycaemic episodes by trial, classification and treatment day - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
ONWARDS 5								
Number of subjects	542				538			
PYE (years)	559.54				560.72			
Hypoglycaemia alert value (level 1)								
Day 1	59	(10.9)	85	104.99	59	(11.0)	120	148.62
Day 2	101	(18.6)	207	258.86	56	(10.4)	123	153.14
Day 3	111	(20.5)	264	330.66	61	(11.3)	112	139.77
Day 4	88	(16.2)	188	235.66	58	(10.8)	128	159.95
Day 5	65	(12.0)	119	149.26	65	(12.1)	126	157.58
Day 6	58	(10.7)	89	111.71	58	(10.8)	101	126.51
Day 7	48	(8.9)	76	95.48	65	(12.1)	141	176.92
Clinically significant hypoglycaemia (level 2)								
Day 1	9	(1.7)	9	11.12	6	(1.1)	8	9.91
Day 2	15	(2.8)	17	21.26	6	(1.1)	10	12.45
Day 3	13	(2.4)	19	23.80	12	(2.2)	12	14.97
Day 4	13	(2.4)	17	21.31	11	(2.0)	14	17.49
Day 5	14	(2.6)	17	21.32	9	(1.7)	11	13.76
Day 6	13	(2.4)	14	17.57	12	(2.2)	14	17.54
Day 7	10	(1.8)	11	13.82	7	(1.3)	7	8.78
Severe hypoglycaemia (level 3)								
Day 2	0				2	(0.4)	2	2.49
Day 3	0				1	(0.2)	1	1.25
Day 6	0				1	(0.2)	1	1.25
Day 7	0				1	(0.2)	1	1.25
Severe (level 3) or clinically significant (level 2) hypoglycaemia								
Day 1	9	(1.7)	9	11.12	6	(1.1)	8	9.91
Day 2	15	(2.8)	17	21.26	8	(1.5)	12	14.94
Day 3	13	(2.4)	19	23.80	13	(2.4)	13	16.22
Day 4	13	(2.4)	17	21.31	11	(2.0)	14	17.49
Day 5	14	(2.6)	17	21.32	9	(1.7)	11	13.76
Day 6	13	(2.4)	14	17.57	13	(2.4)	15	18.79
Day 7	10	(1.8)	11	13.82	8	(1.5)	8	10.04

%: Percentage of subjects with one or more events, BG: Blood glucose, E: Number of events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Day represents the relative weekdays with day of start of treatment defined as day 1. Day 1 therefore includes day 1, 8, 15, etc., where day 8 is the day of the 2nd dose of insulin icodec for the insulin icodec arm and day of the 8th dose for the daily basal insulin arm etc. Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. A hypoglycaemia alert value (level 1) was excluded from each of ONWARDS 1 and 6 as these had been erroneously included in trial clinical trial reports. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.


adsl.xpt; variable(s): TRAG1 TRAG1N OTMTDURW OTMTDURD SAFFL STDNM USUBJID; criteria: SAFFL == "Y"
adhypo.xpt; variable(s): TRAG1 TRAG1N ANL06FL ANELFL SAFFL ACAT4 ACAT4N ASTDY ASTWK STDNM USUBJID; criteria: SAFFL == "Y" & ANL06FL == "Y" & ANELFL == "Y"

Hypoglycaemic episodes by trial, classification and treatment day - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec				Daily basal insulin			
	N	(%)	E	R	N	(%)	E	R
ONWARDS 6								
Number of subjects	290				292			
PYE (years)	142.31				144.12			
Hypoglycaemia alert value (level 1)								
Day 1	251	(86.6)	1197	5742.11	257	(88.0)	1196	5672.50
Day 2	275	(94.8)	2016	9878.51	259	(88.7)	1126	5447.30
Day 3	269	(92.8)	2107	10387.12	248	(84.9)	1054	5124.78
Day 4	267	(92.1)	1772	8752.17	239	(81.8)	1027	5010.17
Day 5	258	(89.0)	1469	7271.34	240	(82.2)	983	4804.51
Day 6	252	(86.9)	1188	5886.81	249	(85.3)	993	4855.98
Day 7	249	(85.9)	1050	5213.60	253	(86.6)	1022	5011.89
Clinically significant hypoglycaemia (level 2)								
Day 1	123	(42.4)	272	1304.81	109	(37.3)	211	1000.75
Day 2	169	(58.3)	535	2621.53	123	(42.1)	234	1132.03
Day 3	177	(61.0)	592	2918.45	119	(40.8)	222	1079.41
Day 4	167	(57.6)	507	2504.15	108	(37.0)	200	975.69
Day 5	149	(51.4)	354	1752.25	102	(34.9)	199	972.63
Day 6	132	(45.5)	296	1466.75	114	(39.0)	218	1066.07
Day 7	110	(37.9)	233	1156.92	101	(34.6)	194	951.38
Severe hypoglycaemia (level 3)								
Day 1	3	(1.0)	7	33.58	2	(0.7)	3	14.23
Day 2	3	(1.0)	8	39.20	1	(0.3)	2	9.68
Day 3	5	(1.7)	15	73.95	2	(0.7)	2	9.72
Day 4	2	(0.7)	7	34.57	3	(1.0)	3	14.64
Day 5	2	(0.7)	6	29.70	2	(0.7)	2	9.78
Day 6	2	(0.7)	2	9.91	3	(1.0)	3	14.67
Day 7	1	(0.3)	2	9.93	2	(0.7)	2	9.81
Severe (level 3) or clinically significant (level 2) hypoglycaemia								
Day 1	124	(42.8)	279	1338.39	110	(37.7)	214	1014.98
Day 2	169	(58.3)	543	2660.73	123	(42.1)	236	1141.71
Day 3	178	(61.4)	607	2992.40	119	(40.8)	224	1089.14
Day 4	168	(57.9)	514	2538.72	109	(37.3)	203	990.33
Day 5	150	(51.7)	360	1781.95	102	(34.9)	201	982.41
Day 6	134	(46.2)	298	1476.66	114	(39.0)	221	1080.74
Day 7	110	(37.9)	235	1166.85	102	(34.9)	196	961.18

%: Percentage of subjects with one or more events, BG: Blood glucose, E: Number of events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Day represents the relative weekdays with day of start of treatment defined as day 1. Day 1 therefore includes day 1, 8, 15, etc., where day 8 is the day of the 2nd dose of insulin icodec for the insulin icodec arm and day of the 8th dose for the daily basal insulin arm etc. Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. A hypoglycaemia alert value (level 1) was excluded from each of ONWARDS 1 and 6 as these had been erroneously included in trial clinical trial reports. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

7.4.19 Severe (level 3) or clinically significant hypoglycaemia (level 2) by trial and treatment day - ONWARDS 1-5 - on-treatment/main-on-treatment - bar plot - safety analysis set




BG: Blood glucose, PYE: Patient years of exposure (1 PYE = 365.25 days). Safety analysis set. Observed data. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. OD analogues: Once-daily basal insulin analogues (IDeg, IGlar U100, IGlar U300). Data from ONWARDS 1-5, only main part of ONWARDS 1.

adsl.xpt; variable(s): TRTA TRTAN OTMTDURD SAFFL STDNM USUBJID; criteria: SAFFL == "Y" & STDNMN %in% c(1, 2, 3, 4, 5)
adhypo.xpt; variable(s): TRTA TRTAN ANL06FL ANELFL SAFFL ACAT4 ACAT4N ASTDY ASTWK STDNM USUBJID; criteria: SAFFL == "Y" & STDNMN %in% c(1, 2, 3, 4, 5) & ANL06FL == "Y" & ANELFL == "Y"

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:12:57:48 - fhypobar/fhypolev23daybarow15ontsas.png


7.4.20 Severe (level 3) or clinically significant hypoglycaemia (level 2) by treatment day - ONWARDS 6 - main-on-treatment - bar plot - safety analysis set



BG: Blood glucose, PYE: Patient years of exposure (1 PYE = 365.25 days). Safety analysis set. Observed data. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. Data from main part of ONWARDS 6.

adsl.xpt; variable(s): TRTA TRTAN OTMTDURW OTMTDURD SAFFL; criteria: SAFFL == "Y" & STDNMN == 6
adhypo.xpt; variable(s): TRTA TRTAN SAFFL ACAT4 ACAT4N ASTDY ASTWK; criteria: SAFFL == "Y" & STDNMN == 6 & ANL06FL == "Y" & ANELFL == "Y"
nn1436/nn1436-iss/submission_20221024_er
05DEC2022:12:57:53 - fhypobar/fhypolev23daybarow6ontsas.png

7.4.21 Severe (level 3) or clinically significant hypoglycaemia (level 2) by treatment day and phase - ONWARDS 6 - main-on-treatment - bar plot - safety analysis set



BG: Blood glucose, PYE: Patient years of exposure (1 PYE = 365.25 days). Safety analysis set. Observed data. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. Titration phase is defined as from date of first dose of trial product up until week 12 or at the date of the end of treatment visit, whichever comes first. Maintenance phase is defined as from week 12 to date of the end of treatment visit or date of the last visit within the main part, if applicable, whichever comes first. If the end of treatment visit is prior to week 12, then there will be no maintenance phase. Data from main part of ONWARDS 6.

adsl.xpt; variable(s): TRTA TRTAN P01S1 P01S2 P01S1DRD P01S2DRD; criteria: SAFFL == "Y" & STDNMN == 6
adhypo.xpt; variable(s): TRTA TRTAN ANL09FL ANL10FL ACAT4 ACAT4N ASTDY ASTWK; criteria: SAFFL == "Y" & STDNMN == 6 & ANL06FL == "Y" & ANELFL == "Y"

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:12:58:19 - fhypobarphase/fhypolev23daybarow6phaseontsas.png

7.4.22 Duration of hypoglycaemic episodes in 30-minute intervals by trial and classification based on hypoglycaemic episodes form - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec		Daily basal insulin	
	E	(%)	E	(%)
ONWARDS 1				
Number of subjects	492		492	
Hypoglycaemia alert value (level 1)				
Missing duration	596		260	
Non-missing duration	851	(100.0)	371	(100.0)
<30 minutes	547	(64.3)	239	(64.4)
30 - <60 minutes	131	(15.4)	69	(18.6)
60 - <90 minutes	71	(8.3)	25	(6.7)
90 - <120 minutes	17	(2.0)	5	(1.3)
120 - <150 minutes	39	(4.6)	9	(2.4)
150 - <180 minutes	8	(0.9)	3	(0.8)
180 - <210 minutes	6	(0.7)	1	(0.3)
210 - <240 minutes	3	(0.4)	0	
240 - <270 minutes	2	(0.2)	0	
270 - <300 minutes	0		0	
300 - <330 minutes	1	(0.1)	0	
330 - <360 minutes	0		1	(0.3)
>=360 minutes	26	(3.1)	19	(5.1)
Clinically significant hypoglycaemia (level 2)				
Missing duration	37		34	
Non-missing duration	106	(100.0)	41	(100.0)
<30 minutes	50	(47.2)	28	(68.3)
30 - <60 minutes	21	(19.8)	5	(12.2)
60 - <90 minutes	5	(4.7)	0	
90 - <120 minutes	2	(1.9)	4	(9.8)
120 - <150 minutes	11	(10.4)	2	(4.9)
150 - <180 minutes	1	(0.9)	1	(2.4)
180 - <210 minutes	2	(1.9)	0	
210 - <240 minutes	2	(1.9)	0	
240 - <270 minutes	0		0	
270 - <300 minutes	1	(0.9)	0	
300 - <330 minutes	1	(0.9)	0	
330 - <360 minutes	1	(0.9)	0	
>=360 minutes	9	(8.5)	1	(2.4)

%: Percentage of hypoglycaemic episodes, BG: Blood glucose, E: Number of hypoglycaemic episodes. Duration of hypoglycaemic episodes is calculated in minutes with positive durations only contributing to derivations. Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. A hypoglycaemia alert value (level 1) was excluded from each of ONWARDS 1 and 6 as these had been erroneously included in trial clinical trial reports. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Duration of hypoglycaemic episodes in 30-minute intervals by trial and classification based on hypoglycaemic episodes form - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec		Daily basal insulin	
	E	(%)	E	(%)
Severe hypoglycaemia (level 3)				
Missing duration	1		2	
Non-missing duration	0		1	(100.0)
<30 minutes	0		0	
30 - <60 minutes	0		1	(100.0)
60 - <90 minutes	0		0	
90 - <120 minutes	0		0	
120 - <150 minutes	0		0	
150 - <180 minutes	0		0	
180 - <210 minutes	0		0	
210 - <240 minutes	0		0	
240 - <270 minutes	0		0	
270 - <300 minutes	0		0	
300 - <330 minutes	0		0	
330 - <360 minutes	0		0	
>=360 minutes	0		0	
Severe (level 3) or clinically significant (level 2) hypoglycaemia				
Missing duration	38		36	
Non-missing duration	106	(100.0)	42	(100.0)
<30 minutes	50	(47.2)	28	(66.7)
30 - <60 minutes	21	(19.8)	6	(14.3)
60 - <90 minutes	5	(4.7)	0	
90 - <120 minutes	2	(1.9)	4	(9.5)
120 - <150 minutes	11	(10.4)	2	(4.8)
150 - <180 minutes	1	(0.9)	1	(2.4)
180 - <210 minutes	2	(1.9)	0	
210 - <240 minutes	2	(1.9)	0	
240 - <270 minutes	0		0	
270 - <300 minutes	1	(0.9)	0	
300 - <330 minutes	1	(0.9)	0	
330 - <360 minutes	1	(0.9)	0	
>=360 minutes	9	(8.5)	1	(2.4)
ONWARDS 2				
Number of subjects	262		263	

%: Percentage of hypoglycaemic episodes, BG: Blood glucose, E: Number of hypoglycaemic episodes. Duration of hypoglycaemic episodes is calculated in minutes with positive durations only contributing to derivations. Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. A hypoglycaemia alert value (level 1) was excluded from each of ONWARDS 1 and 6 as these had been erroneously included in trial clinical trial reports. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Duration of hypoglycaemic episodes in 30-minute intervals by trial and classification based on hypoglycaemic episodes form - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec		Daily basal insulin	
	E	(%)	E	(%)
Hypoglycaemia alert value (level 1)				
Missing duration	519		234	
Non-missing duration	690	(100.0)	355	(100.0)
<30 minutes	402	(58.3)	244	(68.7)
30 - <60 minutes	156	(22.6)	71	(20.0)
60 - <90 minutes	90	(13.0)	22	(6.2)
90 - <120 minutes	9	(1.3)	5	(1.4)
120 - <150 minutes	11	(1.6)	5	(1.4)
150 - <180 minutes	5	(0.7)	1	(0.3)
180 - <210 minutes	0		0	
210 - <240 minutes	0		0	
240 - <270 minutes	1	(0.1)	0	
270 - <300 minutes	0		0	
300 - <330 minutes	0		0	
330 - <360 minutes	0		0	
>=360 minutes	16	(2.3)	7	(2.0)
Clinically significant hypoglycaemia (level 2)				
Missing duration	49		10	
Non-missing duration	64	(100.0)	31	(100.0)
<30 minutes	31	(48.4)	21	(67.7)
30 - <60 minutes	21	(32.8)	9	(29.0)
60 - <90 minutes	4	(6.2)	1	(3.2)
90 - <120 minutes	3	(4.7)	0	
120 - <150 minutes	0		0	
150 - <180 minutes	0		0	
180 - <210 minutes	0		0	
210 - <240 minutes	1	(1.6)	0	
240 - <270 minutes	0		0	
270 - <300 minutes	0		0	
300 - <330 minutes	0		0	
330 - <360 minutes	0		0	
>=360 minutes	4	(6.2)	0	
Severe hypoglycaemia (level 3)				
Missing duration	0		0	
Non-missing duration	0		1	(100.0)
<30 minutes	0		0	
30 - <60 minutes	0		0	
60 - <90 minutes	0		1	(100.0)
90 - <120 minutes	0		0	
120 - <150 minutes	0		0	
150 - <180 minutes	0		0	
180 - <210 minutes	0		0	
210 - <240 minutes	0		0	
240 - <270 minutes	0		0	
270 - <300 minutes	0		0	
300 - <330 minutes	0		0	
330 - <360 minutes	0		0	
>=360 minutes	0		0	

%: Percentage of hypoglycaemic episodes, BG: Blood glucose, E: Number of hypoglycaemic episodes. Duration of hypoglycaemic episodes is calculated in minutes with positive durations only contributing to derivations. Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. A hypoglycaemia alert value (level 1) was excluded from each of ONWARDS 1 and 6 as these had been erroneously included in trial clinical trial reports. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Duration of hypoglycaemic episodes in 30-minute intervals by trial and classification based on hypoglycaemic episodes form - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec		Daily basal insulin	
	E	(%)	E	(%)
Severe (level 3) or clinically significant (level 2) hypoglycaemia				
Missing duration	49		10	
Non-missing duration	64	(100.0)	32	(100.0)
<30 minutes	31	(48.4)	21	(65.6)
30 - <60 minutes	21	(32.8)	9	(28.1)
60 - <90 minutes	4	(6.2)	2	(6.2)
90 - <120 minutes	3	(4.7)	0	
120 - <150 minutes	0		0	
150 - <180 minutes	0		0	
180 - <210 minutes	0		0	
210 - <240 minutes	1	(1.6)	0	
240 - <270 minutes	0		0	
270 - <300 minutes	0		0	
300 - <330 minutes	0		0	
330 - <360 minutes	0		0	
>=360 minutes	4	(6.2)	0	
ONWARDS 3				
Number of subjects	293		294	
Hypoglycaemia alert value (level 1)				
Missing duration	226		91	
Non-missing duration	174	(100.0)	94	(100.0)
<30 minutes	121	(69.5)	65	(69.1)
30 - <60 minutes	21	(12.1)	17	(18.1)
60 - <90 minutes	11	(6.3)	8	(8.5)
90 - <120 minutes	1	(0.6)	2	(2.1)
120 - <150 minutes	4	(2.3)	1	(1.1)
150 - <180 minutes	2	(1.1)	0	
180 - <210 minutes	4	(2.3)	0	
210 - <240 minutes	0		0	
240 - <270 minutes	1	(0.6)	0	
270 - <300 minutes	0		0	
300 - <330 minutes	2	(1.1)	0	
330 - <360 minutes	0		0	
>=360 minutes	7	(4.0)	1	(1.1)

%: Percentage of hypoglycaemic episodes, BG: Blood glucose, E: Number of hypoglycaemic episodes. Duration of hypoglycaemic episodes is calculated in minutes with positive durations only contributing to derivations. Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. A hypoglycaemia alert value (level 1) was excluded from each of ONWARDS 1 and 6 as these had been erroneously included in trial clinical trial reports. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Duration of hypoglycaemic episodes in 30-minute intervals by trial and classification based on hypoglycaemic episodes form - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec		Daily basal insulin	
	E	(%)	E	(%)
Clinically significant hypoglycaemia (level 2)				
Missing duration	30		13	
Non-missing duration	23	(100.0)	10	(100.0)
<30 minutes	16	(69.6)	7	(70.0)
30 - <60 minutes	2	(8.7)	2	(20.0)
60 - <90 minutes	2	(8.7)	1	(10.0)
90 - <120 minutes	0		0	
120 - <150 minutes	0		0	
150 - <180 minutes	0		0	
180 - <210 minutes	0		0	
210 - <240 minutes	0		0	
240 - <270 minutes	0		0	
270 - <300 minutes	0		0	
300 - <330 minutes	1	(4.3)	0	
330 - <360 minutes	0		0	
>=360 minutes	2	(8.7)	0	
Severe hypoglycaemia (level 3)				
Missing duration	0		0	
Non-missing duration	0		2	(100.0)
<30 minutes	0		2	(100.0)
30 - <60 minutes	0		0	
60 - <90 minutes	0		0	
90 - <120 minutes	0		0	
120 - <150 minutes	0		0	
150 - <180 minutes	0		0	
180 - <210 minutes	0		0	
210 - <240 minutes	0		0	
240 - <270 minutes	0		0	
270 - <300 minutes	0		0	
300 - <330 minutes	0		0	
330 - <360 minutes	0		0	
>=360 minutes	0		0	
Severe (level 3) or clinically significant (level 2) hypoglycaemia				
Missing duration	30		13	
Non-missing duration	23	(100.0)	12	(100.0)
<30 minutes	16	(69.6)	9	(75.0)
30 - <60 minutes	2	(8.7)	2	(16.7)
60 - <90 minutes	2	(8.7)	1	(8.3)
90 - <120 minutes	0		0	
120 - <150 minutes	0		0	
150 - <180 minutes	0		0	
180 - <210 minutes	0		0	
210 - <240 minutes	0		0	
240 - <270 minutes	0		0	
270 - <300 minutes	0		0	
300 - <330 minutes	1	(4.3)	0	
330 - <360 minutes	0		0	
>=360 minutes	2	(8.7)	0	

%: Percentage of hypoglycaemic episodes, BG: Blood glucose, E: Number of hypoglycaemic episodes. Duration of hypoglycaemic episodes is calculated in minutes with positive durations only contributing to derivations. Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. A hypoglycaemia alert value (level 1) was excluded from each of ONWARDS 1 and 6 as these had been erroneously included in trial clinical trial reports. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Duration of hypoglycaemic episodes in 30-minute intervals by trial and classification based on hypoglycaemic episodes form - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec		Daily basal insulin	
	E	(%)	E	(%)
ONWARDS 4				
Number of subjects	291		291	
Hypoglycaemia alert value (level 1)				
Missing duration	1880		1926	
Non-missing duration	3384	(100.0)	2219	(100.0)
<30 minutes	2407	(71.1)	1655	(74.6)
30 - <60 minutes	582	(17.2)	342	(15.4)
60 - <90 minutes	203	(6.0)	126	(5.7)
90 - <120 minutes	40	(1.2)	15	(0.7)
120 - <150 minutes	45	(1.3)	15	(0.7)
150 - <180 minutes	12	(0.4)	8	(0.4)
180 - <210 minutes	10	(0.3)	7	(0.3)
210 - <240 minutes	5	(0.1)	2	(0.1)
240 - <270 minutes	8	(0.2)	3	(0.1)
270 - <300 minutes	10	(0.3)	4	(0.2)
300 - <330 minutes	9	(0.3)	4	(0.2)
330 - <360 minutes	8	(0.2)	3	(0.1)
>=360 minutes	45	(1.3)	35	(1.6)
Clinically significant hypoglycaemia (level 2)				
Missing duration	257		354	
Non-missing duration	680	(100.0)	581	(100.0)
<30 minutes	442	(65.0)	418	(71.9)
30 - <60 minutes	144	(21.2)	94	(16.2)
60 - <90 minutes	41	(6.0)	28	(4.8)
90 - <120 minutes	7	(1.0)	4	(0.7)
120 - <150 minutes	5	(0.7)	9	(1.5)
150 - <180 minutes	2	(0.3)	3	(0.5)
180 - <210 minutes	4	(0.6)	3	(0.5)
210 - <240 minutes	3	(0.4)	2	(0.3)
240 - <270 minutes	2	(0.3)	1	(0.2)
270 - <300 minutes	3	(0.4)	4	(0.7)
300 - <330 minutes	1	(0.1)	3	(0.5)
330 - <360 minutes	3	(0.4)	1	(0.2)
>=360 minutes	23	(3.4)	11	(1.9)
Severe hypoglycaemia (level 3)				
Missing duration	2		0	
Non-missing duration	5	(100.0)	3	(100.0)
<30 minutes	2	(40.0)	2	(66.7)
30 - <60 minutes	2	(40.0)	0	
60 - <90 minutes	0		0	
90 - <120 minutes	0		0	
120 - <150 minutes	0		1	(33.3)
150 - <180 minutes	0		0	
180 - <210 minutes	0		0	
210 - <240 minutes	0		0	
240 - <270 minutes	1	(20.0)	0	
270 - <300 minutes	0		0	
300 - <330 minutes	0		0	
330 - <360 minutes	0		0	
>=360 minutes	0		0	

%: Percentage of hypoglycaemic episodes, BG: Blood glucose, E: Number of hypoglycaemic episodes. Duration of hypoglycaemic episodes is calculated in minutes with positive durations only contributing to derivations. Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. A hypoglycaemia alert value (level 1) was excluded from each of ONWARDS 1 and 6 as these had been erroneously included in trial clinical trial reports. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Duration of hypoglycaemic episodes in 30-minute intervals by trial and classification based on hypoglycaemic episodes form - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec		Daily basal insulin	
	E	(%)	E	(%)
Severe (level 3) or clinically significant (level 2) hypoglycaemia				
Missing duration	259		354	
Non-missing duration	685	(100.0)	584	(100.0)
<30 minutes	444	(64.8)	420	(71.9)
30 - <60 minutes	146	(21.3)	94	(16.1)
60 - <90 minutes	41	(6.0)	28	(4.8)
90 - <120 minutes	7	(1.0)	4	(0.7)
120 - <150 minutes	5	(0.7)	10	(1.7)
150 - <180 minutes	2	(0.3)	3	(0.5)
180 - <210 minutes	4	(0.6)	3	(0.5)
210 - <240 minutes	3	(0.4)	2	(0.3)
240 - <270 minutes	3	(0.4)	1	(0.2)
270 - <300 minutes	3	(0.4)	4	(0.7)
300 - <330 minutes	1	(0.1)	3	(0.5)
330 - <360 minutes	3	(0.4)	1	(0.2)
>=360 minutes	23	(3.4)	11	(1.9)
ONWARDS 5				
Number of subjects	542		538	
Hypoglycaemia alert value (level 1)				
Missing duration	446		518	
Non-missing duration	582	(100.0)	333	(100.0)
<30 minutes	343	(58.9)	244	(73.3)
30 - <60 minutes	110	(18.9)	41	(12.3)
60 - <90 minutes	63	(10.8)	28	(8.4)
90 - <120 minutes	13	(2.2)	2	(0.6)
120 - <150 minutes	14	(2.4)	9	(2.7)
150 - <180 minutes	5	(0.9)	3	(0.9)
180 - <210 minutes	6	(1.0)	1	(0.3)
210 - <240 minutes	2	(0.3)	1	(0.3)
240 - <270 minutes	4	(0.7)	0	
270 - <300 minutes	2	(0.3)	0	
300 - <330 minutes	3	(0.5)	1	(0.3)
330 - <360 minutes	1	(0.2)	0	
>=360 minutes	16	(2.7)	3	(0.9)
Clinically significant hypoglycaemia (level 2)				
Missing duration	43		42	
Non-missing duration	61	(100.0)	34	(100.0)
<30 minutes	32	(52.5)	31	(91.2)
30 - <60 minutes	9	(14.8)	0	
60 - <90 minutes	11	(18.0)	1	(2.9)
90 - <120 minutes	2	(3.3)	1	(2.9)
120 - <150 minutes	0		0	
150 - <180 minutes	0		0	
180 - <210 minutes	1	(1.6)	0	
210 - <240 minutes	0		0	
240 - <270 minutes	1	(1.6)	0	
270 - <300 minutes	0		0	
300 - <330 minutes	1	(1.6)	0	
330 - <360 minutes	0		0	

%: Percentage of hypoglycaemic episodes, BG: Blood glucose, E: Number of hypoglycaemic episodes. Duration of hypoglycaemic episodes is calculated in minutes with positive durations only contributing to derivations. Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. A hypoglycaemia alert value (level 1) was excluded from each of ONWARDS 1 and 6 as these had been erroneously included in trial clinical trial reports. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Duration of hypoglycaemic episodes in 30-minute intervals by trial and classification based on hypoglycaemic episodes form - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec		Daily basal insulin	
	E	(%)	E	(%)
>=360 minutes	4	(6.6)	1	(2.9)
Severe hypoglycaemia (level 3)				
Missing duration	0		2	
Non-missing duration	0		3	(100.0)
<30 minutes	0		2	(66.7)
30 - <60 minutes	0		1	(33.3)
60 - <90 minutes	0		0	
90 - <120 minutes	0		0	
120 - <150 minutes	0		0	
150 - <180 minutes	0		0	
180 - <210 minutes	0		0	
210 - <240 minutes	0		0	
240 - <270 minutes	0		0	
270 - <300 minutes	0		0	
300 - <330 minutes	0		0	
330 - <360 minutes	0		0	
>=360 minutes	0		0	
Severe (level 3) or clinically significant (level 2) hypoglycaemia				
Missing duration	43		44	
Non-missing duration	61	(100.0)	37	(100.0)
<30 minutes	32	(52.5)	33	(89.2)
30 - <60 minutes	9	(14.8)	1	(2.7)
60 - <90 minutes	11	(18.0)	1	(2.7)
90 - <120 minutes	2	(3.3)	1	(2.7)
120 - <150 minutes	0		0	
150 - <180 minutes	0		0	
180 - <210 minutes	1	(1.6)	0	
210 - <240 minutes	0		0	
240 - <270 minutes	1	(1.6)	0	
270 - <300 minutes	0		0	
300 - <330 minutes	1	(1.6)	0	
330 - <360 minutes	0		0	
>=360 minutes	4	(6.6)	1	(2.7)
ONWARDS 6				
Number of subjects	290		292	
Hypoglycaemia alert value (level 1)				
Missing duration	3853		2584	
Non-missing duration	6946	(100.0)	4817	(100.0)
<30 minutes	5035	(72.5)	3706	(76.9)
30 - <60 minutes	1087	(15.6)	695	(14.4)
60 - <90 minutes	495	(7.1)	240	(5.0)
90 - <120 minutes	70	(1.0)	33	(0.7)
120 - <150 minutes	68	(1.0)	31	(0.6)
150 - <180 minutes	31	(0.4)	12	(0.2)
180 - <210 minutes	28	(0.4)	18	(0.4)
210 - <240 minutes	14	(0.2)	11	(0.2)
240 - <270 minutes	15	(0.2)	14	(0.3)
270 - <300 minutes	18	(0.3)	5	(0.1)

%: Percentage of hypoglycaemic episodes, BG: Blood glucose, E: Number of hypoglycaemic episodes. Duration of hypoglycaemic episodes is calculated in minutes with positive durations only contributing to derivations. Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. A hypoglycaemia alert value (level 1) was excluded from each of ONWARDS 1 and 6 as these had been erroneously included in trial clinical trial reports. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Duration of hypoglycaemic episodes in 30-minute intervals by trial and classification based on hypoglycaemic episodes form - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec		Daily basal insulin	
	E	(%)	E	(%)
300 - <330 minutes	11	(0.2)	8	(0.2)
330 - <360 minutes	15	(0.2)	4	(0.1)
>=360 minutes	59	(0.8)	40	(0.8)
Clinically significant hypoglycaemia (level 2)				
Missing duration	970		413	
Non-missing duration	1819	(100.0)	1065	(100.0)
<30 minutes	1061	(58.3)	712	(66.9)
30 - <60 minutes	293	(16.1)	188	(17.7)
60 - <90 minutes	225	(12.4)	83	(7.8)
90 - <120 minutes	34	(1.9)	17	(1.6)
120 - <150 minutes	45	(2.5)	11	(1.0)
150 - <180 minutes	12	(0.7)	6	(0.6)
180 - <210 minutes	18	(1.0)	7	(0.7)
210 - <240 minutes	14	(0.8)	2	(0.2)
240 - <270 minutes	17	(0.9)	2	(0.2)
270 - <300 minutes	9	(0.5)	4	(0.4)
300 - <330 minutes	8	(0.4)	4	(0.4)
330 - <360 minutes	9	(0.5)	2	(0.2)
>=360 minutes	74	(4.1)	27	(2.5)
Severe hypoglycaemia (level 3)				
Missing duration	3		8	
Non-missing duration	44	(100.0)	9	(100.0)
<30 minutes	34	(77.3)	6	(66.7)
30 - <60 minutes	4	(9.1)	0	
60 - <90 minutes	2	(4.5)	1	(11.1)
90 - <120 minutes	2	(4.5)	0	
120 - <150 minutes	0		1	(11.1)
150 - <180 minutes	0		0	
180 - <210 minutes	1	(2.3)	1	(11.1)
210 - <240 minutes	0		0	
240 - <270 minutes	1	(2.3)	0	
270 - <300 minutes	0		0	
300 - <330 minutes	0		0	
330 - <360 minutes	0		0	
>=360 minutes	0		0	
Severe (level 3) or clinically significant (level 2) hypoglycaemia				
Missing duration	973		421	
Non-missing duration	1863	(100.0)	1074	(100.0)
<30 minutes	1095	(58.8)	718	(66.9)
30 - <60 minutes	297	(15.9)	188	(17.5)
60 - <90 minutes	227	(12.2)	84	(7.8)
90 - <120 minutes	36	(1.9)	17	(1.6)
120 - <150 minutes	45	(2.4)	12	(1.1)
150 - <180 minutes	12	(0.6)	6	(0.6)
180 - <210 minutes	19	(1.0)	8	(0.7)
210 - <240 minutes	14	(0.8)	2	(0.2)
240 - <270 minutes	18	(1.0)	2	(0.2)
270 - <300 minutes	9	(0.5)	4	(0.4)
300 - <330 minutes	8	(0.4)	4	(0.4)
330 - <360 minutes	9	(0.5)	2	(0.2)
>=360 minutes	74	(4.0)	27	(2.5)

%: Percentage of hypoglycaemic episodes, BG: Blood glucose, E: Number of hypoglycaemic episodes. Duration of hypoglycaemic episodes is calculated in minutes with positive durations only contributing to derivations. Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. A hypoglycaemia alert value (level 1) was excluded from each of ONWARDS 1 and 6 as these had been erroneously included in trial clinical trial reports. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

7.4.23 Duration of hypoglycaemic episodes by trial and classification - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec	Daily basal insulin
ONWARDS 1		
Number of hypoglycaemia alert value (level 1)	1447	631
Number of clinically significant hypoglycaemia (level 2)	143	75
Number of severe hypoglycaemia (level 3)	1	3
Number of severe (level 3) or clinically significant (level 2) hypoglycaemia	144	78
Hypoglycaemia alert value (level 1)		
E	851	371
Geom.mean (CV%)	19.3 (265.0)	18.8 (323.5)
Median	20.0	20.0
P25; P75	10.0; 45.0	9.0; 40.0
Min ; Max	1 ; 1440	1 ; 1440
Clinically significant hypoglycaemia (level 2)		
E	106	41
Geom.mean (CV%)	24.9 (680.2)	10.5 (556.9)
Median	31.5	14.0
P25; P75	5.2; 120.0	1.0; 36.0
Min ; Max	1 ; 1436	1 ; 505
Severe hypoglycaemia (level 3)		
E	0	1
Geom.mean (CV%)		54.0 (-)
Median		54.0
P25; P75		54.0; 54.0
Min ; Max		54 ; 54
Severe (level 3) or clinically significant (level 2) hypoglycaemia		
E	106	42
Geom.mean (CV%)	24.9 (680.2)	10.9 (551.0)
Median	31.5	14.0
P25; P75	5.2; 120.0	1.0; 39.0
Min ; Max	1 ; 1436	1 ; 505

BG: Blood glucose, CV: Coefficient of variation, E: Number of hypoglycaemic episodes with non-missing duration, P25: 25th percentile, P75: 75th percentile. Duration of hypoglycaemic episodes is calculated in minutes with positive durations only contributing to derivations. Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. A hypoglycaemia alert value (level 1) was excluded from each of ONWARDS 1 and 6 as these had been erroneously included in trial clinical trial reports. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Duration of hypoglycaemic episodes by trial and classification - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec	Daily basal insulin
ONWARDS 2		
Number of hypoglycaemia alert value (level 1)	1209	589
Number of clinically significant hypoglycaemia (level 2)	113	41
Number of severe hypoglycaemia (level 3)	0	1
Number of severe (level 3) or clinically significant (level 2) hypoglycaemia	113	42
Hypoglycaemia alert value (level 1)		
E	690	355
Geom.mean (CV%)	20.2 (229.4)	17.7 (180.8)
Median	24.0	19.0
P25; P75	11.2; 46.0	11.0; 35.5
Min ; Max	1 ; 1440	1 ; 1389
Clinically significant hypoglycaemia (level 2)		
E	64	31
Geom.mean (CV%)	29.2 (222.4)	18.1 (96.2)
Median	30.0	20.0
P25; P75	15.0; 48.5	13.0; 30.0
Min ; Max	1 ; 1407	1 ; 60
Severe hypoglycaemia (level 3)		
E	0	1
Geom.mean (CV%)		63.0 (-)
Median		63.0
P25; P75		63.0; 63.0
Min ; Max		63 ; 63
Severe (level 3) or clinically significant (level 2) hypoglycaemia		
E	64	32
Geom.mean (CV%)	29.2 (222.4)	18.9 (98.9)
Median	30.0	22.0
P25; P75	15.0; 48.5	13.0; 30.2
Min ; Max	1 ; 1407	1 ; 63

BG: Blood glucose, CV: Coefficient of variation, E: Number of hypoglycaemic episodes with non-missing duration, P25: 25th percentile, P75: 75th percentile. Duration of hypoglycaemic episodes is calculated in minutes with positive durations only contributing to derivations. Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. A hypoglycaemia alert value (level 1) was excluded from each of ONWARDS 1 and 6 as these had been erroneously included in trial clinical trial reports. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Duration of hypoglycaemic episodes by trial and classification - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec	Daily basal insulin
ONWARDS 3		
Number of hypoglycaemia alert value (level 1)	400	185
Number of clinically significant hypoglycaemia (level 2)	53	23
Number of severe hypoglycaemia (level 3)	0	2
Number of severe (level 3) or clinically significant (level 2) hypoglycaemia	53	25
Hypoglycaemia alert value (level 1)		
E	174	94
Geom.mean (CV%)	19.3 (244.7)	19.5 (133.1)
Median	18.0	20.0
P25; P75	10.0; 39.8	14.2; 32.8
Min ; Max	1 ; 1427	1 ; 766
Clinically significant hypoglycaemia (level 2)		
E	23	10
Geom.mean (CV%)	18.8 (437.3)	18.4 (114.2)
Median	19.0	18.0
P25; P75	5.5; 39.0	10.8; 37.0
Min ; Max	2 ; 1395	3 ; 62
Severe hypoglycaemia (level 3)		
E	0	2
Geom.mean (CV%)		21.4 (9.9)
Median		21.5
P25; P75		20.8; 22.2
Min ; Max		20 ; 23
Severe (level 3) or clinically significant (level 2) hypoglycaemia		
E	23	12
Geom.mean (CV%)	18.8 (437.3)	18.9 (99.4)
Median	19.0	20.0
P25; P75	5.5; 39.0	12.2; 31.0
Min ; Max	2 ; 1395	3 ; 62

BG: Blood glucose, CV: Coefficient of variation, E: Number of hypoglycaemic episodes with non-missing duration, P25: 25th percentile, P75: 75th percentile. Duration of hypoglycaemic episodes is calculated in minutes with positive durations only contributing to derivations. Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. A hypoglycaemia alert value (level 1) was excluded from each of ONWARDS 1 and 6 as these had been erroneously included in trial clinical trial reports. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Duration of hypoglycaemic episodes by trial and classification - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec	Daily basal insulin
ONWARDS 4		
Number of hypoglycaemia alert value (level 1)	5264	4145
Number of clinically significant hypoglycaemia (level 2)	937	935
Number of severe hypoglycaemia (level 3)	7	3
Number of severe (level 3) or clinically significant (level 2) hypoglycaemia	944	938
Hypoglycaemia alert value (level 1)		
E	3384	2219
Geom.mean (CV%)	18.7 (138.1)	18.1 (134.0)
Median	18.0	18.0
P25; P75	10.0; 32.2	11.0; 30.0
Min ; Max	1 ; 1423	1 ; 1242
Clinically significant hypoglycaemia (level 2)		
E	680	581
Geom.mean (CV%)	23.6 (151.1)	19.9 (137.1)
Median	21.5	18.0
P25; P75	14.0; 38.0	11.0; 32.0
Min ; Max	1 ; 1418	1 ; 877
Severe hypoglycaemia (level 3)		
E	5	3
Geom.mean (CV%)	40.6 (172.6)	40.2 (141.6)
Median	31.0	23.0
P25; P75	17.0; 58.0	22.0; 79.0
Min ; Max	14 ; 259	21 ; 135
Severe (level 3) or clinically significant (level 2) hypoglycaemia		
E	685	584
Geom.mean (CV%)	23.7 (151.3)	19.9 (137.2)
Median	22.0	18.0
P25; P75	14.0; 38.0	11.0; 32.0
Min ; Max	1 ; 1418	1 ; 877

BG: Blood glucose, CV: Coefficient of variation, E: Number of hypoglycaemic episodes with non-missing duration, P25: 25th percentile, P75: 75th percentile. Duration of hypoglycaemic episodes is calculated in minutes with positive durations only contributing to derivations. Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. A hypoglycaemia alert value (level 1) was excluded from each of ONWARDS 1 and 6 as these had been erroneously included in trial clinical trial reports. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Duration of hypoglycaemic episodes by trial and classification - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec	Daily basal insulin
ONWARDS 5		
Number of hypoglycaemia alert value (level 1)	1028	851
Number of clinically significant hypoglycaemia (level 2)	104	76
Number of severe hypoglycaemia (level 3)	0	5
Number of severe (level 3) or clinically significant (level 2) hypoglycaemia	104	81
Hypoglycaemia alert value (level 1)		
E	582	333
Geom.mean (CV%)	20.0 (252.3)	16.8 (169.1)
Median	20.0	17.0
P25; P75	9.0; 55.0	10.0; 30.0
Min ; Max	1 ; 1440	1 ; 1322
Clinically significant hypoglycaemia (level 2)		
E	61	34
Geom.mean (CV%)	19.3 (613.6)	17.1 (177.8)
Median	27.0	18.5
P25; P75	5.0; 60.0	13.2; 23.8
Min ; Max	1 ; 1438	1 ; 1438
Severe hypoglycaemia (level 3)		
E	0	3
Geom.mean (CV%)		13.4 (117.9)
Median		15.0
P25; P75		10.0; 23.5
Min ; Max		5 ; 32
Severe (level 3) or clinically significant (level 2) hypoglycaemia		
E	61	37
Geom.mean (CV%)	19.3 (613.6)	16.7 (170.1)
Median	27.0	18.0
P25; P75	5.0; 60.0	13.0; 24.0
Min ; Max	1 ; 1438	1 ; 1438

BG: Blood glucose, CV: Coefficient of variation, E: Number of hypoglycaemic episodes with non-missing duration, P25: 25th percentile, P75: 75th percentile. Duration of hypoglycaemic episodes is calculated in minutes with positive durations only contributing to derivations. Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. A hypoglycaemia alert value (level 1) was excluded from each of ONWARDS 1 and 6 as these had been erroneously included in trial clinical trial reports. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Duration of hypoglycaemic episodes by trial and classification - on-treatment/main-on-treatment - summary - safety analysis set

	Insulin icodec	Daily basal insulin
ONWARDS 6		
Number of hypoglycaemia alert value (level 1)	10799	7401
Number of clinically significant hypoglycaemia (level 2)	2789	1478
Number of severe hypoglycaemia (level 3)	47	17
Number of severe (level 3) or clinically significant (level 2) hypoglycaemia	2836	1495
Hypoglycaemia alert value (level 1)		
E	6946	4817
Geom.mean (CV%)	18.8 (126.7)	16.8 (126.3)
Median	19.0	17.0
P25; P75	11.0; 31.0	10.0; 28.0
Min ; Max	1 ; 1440	1 ; 1327
Clinically significant hypoglycaemia (level 2)		
E	1819	1065
Geom.mean (CV%)	28.2 (172.1)	21.8 (158.1)
Median	24.0	21.0
P25; P75	15.0; 60.0	13.0; 37.0
Min ; Max	1 ; 1326	1 ; 1048
Severe hypoglycaemia (level 3)		
E	44	9
Geom.mean (CV%)	18.6 (102.9)	27.7 (153.6)
Median	13.0	14.0
P25; P75	11.0; 19.5	12.0; 60.0
Min ; Max	9 ; 240	11 ; 180
Severe (level 3) or clinically significant (level 2) hypoglycaemia		
E	1863	1074
Geom.mean (CV%)	27.9 (170.7)	21.9 (158.0)
Median	24.0	21.0
P25; P75	14.0; 60.0	13.0; 37.0
Min ; Max	1 ; 1326	1 ; 1048

BG: Blood glucose, CV: Coefficient of variation, E: Number of hypoglycaemic episodes with non-missing duration, P25: 25th percentile, P75: 75th percentile. Duration of hypoglycaemic episodes is calculated in minutes with positive durations only contributing to derivations. Hypoglycaemia alert value (level 1): Plasma glucose value of < 3.9 mmol/L (70 mg/dL) and >= 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. A hypoglycaemia alert value (level 1) was excluded from each of ONWARDS 1 and 6 as these had been erroneously included in trial clinical trial reports. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

adhypo.xpt; variable(s): STDNM, ACAT4, TRAG1, AENDTM, ASTDTM; criteria: SAFFL == "Y", ANL06FL == "Y", ANELFL="Y"

7.4.24 Severe (level 3) or clinically significant hypoglycaemia (level 2) by trial - on-treatment/main-on-treatment - summary of categories of total number of episodes - safety analysis set

	Insulin icodec		Daily basal insulin	
	N	(%)	N	(%)
ONWARDS 1				
Number of subjects	492		492	
Severe (level 3) or clinically significant (level 2) hypoglycaemia				
No episodes	444	(90.2)	440	(89.4)
1-9 episodes	45	(9.1)	52	(10.6)
10-19 episodes	1	(0.2)	0	
>=20 episodes	2	(0.4)	0	
ONWARDS 2				
Number of subjects	262		263	
Severe (level 3) or clinically significant (level 2) hypoglycaemia				
No episodes	225	(85.9)	244	(92.8)
1-9 episodes	35	(13.4)	19	(7.2)
10-19 episodes	1	(0.4)	0	
>=20 episodes	1	(0.4)	0	
ONWARDS 3				
Number of subjects	293		294	
Severe (level 3) or clinically significant (level 2) hypoglycaemia				
No episodes	267	(91.1)	276	(93.9)
1-9 episodes	26	(8.9)	18	(6.1)
10-19 episodes	0		0	
>=20 episodes	0		0	
ONWARDS 4				
Number of subjects	291		291	
Severe (level 3) or clinically significant (level 2) hypoglycaemia				
No episodes	141	(48.5)	129	(44.3)
1-9 episodes	120	(41.2)	132	(45.4)
10-19 episodes	20	(6.9)	21	(7.2)
>=20 episodes	10	(3.4)	9	(3.1)
ONWARDS 5				
Number of subjects	542		538	
Severe (level 3) or clinically significant (level 2) hypoglycaemia				
No episodes	478	(88.2)	493	(91.6)
1-9 episodes	64	(11.8)	44	(8.2)
10-19 episodes	0		1	(0.2)
>=20 episodes	0		0	


%: Percentage of subjects, BG: Blood glucose, N: Number of subjects. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Severe (level 3) or clinically significant hypoglycaemia (level 2) by trial - on-treatment/main-on-treatment - summary of categories of total number of episodes - safety analysis set

	Insulin icodec		Daily basal insulin	
	N	(%)	N	(%)
ONWARDS 6				
Number of subjects	290		292	
Severe (level 3) or clinically significant (level 2) hypoglycaemia				
No episodes	43	(14.8)	69	(23.6)
1-9 episodes	139	(47.9)	171	(58.6)
10-19 episodes	65	(22.4)	35	(12.0)
>=20 episodes	43	(14.8)	17	(5.8)

%: Percentage of subjects, BG: Blood glucose, N: Number of subjects. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.


7.4.25 Severe (level 3) or clinically significant hypoglycaemia (level 2) by trial - ONWARDS 1-5 - on-treatment/main-on-treatment - bar plot of total number of episodes - safety analysis set



BG: Blood glucose. Safety analysis set. Observed data. Percentage of subjects with no episodes is omitted. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. OD analogues: Once-daily basal insulin analogues (IDeg, IGlar U100, IGlar U300). Data from ONWARDS 1-5, only main part of ONWARDS 1.

adsl.xpt; variable(s): TRT01A TRT01AN; criteria: STDNMN %in% c(1,2,3,4,5) & SAFFL == "Y"
adhypo.xpt; variable(s): TRTA TRTAN ACAT4 ACAT4N STDNM; criteria: SAFFL == "Y" & ANL06FL == "Y" & ANELFL == "Y" & STDNMN %in% c(1, 2, 3, 4, 5)
nn1436/nn1436-iss/submission_20221024_er
05DEC2022:12:58:43 - fhypodistbar/fhypolev23distbarow15ontsas.png

7.4.26 Severe (level 3) or clinically significant hypoglycaemia (level 2) - ONWARDS 6 - main-on-treatment - bar plot of total number of episodes - safety analysis set



BG: Blood glucose. Safety analysis set. Observed data. Clinically significant hypoglycaemia (level 2): Plasma glucose value of < 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3): Hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. Data from main part of ONWARDS 6.

adsl.xpt; variable(s): TRT01A TRT01AN; criteria: STDNMN == 6 & SAFFL == "Y"
adhypo.xpt; variable(s): TRTA TRTAN ACAT4 ACAT4N STDNM; criteria: SAFFL == "Y" & ANL06FL == "Y" & ANELFL == "Y" & STDNMN == 6
adhypoen.xpt; variable(s): TRTA TRTAN PARAM AVAL; criteria: SAFFL == "Y"

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:12:58:48 - fhypodistbar/fhypolev23distbarow6ontsas.png

7.4.27 Demographics and baseline characteristics by categories of total number of severe (level 3) or clinically significant hypoglycaemia (level 2) in insulin icodec arm - ONWARDS 6 - summary of categorical variables - safety analysis set

	No episodes		1-9 episodes		10-19 episodes		>= 20 episodes	
	N	(%)	N	(%)	N	(%)	N	(%)
Number of subjects	43		139		65		43	
Sex								
N	43	(100.0)	139	(100.0)	65	(100.0)	43	(100.0)
Male	31	(72.1)	73	(52.5)	37	(56.9)	24	(55.8)
Female	12	(27.9)	66	(47.5)	28	(43.1)	19	(44.2)
Race								
N	43	(100.0)	139	(100.0)	65	(100.0)	43	(100.0)
White	36	(83.7)	110	(79.1)	49	(75.4)	35	(81.4)
Black or African American	1	(2.3)	7	(5.0)	1	(1.5)	0	
Asian	6	(14.0)	22	(15.8)	15	(23.1)	8	(18.6)
BMI (kg/m^2)								
N	43	(100.0)	139	(100.0)	65	(100.0)	43	(100.0)
<25	10	(23.3)	49	(35.3)	29	(44.6)	17	(39.5)
>=25 - <30	20	(46.5)	59	(42.4)	19	(29.2)	20	(46.5)
>=30 - <35	10	(23.3)	20	(14.4)	13	(20.0)	3	(7.0)
>=35	3	(7.0)	11	(7.9)	4	(6.2)	3	(7.0)
Duration of diabetes								
N	43	(100.0)	139	(100.0)	65	(100.0)	43	(100.0)
<10 years	15	(34.9)	41	(29.5)	14	(21.5)	5	(11.6)
>=10 years	28	(65.1)	98	(70.5)	51	(78.5)	38	(88.4)
HbA1c								
N	43	(100.0)	139	(100.0)	65	(100.0)	43	(100.0)
<8% (<64 mmol/mol)	29	(67.4)	95	(68.3)	41	(63.1)	24	(55.8)
>=8% (>=64 mmol/mol)	14	(32.6)	44	(31.7)	24	(36.9)	19	(44.2)
Renal function (eGFR, mL/min/1.73m^2)								
N	43	(100.0)	139	(100.0)	65	(100.0)	43	(100.0)
Normal (>=90)	27	(62.8)	97	(69.8)	43	(66.2)	30	(69.8)
Mild impairment (>=60 - <90)	13	(30.2)	41	(29.5)	22	(33.8)	12	(27.9)
Moderate impairment (>=30 - <60)	3	(7.0)	1	(0.7)	0		1	(2.3)
Insulin treatment regimen								
N	43	(100.0)	139	(100.0)	65	(100.0)	43	(100.0)
Basal OD + Bolus TID	37	(86.0)	103	(74.1)	52	(80.0)	36	(83.7)
Basal BID + Bolus TID	1	(2.3)	20	(14.4)	7	(10.8)	5	(11.6)
Basal OD + Bolus BID	0		7	(5.0)	2	(3.1)	1	(2.3)
Basal OD + Bolus OTHER	1	(2.3)	5	(3.6)	1	(1.5)	1	(2.3)
Basal OD + Bolus QID	2	(4.7)	1	(0.7)	1	(1.5)	0	
Basal BID + Bolus >QID	0		1	(0.7)	1	(1.5)	0	
Basal BID + Bolus QID	1	(2.3)	0		1	(1.5)	0	
Basal BID + Bolus BID	1	(2.3)	0		0		0	
Basal BID + Bolus OTHER	0		1	(0.7)	0		0	
Basal OD + Bolus >QID	0		1	(0.7)	0		0	

%: Percentage of subjects, BMI: Body mass index, eGFR: Estimated glomerular filtration rate, N: Number of subjects, OD: Once daily, BID: Bis in die (twice a day), TID: Ter in die (three times a day), QID: Quarter in die (four times a day). Other frequency includes carb counters. Renal function categories are based on eGFR derived using the 2009 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation. The duration of diabetes is calculated as the time from date of diagnosis to the randomisation date. Data from main part of ONWARDS 6.

Demographics and baseline characteristics by categories of total number of severe (level 3) or clinically significant hypoglycaemia (level 2) in insulin icodec arm - ONWARDS 6 - summary of categorical variables - safety analysis set

	No episodes		1-9 episodes		10-19 episodes		>= 20 episodes	
	N	(%)	N	(%)	N	(%)	N	(%)
Permanent discontinuation of trial product								
N	43	(100.0)	139	(100.0)	65	(100.0)	43	(100.0)
No	38	(88.4)	128	(92.1)	63	(96.9)	43	(100.0)
Yes	5	(11.6)	11	(7.9)	2	(3.1)	0	
Withdrawn from trial								
N	43	(100.0)	139	(100.0)	65	(100.0)	43	(100.0)
No	38	(88.4)	133	(95.7)	65	(100.0)	43	(100.0)
Yes	5	(11.6)	6	(4.3)	0		0	

%: Percentage of subjects, BMI: Body mass index, eGFR: Estimated glomerular filtration rate, N: Number of subjects, OD: Once daily, BID: Bis in die (twice a day), TID: Ter in die (three times a day), QID: Quarter in die (four times a day). Other frequency includes carb counters. Renal function categories are based on eGFR derived using the 2009 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation. The duration of diabetes is calculated as the time from date of diagnosis to the randomisation date. Data from main part of ONWARDS 6.

adsl.xpt; variable(s): SEX, RACE2, ETHNIC, BMIG1BL, GFRGR1, CPCLGR1, DIABGR1, HBAGR1; criteria: SAFFL == "Y", TRT01A == "Ico"
adhypo.xpt; variable(s): TOTINSRG; criteria: SAFFL == "Y", ANL05FL == "Y", ANELFL="Y"
nn1436/nn1436-iss/submission_20221024_er
06DEC2022:12:52:41 - thypolev23basecat/thypolev23basecaticoow6sumsas.txt

7.4.28 Demographics and baseline characteristics by categories of total number of severe (level 3) or clinically significant hypoglycaemia (level 2) in insulin degludec arm - ONWARDS 6 - summary of categorical variables - safety analysis set

	No episodes		1-9 episodes		10-19 episodes		>= 20 episodes	
	N	(%)	N	(%)	N	(%)	N	(%)
Number of subjects	69		171		35		17	
Sex								
N	69	(100.0)	171	(100.0)	35	(100.0)	17	(100.0)
Male	40	(58.0)	106	(62.0)	19	(54.3)	7	(41.2)
Female	29	(42.0)	65	(38.0)	16	(45.7)	10	(58.8)
Race								
N	69	(100.0)	171	(100.0)	35	(100.0)	17	(100.0)
White	45	(65.2)	133	(77.8)	28	(80.0)	12	(70.6)
Black or African American	1	(1.4)	1	(0.6)	0		0	
Asian	23	(33.3)	37	(21.6)	7	(20.0)	5	(29.4)
BMI (kg/m^2)								
N	69	(100.0)	171	(100.0)	35	(100.0)	17	(100.0)
<25	26	(37.7)	86	(50.3)	16	(45.7)	7	(41.2)
>=25 - <30	24	(34.8)	58	(33.9)	13	(37.1)	7	(41.2)
>=30 - <35	15	(21.7)	18	(10.5)	5	(14.3)	3	(17.6)
>=35	4	(5.8)	9	(5.3)	1	(2.9)	0	
Duration of diabetes								
N	69	(100.0)	171	(100.0)	35	(100.0)	17	(100.0)
<10 years	19	(27.5)	53	(31.0)	7	(20.0)	3	(17.6)
>=10 years	50	(72.5)	118	(69.0)	28	(80.0)	14	(82.4)
HbA1c								
N	69	(100.0)	171	(100.0)	35	(100.0)	17	(100.0)
<8% (<64 mmol/mol)	42	(60.9)	118	(69.0)	20	(57.1)	9	(52.9)
>=8% (>=64 mmol/mol)	27	(39.1)	53	(31.0)	15	(42.9)	8	(47.1)
Renal function (eGFR, mL/min/1.73m^2)								
N	69	(100.0)	171	(100.0)	35	(100.0)	17	(100.0)
Normal (>=90)	39	(56.5)	115	(67.3)	24	(68.6)	12	(70.6)
Mild impairment (>=60 - <90)	27	(39.1)	50	(29.2)	11	(31.4)	5	(29.4)
Moderate impairment (>=30 - <60)	3	(4.3)	6	(3.5)	0		0	
Insulin treatment regimen								
N	69	(100.0)	171	(100.0)	35	(100.0)	17	(100.0)
Basal OD + Bolus TID	57	(82.6)	131	(76.6)	30	(85.7)	15	(88.2)
Basal BID + Bolus TID	4	(5.8)	25	(14.6)	4	(11.4)	2	(11.8)
Basal OD + Bolus BID	2	(2.9)	5	(2.9)	1	(2.9)	0	
Basal OD + Bolus OTHER	2	(2.9)	4	(2.3)	0		0	
Basal OD + Bolus QID	1	(1.4)	0		0		0	
Basal BID + Bolus QID	1	(1.4)	2	(1.2)	0		0	
Basal BID + Bolus OTHER	1	(1.4)	0		0		0	
Basal OD + Bolus >QID	1	(1.4)	4	(2.3)	0		0	

%: Percentage of subjects, BMI: Body mass index, eGFR: Estimated glomerular filtration rate, N: Number of subjects, OD: Once daily, BID: Bis in die (twice a day), TID: Ter in die (three times a day), QID: Quarter in die (four times a day). Other frequency includes carb counters. Renal function categories are based on eGFR derived using the 2009 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation. The duration of diabetes is calculated as the time from date of diagnosis to the randomisation date. Data from main part of ONWARDS 6.

Demographics and baseline characteristics by categories of total number of severe (level 3) or clinically significant hypoglycaemia (level 2) in insulin degludec arm - ONWARDS 6 - summary of categorical variables - safety analysis set

	No episodes		1-9 episodes		10-19 episodes		>= 20 episodes	
	N	(%)	N	(%)	N	(%)	N	(%)
Permanent discontinuation of trial product								
N	69	(100.0)	171	(100.0)	35	(100.0)	17	(100.0)
No	65	(94.2)	167	(97.7)	34	(97.1)	17	(100.0)
Yes	4	(5.8)	4	(2.3)	1	(2.9)	0	
Withdrawn from trial								
N	69	(100.0)	171	(100.0)	35	(100.0)	17	(100.0)
No	66	(95.7)	167	(97.7)	34	(97.1)	17	(100.0)
Yes	3	(4.3)	4	(2.3)	1	(2.9)	0	

%: Percentage of subjects, BMI: Body mass index, eGFR: Estimated glomerular filtration rate, N: Number of subjects, OD: Once daily, BID: Bis in die (twice a day), TID: Ter in die (three times a day), QID: Quarter in die (four times a day). Other frequency includes carb counters. Renal function categories are based on eGFR derived using the 2009 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation. The duration of diabetes is calculated as the time from date of diagnosis to the randomisation date. Data from main part of ONWARDS 6.

7.4.29 Demographics and baseline characteristics by categories of total number of severe (level 3) or clinically significant hypoglycaemia (level 2) in insulin icodec arm - ONWARDS 6 - summary of continuous variables - safety analysis set

	No episodes	1-9 episodes	10-19 episodes	>= 20 episodes
Number of subjects	43	139	65	43
Age (years)				
N	43	139	65	43
Mean (SD)	48.74 (12.90)	44.17 (14.76)	41.71 (12.91)	42.26 (13.71)
Median	51.00	43.00	40.00	40.00
Min ; Max	27.00 ; 76.00	18.00 ; 82.00	19.00 ; 73.00	21.00 ; 68.00
Body weight (kg)				
N	43	139	65	43
Mean (SD)	82.88 (13.50)	78.98 (17.26)	77.01 (18.99)	75.82 (19.87)
Median	83.30	77.10	77.50	73.90
Min ; Max	56.50 ; 123.50	41.30 ; 135.50	42.90 ; 117.40	39.60 ; 160.30
BMI (kg/m^2)				
N	43	139	65	43
Mean (SD)	28.11 (4.32)	26.96 (5.25)	26.25 (4.94)	26.09 (4.99)
Median	27.09	26.12	25.63	26.55
Min ; Max	21.30 ; 38.63	17.41 ; 46.61	16.55 ; 37.69	18.58 ; 43.48
Duration of diabetes (years)				
N	43	139	65	43
Mean (SD)	16.45 (13.62)	19.88 (13.28)	20.69 (13.69)	23.23 (11.14)
Median	13.75	18.76	17.10	23.69
Min ; Max	1.13 ; 49.38	1.28 ; 59.57	1.79 ; 56.71	3.08 ; 48.52
HbA1c (%)				
N	43	139	65	43
Mean (SD)	7.42 (1.04)	7.56 (0.93)	7.63 (0.97)	7.80 (0.94)
Median	7.40	7.50	7.70	7.80
Min ; Max	5.40 ; 9.60	5.10 ; 9.60	5.70 ; 9.30	6.20 ; 10.00
FPG (mmol/L)				
N	40	133	62	41
Mean (SD)	9.20 (3.18)	9.67 (3.71)	10.79 (4.47)	10.29 (5.26)
Median	8.55	9.00	9.90	9.90
Min ; Max	3.20 ; 16.80	3.60 ; 22.00	3.30 ; 21.90	2.40 ; 24.50

BMI: Body mass index, FPG: Fasting plasma glucose, N: Number of subjects, SD: Standard deviation.
The duration of diabetes is calculated as the time from date of diagnosis to the randomisation date.
Data from main part of ONWARDS 6.

7.4.30 Demographics and baseline characteristics by categories of total number of severe (level 3) or clinically significant hypoglycaemia (level 2) in insulin degludec arm - ONWARDS 6 - summary of continuous variables - safety analysis set

	No episodes	1-9 episodes	10-19 episodes	>= 20 episodes
Number of subjects	69	171	35	17
Age (years)				
N	69	171	35	17
Mean (SD)	48.86 (14.00)	42.94 (13.92)	42.17 (13.37)	42.35 (14.03)
Median	49.00	43.00	39.00	42.00
Min ; Max	18.00 ; 79.00	18.00 ; 76.00	19.00 ; 67.00	23.00 ; 71.00
Body weight (kg)				
N	69	171	35	17
Mean (SD)	77.60 (18.06)	77.04 (16.47)	76.96 (18.02)	75.96 (12.82)
Median	75.50	75.50	80.30	77.00
Min ; Max	41.30 ; 124.10	41.00 ; 131.60	44.70 ; 116.50	52.00 ; 105.00
BMI (kg/m^2)				
N	69	171	35	17
Mean (SD)	27.23 (4.97)	25.86 (4.43)	25.67 (4.25)	26.33 (3.92)
Median	26.58	24.97	25.12	25.83
Min ; Max	19.31 ; 39.53	16.21 ; 40.32	18.98 ; 35.01	20.31 ; 33.52
Duration of diabetes (years)				
N	69	171	35	17
Mean (SD)	18.38 (13.30)	18.25 (12.66)	22.36 (13.22)	21.82 (12.30)
Median	16.22	15.73	21.28	19.46
Min ; Max	1.23 ; 59.53	1.11 ; 62.46	2.23 ; 53.63	5.43 ; 53.76
HbA1c (%)				
N	69	171	35	17
Mean (SD)	7.67 (0.96)	7.55 (0.92)	7.83 (0.86)	7.96 (0.97)
Median	7.70	7.50	7.70	7.70
Min ; Max	5.80 ; 10.10	5.50 ; 9.90	6.10 ; 10.00	6.10 ; 9.80
FPG (mmol/L)				
N	69	169	33	16
Mean (SD)	9.61 (3.88)	9.54 (3.97)	9.83 (4.15)	9.01 (4.95)
Median	8.70	8.70	10.40	7.95
Min ; Max	4.40 ; 27.70	2.20 ; 21.10	2.20 ; 18.40	3.40 ; 21.40

BMI: Body mass index, FPG: Fasting plasma glucose, N: Number of subjects, SD: Standard deviation.
The duration of diabetes is calculated as the time from date of diagnosis to the randomisation date.
Data from main part of ONWARDS 6.

インスリン イコデク（遺伝子組換え）

2.7.4.7. 付録
5. 臨床検査値の評価

ノボ ノルディスク ファーマ株式会社

Table of contents

Page

7.5.1 Haematology by treatment week - change from baseline - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool....3
7.5.2 Haematology by treatment week - change from baseline - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool....14
7.5.3 Haematology by trial - erythrocytes - baseline and end-of-treatment - on-treatment/main-on-treatment - box plot - safety analysis set....25
7.5.4 Haematology by trial - haematocrit - baseline and end-of-treatment - on-treatment/main-on-treatment - box plot - safety analysis set....26
7.5.5 Haematology by trial - haemoglobin - baseline and end-of-treatment - on-treatment/main-on-treatment - box plot - safety analysis set....27
7.5.6 Haematology by trial - leukocytes - baseline and end-of-treatment - on-treatment/main-on-treatment - box plot - safety analysis set....28
7.5.7 Haematology by trial - thrombocytes - baseline and end-of-treatment - on-treatment/main-on-treatment - box plot - safety analysis set....29
7.5.8 Haematology by trial - eosinophils - baseline and end-of-treatment - on-treatment/main-on-treatment - box plot - safety analysis set....30
7.5.9 Haematology by trial - neutrophils - baseline and end-of-treatment - on-treatment/main-on-treatment - box plot - safety analysis set....31
7.5.10 Haematology by trial - basophils - baseline and end-of-treatment - on-treatment/main-on-treatment - box plot - safety analysis set....32
7.5.11 Haematology by trial - monocytes - baseline and end-of-treatment - on-treatment/main-on-treatment - box plot - safety analysis set....33
7.5.12 Haematology by trial - lymphocytes - baseline and end-of-treatment - on-treatment/main-on-treatment - box plot - safety analysis set....34
7.5.13 Biochemistry by treatment week - change from baseline - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool....35
7.5.14 Biochemistry by treatment week - change from baseline - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool....45
7.5.15 Biochemistry by trial - albumin serum - baseline and end-of-treatment - on-treatment/main-on-treatment - box plot - safety analysis set....55
7.5.16 Biochemistry by trial - alkaline phosphatase - baseline and end-of-treatment - on-treatment/main-on-treatment - box plot - safety analysis set....56
7.5.17 Biochemistry by trial - alanine aminotransferase - baseline and end-of-treatment - on-treatment/main-on-treatment - box plot - safety analysis set....57
7.5.18 Biochemistry by trial - aspartate aminotransferase - baseline and end-of-treatment - on-treatment/main-on-treatment - box plot - safety analysis set....58
7.5.19 Biochemistry by trial - creatinine - baseline and end-of-treatment - on-treatment/main-on-treatment - box plot - safety analysis set....59
7.5.20 Biochemistry by trial - potassium - baseline and end-of-treatment - on-treatment/main-on-treatment - box plot - safety analysis set....60
7.5.21 Biochemistry by trial - sodium - baseline and end-of-treatment - on-treatment/main-on-treatment - box plot - safety analysis set....61

7.5.22 Biochemistry by trial - total bilirubin - baseline and end-of-treatment - on-treatment/main-on-treatment - box plot - safety analysis set 62
7.5.23 HDL by treatment week - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool 63
7.5.24 HDL by treatment week - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool 65
7.5.25 HDL by treatment week and trial - on-treatment/main-on-treatment - geometric mean plot - safety analysis set 67
7.5.26 LDL by treatment week - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool 68
7.5.27 LDL by treatment week - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool 70
7.5.28 LDL by treatment week and trial - on-treatment/main-on-treatment - geometric mean plot - safety analysis set 72
7.5.29 Triglycerides by treatment week - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool 73
7.5.30 Triglycerides by treatment week - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool 75
7.5.31 Triglycerides by treatment week and trial - on-treatment/main-on-treatment - geometric mean plot - safety analysis set 77
7.5.32 Total cholesterol by treatment week - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool 78
7.5.33 Total cholesterol by treatment week - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool 80
7.5.34 Total cholesterol by treatment week and trial - on-treatment/main-on-treatment - geometric mean plot - safety analysis set 82
7.5.35 Free fatty acids by treatment week - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool 83
7.5.36 Free fatty acids by treatment week - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool 85
7.5.37 Free fatty acids by treatment week and trial - on-treatment/main-on-treatment - geometric mean plot - safety analysis set 87
7.5.38 eGFR by treatment week - change from baseline - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool 88
7.5.39 eGFR by treatment week - change from baseline - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool 89
7.5.40 eGFR by trial - baseline and end-of-treatment - on-treatment/main-on-treatment - box plot - safety analysis set 90
7.5.41 Liver parameters by categories of highest (ALT, AST, total bilirubin) or lowest (albumin) post baseline value - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool 91
7.5.42 Liver parameters by categories of highest (ALT, AST, total bilirubin) or lowest (albumin) post baseline value - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool 92

7.5 Clinical laboratory evaluations

7.5.1 Haematology by treatment week - change from baseline - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec	Daily basal insulin
Number of subjects	2170	2170
Change from Baseline, Erythrocytes (10^12/L)		
Week 10 visit		
N	1543	1557
Mean (SD)	-0.03 (0.27)	-0.02 (0.26)
Median	0.00	0.00
Min ; Max	-1.40 ; 1.50	-1.60 ; 1.70
Week 26 visit		
N	1515	1520
Mean (SD)	-0.01 (0.29)	-0.01 (0.28)
Median	0.00	0.00
Min ; Max	-1.20 ; 1.80	-1.40 ; 1.30
Week 36 visit		
N	461	464
Mean (SD)	-0.05 (0.29)	-0.07 (0.28)
Median	0.00	-0.10
Min ; Max	-1.30 ; 1.60	-1.50 ; 1.60
Week 52 visit		
N	916	930
Mean (SD)	-0.03 (0.29)	-0.04 (0.30)
Median	0.00	0.00
Min ; Max	-1.20 ; 2.20	-2.40 ; 1.20
End-of-treatment visit		
N	1959	1979
Mean (SD)	-0.01 (0.29)	-0.00 (0.29)
Median	0.00	0.00
Min ; Max	-1.20 ; 2.20	-2.40 ; 1.30
Lowest post baseline value		
N	2083	2085
Mean (SD)	-0.11 (0.28)	-0.10 (0.28)
Median	-0.10	-0.10
Min ; Max	-1.40 ; 1.50	-2.40 ; 1.30
Highest post baseline value		
N	2083	2085
Mean (SD)	0.07 (0.28)	0.07 (0.28)
Median	0.10	0.10
Min ; Max	-1.20 ; 2.20	-2.40 ; 1.70

N: Number of subjects, SD: Standard deviation. Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6. Eosinophils, neutrophils, basophils, monocytes and lymphocytes were not collected in ONWARDS 6.

Haematology by treatment week - change from baseline - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec	Daily basal insulin
Change from Baseline, Haematocrit Blood (%)		
Week 10 visit		
N	1444	1441
Mean (SD)	-0.26 (2.69)	-0.20 (2.54)
Median	-0.20	-0.30
Min ; Max	-29.60 ; 12.60	-15.20 ; 13.60
Week 26 visit		
N	1398	1407
Mean (SD)	-0.53 (2.74)	-0.56 (2.62)
Median	-0.70	-0.50
Min ; Max	-12.20 ; 19.70	-12.80 ; 14.60
Week 36 visit		
N	440	444
Mean (SD)	-0.70 (2.70)	-0.95 (2.68)
Median	-0.70	-0.90
Min ; Max	-9.10 ; 15.70	-13.90 ; 9.40
Week 52 visit		
N	841	841
Mean (SD)	-0.77 (2.88)	-0.70 (2.88)
Median	-0.90	-0.70
Min ; Max	-14.30 ; 13.30	-12.10 ; 15.40
End-of-treatment visit		
N	1797	1799
Mean (SD)	-0.70 (2.78)	-0.59 (2.78)
Median	-0.80	-0.50
Min ; Max	-14.30 ; 14.30	-12.80 ; 15.40
Lowest post baseline value		
N	1987	1977
Mean (SD)	-1.33 (2.70)	-1.19 (2.66)
Median	-1.30	-1.20
Min ; Max	-29.60 ; 12.00	-15.20 ; 15.40
Highest post baseline value		
N	1987	1977
Mean (SD)	0.26 (2.82)	0.32 (2.67)
Median	0.20	0.30
Min ; Max	-29.60 ; 19.70	-11.80 ; 15.40

N: Number of subjects, SD: Standard deviation. Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6. Eosinophils, neutrophils, basophils, monocytes and lymphocytes were not collected in ONWARDS 6.

adsl.xpt; variable(s): NA; criteria: SAFFL == "Y" & POOLGR2 == "Phase 3a pool"
adlb.xpt; variable(s): CHG; criteria: SAFFL == "Y" & PARCAT1 == "HAEMATOLOGY" & PARAMCD %in% c("RBCB", "HCTB", "HGBB2", "HGBB", "WBCB", "PLATB", "BASOLEB", "EOSLEB", "LYMLEB", "MONOLEB", "NEUTLEB") & ANELFL == "Y" & ANL06FL == "Y" & DTYPE %in% c("", "HALFLOQ", "ULOQ", "MINIMUM", "MAXIMUM", "LVPD", "EOT") & CHG != " " & POOLGR2 == "Phase 3a pool"
nn1436/nn1436-iss/submission_20221024_er
05DEC2022:13:01:05 - tsumcont/tlbchbhaematologysumontp3asas.txt

Haematology by treatment week - change from baseline - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec	Daily basal insulin
Change from Baseline, Haemoglobin Blood (mmol/L)		
Week 10 visit		
N	1543	1556
Mean (SD)	-0.08 (0.49)	-0.05 (0.47)
Median	-0.12	-0.06
Min ; Max	-2.23 ; 2.42	-3.16 ; 3.29
Week 26 visit		
N	1515	1520
Mean (SD)	-0.12 (0.54)	-0.10 (0.50)
Median	-0.12	-0.06
Min ; Max	-2.85 ; 3.97	-2.29 ; 3.10
Week 36 visit		
N	461	464
Mean (SD)	-0.13 (0.55)	-0.16 (0.54)
Median	-0.12	-0.19
Min ; Max	-2.29 ; 3.41	-2.67 ; 2.05
Week 52 visit		
N	914	930
Mean (SD)	-0.28 (0.57)	-0.26 (0.57)
Median	-0.25	-0.25
Min ; Max	-3.35 ; 3.10	-3.84 ; 2.36
End-of-treatment visit		
N	1957	1979
Mean (SD)	-0.19 (0.55)	-0.15 (0.54)
Median	-0.19	-0.12
Min ; Max	-3.35 ; 3.10	-3.84 ; 3.10
Lowest post baseline value		
N	2081	2085
Mean (SD)	-0.32 (0.51)	-0.27 (0.51)
Median	-0.31	-0.25
Min ; Max	-3.35 ; 2.42	-3.84 ; 3.04
Highest post baseline value		
N	2081	2085
Mean (SD)	-0.00 (0.54)	0.02 (0.53)
Median	0.00	0.00
Min ; Max	-2.54 ; 3.97	-3.84 ; 3.29

N: Number of subjects, SD: Standard deviation. Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6. Eosinophils, neutrophils, basophils, monocytes and lymphocytes were not collected in ONWARDS 6.

Haematology by treatment week - change from baseline - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec	Daily basal insulin
Change from Baseline, Haemoglobin Blood (g/dL)		
Week 10 visit		
N	1543	1556
Mean (SD)	-0.13 (0.79)	-0.07 (0.76)
Median	-0.20	-0.10
Min ; Max	-3.60 ; 3.90	-5.10 ; 5.30
Week 26 visit		
N	1515	1520
Mean (SD)	-0.19 (0.87)	-0.16 (0.80)
Median	-0.20	-0.10
Min ; Max	-4.60 ; 6.40	-3.70 ; 5.00
Week 36 visit		
N	461	464
Mean (SD)	-0.21 (0.89)	-0.26 (0.87)
Median	-0.20	-0.30
Min ; Max	-3.70 ; 5.50	-4.30 ; 3.30
Week 52 visit		
N	914	930
Mean (SD)	-0.45 (0.91)	-0.42 (0.92)
Median	-0.40	-0.40
Min ; Max	-5.40 ; 5.00	-6.20 ; 3.80
End-of-treatment visit		
N	1957	1979
Mean (SD)	-0.31 (0.89)	-0.25 (0.88)
Median	-0.30	-0.20
Min ; Max	-5.40 ; 5.00	-6.20 ; 5.00
Lowest post baseline value		
N	2081	2085
Mean (SD)	-0.51 (0.83)	-0.44 (0.82)
Median	-0.50	-0.40
Min ; Max	-5.40 ; 3.90	-6.20 ; 4.90
Highest post baseline value		
N	2081	2085
Mean (SD)	-0.00 (0.87)	0.03 (0.85)
Median	0.00	0.00
Min ; Max	-4.10 ; 6.40	-6.20 ; 5.30

N: Number of subjects, SD: Standard deviation. Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6. Eosinophils, neutrophils, basophils, monocytes and lymphocytes were not collected in ONWARDS 6.

adsl.xpt; variable(s): NA; criteria: SAFFL == "Y" & POOLGR2 == "Phase 3a pool"
adlb.xpt; variable(s): CHG; criteria: SAFFL == "Y" & PARCAT1 == "HAEMATOLOGY" & PARAMCD %in% c("RBCB", "HCTB", "HGBB2", "HGBB", "WBCB", "PLATB", "BASOLEB", "EOSLEB", "LYMLEB", "MONOLEB", "NEUTLEB") & ANELFL == "Y" & ANL06FL == "Y" & DTYPE %in% c("", "HALFLOQ", "ULOQ", "MINIMUM", "MAXIMUM", "LVPD", "EOT") & CHG != " " & POOLGR2 == "Phase 3a pool"
nn1436/nn1436-iss/submission_20221024_er
05DEC2022:13:01:05 - tsumcont/tlbchbhaematologysumontp3asas.txt

Haematology by treatment week - change from baseline - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec	Daily basal insulin
Change from Baseline, Leukocytes (10^9/L)		
Week 10 visit		
N	1535	1548
Mean (SD)	-0.24 (1.50)	-0.25 (1.43)
Median	-0.20	-0.25
Min ; Max	-7.00 ; 8.50	-7.00 ; 6.60
Week 26 visit		
N	1509	1514
Mean (SD)	-0.27 (1.58)	-0.32 (1.49)
Median	-0.20	-0.30
Min ; Max	-7.50 ; 11.20	-7.80 ; 8.10
Week 36 visit		
N	461	463
Mean (SD)	0.09 (1.79)	-0.08 (1.74)
Median	0.00	-0.10
Min ; Max	-7.00 ; 8.20	-7.30 ; 9.40
Week 52 visit		
N	914	928
Mean (SD)	-0.19 (1.56)	-0.31 (1.65)
Median	-0.20	-0.30
Min ; Max	-7.70 ; 6.90	-9.40 ; 11.30
End-of-treatment visit		
N	1952	1972
Mean (SD)	-0.28 (1.56)	-0.34 (1.57)
Median	-0.30	-0.40
Min ; Max	-7.70 ; 11.20	-9.40 ; 11.30
Lowest post baseline value		
N	2077	2079
Mean (SD)	-0.70 (1.47)	-0.74 (1.46)
Median	-0.60	-0.70
Min ; Max	-7.70 ; 6.20	-9.40 ; 7.00
Highest post baseline value		
N	2077	2079
Mean (SD)	0.27 (1.64)	0.22 (1.58)
Median	0.20	0.20
Min ; Max	-7.70 ; 11.20	-9.40 ; 11.30

N: Number of subjects, SD: Standard deviation. Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6. Eosinophils, neutrophils, basophils, monocytes and lymphocytes were not collected in ONWARDS 6.

Haematology by treatment week - change from baseline - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec	Daily basal insulin
Change from Baseline, Thrombocytes (10^9/L)		
Week 10 visit		
N	1525	1540
Mean (SD)	2.06 (38.77)	1.51 (36.78)
Median	2.00	2.00
Min ; Max	-318.00 ; 290.00	-191.00 ; 215.00
Week 26 visit		
N	1498	1502
Mean (SD)	5.73 (40.82)	3.45 (38.65)
Median	5.00	3.00
Min ; Max	-198.00 ; 337.00	-304.00 ; 255.00
Week 36 visit		
N	456	461
Mean (SD)	13.44 (43.53)	6.57 (41.00)
Median	11.50	5.00
Min ; Max	-154.00 ; 352.00	-165.00 ; 236.00
Week 52 visit		
N	905	920
Mean (SD)	11.23 (42.14)	7.90 (44.47)
Median	10.00	6.50
Min ; Max	-232.00 ; 300.00	-183.00 ; 290.00
End-of-treatment visit		
N	1937	1954
Mean (SD)	7.37 (42.08)	4.89 (41.13)
Median	6.00	4.00
Min ; Max	-232.00 ; 337.00	-304.00 ; 290.00
Lowest post baseline value		
N	2065	2064
Mean (SD)	-6.38 (37.65)	-7.03 (38.02)
Median	-5.00	-5.00
Min ; Max	-318.00 ; 180.00	-304.00 ; 288.00
Highest post baseline value		
N	2065	2064
Mean (SD)	18.53 (43.55)	15.59 (40.87)
Median	16.00	13.00
Min ; Max	-232.00 ; 352.00	-191.00 ; 290.00

N: Number of subjects, SD: Standard deviation. Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6. Eosinophils, neutrophils, basophils, monocytes and lymphocytes were not collected in ONWARDS 6.

Haematology by treatment week - change from baseline - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec	Daily basal insulin
Change from Baseline, Basophils Blood (%)		
Week 10 visit		
N	1238	1231
Mean (SD)	-0.04 (0.44)	-0.03 (0.45)
Median	0.00	0.00
Min ; Max	-2.00 ; 1.50	-1.50 ; 1.40
Week 26 visit		
N	1208	1207
Mean (SD)	-0.01 (0.55)	-0.02 (0.45)
Median	0.00	0.00
Min ; Max	-2.50 ; 9.90	-1.70 ; 1.50
Week 36 visit		
N	455	454
Mean (SD)	-0.05 (0.46)	-0.07 (0.46)
Median	-0.10	-0.10
Min ; Max	-1.30 ; 1.20	-1.80 ; 1.30
Week 52 visit		
N	885	899
Mean (SD)	-0.04 (0.45)	-0.08 (0.44)
Median	-0.10	-0.10
Min ; Max	-1.30 ; 2.90	-1.60 ; 2.40
End-of-treatment visit		
N	1633	1645
Mean (SD)	-0.01 (0.52)	-0.03 (0.44)
Median	0.00	0.00
Min ; Max	-2.50 ; 9.90	-1.70 ; 2.40
Lowest post baseline value		
N	1762	1756
Mean (SD)	-0.17 (0.45)	-0.19 (0.45)
Median	-0.20	-0.20
Min ; Max	-2.50 ; 2.90	-1.80 ; 2.40
Highest post baseline value		
N	1762	1756
Mean (SD)	0.13 (0.50)	0.10 (0.43)
Median	0.10	0.10
Min ; Max	-2.10 ; 9.90	-1.30 ; 2.40

N: Number of subjects, SD: Standard deviation. Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6. Eosinophils, neutrophils, basophils, monocytes and lymphocytes were not collected in ONWARDS 6.

adsl.xpt; variable(s): NA; criteria: SAFFL == "Y" & POOLGR2 == "Phase 3a pool"
adlb.xpt; variable(s): CHG; criteria: SAFFL == "Y" & PARCAT1 == "HAEMATOLOGY" & PARAMCD %in% c("RBCB", "HCTB", "HGBB2", "HGBB", "WBCB", "PLATB", "BASOLEB", "EOSLEB", "LYMLEB", "MONOLEB", "NEUTLEB") & ANELFL == "Y" & ANL06FL == "Y" & DTYPE %in% c("", "HALFLOQ", "ULOQ", "MINIMUM", "MAXIMUM", "LVPD", "EOT") & CHG != " " & POOLGR2 == "Phase 3a pool"
nn1436/nn1436-iss/submission_20221024_er
05DEC2022:13:01:05 - tsumcont/tlbchbhaematologysumontp3asas.txt

Haematology by treatment week - change from baseline - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec	Daily basal insulin
Change from Baseline, Eosinophils Blood (%)		
Week 10 visit		
N	1238	1231
Mean (SD)	0.20 (1.97)	0.15 (2.16)
Median	0.20	0.10
Min ; Max	-27.80 ; 9.10	-16.60 ; 16.40
Week 26 visit		
N	1208	1207
Mean (SD)	0.40 (2.24)	0.15 (2.43)
Median	0.30	0.20
Min ; Max	-32.00 ; 14.00	-32.60 ; 13.60
Week 36 visit		
N	455	454
Mean (SD)	0.39 (1.92)	0.26 (2.34)
Median	0.30	0.30
Min ; Max	-6.90 ; 14.00	-20.10 ; 12.50
Week 52 visit		
N	885	899
Mean (SD)	0.42 (2.03)	0.19 (2.16)
Median	0.30	0.20
Min ; Max	-9.20 ; 18.10	-21.00 ; 13.70
End-of-treatment visit		
N	1633	1645
Mean (SD)	0.40 (2.16)	0.17 (2.24)
Median	0.30	0.20
Min ; Max	-32.00 ; 18.10	-21.00 ; 13.70
Lowest post baseline value		
N	1762	1756
Mean (SD)	-0.22 (1.89)	-0.39 (2.05)
Median	-0.10	-0.20
Min ; Max	-32.00 ; 13.10	-32.60 ; 9.50
Highest post baseline value		
N	1762	1756
Mean (SD)	0.94 (2.33)	0.76 (2.39)
Median	0.70	0.50
Min ; Max	-27.80 ; 18.10	-16.60 ; 16.40

N: Number of subjects, SD: Standard deviation. Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6. Eosinophils, neutrophils, basophils, monocytes and lymphocytes were not collected in ONWARDS 6.

Haematology by treatment week - change from baseline - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec	Daily basal insulin
Change from Baseline, Lymphocytes Blood (%)		
Week 10 visit		
N	1238	1232
Mean (SD)	0.29 (6.63)	0.39 (6.74)
Median	0.10	0.70
Min ; Max	-62.70 ; 29.20	-48.80 ; 34.50
Week 26 visit		
N	1208	1207
Mean (SD)	-0.27 (6.96)	0.05 (6.56)
Median	-0.50	0.20
Min ; Max	-50.50 ; 43.20	-50.40 ; 22.70
Week 36 visit		
N	455	454
Mean (SD)	-0.82 (7.60)	-0.17 (7.14)
Median	-0.50	0.05
Min ; Max	-35.30 ; 25.40	-34.20 ; 26.40
Week 52 visit		
N	885	899
Mean (SD)	-0.78 (6.37)	-0.31 (6.63)
Median	-0.70	-0.50
Min ; Max	-26.40 ; 29.10	-32.20 ; 30.90
End-of-treatment visit		
N	1633	1645
Mean (SD)	-0.46 (6.75)	-0.02 (6.50)
Median	-0.60	-0.10
Min ; Max	-50.50 ; 43.20	-50.40 ; 30.90
Lowest post baseline value		
N	1762	1756
Mean (SD)	-2.43 (6.35)	-2.07 (6.49)
Median	-2.15	-1.80
Min ; Max	-62.70 ; 29.10	-50.40 ; 28.50
Highest post baseline value		
N	1762	1756
Mean (SD)	1.78 (6.55)	2.13 (6.33)
Median	1.30	2.10
Min ; Max	-50.50 ; 43.20	-48.80 ; 34.50

N: Number of subjects, SD: Standard deviation. Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6. Eosinophils, neutrophils, basophils, monocytes and lymphocytes were not collected in ONWARDS 6.

Haematology by treatment week - change from baseline - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec	Daily basal insulin
Change from Baseline, Monocytes Blood (%)		
Week 10 visit		
N	1238	1232
Mean (SD)	-0.17 (1.87)	0.05 (1.95)
Median	-0.20	0.00
Min ; Max	-11.80 ; 8.00	-9.40 ; 11.80
Week 26 visit		
N	1208	1207
Mean (SD)	0.10 (2.24)	0.27 (2.09)
Median	0.00	0.20
Min ; Max	-13.50 ; 15.70	-9.00 ; 11.20
Week 36 visit		
N	455	454
Mean (SD)	0.04 (2.46)	0.24 (2.16)
Median	0.00	0.30
Min ; Max	-13.60 ; 11.00	-8.60 ; 11.00
Week 52 visit		
N	885	899
Mean (SD)	-0.05 (2.10)	0.07 (2.10)
Median	-0.10	0.10
Min ; Max	-10.80 ; 10.90	-13.60 ; 10.50
End-of-treatment visit		
N	1633	1645
Mean (SD)	0.14 (2.10)	0.30 (2.09)
Median	0.00	0.20
Min ; Max	-10.80 ; 15.70	-13.60 ; 11.20
Lowest post baseline value		
N	1762	1756
Mean (SD)	-0.67 (1.89)	-0.49 (1.93)
Median	-0.60	-0.45
Min ; Max	-13.60 ; 10.90	-13.60 ; 8.30
Highest post baseline value		
N	1762	1756
Mean (SD)	0.65 (2.18)	0.80 (2.15)
Median	0.40	0.70
Min ; Max	-11.80 ; 15.70	-13.60 ; 11.80

N: Number of subjects, SD: Standard deviation. Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6. Eosinophils, neutrophils, basophils, monocytes and lymphocytes were not collected in ONWARDS 6.

Haematology by treatment week - change from baseline - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec	Daily basal insulin
Change from Baseline, Neutrophils Blood (%)		
Week 10 visit		
N	1238	1232
Mean (SD)	-0.28 (7.88)	-0.55 (8.35)
Median	-0.10	-0.60
Min ; Max	-27.40 ; 73.40	-41.90 ; 54.80
Week 26 visit		
N	1208	1207
Mean (SD)	-0.22 (8.72)	-0.45 (8.05)
Median	0.20	-0.50
Min ; Max	-62.00 ; 59.40	-31.30 ; 55.20
Week 36 visit		
N	455	454
Mean (SD)	0.44 (9.46)	-0.26 (8.68)
Median	0.40	-0.70
Min ; Max	-30.90 ; 50.50	-30.70 ; 34.00
Week 52 visit		
N	887	899
Mean (SD)	0.44 (7.91)	0.13 (8.24)
Median	0.70	0.20
Min ; Max	-41.00 ; 30.40	-40.50 ; 37.80
End-of-treatment visit		
N	1635	1645
Mean (SD)	-0.09 (8.43)	-0.42 (8.08)
Median	0.30	-0.40
Min ; Max	-62.00 ; 59.40	-40.50 ; 55.20
Lowest post baseline value		
N	1763	1756
Mean (SD)	-2.60 (8.24)	-2.89 (7.93)
Median	-2.00	-2.70
Min ; Max	-62.00 ; 59.40	-41.90 ; 54.80
Highest post baseline value		
N	1763	1756
Mean (SD)	2.64 (7.72)	2.27 (7.94)
Median	2.40	2.20
Min ; Max	-34.80 ; 73.40	-37.90 ; 55.20

N: Number of subjects, SD: Standard deviation. Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6. Eosinophils, neutrophils, basophils, monocytes and lymphocytes were not collected in ONWARDS 6.

7.5.2 Haematology by treatment week - change from baseline - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec	Daily basal insulin
Number of subjects	1880	1878
Change from Baseline, Erythrocytes (10^12/L)		
Week 10 visit		
N	1270	1277
Mean (SD)	-0.04 (0.28)	-0.03 (0.27)
Median	0.00	0.00
Min ; Max	-1.40 ; 1.40	-1.60 ; 1.50
Week 26 visit		
N	1249	1243
Mean (SD)	-0.02 (0.30)	-0.02 (0.28)
Median	0.00	0.00
Min ; Max	-1.20 ; 1.60	-1.40 ; 1.30
Week 36 visit		
N	461	464
Mean (SD)	-0.05 (0.29)	-0.07 (0.28)
Median	0.00	-0.10
Min ; Max	-1.30 ; 1.60	-1.50 ; 1.60
Week 52 visit		
N	916	930
Mean (SD)	-0.03 (0.29)	-0.04 (0.30)
Median	0.00	0.00
Min ; Max	-1.20 ; 2.20	-2.40 ; 1.20
End-of-treatment visit		
N	1693	1702
Mean (SD)	-0.01 (0.29)	-0.01 (0.30)
Median	0.00	0.00
Min ; Max	-1.20 ; 2.20	-2.40 ; 1.30
Lowest post baseline value		
N	1798	1797
Mean (SD)	-0.12 (0.28)	-0.11 (0.29)
Median	-0.10	-0.10
Min ; Max	-1.40 ; 1.40	-2.40 ; 1.30
Highest post baseline value		
N	1798	1797
Mean (SD)	0.06 (0.29)	0.06 (0.28)
Median	0.00	0.00
Min ; Max	-1.20 ; 2.20	-2.40 ; 1.60

N: Number of subjects, SD: Standard deviation, Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4: Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Haematology by treatment week - change from baseline - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec	Daily basal insulin
Change from Baseline, Haematocrit Blood (%)		
Week 10 visit		
N	1184	1169
Mean (SD)	-0.28 (2.77)	-0.25 (2.61)
Median	-0.20	-0.30
Min ; Max	-29.60 ; 12.60	-15.20 ; 13.60
Week 26 visit		
N	1153	1149
Mean (SD)	-0.51 (2.83)	-0.60 (2.66)
Median	-0.70	-0.60
Min ; Max	-12.20 ; 19.70	-12.80 ; 14.60
Week 36 visit		
N	440	444
Mean (SD)	-0.70 (2.70)	-0.95 (2.68)
Median	-0.70	-0.90
Min ; Max	-9.10 ; 15.70	-13.90 ; 9.40
Week 52 visit		
N	841	841
Mean (SD)	-0.77 (2.88)	-0.70 (2.88)
Median	-0.90	-0.70
Min ; Max	-14.30 ; 13.30	-12.10 ; 15.40
End-of-treatment visit		
N	1552	1541
Mean (SD)	-0.71 (2.84)	-0.62 (2.83)
Median	-0.80	-0.60
Min ; Max	-14.30 ; 14.30	-12.80 ; 15.40
Lowest post baseline value		
N	1711	1693
Mean (SD)	-1.37 (2.76)	-1.24 (2.73)
Median	-1.40	-1.20
Min ; Max	-29.60 ; 12.00	-15.20 ; 15.40
Highest post baseline value		
N	1711	1693
Mean (SD)	0.25 (2.90)	0.29 (2.74)
Median	0.10	0.20
Min ; Max	-29.60 ; 19.70	-11.80 ; 15.40

N: Number of subjects, SD: Standard deviation, Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4: Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Haematology by treatment week - change from baseline - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec	Daily basal insulin
Change from Baseline, Haemoglobin Blood (mmol/L)		
Week 10 visit		
N	1270	1276
Mean (SD)	-0.10 (0.50)	-0.07 (0.48)
Median	-0.12	-0.06
Min ; Max	-2.23 ; 2.36	-3.16 ; 3.29
Week 26 visit		
N	1249	1243
Mean (SD)	-0.12 (0.56)	-0.11 (0.50)
Median	-0.12	-0.12
Min ; Max	-2.85 ; 3.97	-2.29 ; 3.10
Week 36 visit		
N	461	464
Mean (SD)	-0.13 (0.55)	-0.16 (0.54)
Median	-0.12	-0.19
Min ; Max	-2.29 ; 3.41	-2.67 ; 2.05
Week 52 visit		
N	914	930
Mean (SD)	-0.28 (0.57)	-0.26 (0.57)
Median	-0.25	-0.25
Min ; Max	-3.35 ; 3.10	-3.84 ; 2.36
End-of-treatment visit		
N	1691	1702
Mean (SD)	-0.21 (0.56)	-0.17 (0.56)
Median	-0.25	-0.19
Min ; Max	-3.35 ; 3.10	-3.84 ; 3.10
Lowest post baseline value		
N	1796	1797
Mean (SD)	-0.33 (0.53)	-0.29 (0.52)
Median	-0.31	-0.25
Min ; Max	-3.35 ; 2.36	-3.84 ; 3.04
Highest post baseline value		
N	1796	1797
Mean (SD)	-0.02 (0.55)	-0.00 (0.54)
Median	-0.06	0.00
Min ; Max	-2.54 ; 3.97	-3.84 ; 3.29

N: Number of subjects, SD: Standard deviation, Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4: Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Haematology by treatment week - change from baseline - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec	Daily basal insulin
Change from Baseline, Haemoglobin Blood (g/dL)		
Week 10 visit		
N	1270	1276
Mean (SD)	-0.16 (0.81)	-0.11 (0.77)
Median	-0.20	-0.10
Min ; Max	-3.60 ; 3.80	-5.10 ; 5.30
Week 26 visit		
N	1249	1243
Mean (SD)	-0.20 (0.90)	-0.18 (0.81)
Median	-0.20	-0.20
Min ; Max	-4.60 ; 6.40	-3.70 ; 5.00
Week 36 visit		
N	461	464
Mean (SD)	-0.21 (0.89)	-0.26 (0.87)
Median	-0.20	-0.30
Min ; Max	-3.70 ; 5.50	-4.30 ; 3.30
Week 52 visit		
N	914	930
Mean (SD)	-0.45 (0.91)	-0.42 (0.92)
Median	-0.40	-0.40
Min ; Max	-5.40 ; 5.00	-6.20 ; 3.80
End-of-treatment visit		
N	1691	1702
Mean (SD)	-0.33 (0.91)	-0.28 (0.90)
Median	-0.40	-0.30
Min ; Max	-5.40 ; 5.00	-6.20 ; 5.00
Lowest post baseline value		
N	1796	1797
Mean (SD)	-0.54 (0.85)	-0.47 (0.84)
Median	-0.50	-0.40
Min ; Max	-5.40 ; 3.80	-6.20 ; 4.90
Highest post baseline value		
N	1796	1797
Mean (SD)	-0.03 (0.89)	-0.00 (0.87)
Median	-0.10	0.00
Min ; Max	-4.10 ; 6.40	-6.20 ; 5.30

N: Number of subjects, SD: Standard deviation, Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4: Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Haematology by treatment week - change from baseline - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec	Daily basal insulin
Change from Baseline, Leukocytes (10^9/L)		
Week 10 visit		
N	1262	1269
Mean (SD)	-0.23 (1.56)	-0.23 (1.45)
Median	-0.20	-0.20
Min ; Max	-7.00 ; 8.50	-7.00 ; 6.60
Week 26 visit		
N	1243	1237
Mean (SD)	-0.22 (1.63)	-0.27 (1.50)
Median	-0.20	-0.30
Min ; Max	-7.50 ; 11.20	-7.80 ; 6.70
Week 36 visit		
N	461	463
Mean (SD)	0.09 (1.79)	-0.08 (1.74)
Median	0.00	-0.10
Min ; Max	-7.00 ; 8.20	-7.30 ; 9.40
Week 52 visit		
N	914	928
Mean (SD)	-0.19 (1.56)	-0.31 (1.65)
Median	-0.20	-0.30
Min ; Max	-7.70 ; 6.90	-9.40 ; 11.30
End-of-treatment visit		
N	1686	1695
Mean (SD)	-0.24 (1.60)	-0.31 (1.59)
Median	-0.20	-0.30
Min ; Max	-7.70 ; 11.20	-9.40 ; 11.30
Lowest post baseline value		
N	1792	1791
Mean (SD)	-0.67 (1.51)	-0.72 (1.48)
Median	-0.60	-0.60
Min ; Max	-7.70 ; 6.20	-9.40 ; 7.00
Highest post baseline value		
N	1792	1791
Mean (SD)	0.32 (1.69)	0.25 (1.61)
Median	0.20	0.20
Min ; Max	-7.70 ; 11.20	-9.40 ; 11.30

N: Number of subjects, SD: Standard deviation, Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4: Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Haematology by treatment week - change from baseline - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec	Daily basal insulin
Change from Baseline, Thrombocytes (10^9/L)		
Week 10 visit		
N	1253	1263
Mean (SD)	3.20 (39.43)	1.67 (36.91)
Median	2.00	2.00
Min ; Max	-318.00 ; 290.00	-187.00 ; 215.00
Week 26 visit		
N	1233	1227
Mean (SD)	7.36 (40.78)	4.54 (38.00)
Median	6.00	4.00
Min ; Max	-170.00 ; 337.00	-202.00 ; 255.00
Week 36 visit		
N	456	461
Mean (SD)	13.44 (43.53)	6.57 (41.00)
Median	11.50	5.00
Min ; Max	-154.00 ; 352.00	-165.00 ; 236.00
Week 52 visit		
N	905	920
Mean (SD)	11.23 (42.14)	7.90 (44.47)
Median	10.00	6.50
Min ; Max	-232.00 ; 300.00	-183.00 ; 290.00
End-of-treatment visit		
N	1672	1679
Mean (SD)	8.84 (42.19)	5.92 (41.05)
Median	8.00	5.00
Min ; Max	-232.00 ; 337.00	-202.00 ; 290.00
Lowest post baseline value		
N	1780	1778
Mean (SD)	-5.09 (38.03)	-6.17 (38.10)
Median	-4.00	-5.00
Min ; Max	-318.00 ; 180.00	-211.00 ; 288.00
Highest post baseline value		
N	1780	1778
Mean (SD)	20.07 (44.31)	16.27 (41.43)
Median	17.00	14.00
Min ; Max	-232.00 ; 352.00	-187.00 ; 290.00

N: Number of subjects, SD: Standard deviation, Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4: Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Haematology by treatment week - change from baseline - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec	Daily basal insulin
Change from Baseline, Basophils Blood (%)		
Week 10 visit		
N	1238	1231
Mean (SD)	-0.04 (0.44)	-0.03 (0.45)
Median	0.00	0.00
Min ; Max	-2.00 ; 1.50	-1.50 ; 1.40
Week 26 visit		
N	1208	1207
Mean (SD)	-0.01 (0.55)	-0.02 (0.45)
Median	0.00	0.00
Min ; Max	-2.50 ; 9.90	-1.70 ; 1.50
Week 36 visit		
N	455	454
Mean (SD)	-0.05 (0.46)	-0.07 (0.46)
Median	-0.10	-0.10
Min ; Max	-1.30 ; 1.20	-1.80 ; 1.30
Week 52 visit		
N	885	899
Mean (SD)	-0.04 (0.45)	-0.08 (0.44)
Median	-0.10	-0.10
Min ; Max	-1.30 ; 2.90	-1.60 ; 2.40
End-of-treatment visit		
N	1633	1645
Mean (SD)	-0.01 (0.52)	-0.03 (0.44)
Median	0.00	0.00
Min ; Max	-2.50 ; 9.90	-1.70 ; 2.40
Lowest post baseline value		
N	1762	1756
Mean (SD)	-0.17 (0.45)	-0.19 (0.45)
Median	-0.20	-0.20
Min ; Max	-2.50 ; 2.90	-1.80 ; 2.40
Highest post baseline value		
N	1762	1756
Mean (SD)	0.13 (0.50)	0.10 (0.43)
Median	0.10	0.10
Min ; Max	-2.10 ; 9.90	-1.30 ; 2.40

N: Number of subjects, SD: Standard deviation, Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4: Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

adsl.xpt; variable(s): NA; criteria: SAFFL == "Y" & POOLGR1 == "T2D pool"
adlb.xpt; variable(s): CHG; criteria: SAFFL == "Y" & PARCAT1 == "HAEMATOLOGY" & PARAMCD %in% c("RBCB", "HCTB", "HGBB2", "HGBB", "WBCB", "PLATB", "BASOLEB", "EOSLEB", "LYMLEB", "MONOLEB", "NEUTLEB") & ANELFL == "Y" & ANL06FL == "Y" & DTYPE %in% c("", "HALFLOQ", "ULOQ", "MINIMUM", "MAXIMUM", "LVPD", "EOT") & CHG != " " & POOLGR1 == "T2D pool"
nn1436/nn1436-iss/submission_20221024_er
05DEC2022:13:01:13 - tsumcont/tlbchbhaematologysumontt2dsas.txt

Haematology by treatment week - change from baseline - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec	Daily basal insulin
Change from Baseline, Eosinophils Blood (%)		
Week 10 visit		
N	1238	1231
Mean (SD)	0.20 (1.97)	0.15 (2.16)
Median	0.20	0.10
Min ; Max	-27.80 ; 9.10	-16.60 ; 16.40
Week 26 visit		
N	1208	1207
Mean (SD)	0.40 (2.24)	0.15 (2.43)
Median	0.30	0.20
Min ; Max	-32.00 ; 14.00	-32.60 ; 13.60
Week 36 visit		
N	455	454
Mean (SD)	0.39 (1.92)	0.26 (2.34)
Median	0.30	0.30
Min ; Max	-6.90 ; 14.00	-20.10 ; 12.50
Week 52 visit		
N	885	899
Mean (SD)	0.42 (2.03)	0.19 (2.16)
Median	0.30	0.20
Min ; Max	-9.20 ; 18.10	-21.00 ; 13.70
End-of-treatment visit		
N	1633	1645
Mean (SD)	0.40 (2.16)	0.17 (2.24)
Median	0.30	0.20
Min ; Max	-32.00 ; 18.10	-21.00 ; 13.70
Lowest post baseline value		
N	1762	1756
Mean (SD)	-0.22 (1.89)	-0.39 (2.05)
Median	-0.10	-0.20
Min ; Max	-32.00 ; 13.10	-32.60 ; 9.50
Highest post baseline value		
N	1762	1756
Mean (SD)	0.94 (2.33)	0.76 (2.39)
Median	0.70	0.50
Min ; Max	-27.80 ; 18.10	-16.60 ; 16.40

N: Number of subjects, SD: Standard deviation, Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4: Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Haematology by treatment week - change from baseline - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec	Daily basal insulin
Change from Baseline, Lymphocytes Blood (%)		
Week 10 visit		
N	1238	1232
Mean (SD)	0.29 (6.63)	0.39 (6.74)
Median	0.10	0.70
Min ; Max	-62.70 ; 29.20	-48.80 ; 34.50
Week 26 visit		
N	1208	1207
Mean (SD)	-0.27 (6.96)	0.05 (6.56)
Median	-0.50	0.20
Min ; Max	-50.50 ; 43.20	-50.40 ; 22.70
Week 36 visit		
N	455	454
Mean (SD)	-0.82 (7.60)	-0.17 (7.14)
Median	-0.50	0.05
Min ; Max	-35.30 ; 25.40	-34.20 ; 26.40
Week 52 visit		
N	885	899
Mean (SD)	-0.78 (6.37)	-0.31 (6.63)
Median	-0.70	-0.50
Min ; Max	-26.40 ; 29.10	-32.20 ; 30.90
End-of-treatment visit		
N	1633	1645
Mean (SD)	-0.46 (6.75)	-0.02 (6.50)
Median	-0.60	-0.10
Min ; Max	-50.50 ; 43.20	-50.40 ; 30.90
Lowest post baseline value		
N	1762	1756
Mean (SD)	-2.43 (6.35)	-2.07 (6.49)
Median	-2.15	-1.80
Min ; Max	-62.70 ; 29.10	-50.40 ; 28.50
Highest post baseline value		
N	1762	1756
Mean (SD)	1.78 (6.55)	2.13 (6.33)
Median	1.30	2.10
Min ; Max	-50.50 ; 43.20	-48.80 ; 34.50

N: Number of subjects, SD: Standard deviation, Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4: Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Haematology by treatment week - change from baseline - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec	Daily basal insulin
Change from Baseline, Monocytes Blood (%)		
Week 10 visit		
N	1238	1232
Mean (SD)	-0.17 (1.87)	0.05 (1.95)
Median	-0.20	0.00
Min ; Max	-11.80 ; 8.00	-9.40 ; 11.80
Week 26 visit		
N	1208	1207
Mean (SD)	0.10 (2.24)	0.27 (2.09)
Median	0.00	0.20
Min ; Max	-13.50 ; 15.70	-9.00 ; 11.20
Week 36 visit		
N	455	454
Mean (SD)	0.04 (2.46)	0.24 (2.16)
Median	0.00	0.30
Min ; Max	-13.60 ; 11.00	-8.60 ; 11.00
Week 52 visit		
N	885	899
Mean (SD)	-0.05 (2.10)	0.07 (2.10)
Median	-0.10	0.10
Min ; Max	-10.80 ; 10.90	-13.60 ; 10.50
End-of-treatment visit		
N	1633	1645
Mean (SD)	0.14 (2.10)	0.30 (2.09)
Median	0.00	0.20
Min ; Max	-10.80 ; 15.70	-13.60 ; 11.20
Lowest post baseline value		
N	1762	1756
Mean (SD)	-0.67 (1.89)	-0.49 (1.93)
Median	-0.60	-0.45
Min ; Max	-13.60 ; 10.90	-13.60 ; 8.30
Highest post baseline value		
N	1762	1756
Mean (SD)	0.65 (2.18)	0.80 (2.15)
Median	0.40	0.70
Min ; Max	-11.80 ; 15.70	-13.60 ; 11.80

N: Number of subjects, SD: Standard deviation, Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4: Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

adsl.xpt; variable(s): NA; criteria: SAFFL == "Y" & POOLGR1 == "T2D pool"
adlb.xpt; variable(s): CHG; criteria: SAFFL == "Y" & PARCAT1 == "HAEMATOLOGY" & PARAMCD %in% c("RBCB", "HCTB", "HGBB2", "HGBB", "WBCB", "PLATB", "BASOLEB", "EOSLEB", "LYMLEB", "MONOLEB", "NEUTLEB") & ANELFL == "Y" & ANL06FL == "Y" & DTYPE %in% c("", "HALFLOQ", "ULOQ", "MINIMUM", "MAXIMUM", "LVPD", "EOT") & CHG != " " & POOLGR1 == "T2D pool"
nn1436/nn1436-iss/submission_20221024_er
05DEC2022:13:01:13 - tsumcont/tlbchbhaematologysumontt2dsas.txt


Haematology by treatment week - change from baseline - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec	Daily basal insulin
Change from Baseline, Neutrophils Blood (%)		
Week 10 visit		
N	1238	1232
Mean (SD)	-0.28 (7.88)	-0.55 (8.35)
Median	-0.10	-0.60
Min ; Max	-27.40 ; 73.40	-41.90 ; 54.80
Week 26 visit		
N	1208	1207
Mean (SD)	-0.22 (8.72)	-0.45 (8.05)
Median	0.20	-0.50
Min ; Max	-62.00 ; 59.40	-31.30 ; 55.20
Week 36 visit		
N	455	454
Mean (SD)	0.44 (9.46)	-0.26 (8.68)
Median	0.40	-0.70
Min ; Max	-30.90 ; 50.50	-30.70 ; 34.00
Week 52 visit		
N	887	899
Mean (SD)	0.44 (7.91)	0.13 (8.24)
Median	0.70	0.20
Min ; Max	-41.00 ; 30.40	-40.50 ; 37.80
End-of-treatment visit		
N	1635	1645
Mean (SD)	-0.09 (8.43)	-0.42 (8.08)
Median	0.30	-0.40
Min ; Max	-62.00 ; 59.40	-40.50 ; 55.20
Lowest post baseline value		
N	1763	1756
Mean (SD)	-2.60 (8.24)	-2.89 (7.93)
Median	-2.00	-2.70
Min ; Max	-62.00 ; 59.40	-41.90 ; 54.80
Highest post baseline value		
N	1763	1756
Mean (SD)	2.64 (7.72)	2.27 (7.94)
Median	2.40	2.20
Min ; Max	-34.80 ; 73.40	-37.90 ; 55.20

N: Number of subjects, SD: Standard deviation, Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4: Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

adsl.xpt; variable(s): NA; criteria: SAFFL == "Y" & POOLGR1 == "T2D pool"
adlb.xpt; variable(s): CHG; criteria: SAFFL == "Y" & PARCAT1 == "HAEMATOLOGY" & PARAMCD %in% c("RBCB", "HCTB", "HGBB2", "HGBB", "WBCB", "PLATB", "BASOLEB", "EOSLEB", "LYMLEB", "MONOLEB", "NEUTLEB") & ANELFL == "Y" & ANL06FL == "Y" & DTYPE %in% c("", "HALFLOQ", "ULOQ", "MINIMUM", "MAXIMUM", "LVPD", "EOT") & CHG != " " & POOLGR1 == "T2D pool"
nn1436/nn1436-iss/submission_20221024_er
05DEC2022:13:01:13 - tsumcont/tlbchbhaematologysumontt2dsas.txt

7.5.3 Haematology by trial - erythrocytes - baseline and end-of-treatment - on-treatment/main-on-treatment - box plot - safety analysis set




Safety analysis set. Observed data. Legend: Mean (symbol), median (centre line), 25th and 75th percentiles (box), and extremes (circles). Whiskers are from 2.5% - 97.5%. Numbers of values above 6.9 appears in the right panel. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. OD analogues: Once-daily basal insulin analogues (IDeg, IGlar U100, IGlar U300). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

adlb.xpt; variable(s): STDNM PARAM AVISIT3 AVISIT3N AVAL; criteria: SAFFL == "Y" & ANELFL == "Y" & PARAMCD == "RBCB" & ANL06FL == "Y"

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:13:02:58 - fbox/flberythrocytesboxontsas.png

7.5.4 Haematology by trial - haematocrit - baseline and end-of-treatment - on-treatment/main-on-treatment - box plot - safety analysis set




Safety analysis set. Observed data. Legend: Mean (symbol), median (centre line), 25th and 75th percentiles (box), and extremes (circles). Whiskers are from 2.5% - 97.5%. Numbers of values above 61.3 appears in the right panel. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. OD analogues: Once-daily basal insulin analogues (IDeg, IGlar U100, IGlar U300). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

adlb.xpt; variable(s): STDNM PARAM AVISIT3 AVISIT3N AVAL; criteria: SAFFL == "Y" & ANELFL == "Y" & PARAMCD == "HCTB" & ANL06FL == "Y"

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:13:03:15 - fbox/flbhaematocritboxontsas.png

7.5.5 Haematology by trial - haemoglobin - baseline and end-of-treatment - on-treatment/main-on-treatment - box plot - safety analysis set




Safety analysis set. Observed data. Legend: Mean (symbol), median (centre line), 25th and 75th percentiles (box), and extremes (circles). Whiskers are from 2.5% - 97.5%. Numbers of values above 12.7 appears in the right panel. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. OD analogues: Once-daily basal insulin analogues (IDeg, IGlar U100, IGlar U300). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

adlb.xpt; variable(s): STDNM PARAM AVISIT3 AVISIT3N AVAL; criteria: SAFFL == "Y" & ANELFL == "Y" & PARAMCD %in% c("HGBB", "HGBB2") & ANL06FL == "Y"

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:13:03:31 - fbox/flbhaemoglobinboxontsas.png

7.5.6 Haematology by trial - leukocytes - baseline and end-of-treatment - on-treatment/main-on-treatment - box plot - safety analysis set




Safety analysis set. Observed data. Legend: Mean (symbol), median (centre line), 25th and 75th percentiles (box), and extremes (circles). Whiskers are from 2.5% - 97.5%. Numbers of values above 14.2 appears in the right panel. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. OD analogues: Once-daily basal insulin analogues (IDeg, IGlar U100, IGlar U300). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

adlb.xpt; variable(s): STDNM PARAM AVISIT3 AVISIT3N AVAL; criteria: SAFFL == "Y" & ANELFL == "Y" & PARAMCD == "WBCB" & ANL06FL == "Y"

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:13:03:48 - fbox/flbleukocytesboxontsas.png

7.5.7 Haematology by trial - thrombocytes - baseline and end-of-treatment - on-treatment/main-on-treatment - box plot - safety analysis set




Safety analysis set. Observed data. Legend: Mean (symbol), median (centre line), 25th and 75th percentiles (box), and extremes (circles). Whiskers are from 2.5% - 97.5%. Numbers of values above 497.8 appears in the right panel. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. OD analogues: Once-daily basal insulin analogues (IDeg, IGlar U100, IGlar U300). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

adlb.xpt; variable(s): STDNM PARAM AVISIT3 AVISIT3N AVAL; criteria: SAFFL == "Y" & ANELFL == "Y" & PARAMCD == "PLATB" & ANL06FL == "Y"

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:13:04:05 - fbox/flbthrombocytesboxontsas.png

7.5.8 Haematology by trial - eosinophils - baseline and end-of-treatment - on-treatment/main-on-treatment - box plot - safety analysis set




Safety analysis set. Observed data. Legend: Mean (symbol), median (centre line), 25th and 75th percentiles (box), and extremes (circles). Whiskers are from 2.5% - 97.5%. Numbers of values above 9.1 appears in the right panel. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4: Week 26. OD analogues: Once-daily basal insulin analogues (IDeg, IGlar U100, IGlar U300). Data from ONWARDS 1-5, only main part of ONWARDS 1. Eosinophils was not collected in ONWARDS 6.

adlb.xpt; variable(s): STDNM PARAM AVISIT3 AVISIT3N AVAL; criteria: SAFFL == "Y" & ANELFL == "Y" & PARAMCD == "EOSLEB" & ANL06FL == "Y"

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:13:04:22 - fbox/flbeosinophilsboxontsas.png

7.5.9 Haematology by trial - neutrophils - baseline and end-of-treatment - on-treatment/main-on-treatment - box plot - safety analysis set




Safety analysis set. Observed data. Legend: Mean (symbol), median (centre line), 25th and 75th percentiles (box), and extremes (circles). Whiskers are from 2.5% - 97.5%. Numbers of values above 94.9 appears in the right panel. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4: Week 26. OD analogues: Once-daily basal insulin analogues (IDeg, IGlar U100, IGlar U300). Data from ONWARDS 1-5, only main part of ONWARDS 1. Neutrophils was not collected in ONWARDS 6.

adlb.xpt; variable(s): STDNM PARAM AVISIT3 AVISIT3N AVAL; criteria: SAFFL == "Y" & ANELFL == "Y" & PARAMCD == "NEUTLEB" & ANL06FL == "Y"

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:13:04:38 - fbox/flbneutrophilsboxontsas.png

7.5.10 Haematology by trial - basophils - baseline and end-of-treatment - on-treatment/main-on-treatment - box plot - safety analysis set




Safety analysis set. Observed data. Legend: Mean (symbol), median (centre line), 25th and 75th percentiles (box), and extremes (circles). Whiskers are from 2.5% - 97.5%. Numbers of values above 2.1 appears in the right panel. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4: Week 26. OD analogues: Once-daily basal insulin analogues (IDeg, IGlar U100, IGlar U300). Data from ONWARDS 1-5, only main part of ONWARDS 1. Basophils was not collected in ONWARDS 6.

adlb.xpt; variable(s): STDNM PARAM AVISIT3 AVISIT3N AVAL; criteria: SAFFL == "Y" & ANELFL == "Y" & PARAMCD == "BASOLEB" & ANL06FL == "Y"

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:13:04:55 - fbox/flbbasophilsboxontsas.png

7.5.11 Haematology by trial - monocytes - baseline and end-of-treatment - on-treatment/main-on-treatment - box plot - safety analysis set




Safety analysis set. Observed data. Legend: Mean (symbol), median (centre line), 25th and 75th percentiles (box), and extremes (circles). Whiskers are from 2.5% - 97.5%. Numbers of values above 13.9 appears in the right panel. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4: Week 26. OD analogues: Once-daily basal insulin analogues (IDeg, IGlar U100, IGlar U300). Data from ONWARDS 1-5, only main part of ONWARDS 1. Monocytes was not collected in ONWARDS 6.

adlb.xpt; variable(s): STDNM PARAM AVISIT3 AVISIT3N AVAL; criteria: SAFFL == "Y" & ANELFL == "Y" & PARAMCD == "MONOLEB" & ANL06FL == "Y"

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:13:05:13 - fbox/flbmonocytesboxontsas.png

7.5.12 Haematology by trial - lymphocytes - baseline and end-of-treatment - on-treatment/main-on-treatment - box plot - safety analysis set



Safety analysis set. Observed data. Legend: Mean (symbol), median (centre line), 25th and 75th percentiles (box), and extremes (circles). Whiskers are from 2.5% - 97.5%. Numbers of values above 58.1 appears in the right panel. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4: Week 26. OD analogues: Once-daily basal insulin analogues (IDeg, IGlar U100, IGlar U300). Data from ONWARDS 1-5, only main part of ONWARDS 1. Lymphocytes was not collected in ONWARDS 6.

adlb.xpt; variable(s): STDNM PARAM AVISIT3 AVISIT3N AVAL; criteria: SAFFL == "Y" & ANELFL == "Y" & PARAMCD == "LYMLEB" & ANL06FL == "Y"

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:13:05:28 - fbox/flblymphocytesboxontsas.png

7.5.13 Biochemistry by treatment week - change from baseline - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec	Daily basal insulin
Number of subjects	2170	2170
Change from Baseline, Alanine aminotransferase (U/L)		
Week 10 visit		
N	1572	1570
Mean (SD)	-3.52 (10.83)	-1.55 (10.91)
Median	-2.00	-1.00
Min ; Max	-76.00 ; 107.00	-58.00 ; 107.00
Week 26 visit		
N	1529	1532
Mean (SD)	-3.86 (12.20)	-1.74 (12.16)
Median	-2.00	-1.00
Min ; Max	-79.00 ; 86.00	-64.00 ; 113.00
Week 36 visit		
N	470	474
Mean (SD)	-6.43 (16.38)	-4.32 (12.79)
Median	-5.00	-3.00
Min ; Max	-81.00 ; 132.00	-59.00 ; 74.00
Week 52 visit		
N	937	949
Mean (SD)	-6.32 (14.77)	-2.46 (52.97)
Median	-4.00	-2.00
Min ; Max	-104.00 ; 86.00	-116.00 ; 1561.00
End-of-treatment visit		
N	1988	2000
Mean (SD)	-4.20 (13.18)	-1.50 (37.35)
Median	-2.00	-1.00
Min ; Max	-104.00 ; 86.00	-116.00 ; 1561.00
Lowest post baseline value		
N	2095	2091
Mean (SD)	-6.52 (12.78)	-5.02 (11.65)
Median	-4.00	-3.00
Min ; Max	-104.00 ; 154.00	-147.00 ; 82.00
Highest post baseline value		
N	2095	2091
Mean (SD)	-1.28 (14.11)	1.45 (36.90)
Median	0.00	1.00
Min ; Max	-104.00 ; 154.00	-116.00 ; 1561.00

N: Number of subjects, SD: Standard deviation. Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

adsl.xpt; variable(s): NA; criteria: SAFFL == "Y" & POOLGR2 == "Phase 3a pool"
adlb.xpt; variable(s): CHG; criteria: SAFFL == "Y" & PARCAT1 == "BIOCHEMISTRY" & PARAMCD %in% c("ALPS", "ALTS", "ASTS", "ALBS", "CREATS", "CREATS2", "BILIS", "BILIS2", "SODIUMS", "KS") & ANELFL == "Y" & ANL06FL == "Y" & DTYPE %in% c("", "HALFLOQ", "ULOQ", "MINIMUM", "MAXIMUM", "LVPD", "EOT") & CHG != " " & POOLGR2 == "Phase 3a pool"
nn1436/nn1436-iss/submission_20221024_er
05DEC2022:13:01:19 - tsumcont/tlbchbbiochemestrysump3asas.txt

Biochemistry by treatment week - change from baseline - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec	Daily basal insulin
Change from Baseline, Albumin (g/dL)		
Week 10 visit		
N	1580	1581
Mean (SD)	-0.05 (0.26)	-0.04 (0.25)
Median	0.00	0.00
Min ; Max	-1.60 ; 1.10	-1.70 ; 1.10
Week 26 visit		
N	1552	1557
Mean (SD)	-0.06 (0.26)	-0.05 (0.26)
Median	-0.10	0.00
Min ; Max	-0.90 ; 1.50	-1.70 ; 1.00
Week 36 visit		
N	471	477
Mean (SD)	-0.12 (0.26)	-0.11 (0.25)
Median	-0.10	-0.10
Min ; Max	-0.90 ; 1.10	-0.80 ; 0.60
Week 52 visit		
N	949	961
Mean (SD)	-0.09 (0.27)	-0.08 (0.26)
Median	-0.10	-0.10
Min ; Max	-1.30 ; 1.40	-1.00 ; 0.80
End-of-treatment visit		
N	2021	2035
Mean (SD)	-0.06 (0.27)	-0.05 (0.26)
Median	-0.10	0.00
Min ; Max	-1.30 ; 1.50	-1.70 ; 1.00
Lowest post baseline value		
N	2106	2103
Mean (SD)	-0.15 (0.25)	-0.14 (0.26)
Median	-0.15	-0.10
Min ; Max	-1.60 ; 0.80	-1.70 ; 0.70
Highest post baseline value		
N	2106	2103
Mean (SD)	0.03 (0.26)	0.04 (0.24)
Median	0.00	0.00
Min ; Max	-1.00 ; 1.50	-1.70 ; 1.10

N: Number of subjects, SD: Standard deviation. Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

adsl.xpt; variable(s): NA; criteria: SAFFL == "Y" & POOLGR2 == "Phase 3a pool"
adlb.xpt; variable(s): CHG; criteria: SAFFL == "Y" & PARCAT1 == "BIOCHEMISTRY" & PARAMCD %in% c("ALPS", "ALTS", "ASTS", "ALBS", "CREATS", "CREATS2", "BILIS", "BILIS2", "SODIUMS", "KS") & ANELFL == "Y" & ANL06FL == "Y" & DTYPE %in% c("", "HALFLOQ", "ULOQ", "MINIMUM", "MAXIMUM", "LVPD", "EOT") & CHG != " " & POOLGR2 == "Phase 3a pool"
nn1436/nn1436-iss/submission_20221024_er
05DEC2022:13:01:19 - tsumcont/tlbchbbiochemestrysump3asas.txt

Biochemistry by treatment week - change from baseline - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec	Daily basal insulin
Change from Baseline, Alkaline phosphatase (U/L)		
Week 10 visit		
N	1577	1576
Mean (SD)	-2.44 (14.61)	-3.39 (15.56)
Median	-2.00	-3.00
Min ; Max	-93.00 ; 194.00	-170.00 ; 159.00
Week 26 visit		
N	1546	1547
Mean (SD)	-1.58 (14.04)	-2.87 (21.29)
Median	-1.00	-3.00
Min ; Max	-94.00 ; 66.00	-163.00 ; 470.00
Week 36 visit		
N	470	475
Mean (SD)	-0.10 (14.90)	-2.45 (17.28)
Median	0.00	-2.00
Min ; Max	-55.00 ; 56.00	-92.00 ; 190.00
Week 52 visit		
N	946	956
Mean (SD)	0.13 (15.40)	-0.75 (20.70)
Median	0.00	-1.00
Min ; Max	-57.00 ; 59.00	-105.00 ; 352.00
End-of-treatment visit		
N	2013	2020
Mean (SD)	-0.47 (14.69)	-1.56 (21.45)
Median	0.00	-2.00
Min ; Max	-94.00 ; 66.00	-163.00 ; 470.00
Lowest post baseline value		
N	2103	2098
Mean (SD)	-5.14 (14.71)	-6.26 (15.87)
Median	-4.00	-5.00
Min ; Max	-94.00 ; 176.00	-170.00 ; 142.00
Highest post baseline value		
N	2103	2098
Mean (SD)	3.24 (15.46)	2.26 (21.40)
Median	2.00	1.00
Min ; Max	-87.00 ; 194.00	-163.00 ; 470.00

N: Number of subjects, SD: Standard deviation. Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

adsl.xpt; variable(s): NA; criteria: SAFFL == "Y" & POOLGR2 == "Phase 3a pool"
adlb.xpt; variable(s): CHG; criteria: SAFFL == "Y" & PARCAT1 == "BIOCHEMISTRY" & PARAMCD %in% c("ALPS", "ALTS", "ASTS", "ALBS", "CREATS", "CREATS2", "BILIS", "BILIS2", "SODIUMS", "KS") & ANELFL == "Y" & ANL06FL == "Y" & DTYPE %in% c("", "HALFLOQ", "ULOQ", "MINIMUM", "MAXIMUM", "LVPD", "EOT") & CHG != " " & POOLGR2 == "Phase 3a pool"
nn1436/nn1436-iss/submission_20221024_er
05DEC2022:13:01:19 - tsumcont/tlbchbbiochemestrysump3asas.txt

Biochemistry by treatment week - change from baseline - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec	Daily basal insulin
Change from Baseline, Aspartate aminotransferase (U/L)		
Week 10 visit		
N	1549	1546
Mean (SD)	-1.50 (11.52)	-0.17 (9.25)
Median	-1.00	0.00
Min ; Max	-83.00 ; 284.00	-97.00 ; 131.00
Week 26 visit		
N	1517	1524
Mean (SD)	-1.24 (13.30)	-0.09 (10.59)
Median	-1.00	0.00
Min ; Max	-86.00 ; 327.00	-96.00 ; 158.00
Week 36 visit		
N	464	469
Mean (SD)	-2.27 (12.60)	-1.36 (8.45)
Median	-2.00	-1.00
Min ; Max	-63.00 ; 123.00	-34.00 ; 51.00
Week 52 visit		
N	918	934
Mean (SD)	-1.89 (11.44)	2.95 (122.96)
Median	-1.00	0.00
Min ; Max	-78.00 ; 98.00	-60.00 ; 3744.00
End-of-treatment visit		
N	1960	1982
Mean (SD)	-1.26 (13.01)	1.47 (84.74)
Median	-1.00	0.00
Min ; Max	-86.00 ; 327.00	-96.00 ; 3744.00
Lowest post baseline value		
N	2075	2072
Mean (SD)	-3.51 (10.31)	-2.56 (8.48)
Median	-2.00	-1.00
Min ; Max	-86.00 ; 133.00	-97.00 ; 97.00
Highest post baseline value		
N	2075	2072
Mean (SD)	0.99 (15.16)	3.52 (83.04)
Median	1.00	1.00
Min ; Max	-86.00 ; 327.00	-96.00 ; 3744.00

N: Number of subjects, SD: Standard deviation. Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

adsl.xpt; variable(s): NA; criteria: SAFFL == "Y" & POOLGR2 == "Phase 3a pool"
adlb.xpt; variable(s): CHG; criteria: SAFFL == "Y" & PARCAT1 == "BIOCHEMISTRY" & PARAMCD %in% c("ALPS", "ALTS", "ASTS", "ALBS", "CREATS", "CREATS2", "BILIS", "BILIS2", "SODIUMS", "KS") & ANELFL == "Y" & ANL06FL == "Y" & DTYPE %in% c("", "HALFLOQ", "ULOQ", "MINIMUM", "MAXIMUM", "LVPD", "EOT") & CHG != " " & POOLGR2 == "Phase 3a pool"
nn1436/nn1436-iss/submission_20221024_er
05DEC2022:13:01:19 - tsumcont/tlbchbbiochemestrysump3asas.txt

Biochemistry by treatment week - change from baseline - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec	Daily basal insulin
Change from Baseline, Creatinine (umol/L)		
Week 10 visit		
N	1580	1577
Mean (SD)	1.23 (9.57)	0.42 (9.49)
Median	1.00	0.00
Min ; Max	-48.00 ; 58.00	-53.00 ; 51.00
Week 26 visit		
N	1548	1549
Mean (SD)	1.50 (10.32)	0.47 (10.09)
Median	1.00	0.00
Min ; Max	-47.00 ; 55.00	-56.00 ; 74.00
Week 36 visit		
N	471	475
Mean (SD)	1.14 (11.68)	-0.28 (11.11)
Median	1.00	-1.00
Min ; Max	-58.00 ; 64.00	-52.00 ; 48.00
Week 52 visit		
N	947	958
Mean (SD)	2.49 (12.33)	1.80 (11.43)
Median	2.00	1.00
Min ; Max	-59.00 ; 93.00	-62.00 ; 48.00
End-of-treatment visit		
N	2015	2024
Mean (SD)	2.17 (11.36)	1.31 (10.62)
Median	2.00	1.00
Min ; Max	-59.00 ; 93.00	-62.00 ; 74.00
Lowest post baseline value		
N	2103	2101
Mean (SD)	-0.96 (10.54)	-1.84 (10.06)
Median	-1.00	-2.00
Min ; Max	-59.00 ; 93.00	-62.00 ; 46.00
Highest post baseline value		
N	2103	2101
Mean (SD)	5.25 (11.43)	4.23 (10.35)
Median	5.00	4.00
Min ; Max	-59.00 ; 155.00	-62.00 ; 74.00

N: Number of subjects, SD: Standard deviation. Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Biochemistry by treatment week - change from baseline - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec	Daily basal insulin
Change from Baseline, Creatinine (mg/dL)		
Week 10 visit		
N	1580	1577
Mean (SD)	0.01 (0.11)	0.00 (0.11)
Median	0.01	0.00
Min ; Max	-0.54 ; 0.66	-0.60 ; 0.58
Week 26 visit		
N	1548	1549
Mean (SD)	0.02 (0.12)	0.01 (0.11)
Median	0.01	0.00
Min ; Max	-0.53 ; 0.62	-0.63 ; 0.84
Week 36 visit		
N	471	475
Mean (SD)	0.01 (0.13)	-0.00 (0.13)
Median	0.01	-0.01
Min ; Max	-0.66 ; 0.72	-0.59 ; 0.54
Week 52 visit		
N	947	958
Mean (SD)	0.03 (0.14)	0.02 (0.13)
Median	0.02	0.01
Min ; Max	-0.67 ; 1.05	-0.70 ; 0.54
End-of-treatment visit		
N	2015	2024
Mean (SD)	0.02 (0.13)	0.01 (0.12)
Median	0.02	0.01
Min ; Max	-0.67 ; 1.05	-0.70 ; 0.84
Lowest post baseline value		
N	2103	2101
Mean (SD)	-0.01 (0.12)	-0.02 (0.11)
Median	-0.01	-0.02
Min ; Max	-0.67 ; 1.05	-0.70 ; 0.52
Highest post baseline value		
N	2103	2101
Mean (SD)	0.06 (0.13)	0.05 (0.12)
Median	0.06	0.05
Min ; Max	-0.67 ; 1.75	-0.70 ; 0.84

N: Number of subjects, SD: Standard deviation. Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Biochemistry by treatment week - change from baseline - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec	Daily basal insulin
Change from Baseline, Potassium (mmol/L)		
Week 10 visit		
N	1577	1575
Mean (SD)	0.02 (0.47)	-0.01 (0.43)
Median	0.02	-0.01
Min ; Max	-5.18 ; 3.31	-2.24 ; 2.24
Week 26 visit		
N	1545	1549
Mean (SD)	0.01 (0.50)	0.01 (0.51)
Median	0.01	-0.01
Min ; Max	-4.76 ; 6.20	-2.22 ; 5.49
Week 36 visit		
N	470	477
Mean (SD)	-0.03 (0.47)	-0.08 (0.40)
Median	0.01	-0.07
Min ; Max	-5.25 ; 1.30	-2.23 ; 1.28
Week 52 visit		
N	942	958
Mean (SD)	-0.02 (0.53)	-0.03 (0.53)
Median	-0.02	-0.04
Min ; Max	-5.31 ; 6.19	-2.03 ; 5.47
End-of-treatment visit		
N	2008	2024
Mean (SD)	-0.00 (0.52)	-0.00 (0.50)
Median	0.00	-0.02
Min ; Max	-5.31 ; 6.20	-2.03 ; 5.47
Lowest post baseline value		
N	2099	2099
Mean (SD)	-0.15 (0.42)	-0.16 (0.41)
Median	-0.12	-0.16
Min ; Max	-5.63 ; 1.51	-2.24 ; 1.69
Highest post baseline value		
N	2099	2099
Mean (SD)	0.15 (0.53)	0.15 (0.52)
Median	0.13	0.12
Min ; Max	-4.76 ; 6.20	-2.03 ; 5.49

N: Number of subjects, SD: Standard deviation. Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Biochemistry by treatment week - change from baseline - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec	Daily basal insulin
Change from Baseline, Sodium (mmol/L)		
Week 10 visit		
N	1580	1578
Mean (SD)	0.74 (2.92)	0.86 (2.77)
Median	1.00	1.00
Min ; Max	-31.00 ; 18.00	-26.00 ; 19.00
Week 26 visit		
N	1549	1552
Mean (SD)	1.05 (3.06)	1.18 (3.21)
Median	1.00	1.00
Min ; Max	-12.00 ; 39.00	-9.00 ; 44.00
Week 36 visit		
N	470	477
Mean (SD)	0.91 (2.68)	0.83 (2.64)
Median	1.00	1.00
Min ; Max	-8.00 ; 9.00	-6.00 ; 14.00
Week 52 visit		
N	948	960
Mean (SD)	1.47 (3.37)	1.40 (3.37)
Median	1.00	1.00
Min ; Max	-9.00 ; 39.00	-17.00 ; 43.00
End-of-treatment visit		
N	2018	2029
Mean (SD)	1.23 (3.27)	1.30 (3.23)
Median	1.00	1.00
Min ; Max	-12.00 ; 39.00	-17.00 ; 44.00
Lowest post baseline value		
N	2105	2103
Mean (SD)	0.06 (2.91)	0.15 (2.79)
Median	0.00	0.00
Min ; Max	-31.00 ; 16.00	-26.00 ; 15.00
Highest post baseline value		
N	2105	2103
Mean (SD)	1.99 (3.16)	2.11 (3.28)
Median	2.00	2.00
Min ; Max	-15.00 ; 39.00	-17.00 ; 44.00

N: Number of subjects, SD: Standard deviation. Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

adsl.xpt; variable(s): NA; criteria: SAFFL == "Y" & POOLGR2 == "Phase 3a pool"
adlb.xpt; variable(s): CHG; criteria: SAFFL == "Y" & PARCAT1 == "BIOCHEMISTRY" & PARAMCD %in% c("ALPS", "ALTS", "ASTS", "ALBS", "CREATS", "CREATS2", "BILIS", "BILIS2", "SODIUMS", "KS") & ANELFL == "Y" & ANL06FL == "Y" & DTYPE %in% c("", "HALFLOQ", "ULOQ", "MINIMUM", "MAXIMUM", "LVPD", "EOT") & CHG != " " & POOLGR2 == "Phase 3a pool"
nn1436/nn1436-iss/submission_20221024_er
05DEC2022:13:01:19 - tsumcont/tlbchbbiochemestrysump3asas.txt

Biochemistry by treatment week - change from baseline - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec	Daily basal insulin
Change from Baseline, Total bilirubin (umol/L)		
Week 10 visit		
N	1561	1559
Mean (SD)	0.19 (3.26)	0.19 (3.22)
Median	0.00	0.00
Min ; Max	-17.00 ; 16.00	-21.00 ; 24.50
Week 26 visit		
N	1532	1538
Mean (SD)	0.15 (3.46)	0.15 (3.81)
Median	0.00	0.00
Min ; Max	-25.00 ; 20.00	-20.00 ; 73.00
Week 36 visit		
N	469	473
Mean (SD)	-0.09 (3.12)	-0.22 (2.82)
Median	0.00	0.00
Min ; Max	-17.00 ; 12.00	-11.00 ; 14.00
Week 52 visit		
N	940	946
Mean (SD)	-0.36 (3.05)	-0.20 (3.11)
Median	0.00	0.00
Min ; Max	-16.00 ; 10.00	-13.00 ; 16.00
End-of-treatment visit		
N	1994	2004
Mean (SD)	-0.08 (3.39)	-0.03 (3.60)
Median	0.00	0.00
Min ; Max	-25.00 ; 20.00	-16.00 ; 73.00
Lowest post baseline value		
N	2096	2090
Mean (SD)	-0.94 (7.16)	-1.04 (3.01)
Median	-1.00	-1.00
Min ; Max	-25.00 ; 295.00	-21.00 ; 24.50
Highest post baseline value		
N	2096	2090
Mean (SD)	1.15 (7.26)	1.07 (3.64)
Median	1.00	1.00
Min ; Max	-17.00 ; 295.00	-13.00 ; 73.00

N: Number of subjects, SD: Standard deviation. Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

adsl.xpt; variable(s): NA; criteria: SAFFL == "Y" & POOLGR2 == "Phase 3a pool"
adlb.xpt; variable(s): CHG; criteria: SAFFL == "Y" & PARCAT1 == "BIOCHEMISTRY" & PARAMCD %in% c("ALPS", "ALTS", "ASTS", "ALBS", "CREATS", "CREATS2", "BILIS", "BILIS2", "SODIUMS", "KS") & ANELFL == "Y" & ANL06FL == "Y" & DTYPE %in% c("", "HALFLOQ", "ULOQ", "MINIMUM", "MAXIMUM", "LVPD", "EOT") & CHG != " " & POOLGR2 == "Phase 3a pool"
nn1436/nn1436-iss/submission_20221024_er
05DEC2022:13:01:19 - tsumcont/tlbchbbiochemestrysump3asas.txt

Biochemistry by treatment week - change from baseline - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec	Daily basal insulin
Change from Baseline, Total bilirubin (mg/dL)		
Week 10 visit		
N	1561	1559
Mean (SD)	0.01 (0.19)	0.01 (0.19)
Median	0.00	0.00
Min ; Max	-0.99 ; 0.94	-1.23 ; 1.43
Week 26 visit		
N	1532	1538
Mean (SD)	0.01 (0.20)	0.01 (0.22)
Median	0.00	0.00
Min ; Max	-1.46 ; 1.17	-1.17 ; 4.27
Week 36 visit		
N	469	473
Mean (SD)	-0.01 (0.18)	-0.01 (0.16)
Median	0.00	0.00
Min ; Max	-0.99 ; 0.70	-0.64 ; 0.82
Week 52 visit		
N	940	946
Mean (SD)	-0.02 (0.18)	-0.01 (0.18)
Median	0.00	0.00
Min ; Max	-0.94 ; 0.58	-0.76 ; 0.94
End-of-treatment visit		
N	1994	2004
Mean (SD)	-0.00 (0.20)	-0.00 (0.21)
Median	0.00	0.00
Min ; Max	-1.46 ; 1.17	-0.94 ; 4.27
Lowest post baseline value		
N	2096	2090
Mean (SD)	-0.06 (0.42)	-0.06 (0.18)
Median	-0.06	-0.06
Min ; Max	-1.46 ; 17.25	-1.23 ; 1.43
Highest post baseline value		
N	2096	2090
Mean (SD)	0.07 (0.42)	0.06 (0.21)
Median	0.06	0.06
Min ; Max	-0.99 ; 17.25	-0.76 ; 4.27

N: Number of subjects, SD: Standard deviation. Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

adsl.xpt; variable(s): NA; criteria: SAFFL == "Y" & POOLGR2 == "Phase 3a pool"
adlb.xpt; variable(s): CHG; criteria: SAFFL == "Y" & PARCAT1 == "BIOCHEMISTRY" & PARAMCD %in% c("ALPS", "ALTS", "ASTS", "ALBS", "CREATS", "CREATS2", "BILIS", "BILIS2", "SODIUMS", "KS") & ANELFL == "Y" & ANL06FL == "Y" & DTYPE %in% c("", "HALFLOQ", "ULOQ", "MINIMUM", "MAXIMUM", "LVPD", "EOT") & CHG != " " & POOLGR2 == "Phase 3a pool"
nn1436/nn1436-iss/submission_20221024_er
05DEC2022:13:01:19 - tsumcont/tlbchbbiochemestrysump3asas.txt

7.5.14 Biochemistry by treatment week - change from baseline - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec	Daily basal insulin
Number of subjects	1880	1878
Change from Baseline, Alanine aminotransferase (U/L)		
Week 10 visit		
N	1294	1286
Mean (SD)	-4.41 (10.96)	-2.05 (10.89)
Median	-3.00	-1.00
Min ; Max	-76.00 ; 53.00	-53.00 ; 107.00
Week 26 visit		
N	1261	1252
Mean (SD)	-4.85 (12.74)	-2.39 (12.41)
Median	-3.00	-2.00
Min ; Max	-79.00 ; 86.00	-55.00 ; 113.00
Week 36 visit		
N	470	474
Mean (SD)	-6.43 (16.38)	-4.32 (12.79)
Median	-5.00	-3.00
Min ; Max	-81.00 ; 132.00	-59.00 ; 74.00
Week 52 visit		
N	937	949
Mean (SD)	-6.32 (14.77)	-2.46 (52.97)
Median	-4.00	-2.00
Min ; Max	-104.00 ; 86.00	-116.00 ; 1561.00
End-of-treatment visit		
N	1720	1720
Mean (SD)	-4.99 (13.67)	-1.93 (40.04)
Median	-3.00	-2.00
Min ; Max	-104.00 ; 86.00	-116.00 ; 1561.00
Lowest post baseline value		
N	1810	1804
Mean (SD)	-7.29 (13.36)	-5.55 (12.12)
Median	-5.00	-3.00
Min ; Max	-104.00 ; 154.00	-147.00 ; 82.00
Highest post baseline value		
N	1810	1804
Mean (SD)	-1.98 (14.59)	1.11 (39.41)
Median	-1.00	0.00
Min ; Max	-104.00 ; 154.00	-116.00 ; 1561.00

N: Number of subjects, SD: Standard deviation, Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4: Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

adsl.xpt; variable(s): NA; criteria: SAFFL == "Y" & POOLGR1 == "T2D pool"
adlb.xpt; variable(s): CHG; criteria: SAFFL == "Y" & PARCAT1 == "BIOCHEMISTRY" & PARAMCD %in% c("ALPS", "ALTS", "ASTS", "ALBS", "CREATS", "CREATS2", "BILIS", "BILIS2", "SODIUMS", "KS") & ANELFL == "Y" & ANL06FL == "Y" & DTYPE %in% c("", "HALFLOQ", "ULOQ", "MINIMUM", "MAXIMUM", "LVPD", "EOT") & CHG != " " & POOLGR1 == "T2D pool"
nn1436/nn1436-iss/submission_20221024_er
05DEC2022:13:01:26 - tsumcont/tlbchbbiochemestrysumt2dsas.txt

Biochemistry by treatment week - change from baseline - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec	Daily basal insulin
Change from Baseline, Albumin (g/dL)		
Week 10 visit		
N	1299	1296
Mean (SD)	-0.06 (0.26)	-0.05 (0.25)
Median	-0.10	-0.10
Min ; Max	-1.60 ; 0.90	-1.70 ; 1.10
Week 26 visit		
N	1283	1276
Mean (SD)	-0.07 (0.26)	-0.07 (0.26)
Median	-0.10	-0.10
Min ; Max	-0.90 ; 1.50	-1.70 ; 1.00
Week 36 visit		
N	471	477
Mean (SD)	-0.12 (0.26)	-0.11 (0.25)
Median	-0.10	-0.10
Min ; Max	-0.90 ; 1.10	-0.80 ; 0.60
Week 52 visit		
N	949	961
Mean (SD)	-0.09 (0.27)	-0.08 (0.26)
Median	-0.10	-0.10
Min ; Max	-1.30 ; 1.40	-1.00 ; 0.80
End-of-treatment visit		
N	1752	1754
Mean (SD)	-0.07 (0.27)	-0.06 (0.27)
Median	-0.10	-0.10
Min ; Max	-1.30 ; 1.50	-1.70 ; 1.00
Lowest post baseline value		
N	1821	1816
Mean (SD)	-0.16 (0.25)	-0.15 (0.26)
Median	-0.20	-0.10
Min ; Max	-1.60 ; 0.80	-1.70 ; 0.70
Highest post baseline value		
N	1821	1816
Mean (SD)	0.02 (0.26)	0.03 (0.25)
Median	0.00	0.00
Min ; Max	-1.00 ; 1.50	-1.70 ; 1.10

N: Number of subjects, SD: Standard deviation, Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4: Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

adsl.xpt; variable(s): NA; criteria: SAFFL == "Y" & POOLGR1 == "T2D pool"
adlb.xpt; variable(s): CHG; criteria: SAFFL == "Y" & PARCAT1 == "BIOCHEMISTRY" & PARAMCD %in% c("ALPS", "ALTS", "ASTS", "ALBS", "CREATS", "CREATS2", "BILIS", "BILIS2", "SODIUMS", "KS") & ANELFL == "Y" & ANL06FL == "Y" & DTYPE %in% c("", "HALFLOQ", "ULOQ", "MINIMUM", "MAXIMUM", "LVPD", "EOT") & CHG != " " & POOLGR1 == "T2D pool"
nn1436/nn1436-iss/submission_20221024_er
05DEC2022:13:01:26 - tsumcont/tlbchbbiochemestrysumt2dsas.txt

Biochemistry by treatment week - change from baseline - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec	Daily basal insulin
Change from Baseline, Alkaline phosphatase (U/L)		
Week 10 visit		
N	1297	1291
Mean (SD)	-2.68 (15.15)	-3.55 (15.44)
Median	-3.00	-3.00
Min ; Max	-93.00 ; 194.00	-75.00 ; 159.00
Week 26 visit		
N	1278	1266
Mean (SD)	-1.93 (14.53)	-3.16 (22.25)
Median	-1.00	-3.00
Min ; Max	-94.00 ; 66.00	-84.00 ; 470.00
Week 36 visit		
N	470	475
Mean (SD)	-0.10 (14.90)	-2.45 (17.28)
Median	0.00	-2.00
Min ; Max	-55.00 ; 56.00	-92.00 ; 190.00
Week 52 visit		
N	946	956
Mean (SD)	0.13 (15.40)	-0.75 (20.70)
Median	0.00	-1.00
Min ; Max	-57.00 ; 59.00	-105.00 ; 352.00
End-of-treatment visit		
N	1745	1739
Mean (SD)	-0.56 (15.14)	-1.55 (22.18)
Median	0.00	-2.00
Min ; Max	-94.00 ; 66.00	-105.00 ; 470.00
Lowest post baseline value		
N	1818	1811
Mean (SD)	-5.30 (15.23)	-6.34 (15.98)
Median	-4.00	-6.00
Min ; Max	-94.00 ; 176.00	-105.00 ; 142.00
Highest post baseline value		
N	1818	1811
Mean (SD)	3.26 (16.02)	2.39 (22.12)
Median	2.00	1.00
Min ; Max	-87.00 ; 194.00	-74.00 ; 470.00

N: Number of subjects, SD: Standard deviation, Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4: Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

adsl.xpt; variable(s): NA; criteria: SAFFL == "Y" & POOLGR1 == "T2D pool"
adlb.xpt; variable(s): CHG; criteria: SAFFL == "Y" & PARCAT1 == "BIOCHEMISTRY" & PARAMCD %in% c("ALPS", "ALTS", "ASTS", "ALBS", "CREATS", "CREATS2", "BILIS", "BILIS2", "SODIUMS", "KS") & ANELFL == "Y" & ANL06FL == "Y" & DTYPE %in% c("", "HALFLOQ", "ULOQ", "MINIMUM", "MAXIMUM", "LVPD", "EOT") & CHG != " " & POOLGR1 == "T2D pool"
nn1436/nn1436-iss/submission_20221024_er
05DEC2022:13:01:26 - tsumcont/tlbchbbiochemestrysumt2dsas.txt

Biochemistry by treatment week - change from baseline - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec	Daily basal insulin
Change from Baseline, Aspartate aminotransferase (U/L)		
Week 10 visit		
N	1276	1267
Mean (SD)	-1.97 (9.15)	-0.39 (8.18)
Median	-1.00	0.00
Min ; Max	-83.00 ; 75.00	-97.00 ; 97.00
Week 26 visit		
N	1252	1246
Mean (SD)	-1.52 (14.13)	-0.27 (11.09)
Median	-1.00	0.00
Min ; Max	-69.00 ; 327.00	-96.00 ; 158.00
Week 36 visit		
N	464	469
Mean (SD)	-2.27 (12.60)	-1.36 (8.45)
Median	-2.00	-1.00
Min ; Max	-63.00 ; 123.00	-34.00 ; 51.00
Week 52 visit		
N	918	934
Mean (SD)	-1.89 (11.44)	2.95 (122.96)
Median	-1.00	0.00
Min ; Max	-78.00 ; 98.00	-60.00 ; 3744.00
End-of-treatment visit		
N	1695	1704
Mean (SD)	-1.48 (13.60)	1.59 (91.34)
Median	-1.00	0.00
Min ; Max	-78.00 ; 327.00	-96.00 ; 3744.00
Lowest post baseline value		
N	1792	1786
Mean (SD)	-3.74 (10.66)	-2.73 (8.76)
Median	-2.00	-1.00
Min ; Max	-86.00 ; 133.00	-97.00 ; 97.00
Highest post baseline value		
N	1792	1786
Mean (SD)	0.70 (14.55)	3.62 (89.28)
Median	1.00	1.00
Min ; Max	-86.00 ; 327.00	-96.00 ; 3744.00

N: Number of subjects, SD: Standard deviation, Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4: Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

adsl.xpt; variable(s): NA; criteria: SAFFL == "Y" & POOLGR1 == "T2D pool"
adlb.xpt; variable(s): CHG; criteria: SAFFL == "Y" & PARCAT1 == "BIOCHEMISTRY" & PARAMCD %in% c("ALPS", "ALTS", "ASTS", "ALBS", "CREATS", "CREATS2", "BILIS", "BILIS2", "SODIUMS", "KS") & ANELFL == "Y" & ANL06FL == "Y" & DTYPE %in% c("", "HALFLOQ", "ULOQ", "MINIMUM", "MAXIMUM", "LVPD", "EOT") & CHG != " " & POOLGR1 == "T2D pool"
nn1436/nn1436-iss/submission_20221024_er
05DEC2022:13:01:26 - tsumcont/tlbchbbiochemestrysumt2dsas.txt

Biochemistry by treatment week - change from baseline - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec	Daily basal insulin
Change from Baseline, Creatinine (umol/L)		
Week 10 visit		
N	1299	1292
Mean (SD)	1.13 (9.95)	0.42 (9.86)
Median	1.00	0.00
Min ; Max	-39.00 ; 58.00	-53.00 ; 49.00
Week 26 visit		
N	1280	1268
Mean (SD)	1.48 (10.70)	0.39 (10.57)
Median	1.00	0.00
Min ; Max	-47.00 ; 55.00	-56.00 ; 74.00
Week 36 visit		
N	471	475
Mean (SD)	1.14 (11.68)	-0.28 (11.11)
Median	1.00	-1.00
Min ; Max	-58.00 ; 64.00	-52.00 ; 48.00
Week 52 visit		
N	947	958
Mean (SD)	2.49 (12.33)	1.80 (11.43)
Median	2.00	1.00
Min ; Max	-59.00 ; 93.00	-62.00 ; 48.00
End-of-treatment visit		
N	1747	1743
Mean (SD)	2.26 (11.77)	1.39 (11.03)
Median	2.00	1.00
Min ; Max	-59.00 ; 93.00	-62.00 ; 74.00
Lowest post baseline value		
N	1818	1814
Mean (SD)	-0.99 (10.97)	-1.76 (10.49)
Median	-1.00	-2.00
Min ; Max	-59.00 ; 93.00	-62.00 ; 46.00
Highest post baseline value		
N	1818	1814
Mean (SD)	5.44 (11.89)	4.36 (10.75)
Median	5.00	4.00
Min ; Max	-59.00 ; 155.00	-62.00 ; 74.00

N: Number of subjects, SD: Standard deviation, Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4: Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

adsl.xpt; variable(s): NA; criteria: SAFFL == "Y" & POOLGR1 == "T2D pool"
adlb.xpt; variable(s): CHG; criteria: SAFFL == "Y" & PARCAT1 == "BIOCHEMISTRY" & PARAMCD %in% c("ALPS", "ALTS", "ASTS", "ALBS", "CREATS", "CREATS2", "BILIS", "BILIS2", "SODIUMS", "KS") & ANELFL == "Y" & ANL06FL == "Y" & DTYPE %in% c("", "HALFLOQ", "ULOQ", "MINIMUM", "MAXIMUM", "LVPD", "EOT") & CHG != " " & POOLGR1 == "T2D pool"
nn1436/nn1436-iss/submission_20221024_er
05DEC2022:13:01:26 - tsumcont/tlbchbbiochemestrysumt2dsas.txt

Biochemistry by treatment week - change from baseline - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec	Daily basal insulin
Change from Baseline, Creatinine (mg/dL)		
Week 10 visit		
N	1299	1292
Mean (SD)	0.01 (0.11)	0.00 (0.11)
Median	0.01	0.00
Min ; Max	-0.44 ; 0.66	-0.60 ; 0.55
Week 26 visit		
N	1280	1268
Mean (SD)	0.02 (0.12)	0.00 (0.12)
Median	0.01	0.00
Min ; Max	-0.53 ; 0.62	-0.63 ; 0.84
Week 36 visit		
N	471	475
Mean (SD)	0.01 (0.13)	-0.00 (0.13)
Median	0.01	-0.01
Min ; Max	-0.66 ; 0.72	-0.59 ; 0.54
Week 52 visit		
N	947	958
Mean (SD)	0.03 (0.14)	0.02 (0.13)
Median	0.02	0.01
Min ; Max	-0.67 ; 1.05	-0.70 ; 0.54
End-of-treatment visit		
N	1747	1743
Mean (SD)	0.03 (0.13)	0.02 (0.12)
Median	0.02	0.01
Min ; Max	-0.67 ; 1.05	-0.70 ; 0.84
Lowest post baseline value		
N	1818	1814
Mean (SD)	-0.01 (0.12)	-0.02 (0.12)
Median	-0.01	-0.02
Min ; Max	-0.67 ; 1.05	-0.70 ; 0.52
Highest post baseline value		
N	1818	1814
Mean (SD)	0.06 (0.13)	0.05 (0.12)
Median	0.06	0.05
Min ; Max	-0.67 ; 1.75	-0.70 ; 0.84

N: Number of subjects, SD: Standard deviation, Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4: Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

adsl.xpt; variable(s): NA; criteria: SAFFL == "Y" & POOLGR1 == "T2D pool"
adlb.xpt; variable(s): CHG; criteria: SAFFL == "Y" & PARCAT1 == "BIOCHEMISTRY" & PARAMCD %in% c("ALPS", "ALTS", "ASTS", "ALBS", "CREATS", "CREATS2", "BILIS", "BILIS2", "SODIUMS", "KS") & ANELFL == "Y" & ANL06FL == "Y" & DTYPE %in% c("", "HALFLOQ", "ULOQ", "MINIMUM", "MAXIMUM", "LVPD", "EOT") & CHG != " " & POOLGR1 == "T2D pool"
nn1436/nn1436-iss/submission_20221024_er
05DEC2022:13:01:26 - tsumcont/tlbchbbiochemestrysumt2dsas.txt

Biochemistry by treatment week - change from baseline - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec	Daily basal insulin
Change from Baseline, Potassium (mmol/L)		
Week 10 visit		
N	1297	1291
Mean (SD)	0.01 (0.48)	-0.02 (0.42)
Median	0.01	-0.02
Min ; Max	-5.18 ; 3.31	-2.24 ; 2.17
Week 26 visit		
N	1277	1269
Mean (SD)	-0.00 (0.50)	-0.01 (0.52)
Median	-0.01	-0.03
Min ; Max	-4.76 ; 6.20	-2.22 ; 5.49
Week 36 visit		
N	470	477
Mean (SD)	-0.03 (0.47)	-0.08 (0.40)
Median	0.01	-0.07
Min ; Max	-5.25 ; 1.30	-2.23 ; 1.28
Week 52 visit		
N	942	958
Mean (SD)	-0.02 (0.53)	-0.03 (0.53)
Median	-0.02	-0.04
Min ; Max	-5.31 ; 6.19	-2.03 ; 5.47
End-of-treatment visit		
N	1740	1744
Mean (SD)	-0.01 (0.51)	-0.01 (0.50)
Median	-0.01	-0.03
Min ; Max	-5.31 ; 6.20	-2.03 ; 5.47
Lowest post baseline value		
N	1814	1812
Mean (SD)	-0.16 (0.42)	-0.17 (0.40)
Median	-0.14	-0.18
Min ; Max	-5.63 ; 1.51	-2.24 ; 1.34
Highest post baseline value		
N	1814	1812
Mean (SD)	0.14 (0.53)	0.14 (0.53)
Median	0.12	0.10
Min ; Max	-4.76 ; 6.20	-2.03 ; 5.49

N: Number of subjects, SD: Standard deviation, Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4: Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Biochemistry by treatment week - change from baseline - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec	Daily basal insulin
Change from Baseline, Sodium (mmol/L)		
Week 10 visit		
N	1299	1293
Mean (SD)	0.87 (2.88)	0.93 (2.73)
Median	1.00	1.00
Min ; Max	-31.00 ; 14.00	-26.00 ; 19.00
Week 26 visit		
N	1281	1272
Mean (SD)	1.16 (3.02)	1.22 (3.28)
Median	1.00	1.00
Min ; Max	-12.00 ; 39.00	-9.00 ; 44.00
Week 36 visit		
N	470	477
Mean (SD)	0.91 (2.68)	0.83 (2.64)
Median	1.00	1.00
Min ; Max	-8.00 ; 9.00	-6.00 ; 14.00
Week 52 visit		
N	948	960
Mean (SD)	1.47 (3.37)	1.40 (3.37)
Median	1.00	1.00
Min ; Max	-9.00 ; 39.00	-17.00 ; 43.00
End-of-treatment visit		
N	1750	1749
Mean (SD)	1.34 (3.27)	1.36 (3.28)
Median	1.00	1.00
Min ; Max	-12.00 ; 39.00	-17.00 ; 44.00
Lowest post baseline value		
N	1820	1816
Mean (SD)	0.17 (2.89)	0.23 (2.80)
Median	0.00	0.00
Min ; Max	-31.00 ; 16.00	-26.00 ; 15.00
Highest post baseline value		
N	1820	1816
Mean (SD)	2.09 (3.20)	2.16 (3.34)
Median	2.00	2.00
Min ; Max	-15.00 ; 39.00	-17.00 ; 44.00

N: Number of subjects, SD: Standard deviation, Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4: Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

adsl.xpt; variable(s): NA; criteria: SAFFL == "Y" & POOLGR1 == "T2D pool"
adlb.xpt; variable(s): CHG; criteria: SAFFL == "Y" & PARCAT1 == "BIOCHEMISTRY" & PARAMCD %in% c("ALPS", "ALTS", "ASTS", "ALBS", "CREATS", "CREATS2", "BILIS", "BILIS2", "SODIUMS", "KS") & ANELFL == "Y" & ANL06FL == "Y" & DTYPE %in% c("", "HALFLOQ", "ULOQ", "MINIMUM", "MAXIMUM", "LVPD", "EOT") & CHG != " " & POOLGR1 == "T2D pool"
nn1436/nn1436-iss/submission_20221024_er
05DEC2022:13:01:26 - tsumcont/tlbchbbiochemestrysumt2dsas.txt

Biochemistry by treatment week - change from baseline - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec	Daily basal insulin
Change from Baseline, Total bilirubin (umol/L)		
Week 10 visit		
N	1285	1278
Mean (SD)	-0.01 (3.07)	0.08 (3.15)
Median	0.00	0.00
Min ; Max	-17.00 ; 15.00	-17.00 ; 24.50
Week 26 visit		
N	1266	1259
Mean (SD)	0.03 (3.29)	0.11 (3.79)
Median	0.00	0.00
Min ; Max	-25.00 ; 19.00	-20.00 ; 73.00
Week 36 visit		
N	469	473
Mean (SD)	-0.09 (3.12)	-0.22 (2.82)
Median	0.00	0.00
Min ; Max	-17.00 ; 12.00	-11.00 ; 14.00
Week 52 visit		
N	940	946
Mean (SD)	-0.36 (3.05)	-0.20 (3.11)
Median	0.00	0.00
Min ; Max	-16.00 ; 10.00	-13.00 ; 16.00
End-of-treatment visit		
N	1728	1725
Mean (SD)	-0.20 (3.24)	-0.09 (3.54)
Median	0.00	0.00
Min ; Max	-25.00 ; 19.00	-13.00 ; 73.00
Lowest post baseline value		
N	1812	1803
Mean (SD)	-1.03 (7.57)	-1.08 (2.95)
Median	-1.00	-1.00
Min ; Max	-25.00 ; 295.00	-20.00 ; 24.50
Highest post baseline value		
N	1812	1803
Mean (SD)	0.99 (7.63)	0.94 (3.65)
Median	1.00	1.00
Min ; Max	-17.00 ; 295.00	-13.00 ; 73.00

N: Number of subjects, SD: Standard deviation, Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4: Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

adsl.xpt; variable(s): NA; criteria: SAFFL == "Y" & POOLGR1 == "T2D pool"
adlb.xpt; variable(s): CHG; criteria: SAFFL == "Y" & PARCAT1 == "BIOCHEMISTRY" & PARAMCD %in% c("ALPS", "ALTS", "ASTS", "ALBS", "CREATS", "CREATS2", "BILIS", "BILIS2", "SODIUMS", "KS") & ANELFL == "Y" & ANL06FL == "Y" & DTYPE %in% c("", "HALFLOQ", "ULOQ", "MINIMUM", "MAXIMUM", "LVPD", "EOT") & CHG != " " & POOLGR1 == "T2D pool"
nn1436/nn1436-iss/submission_20221024_er
05DEC2022:13:01:26 - tsumcont/tlbchbbiochemestrysumt2dsas.txt


Biochemistry by treatment week - change from baseline - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec	Daily basal insulin
Change from Baseline, Total bilirubin (mg/dL)		
Week 10 visit		
N	1285	1278
Mean (SD)	-0.00 (0.18)	0.00 (0.18)
Median	0.00	0.00
Min ; Max	-0.99 ; 0.88	-0.99 ; 1.43
Week 26 visit		
N	1266	1259
Mean (SD)	0.00 (0.19)	0.01 (0.22)
Median	0.00	0.00
Min ; Max	-1.46 ; 1.11	-1.17 ; 4.27
Week 36 visit		
N	469	473
Mean (SD)	-0.01 (0.18)	-0.01 (0.16)
Median	0.00	0.00
Min ; Max	-0.99 ; 0.70	-0.64 ; 0.82
Week 52 visit		
N	940	946
Mean (SD)	-0.02 (0.18)	-0.01 (0.18)
Median	0.00	0.00
Min ; Max	-0.94 ; 0.58	-0.76 ; 0.94
End-of-treatment visit		
N	1728	1725
Mean (SD)	-0.01 (0.19)	-0.01 (0.21)
Median	0.00	0.00
Min ; Max	-1.46 ; 1.11	-0.76 ; 4.27
Lowest post baseline value		
N	1812	1803
Mean (SD)	-0.06 (0.44)	-0.06 (0.17)
Median	-0.06	-0.06
Min ; Max	-1.46 ; 17.25	-1.17 ; 1.43
Highest post baseline value		
N	1812	1803
Mean (SD)	0.06 (0.45)	0.06 (0.21)
Median	0.06	0.06
Min ; Max	-0.99 ; 17.25	-0.76 ; 4.27

N: Number of subjects, SD: Standard deviation, Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4: Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

adsl.xpt; variable(s): NA; criteria: SAFFL == "Y" & POOLGR1 == "T2D pool"
adlb.xpt; variable(s): CHG; criteria: SAFFL == "Y" & PARCAT1 == "BIOCHEMISTRY" & PARAMCD %in% c("ALPS", "ALTS", "ASTS", "ALBS", "CREATS", "CREATS2", "BILIS", "BILIS2", "SODIUMS", "KS") & ANELFL == "Y" & ANL06FL == "Y" & DTYPE %in% c("", "HALFLOQ", "ULOQ", "MINIMUM", "MAXIMUM", "LVPD", "EOT") & CHG != " " & POOLGR1 == "T2D pool"
nn1436/nn1436-iss/submission_20221024_er
05DEC2022:13:01:26 - tsumcont/tlbchbbiochemestrysumt2dsas.txt

7.5.15 Biochemistry by trial - albumin serum - baseline and end-of-treatment - on-treatment/main-on-treatment - box plot - safety analysis set




Safety analysis set. Observed data. Legend: Mean (symbol), median (centre line), 25th and 75th percentiles (box), and extremes (circles). Whiskers are from 2.5% - 97.5%. Numbers of values above 5.8 appears in the right panel. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. OD analogues: Once-daily basal insulin analogues (IDeg, IGlar U100, IGlar U300). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

adlb.xpt; variable(s): STDNM PARAM AVISIT3 AVISIT3N AVAL; criteria: SAFFL == "Y" & ANELFL == "Y" & PARAMCD == "ALBS" & ANL06FL == "Y"

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:13:05:44 - fbox/flbalbuminboxontsas.png

7.5.16 Biochemistry by trial - alkaline phosphatase - baseline and end-of-treatment - on-treatment/main-on-treatment - box plot - safety analysis set




Safety analysis set. Observed data. Legend: Mean (symbol), median (centre line), 25th and 75th percentiles (box), and extremes (circles). Whiskers are from 2.5% - 97.5%. Numbers of values above 167.6 appears in the right panel. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. OD analogues: Once-daily basal insulin analogues (IDeg, IGlar U100, IGlar U300). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

adlb.xpt; variable(s): STDNM PARAM AVISIT3 AVISIT3N AVAL; criteria: SAFFL == "Y" & ANELFL == "Y" & PARAMCD == "ALPS" & ANL06FL == "Y"

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:13:06:01 - fbox/flbalkalineboxontsas.png

7.5.17 Biochemistry by trial - alanine aminotransferase - baseline and end-of-treatment - on-treatment/main-on-treatment - box plot - safety analysis set




Safety analysis set. Observed data. Legend: Mean (symbol), median (centre line), 25th and 75th percentiles (box), and extremes (circles). Whiskers are from 2.5% - 97.5%. Numbers of values above 65.9 appears in the right panel. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. OD analogues: Once-daily basal insulin analogues (IDeg, IGlar U100, IGlar U300). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

adlb.xpt; variable(s): STDNM PARAM AVISIT3 AVISIT3N AVAL; criteria: SAFFL == "Y" & ANELFL == "Y" & PARAMCD == "ALTS" & ANL06FL == "Y"

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:13:06:17 - fbox/flbalanineboxontsas.png

7.5.18 Biochemistry by trial - aspartate aminotransferase - baseline and end-of-treatment - on-treatment/main-on-treatment - box plot - safety analysis set




Safety analysis set. Observed data. Legend: Mean (symbol), median (centre line), 25th and 75th percentiles (box), and extremes (circles). Whiskers are from 2.5% - 97.5%. Numbers of values above 45.1 appears in the right panel. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. OD analogues: Once-daily basal insulin analogues (IDeg, IGlar U100, IGlar U300). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

adlb.xpt; variable(s): STDNM PARAM AVISIT3 AVISIT3N AVAL; criteria: SAFFL == "Y" & ANELFL == "Y" & PARAMCD == "ASTS" & ANL06FL == "Y"

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:13:06:35 - fbox/flbaspartateboxontsas.png

7.5.19 Biochemistry by trial - creatinine - baseline and end-of-treatment - on-treatment/main-on-treatment - box plot - safety analysis set




Safety analysis set. Observed data. Legend: Mean (symbol), median (centre line), 25th and 75th percentiles (box), and extremes (circles). Whiskers are from 2.5% - 97.5%. Numbers of values above 155.1 appears in the right panel. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. OD analogues: Once-daily basal insulin analogues (IDeg, IGlar U100, IGlar U300). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

adlb.xpt; variable(s): STDNM PARAM AVISIT3 AVISIT3N AVAL; criteria: SAFFL == "Y" & ANELFL == "Y" & PARAMCD == "CREATS" & ANL06FL == "Y"

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:13:06:52 - fbox/flbcreatinineboxontsas.png

7.5.20 Biochemistry by trial - potassium - baseline and end-of-treatment - on-treatment/main-on-treatment - box plot - safety analysis set




Safety analysis set. Observed data. Legend: Mean (symbol), median (centre line), 25th and 75th percentiles (box), and extremes (circles). Whiskers are from 2.5% - 97.5%. Numbers of values above 6.4 appears in the right panel. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. OD analogues: Once-daily basal insulin analogues (IDeg, IGlar U100, IGlar U300). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

adlb.xpt; variable(s): STDNM PARAM AVISIT3 AVISIT3N AVAL; criteria: SAFFL == "Y" & ANELFL == "Y" & PARAMCD == "KS" & ANL06FL == "Y"

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:13:07:08 - fbox/flbpotassiumboxontsas.png

7.5.21 Biochemistry by trial - sodium - baseline and end-of-treatment - on-treatment/main-on-treatment - box plot - safety analysis set




Safety analysis set. Observed data. Legend: Mean (symbol), median (centre line), 25th and 75th percentiles (box), and extremes (circles). Whiskers are from 2.5% - 97.5%. Numbers of values above 162 appears in the right panel. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. OD analogues: Once-daily basal insulin analogues (IDeg, IGlar U100, IGlar U300). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

adlb.xpt; variable(s): STDNM PARAM AVISIT3 AVISIT3N AVAL; criteria: SAFFL == "Y" & ANELFL == "Y" & PARAMCD == "SODIUMS" & ANL06FL == "Y"

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:13:07:26 - fbox/flbsodiumboxontsas.png

7.5.22 Biochemistry by trial - total bilirubin - baseline and end-of-treatment - on-treatment/main-on-treatment - box plot - safety analysis set



Safety analysis set. Observed data. Legend: Mean (symbol), median (centre line), 25th and 75th percentiles (box), and extremes (circles). Whiskers are from 2.5% - 97.5%. Numbers of values above 20.4 appears in the right panel. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. OD analogues: Once-daily basal insulin analogues (IDeg, IGlar U100, IGlar U300). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

adlb.xpt; variable(s): STDNM PARAM AVISIT3 AVISIT3N AVAL; criteria: SAFFL == "Y" & ANELFL == "Y" & PARAMCD == "BILIS" & ANL06FL == "Y"

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:13:07:42 - fbox/flbbilirubinboxontsas.png

7.5.23 HDL by treatment week - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec	Daily basal insulin
Number of subjects	2170	2170
HDL cholesterol (mmol/L)		
Week 0 visit		
N	2137	2131
Geom.mean (CV%)	1.17 (30.40)	1.19 (29.25)
Median	1.17	1.17
Min ; Max	0.23 ; 3.37	0.18 ; 3.50
Week 10 visit		
N	1579	1574
Geom.mean (CV%)	1.26 (30.58)	1.24 (28.29)
Median	1.27	1.22
Min ; Max	0.18 ; 3.70	0.47 ; 3.65
Week 26 visit		
N	1538	1546
Geom.mean (CV%)	1.24 (29.88)	1.23 (28.29)
Median	1.22	1.22
Min ; Max	0.49 ; 4.01	0.36 ; 4.20
Week 36 visit		
N	471	475
Geom.mean (CV%)	1.18 (26.83)	1.17 (25.98)
Median	1.17	1.17
Min ; Max	0.44 ; 2.93	0.41 ; 2.25
Week 52 visit		
N	945	956
Geom.mean (CV%)	1.15 (27.53)	1.14 (26.21)
Median	1.14	1.14
Min ; Max	0.39 ; 2.87	0.36 ; 2.38
End-of-treatment visit		
N	2004	2021
Geom.mean (CV%)	1.20 (29.84)	1.20 (28.59)
Median	1.19	1.19
Min ; Max	0.39 ; 4.01	0.36 ; 4.20
Lowest post baseline value		
N	2102	2099
Geom.mean (CV%)	1.15 (30.30)	1.14 (28.27)
Median	1.14	1.14
Min ; Max	0.18 ; 3.70	0.36 ; 3.65
Highest post baseline value		
N	2102	2099
Geom.mean (CV%)	1.27 (30.38)	1.26 (27.97)
Median	1.27	1.24
Min ; Max	0.18 ; 4.01	0.47 ; 4.20

CV: Coefficient of variation, HDL: High-density lipoprotein, N: Number of subjects. Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

HDL by treatment week - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec	Daily basal insulin
HDL cholesterol (mg/dL)		
Week 0 visit		
N	2137	2131
Geom.mean (CV%)	45.35 (30.40)	45.91 (29.25)
Median	45.17	45.17
Min ; Max	8.88 ; 130.12	6.95 ; 135.13
Week 10 visit		
N	1579	1574
Geom.mean (CV%)	48.76 (30.58)	47.97 (28.29)
Median	49.03	47.10
Min ; Max	6.95 ; 142.86	18.15 ; 140.93
Week 26 visit		
N	1538	1546
Geom.mean (CV%)	47.89 (29.88)	47.59 (28.29)
Median	47.10	47.10
Min ; Max	18.92 ; 154.83	13.90 ; 162.16
Week 36 visit		
N	471	475
Geom.mean (CV%)	45.65 (26.83)	45.07 (25.98)
Median	45.17	45.17
Min ; Max	16.99 ; 113.13	15.83 ; 86.87
Week 52 visit		
N	945	956
Geom.mean (CV%)	44.36 (27.53)	43.85 (26.21)
Median	44.02	44.02
Min ; Max	15.06 ; 110.81	13.90 ; 91.89
End-of-treatment visit		
N	2004	2021
Geom.mean (CV%)	46.52 (29.84)	46.18 (28.59)
Median	45.95	45.95
Min ; Max	15.06 ; 154.83	13.90 ; 162.16
Lowest post baseline value		
N	2102	2099
Geom.mean (CV%)	44.43 (30.30)	44.04 (28.27)
Median	44.02	44.02
Min ; Max	6.95 ; 142.86	13.90 ; 140.93
Highest post baseline value		
N	2102	2099
Geom.mean (CV%)	49.18 (30.38)	48.70 (27.97)
Median	49.03	47.88
Min ; Max	6.95 ; 154.83	18.15 ; 162.16

CV: Coefficient of variation, HDL: High-density lipoprotein, N: Number of subjects. Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

7.5.24 HDL by treatment week - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec	Daily basal insulin
Number of subjects	1880	1878
HDL cholesterol (mmol/L)		
Week 0 visit		
N	1852	1841
Geom.mean (CV%)	1.13 (28.22)	1.14 (26.77)
Median	1.11	1.14
Min ; Max	0.23 ; 3.03	0.36 ; 2.82
Week 10 visit		
N	1300	1290
Geom.mean (CV%)	1.21 (28.78)	1.19 (26.52)
Median	1.22	1.17
Min ; Max	0.18 ; 2.87	0.47 ; 2.90
Week 26 visit		
N	1270	1266
Geom.mean (CV%)	1.19 (27.87)	1.18 (25.98)
Median	1.17	1.17
Min ; Max	0.49 ; 3.34	0.36 ; 2.46
Week 36 visit		
N	471	475
Geom.mean (CV%)	1.18 (26.83)	1.17 (25.98)
Median	1.17	1.17
Min ; Max	0.44 ; 2.93	0.41 ; 2.25
Week 52 visit		
N	945	956
Geom.mean (CV%)	1.15 (27.53)	1.14 (26.21)
Median	1.14	1.14
Min ; Max	0.39 ; 2.87	0.36 ; 2.38
End-of-treatment visit		
N	1736	1741
Geom.mean (CV%)	1.16 (28.00)	1.15 (26.58)
Median	1.14	1.14
Min ; Max	0.39 ; 3.34	0.36 ; 2.46
Lowest post baseline value		
N	1817	1812
Geom.mean (CV%)	1.11 (28.53)	1.10 (26.45)
Median	1.09	1.09
Min ; Max	0.18 ; 2.95	0.36 ; 2.46
Highest post baseline value		
N	1817	1812
Geom.mean (CV%)	1.23 (28.72)	1.22 (26.15)
Median	1.22	1.22
Min ; Max	0.18 ; 3.34	0.47 ; 2.90


CV: Coefficient of variation, HDL: High-density lipoprotein, N: Number of subjects, Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4: Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

HDL by treatment week - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec	Daily basal insulin
HDL cholesterol (mg/dL)		
Week 0 visit		
N	1852	1841
Geom.mean (CV%)	43.51 (28.22)	44.02 (26.77)
Median	42.86	44.02
Min ; Max	8.88 ; 116.99	13.90 ; 108.88
Week 10 visit		
N	1300	1290
Geom.mean (CV%)	46.54 (28.78)	45.90 (26.52)
Median	47.10	45.17
Min ; Max	6.95 ; 110.81	18.15 ; 111.97
Week 26 visit		
N	1270	1266
Geom.mean (CV%)	45.84 (27.87)	45.46 (25.98)
Median	45.17	45.17
Min ; Max	18.92 ; 128.96	13.90 ; 94.98
Week 36 visit		
N	471	475
Geom.mean (CV%)	45.65 (26.83)	45.07 (25.98)
Median	45.17	45.17
Min ; Max	16.99 ; 113.13	15.83 ; 86.87
Week 52 visit		
N	945	956
Geom.mean (CV%)	44.36 (27.53)	43.85 (26.21)
Median	44.02	44.02
Min ; Max	15.06 ; 110.81	13.90 ; 91.89
End-of-treatment visit		
N	1736	1741
Geom.mean (CV%)	44.85 (28.00)	44.45 (26.58)
Median	44.02	44.02
Min ; Max	15.06 ; 128.96	13.90 ; 94.98
Lowest post baseline value		
N	1817	1812
Geom.mean (CV%)	42.75 (28.53)	42.42 (26.45)
Median	42.08	42.08
Min ; Max	6.95 ; 113.90	13.90 ; 94.98
Highest post baseline value		
N	1817	1812
Geom.mean (CV%)	47.30 (28.72)	46.94 (26.15)
Median	47.10	47.10
Min ; Max	6.95 ; 128.96	18.15 ; 111.97

CV: Coefficient of variation, HDL: High-density lipoprotein, N: Number of subjects, Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4: Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

7.5.25 HDL by treatment week and trial - on-treatment/main-on-treatment - geometric mean plot - safety analysis set



Safety analysis set. Observed data. HDL: High-density lipoprotein. Legend: Geometric mean (symbol) and mean ± standard error to the mean on log-scale back transformed (error bars). OD analogues: Once-daily basal insulin analogues (IDeg, IGlar U100, IGlar U300). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

adlb.xpt; variable(s): STDNM PARAM AVISIT3N AVAL; criteria: SAFFL == "Y" & PARAMCD %in% c("HDLS", "HDLS2") & ANELFL == "Y" & ANL06FL == "Y" & AVAL != " " & DTYPE %in% c("", "HALFLOQ", "ULOQ", "LVPD")

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:12:57:06 - fgeomean/flbhdlgeomeanontsas.png

7.5.26 LDL by treatment week - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec	Daily basal insulin
Number of subjects	2170	2170
LDL cholesterol (mmol/L)		
Week 0 visit		
N	2128	2120
Geom.mean (CV%)	2.06 (46.85)	2.11 (48.59)
Median	2.17	2.21
Min ; Max	0.26 ; 6.88	0.26 ; 7.32
Week 10 visit		
N	1579	1572
Geom.mean (CV%)	2.12 (41.68)	2.14 (42.01)
Median	2.19	2.24
Min ; Max	0.26 ; 6.04	0.26 ; 5.78
Week 26 visit		
N	1538	1546
Geom.mean (CV%)	2.11 (42.28)	2.16 (42.41)
Median	2.19	2.22
Min ; Max	0.26 ; 5.44	0.26 ; 6.20
Week 36 visit		
N	471	474
Geom.mean (CV%)	2.06 (43.17)	2.13 (44.74)
Median	2.17	2.21
Min ; Max	0.26 ; 5.21	0.26 ; 5.95
Week 52 visit		
N	943	955
Geom.mean (CV%)	1.98 (48.49)	2.03 (49.60)
Median	2.07	2.13
Min ; Max	0.11 ; 5.68	0.26 ; 7.56
End-of-treatment visit		
N	2002	2020
Geom.mean (CV%)	2.06 (45.20)	2.10 (46.49)
Median	2.13	2.19
Min ; Max	0.11 ; 5.68	0.26 ; 7.56
Lowest post baseline value		
N	2099	2098
Geom.mean (CV%)	1.87 (46.05)	1.90 (47.41)
Median	1.93	1.96
Min ; Max	0.11 ; 5.44	0.26 ; 7.56
Highest post baseline value		
N	2099	2098
Geom.mean (CV%)	2.26 (42.37)	2.29 (44.37)
Median	2.32	2.39
Min ; Max	0.26 ; 6.04	0.26 ; 7.56

CV: Coefficient of variation, LDL: Low-density lipoprotein, N: Number of subjects. Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

adsl.xpt; variable(s): NA; criteria: SAFFL == "Y" & POOLGR2 == "Phase 3a pool"
adlb.xpt; variable(s): AVAL; criteria: SAFFL == "Y" & PARAMCD %in% c("COMLDLS", "COMLDLS2") & ANELFL == "Y" & ANL06FL == "Y" & POOLGR2 == "Phase 3a pool" & DTYPE %in% c("", "HALFLOQ", "ULOQ", "MINIMUM", "MAXIMUM", "LVPD", "EOT")
nn1436/nn1436-iss/submission_20221024_er
05DEC2022:13:01:39 - tsumcont/tlbldlsumontp3asas.txt

LDL by treatment week - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec	Daily basal insulin
LDL cholesterol (mg/dL)		
Week 0 visit		
N	2128	2120
Geom.mean (CV%)	79.60 (46.85)	81.35 (48.59)
Median	83.78	85.33
Min ; Max	10.04 ; 265.64	10.04 ; 282.63
Week 10 visit		
N	1579	1572
Geom.mean (CV%)	81.94 (41.68)	82.74 (42.01)
Median	84.56	86.49
Min ; Max	10.04 ; 233.20	10.04 ; 223.17
Week 26 visit		
N	1538	1546
Geom.mean (CV%)	81.55 (42.28)	83.48 (42.41)
Median	84.36	85.71
Min ; Max	10.04 ; 210.04	10.04 ; 239.38
Week 36 visit		
N	471	474
Geom.mean (CV%)	79.73 (43.17)	82.15 (44.74)
Median	83.78	85.14
Min ; Max	10.04 ; 201.16	10.04 ; 229.73
Week 52 visit		
N	943	955
Geom.mean (CV%)	76.63 (48.49)	78.31 (49.60)
Median	79.92	82.24
Min ; Max	4.25 ; 219.30	10.04 ; 291.89
End-of-treatment visit		
N	2002	2020
Geom.mean (CV%)	79.51 (45.20)	81.14 (46.49)
Median	82.24	84.56
Min ; Max	4.25 ; 219.30	10.04 ; 291.89
Lowest post baseline value		
N	2099	2098
Geom.mean (CV%)	72.10 (46.05)	73.36 (47.41)
Median	74.52	75.68
Min ; Max	4.25 ; 210.04	10.04 ; 291.89
Highest post baseline value		
N	2099	2098
Geom.mean (CV%)	87.30 (42.37)	88.45 (44.37)
Median	89.58	92.28
Min ; Max	10.04 ; 233.20	10.04 ; 291.89

CV: Coefficient of variation, LDL: Low-density lipoprotein, N: Number of subjects. Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

7.5.27 LDL by treatment week - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec	Daily basal insulin
Number of subjects	1880	1878
LDL cholesterol (mmol/L)		
Week 0 visit		
N	1843	1831
Geom.mean (CV%)	2.01 (47.94)	2.05 (50.13)
Median	2.13	2.15
Min ; Max	0.26 ; 6.88	0.26 ; 7.32
Week 10 visit		
N	1300	1288
Geom.mean (CV%)	2.07 (42.71)	2.09 (43.49)
Median	2.13	2.19
Min ; Max	0.26 ; 5.93	0.26 ; 5.78
Week 26 visit		
N	1270	1266
Geom.mean (CV%)	2.07 (43.50)	2.10 (43.63)
Median	2.15	2.14
Min ; Max	0.26 ; 5.44	0.26 ; 6.20
Week 36 visit		
N	471	474
Geom.mean (CV%)	2.06 (43.17)	2.13 (44.74)
Median	2.17	2.21
Min ; Max	0.26 ; 5.21	0.26 ; 5.95
Week 52 visit		
N	943	955
Geom.mean (CV%)	1.98 (48.49)	2.03 (49.60)
Median	2.07	2.13
Min ; Max	0.11 ; 5.68	0.26 ; 7.56
End-of-treatment visit		
N	1734	1740
Geom.mean (CV%)	2.02 (46.36)	2.05 (47.78)
Median	2.10	2.13
Min ; Max	0.11 ; 5.68	0.26 ; 7.56
Lowest post baseline value		
N	1814	1811
Geom.mean (CV%)	1.82 (47.19)	1.85 (48.76)
Median	1.89	1.91
Min ; Max	0.11 ; 5.44	0.26 ; 7.56
Highest post baseline value		
N	1814	1811
Geom.mean (CV%)	2.22 (43.48)	2.24 (45.90)
Median	2.27	2.34
Min ; Max	0.26 ; 5.93	0.26 ; 7.56


CV: Coefficient of variation, LDL: Low-density lipoprotein, N: Number of subjects, Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4: Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

LDL by treatment week - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec	Daily basal insulin
LDL cholesterol (mg/dL)		
Week 0 visit		
N	1843	1831
Geom.mean (CV%)	77.73 (47.94)	79.15 (50.13)
Median	82.24	83.01
Min ; Max	10.04 ; 265.64	10.04 ; 282.63
Week 10 visit		
N	1300	1288
Geom.mean (CV%)	79.76 (42.71)	80.61 (43.49)
Median	82.43	84.36
Min ; Max	10.04 ; 228.96	10.04 ; 223.17
Week 26 visit		
N	1270	1266
Geom.mean (CV%)	79.78 (43.50)	81.07 (43.63)
Median	83.01	82.63
Min ; Max	10.04 ; 210.04	10.04 ; 239.38
Week 36 visit		
N	471	474
Geom.mean (CV%)	79.73 (43.17)	82.15 (44.74)
Median	83.78	85.14
Min ; Max	10.04 ; 201.16	10.04 ; 229.73
Week 52 visit		
N	943	955
Geom.mean (CV%)	76.63 (48.49)	78.31 (49.60)
Median	79.92	82.24
Min ; Max	4.25 ; 219.30	10.04 ; 291.89
End-of-treatment visit		
N	1734	1740
Geom.mean (CV%)	77.94 (46.36)	79.06 (47.78)
Median	81.08	82.24
Min ; Max	4.25 ; 219.30	10.04 ; 291.89
Lowest post baseline value		
N	1814	1811
Geom.mean (CV%)	70.26 (47.19)	71.38 (48.76)
Median	72.97	73.75
Min ; Max	4.25 ; 210.04	10.04 ; 291.89
Highest post baseline value		
N	1814	1811
Geom.mean (CV%)	85.68 (43.48)	86.47 (45.90)
Median	87.64	90.35
Min ; Max	10.04 ; 228.96	10.04 ; 291.89

CV: Coefficient of variation, LDL: Low-density lipoprotein, N: Number of subjects, Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4: Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

7.5.28 LDL by treatment week and trial - on-treatment/main-on-treatment - geometric mean plot - safety analysis set



Safety analysis set. Observed data. LDL: Low-density lipoprotein. Legend: Geometric mean (symbol) and mean ± standard error to the mean on log-scale back transformed (error bars). OD analogues: Once-daily basal insulin analogues (IDeg, IGlar U100, IGlar U300). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

adlb.xpt; variable(s): STDNM PARAM AVISIT3N AVAL; criteria: SAFFL == "Y" & PARAMCD %in% c("COMLDLS", "COMLDLS2") & ANELFL == "Y" & ANL06FL == "Y" & AVAL != " " & DTYPE %in% c("", "HALFLOQ", "ULOQ", "LVPD")

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:12:57:12 - fgeomean/flbldlgeomeanontsas.png

7.5.29 Triglycerides by treatment week - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec	Daily basal insulin
Number of subjects	2170	2170
Triglycerides (mmol/L)		
Week 0 visit		
N	2136	2130
Geom.mean (CV%)	1.69 (67.01)	1.70 (67.59)
Median	1.60	1.64
Min ; Max	0.38 ; 18.22	0.28 ; 32.05
Week 10 visit		
N	1579	1574
Geom.mean (CV%)	1.28 (58.59)	1.34 (56.88)
Median	1.22	1.31
Min ; Max	0.34 ; 9.51	0.32 ; 20.59
Week 26 visit		
N	1538	1546
Geom.mean (CV%)	1.26 (58.10)	1.34 (56.94)
Median	1.21	1.29
Min ; Max	0.35 ; 9.92	0.33 ; 47.86
Week 36 visit		
N	471	475
Geom.mean (CV%)	1.54 (51.99)	1.61 (55.77)
Median	1.51	1.58
Min ; Max	0.51 ; 12.52	0.47 ; 12.41
Week 52 visit		
N	945	956
Geom.mean (CV%)	1.53 (55.96)	1.65 (57.13)
Median	1.46	1.55
Min ; Max	0.42 ; 16.03	0.46 ; 13.40
End-of-treatment visit		
N	2004	2021
Geom.mean (CV%)	1.35 (59.93)	1.44 (59.77)
Median	1.30	1.39
Min ; Max	0.35 ; 16.03	0.33 ; 47.86
Lowest post baseline value		
N	2101	2099
Geom.mean (CV%)	1.19 (57.06)	1.27 (57.18)
Median	1.15	1.21
Min ; Max	0.34 ; 13.40	0.32 ; 13.40
Highest post baseline value		
N	2101	2099
Geom.mean (CV%)	1.57 (61.35)	1.67 (60.27)
Median	1.53	1.60
Min ; Max	0.36 ; 16.03	0.44 ; 47.86

CV: Coefficient of variation, N: Number of subjects. Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Triglycerides by treatment week - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec	Daily basal insulin
Triglycerides (mg/dL)		
Week 0 visit		
N	2136	2130
Geom.mean (CV%)	149.97 (67.01)	150.86 (67.59)
Median	142.40	145.96
Min ; Max	33.82 ; 1621.58	24.92 ; 2852.45
Week 10 visit		
N	1579	1574
Geom.mean (CV%)	113.48 (58.59)	119.68 (56.88)
Median	108.58	116.59
Min ; Max	30.26 ; 846.39	28.48 ; 1832.51
Week 26 visit		
N	1538	1546
Geom.mean (CV%)	112.13 (58.10)	118.83 (56.94)
Median	107.69	115.25
Min ; Max	31.15 ; 882.88	29.37 ; 4259.54
Week 36 visit		
N	471	475
Geom.mean (CV%)	136.81 (51.99)	142.95 (55.77)
Median	134.39	140.62
Min ; Max	45.39 ; 1114.28	41.83 ; 1104.49
Week 52 visit		
N	945	956
Geom.mean (CV%)	135.95 (55.96)	146.43 (57.13)
Median	129.94	137.95
Min ; Max	37.38 ; 1426.67	40.94 ; 1192.60
End-of-treatment visit		
N	2004	2021
Geom.mean (CV%)	120.09 (59.93)	128.49 (59.77)
Median	115.70	123.71
Min ; Max	31.15 ; 1426.67	29.37 ; 4259.54
Lowest post baseline value		
N	2101	2099
Geom.mean (CV%)	106.27 (57.06)	112.77 (57.18)
Median	102.35	107.69
Min ; Max	30.26 ; 1192.60	28.48 ; 1192.60
Highest post baseline value		
N	2101	2099
Geom.mean (CV%)	139.76 (61.35)	148.80 (60.27)
Median	136.17	142.40
Min ; Max	32.04 ; 1426.67	39.16 ; 4259.54

CV: Coefficient of variation, N: Number of subjects. Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

7.5.30 Triglycerides by treatment week - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec	Daily basal insulin
Number of subjects	1880	1878
Triglycerides (mmol/L)		
Week 0 visit		
N	1851	1840
Geom.mean (CV%)	1.84 (62.43)	1.86 (63.16)
Median	1.76	1.79
Min ; Max	0.41 ; 18.22	0.42 ; 32.05
Week 10 visit		
N	1300	1290
Geom.mean (CV%)	1.40 (55.31)	1.47 (53.01)
Median	1.36	1.41
Min ; Max	0.34 ; 9.51	0.40 ; 20.59
Week 26 visit		
N	1270	1266
Geom.mean (CV%)	1.39 (53.99)	1.46 (54.11)
Median	1.33	1.40
Min ; Max	0.42 ; 9.92	0.45 ; 47.86
Week 36 visit		
N	471	475
Geom.mean (CV%)	1.54 (51.99)	1.61 (55.77)
Median	1.51	1.58
Min ; Max	0.51 ; 12.52	0.47 ; 12.41
Week 52 visit		
N	945	956
Geom.mean (CV%)	1.53 (55.96)	1.65 (57.13)
Median	1.46	1.55
Min ; Max	0.42 ; 16.03	0.46 ; 13.40
End-of-treatment visit		
N	1736	1741
Geom.mean (CV%)	1.46 (56.09)	1.56 (56.92)
Median	1.40	1.48
Min ; Max	0.42 ; 16.03	0.45 ; 47.86
Lowest post baseline value		
N	1816	1812
Geom.mean (CV%)	1.29 (53.89)	1.37 (54.25)
Median	1.23	1.31
Min ; Max	0.34 ; 13.40	0.40 ; 13.40
Highest post baseline value		
N	1816	1812
Geom.mean (CV%)	1.71 (57.05)	1.81 (56.85)
Median	1.64	1.71
Min ; Max	0.42 ; 16.03	0.45 ; 47.86


CV: Coefficient of variation, N: Number of subjects, Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4: Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Triglycerides by treatment week - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec	Daily basal insulin
Triglycerides (mg/dL)		
Week 0 visit		
N	1851	1840
Geom.mean (CV%)	164.14 (62.43)	165.85 (63.16)
Median	156.64	159.75
Min ; Max	36.49 ; 1621.58	37.38 ; 2852.45
Week 10 visit		
N	1300	1290
Geom.mean (CV%)	124.85 (55.31)	131.21 (53.01)
Median	121.04	125.49
Min ; Max	30.26 ; 846.39	35.60 ; 1832.51
Week 26 visit		
N	1270	1266
Geom.mean (CV%)	123.39 (53.99)	129.86 (54.11)
Median	117.93	124.16
Min ; Max	37.38 ; 882.88	40.05 ; 4259.54
Week 36 visit		
N	471	475
Geom.mean (CV%)	136.81 (51.99)	142.95 (55.77)
Median	134.39	140.62
Min ; Max	45.39 ; 1114.28	41.83 ; 1104.49
Week 52 visit		
N	945	956
Geom.mean (CV%)	135.95 (55.96)	146.43 (57.13)
Median	129.94	137.95
Min ; Max	37.38 ; 1426.67	40.94 ; 1192.60
End-of-treatment visit		
N	1736	1741
Geom.mean (CV%)	130.17 (56.09)	138.78 (56.92)
Median	124.60	131.72
Min ; Max	37.38 ; 1426.67	40.05 ; 4259.54
Lowest post baseline value		
N	1816	1812
Geom.mean (CV%)	115.19 (53.89)	121.91 (54.25)
Median	109.47	116.59
Min ; Max	30.26 ; 1192.60	35.60 ; 1192.60
Highest post baseline value		
N	1816	1812
Geom.mean (CV%)	152.37 (57.05)	161.00 (56.85)
Median	145.96	152.19
Min ; Max	37.38 ; 1426.67	40.05 ; 4259.54

CV: Coefficient of variation, N: Number of subjects, Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4: Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

7.5.31 Triglycerides by treatment week and trial - on-treatment/main-on-treatment - geometric mean plot - safety analysis set



Safety analysis set. Observed data. Legend: Geometric mean (symbol) and mean ± standard error to the mean on log-scale back transformed (error bars). OD analogues: Once-daily basal insulin analogues (IDeg, IGlar U100, IGlar U300). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

adlb.xpt; variable(s): STDNM PARAM AVISIT3N AVAL; criteria: SAFFL == "Y" & PARAMCD %in% c("TRIGS", "TRIGS2") & ANELFL == "Y" & ANL06FL == "Y" & AVAL != " " & DTYPE %in% c("", "HALFLOQ", "ULOQ", "LVPD")

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:12:57:17 - fgeomean/flbtriglyceridesgeomeanontsas.png

7.5.32 Total cholesterol by treatment week - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec	Daily basal insulin
Number of subjects	2170	2170
Total cholesterol (mmol/L)		
Week 0 visit		
N	2149	2146
Geom.mean (CV%)	4.24 (25.22)	4.31 (25.67)
Median	4.25	4.33
Min ; Max	1.58 ; 10.20	1.76 ; 11.03
Week 10 visit		
N	1584	1579
Geom.mean (CV%)	4.17 (24.13)	4.19 (23.91)
Median	4.17	4.22
Min ; Max	1.84 ; 8.68	1.81 ; 8.39
Week 26 visit		
N	1547	1549
Geom.mean (CV%)	4.12 (24.56)	4.20 (24.81)
Median	4.12	4.20
Min ; Max	1.84 ; 8.50	1.63 ; 14.58
Week 36 visit		
N	472	475
Geom.mean (CV%)	4.12 (23.77)	4.22 (24.92)
Median	4.12	4.25
Min ; Max	1.99 ; 7.43	1.71 ; 9.25
Week 52 visit		
N	946	958
Geom.mean (CV%)	4.04 (25.72)	4.13 (25.42)
Median	4.04	4.14
Min ; Max	1.61 ; 8.83	1.81 ; 9.66
End-of-treatment visit		
N	2013	2024
Geom.mean (CV%)	4.09 (25.20)	4.17 (25.27)
Median	4.09	4.19
Min ; Max	1.61 ; 8.83	1.63 ; 14.58
Lowest post baseline value		
N	2103	2101
Geom.mean (CV%)	3.88 (24.40)	3.94 (24.48)
Median	3.89	3.91
Min ; Max	1.61 ; 8.50	1.63 ; 9.66
Highest post baseline value		
N	2103	2101
Geom.mean (CV%)	4.34 (24.77)	4.41 (24.79)
Median	4.33	4.40
Min ; Max	1.76 ; 8.91	1.81 ; 14.58

CV: Coefficient of variation, N: Number of subjects. Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Total cholesterol by treatment week - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec	Daily basal insulin
Total cholesterol (mg/dL)		
Week 0 visit		
N	2149	2146
Geom.mean (CV%)	163.65 (25.22)	166.60 (25.67)
Median	164.09	167.18
Min ; Max	61.00 ; 393.82	67.95 ; 425.87
Week 10 visit		
N	1584	1579
Geom.mean (CV%)	160.85 (24.13)	161.86 (23.91)
Median	161.00	162.93
Min ; Max	71.04 ; 335.13	69.88 ; 323.94
Week 26 visit		
N	1547	1549
Geom.mean (CV%)	159.02 (24.56)	162.07 (24.81)
Median	159.07	162.16
Min ; Max	71.04 ; 328.19	62.93 ; 562.93
Week 36 visit		
N	472	475
Geom.mean (CV%)	159.24 (23.77)	162.79 (24.92)
Median	159.07	164.09
Min ; Max	76.83 ; 286.87	66.02 ; 357.14
Week 52 visit		
N	946	958
Geom.mean (CV%)	155.87 (25.72)	159.29 (25.42)
Median	155.98	159.85
Min ; Max	62.16 ; 340.93	69.88 ; 372.97
End-of-treatment visit		
N	2013	2024
Geom.mean (CV%)	157.87 (25.20)	161.11 (25.27)
Median	157.91	161.58
Min ; Max	62.16 ; 340.93	62.93 ; 562.93
Lowest post baseline value		
N	2103	2101
Geom.mean (CV%)	149.93 (24.40)	152.17 (24.48)
Median	150.19	150.97
Min ; Max	62.16 ; 328.19	62.93 ; 372.97
Highest post baseline value		
N	2103	2101
Geom.mean (CV%)	167.42 (24.77)	170.34 (24.79)
Median	167.18	169.88
Min ; Max	67.95 ; 344.02	69.88 ; 562.93

CV: Coefficient of variation, N: Number of subjects. Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

adsl.xpt; variable(s): NA; criteria: SAFFL == "Y" & POOLGR2 == "Phase 3a pool"
adlb.xpt; variable(s): AVAL; criteria: SAFFL == "Y" & PARAMCD %in% c("CHOLS", "CHOLS2") & ANELFL == "Y" & ANL06FL == "Y" & POOLGR2 == "Phase 3a pool" & DTYPE %in% c("", "HALFLOQ", "ULOQ", "MINIMUM", "MAXIMUM", "LVPD", "EOT")
nn1436/nn1436-iss/submission_20221024_er
05DEC2022:13:01:54 - tsumcont/tlbcholesterolsumontp3asas.txt

7.5.33 Total cholesterol by treatment week - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec	Daily basal insulin
Number of subjects	1880	1878
Total cholesterol (mmol/L)		
Week 0 visit		
N	1861	1855
Geom.mean (CV%)	4.19 (25.60)	4.27 (26.31)
Median	4.20	4.27
Min ; Max	1.58 ; 10.20	1.76 ; 11.03
Week 10 visit		
N	1303	1294
Geom.mean (CV%)	4.10 (24.45)	4.13 (24.46)
Median	4.09	4.17
Min ; Max	1.84 ; 8.31	1.81 ; 8.39
Week 26 visit		
N	1279	1268
Geom.mean (CV%)	4.07 (24.88)	4.13 (25.30)
Median	4.07	4.12
Min ; Max	1.84 ; 7.82	1.63 ; 14.58
Week 36 visit		
N	472	475
Geom.mean (CV%)	4.12 (23.77)	4.22 (24.92)
Median	4.12	4.25
Min ; Max	1.99 ; 7.43	1.71 ; 9.25
Week 52 visit		
N	946	958
Geom.mean (CV%)	4.04 (25.72)	4.13 (25.42)
Median	4.04	4.14
Min ; Max	1.61 ; 8.83	1.81 ; 9.66
End-of-treatment visit		
N	1745	1743
Geom.mean (CV%)	4.05 (25.49)	4.12 (25.67)
Median	4.04	4.12
Min ; Max	1.61 ; 8.83	1.63 ; 14.58
Lowest post baseline value		
N	1818	1814
Geom.mean (CV%)	3.83 (24.60)	3.89 (24.83)
Median	3.84	3.86
Min ; Max	1.61 ; 8.08	1.63 ; 9.66
Highest post baseline value		
N	1818	1814
Geom.mean (CV%)	4.29 (25.21)	4.36 (25.39)
Median	4.30	4.35
Min ; Max	1.76 ; 8.91	1.81 ; 14.58


CV: Coefficient of variation, N: Number of subjects, Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4: Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Total cholesterol by treatment week - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec	Daily basal insulin
Total cholesterol (mg/dL)		
Week 0 visit		
N	1861	1855
Geom.mean (CV%)	161.94 (25.60)	164.82 (26.31)
Median	162.16	164.86
Min ; Max	61.00 ; 393.82	67.95 ; 425.87
Week 10 visit		
N	1303	1294
Geom.mean (CV%)	158.25 (24.45)	159.60 (24.46)
Median	157.91	161.00
Min ; Max	71.04 ; 320.85	69.88 ; 323.94
Week 26 visit		
N	1279	1268
Geom.mean (CV%)	157.05 (24.88)	159.35 (25.30)
Median	157.14	159.07
Min ; Max	71.04 ; 301.93	62.93 ; 562.93
Week 36 visit		
N	472	475
Geom.mean (CV%)	159.24 (23.77)	162.79 (24.92)
Median	159.07	164.09
Min ; Max	76.83 ; 286.87	66.02 ; 357.14
Week 52 visit		
N	946	958
Geom.mean (CV%)	155.87 (25.72)	159.29 (25.42)
Median	155.98	159.85
Min ; Max	62.16 ; 340.93	69.88 ; 372.97
End-of-treatment visit		
N	1745	1743
Geom.mean (CV%)	156.25 (25.49)	158.99 (25.67)
Median	155.98	159.07
Min ; Max	62.16 ; 340.93	62.93 ; 562.93
Lowest post baseline value		
N	1818	1814
Geom.mean (CV%)	147.98 (24.60)	150.19 (24.83)
Median	148.46	149.03
Min ; Max	62.16 ; 311.97	62.93 ; 372.97
Highest post baseline value		
N	1818	1814
Geom.mean (CV%)	165.71 (25.21)	168.48 (25.39)
Median	166.02	167.95
Min ; Max	67.95 ; 344.02	69.88 ; 562.93

CV: Coefficient of variation, N: Number of subjects, Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4: Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

7.5.34 Total cholesterol by treatment week and trial - on-treatment/main-on-treatment - geometric mean plot - safety analysis set



Safety analysis set. Observed data. Legend: Geometric mean (symbol) and mean ± standard error to the mean on log-scale back transformed (error bars). OD analogues: Once-daily basal insulin analogues (IDeg, IGlar U100, IGlar U300). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

adlb.xpt; variable(s): STDNM PARAM AVISIT3N AVAL; criteria: SAFFL == "Y" & PARAMCD %in% c("CHOLS", "CHOLS2") & ANELFL == "Y" & ANL06FL == "Y" & AVAL != " " & DTYPE %in% c("", "HALFLOQ", "ULOQ", "LVPD")

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:12:57:22 - fgeomean/flbcholesterolgeomeanontsas.png

7.5.35 Free fatty acids by treatment week - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec	Daily basal insulin
Number of subjects	2170	2170
Free fatty acids (mmol/L)		
Week 0 visit		
N	1829	1798
Geom.mean (CV%)	0.52 (47.88)	0.53 (48.07)
Median	0.55	0.56
Min ; Max	0.06 ; 2.15	0.06 ; 5.03
Week 10 visit		
N	1278	1282
Geom.mean (CV%)	0.39 (53.28)	0.42 (53.35)
Median	0.40	0.44
Min ; Max	0.03 ; 2.39	0.06 ; 3.36
Week 26 visit		
N	1260	1257
Geom.mean (CV%)	0.38 (51.72)	0.41 (51.29)
Median	0.39	0.41
Min ; Max	0.08 ; 2.02	0.08 ; 4.13
Week 36 visit		
N	468	473
Geom.mean (CV%)	0.37 (47.89)	0.39 (52.10)
Median	0.38	0.40
Min ; Max	0.07 ; 2.42	0.05 ; 1.37
Week 52 visit		
N	944	953
Geom.mean (CV%)	0.39 (48.00)	0.42 (47.11)
Median	0.40	0.43
Min ; Max	0.07 ; 1.76	0.09 ; 1.50
End-of-treatment visit		
N	1737	1731
Geom.mean (CV%)	0.39 (50.73)	0.41 (49.78)
Median	0.40	0.42
Min ; Max	0.07 ; 2.02	0.08 ; 4.13
Lowest post baseline value		
N	1816	1808
Geom.mean (CV%)	0.32 (52.45)	0.34 (51.73)
Median	0.32	0.34
Min ; Max	0.03 ; 1.98	0.05 ; 3.36
Highest post baseline value		
N	1816	1808
Geom.mean (CV%)	0.47 (47.38)	0.49 (47.64)
Median	0.47	0.50
Min ; Max	0.06 ; 2.42	0.09 ; 4.13

CV: Coefficient of variation, N: Number of subjects. Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4: Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Free fatty acids was not collected in ONWARDS 6. Data from ONWARDS 1-5, only main part of ONWARDS 1.

Free fatty acids by treatment week - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec	Daily basal insulin
Free fatty acids (mg/dL)		
Week 0 visit		
N	1829	1798
Geom.mean (CV%)	14.78 (47.88)	14.85 (48.07)
Median	15.51	15.79
Min ; Max	1.69 ; 60.63	1.69 ; 141.85
Week 10 visit		
N	1278	1282
Geom.mean (CV%)	10.89 (53.28)	11.91 (53.35)
Median	11.14	12.41
Min ; Max	0.85 ; 67.40	1.69 ; 94.75
Week 26 visit		
N	1260	1257
Geom.mean (CV%)	10.74 (51.72)	11.51 (51.29)
Median	11.00	11.56
Min ; Max	2.26 ; 56.96	2.26 ; 116.47
Week 36 visit		
N	468	473
Geom.mean (CV%)	10.36 (47.89)	10.95 (52.10)
Median	10.72	11.28
Min ; Max	1.97 ; 68.24	1.41 ; 38.63
Week 52 visit		
N	944	953
Geom.mean (CV%)	11.13 (48.00)	11.78 (47.11)
Median	11.28	12.13
Min ; Max	1.97 ; 49.63	2.54 ; 42.30
End-of-treatment visit		
N	1737	1731
Geom.mean (CV%)	10.96 (50.73)	11.55 (49.78)
Median	11.28	11.84
Min ; Max	1.97 ; 56.96	2.26 ; 116.47
Lowest post baseline value		
N	1816	1808
Geom.mean (CV%)	9.02 (52.45)	9.56 (51.73)
Median	9.02	9.59
Min ; Max	0.85 ; 55.84	1.41 ; 94.75
Highest post baseline value		
N	1816	1808
Geom.mean (CV%)	13.16 (47.38)	13.89 (47.64)
Median	13.39	14.10
Min ; Max	1.69 ; 68.24	2.54 ; 116.47

CV: Coefficient of variation, N: Number of subjects. Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4: Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Free fatty acids was not collected in ONWARDS 6. Data from ONWARDS 1-5, only main part of ONWARDS 1.

adsl.xpt; variable(s): NA; criteria: SAFFL == "Y" & POOLGR2 == "Phase 3a pool"
adlb.xpt; variable(s): AVAL; criteria: SAFFL == "Y" & PARAMCD %in% c("FATACRS", "FATACRS2") & ANELFL == "Y" & ANL06FL == "Y" & POOLGR2 == "Phase 3a pool" & DTYPE %in% c("", "HALFLOQ", "ULOQ", "MINIMUM", "MAXIMUM", "LVPD", "EOT")
nn1436/nn1436-iss/submission_20221024_er
05DEC2022:13:02:02 - tsumcont/tlbffasumontp3asas.txt

7.5.36 Free fatty acids by treatment week - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec	Daily basal insulin
Number of subjects	1880	1878
Free fatty acids (mmol/L)		
Week 0 visit		
N	1829	1798
Geom.mean (CV%)	0.52 (47.88)	0.53 (48.07)
Median	0.55	0.56
Min ; Max	0.06 ; 2.15	0.06 ; 5.03
Week 10 visit		
N	1278	1282
Geom.mean (CV%)	0.39 (53.28)	0.42 (53.35)
Median	0.40	0.44
Min ; Max	0.03 ; 2.39	0.06 ; 3.36
Week 26 visit		
N	1260	1257
Geom.mean (CV%)	0.38 (51.72)	0.41 (51.29)
Median	0.39	0.41
Min ; Max	0.08 ; 2.02	0.08 ; 4.13
Week 36 visit		
N	468	473
Geom.mean (CV%)	0.37 (47.89)	0.39 (52.10)
Median	0.38	0.40
Min ; Max	0.07 ; 2.42	0.05 ; 1.37
Week 52 visit		
N	944	953
Geom.mean (CV%)	0.39 (48.00)	0.42 (47.11)
Median	0.40	0.43
Min ; Max	0.07 ; 1.76	0.09 ; 1.50
End-of-treatment visit		
N	1737	1731
Geom.mean (CV%)	0.39 (50.73)	0.41 (49.78)
Median	0.40	0.42
Min ; Max	0.07 ; 2.02	0.08 ; 4.13
Lowest post baseline value		
N	1816	1808
Geom.mean (CV%)	0.32 (52.45)	0.34 (51.73)
Median	0.32	0.34
Min ; Max	0.03 ; 1.98	0.05 ; 3.36
Highest post baseline value		
N	1816	1808
Geom.mean (CV%)	0.47 (47.38)	0.49 (47.64)
Median	0.47	0.50
Min ; Max	0.06 ; 2.42	0.09 ; 4.13


CV: Coefficient of variation, N: Number of subjects, Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4: Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Free fatty acids by treatment week - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec	Daily basal insulin
Free fatty acids (mg/dL)		
Week 0 visit		
N	1829	1798
Geom.mean (CV%)	14.78 (47.88)	14.85 (48.07)
Median	15.51	15.79
Min ; Max	1.69 ; 60.63	1.69 ; 141.85
Week 10 visit		
N	1278	1282
Geom.mean (CV%)	10.89 (53.28)	11.91 (53.35)
Median	11.14	12.41
Min ; Max	0.85 ; 67.40	1.69 ; 94.75
Week 26 visit		
N	1260	1257
Geom.mean (CV%)	10.74 (51.72)	11.51 (51.29)
Median	11.00	11.56
Min ; Max	2.26 ; 56.96	2.26 ; 116.47
Week 36 visit		
N	468	473
Geom.mean (CV%)	10.36 (47.89)	10.95 (52.10)
Median	10.72	11.28
Min ; Max	1.97 ; 68.24	1.41 ; 38.63
Week 52 visit		
N	944	953
Geom.mean (CV%)	11.13 (48.00)	11.78 (47.11)
Median	11.28	12.13
Min ; Max	1.97 ; 49.63	2.54 ; 42.30
End-of-treatment visit		
N	1737	1731
Geom.mean (CV%)	10.96 (50.73)	11.55 (49.78)
Median	11.28	11.84
Min ; Max	1.97 ; 56.96	2.26 ; 116.47
Lowest post baseline value		
N	1816	1808
Geom.mean (CV%)	9.02 (52.45)	9.56 (51.73)
Median	9.02	9.59
Min ; Max	0.85 ; 55.84	1.41 ; 94.75
Highest post baseline value		
N	1816	1808
Geom.mean (CV%)	13.16 (47.38)	13.89 (47.64)
Median	13.39	14.10
Min ; Max	1.69 ; 68.24	2.54 ; 116.47

CV: Coefficient of variation, N: Number of subjects, Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4: Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

7.5.37 Free fatty acids by treatment week and trial - on-treatment/main-on-treatment - geometric mean plot - safety analysis set



Safety analysis set. Observed data. Legend: Geometric mean (symbol) and mean ± standard error to the mean on log-scale back transformed (error bars). OD analogues: Once-daily basal insulin analogues (IDeg, IGlar U100, IGlar U300). Free fatty acids was not collected in ONWARDS 6. Data from ONWARDS 1-5, only main part of ONWARDS 1.

adlb.xpt; variable(s): STDNM PARAM AVISIT3N AVAL; criteria: SAFFL == "Y" & PARAMCD %in% c("FATACRS", "FATACRS2") & ANELFL == "Y" & ANL06FL == "Y" & AVAL != " " & DTYPE %in% c("", "HALFLOQ", "ULOQ", "LVPD")

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:12:57:27 - fgeomean/flbffageomeanontsas.png

7.5.38 eGFR by treatment week - change from baseline - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec	Daily basal insulin
Number of subjects	2170	2170
Change from Baseline, eGFR Using CKD-EPI Formula (mL/min/1.73m2)		
Week 10 visit		
N	1580	1577
Mean (SD)	-1.19 (8.41)	-0.41 (8.26)
Median	-1.00	0.00
Min ; Max	-46.00 ; 41.00	-46.00 ; 54.00
Week 26 visit		
N	1548	1549
Mean (SD)	-1.36 (8.95)	-0.46 (8.64)
Median	-1.00	0.00
Min ; Max	-53.00 ; 40.00	-56.00 ; 56.00
Week 36 visit		
N	471	475
Mean (SD)	-1.14 (9.92)	0.04 (9.67)
Median	0.00	1.00
Min ; Max	-55.00 ; 35.00	-45.00 ; 53.00
Week 52 visit		
N	947	958
Mean (SD)	-2.14 (9.74)	-1.53 (9.41)
Median	-2.00	-1.00
Min ; Max	-60.00 ; 35.00	-46.00 ; 60.00
End-of-treatment visit		
N	2015	2024
Mean (SD)	-1.91 (9.43)	-1.13 (8.86)
Median	-1.00	-1.00
Min ; Max	-60.00 ; 40.00	-56.00 ; 60.00
Lowest post baseline value		
N	2169	2169
Mean (SD)	-5.78 (7.29)	-4.95 (6.60)
Median	-3.00	-3.00
Min ; Max	-88.00 ; 0.00	-56.00 ; 0.00
Highest post baseline value		
N	2169	2169
Mean (SD)	3.38 (5.49)	3.64 (5.80)
Median	0.00	1.00
Min ; Max	0.00 ; 43.00	0.00 ; 60.00

eGFR: Estimated glomerular filtration rate, N: Number of subjects, SD: Standard deviation. eGFR was derived using the 2009 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation. Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.


adsl.xpt; variable(s): NA; criteria: SAFFL == "Y" & POOLGR2 == "Phase 3a pool"
adlb.xpt; variable(s): CHG; criteria: SAFFL == "Y" & PARAMCD %in% c("GFRES2") & ANELFL == "Y" & ANL06FL == "Y" & DTYPE %in% c("", "HALFLOQ", "ULOQ", "MINIMUM", "MAXIMUM", "LVPD", "EOT", "DERIVED") & CHG != " " & POOLGR2 == "Phase 3a pool"
nn1436/nn1436-iss/submission_20221024_er
05DEC2022:13:02:24 - tsumcont/tlbegfrsumontp3asas.txt

7.5.39 eGFR by treatment week - change from baseline - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec	Daily basal insulin
Number of subjects	1880	1878
Change from Baseline, eGFR Using CKD-EPI Formula (mL/min/1.73m2)		
Week 10 visit		
N	1299	1292
Mean (SD)	-1.08 (8.53)	-0.42 (8.46)
Median	-1.00	0.00
Min ; Max	-46.00 ; 38.00	-46.00 ; 54.00
Week 26 visit		
N	1280	1268
Mean (SD)	-1.32 (9.06)	-0.34 (8.81)
Median	-1.00	0.00
Min ; Max	-53.00 ; 34.00	-56.00 ; 56.00
Week 36 visit		
N	471	475
Mean (SD)	-1.14 (9.92)	0.04 (9.67)
Median	0.00	1.00
Min ; Max	-55.00 ; 35.00	-45.00 ; 53.00
Week 52 visit		
N	947	958
Mean (SD)	-2.14 (9.74)	-1.53 (9.41)
Median	-2.00	-1.00
Min ; Max	-60.00 ; 35.00	-46.00 ; 60.00
End-of-treatment visit		
N	1747	1743
Mean (SD)	-1.97 (9.58)	-1.15 (9.03)
Median	-1.00	-1.00
Min ; Max	-60.00 ; 35.00	-56.00 ; 60.00
Lowest post baseline value		
N	1879	1877
Mean (SD)	-5.85 (7.47)	-5.01 (6.73)
Median	-3.00	-3.00
Min ; Max	-88.00 ; 0.00	-56.00 ; 0.00
Highest post baseline value		
N	1879	1877
Mean (SD)	3.42 (5.56)	3.64 (5.94)
Median	0.00	1.00
Min ; Max	0.00 ; 43.00	0.00 ; 60.00

eGFR: Estimated glomerular filtration rate, N: Number of subjects, SD: Standard deviation, eGFR was derived using the 2009 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation. Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4: Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

7.5.40 eGFR by trial - baseline and end-of-treatment - on-treatment/main-on-treatment - box plot - safety analysis set



Safety analysis set. Observed data. eGFR: Estimated glomerular filtration rate. eGFR was derived using the 2009 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation. Legend: Mean (symbol), median (centre line), 25th and 75th percentiles (box), and extremes (circles). Whiskers are from 2.5% - 97.5%. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. OD analogues: Once-daily basal insulin analogues (IDeg, IGlar U100, IGlar U300). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

adlb.xpt; variable(s): STDNM PARAM AVISIT3 AVISIT3N AVAL; criteria: SAFFL == "Y" & ANELFL == "Y" & PARAMCD == "GFRES2" & ANL06FL == "Y"

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:13:07:58 - fbox/flbegfrboxontsas.png

7.5.41 Liver parameters by categories of highest (ALT, AST, total bilirubin) or lowest (albumin) post baseline value - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec		Daily basal insulin	
	N	(%)	N	(%)
Number of subjects	2170		2170	
Alanine aminotransferase (U/L)				
N	2100		2099	
Normal	1859	(88.5)	1822	(86.8)
High (>ULN)	241	(11.5)	277	(13.2)
>3x ULN	10	(0.5)	9	(0.4)
>5x ULN	0		1	(0.1)
>10x ULN	0		1	(0.1)
>20x ULN	0		1	(0.1)
Aspartate aminotransferase (U/L)				
N	2092		2088	
Normal	1930	(92.3)	1946	(93.2)
High (>ULN)	162	(7.7)	142	(6.8)
>3x ULN	7	(0.3)	8	(0.4)
>5x ULN	2	(0.1)	3	(0.1)
>10x ULN	0		1	(0.1)
>20x ULN	0		1	(0.1)
Albumin (g/dL)				
N	2107		2103	
<.8x LLN	1	(0.1)	0	
Low (<LLN)	10	(0.5)	9	(0.4)
Normal	2096	(99.5)	2093	(99.5)
High (>ULN)	1	(0.1)	1	(0.1)
Total bilirubin (umol/L)				
N	2098		2093	
Normal	2047	(97.6)	2050	(98.0)
High (>ULN)	51	(2.4)	43	(2.0)
>1.5x ULN	10	(0.5)	4	(0.2)
>2x ULN	2	(0.1)	1	(0.1)
>3x ULN	1	(0.1)	1	(0.1)
>10x ULN	1	(0.1)	0	

%: Percentage of subjects, ALT: Alanine aminotransferase, AST: Aspartate aminotransferase, LLN: Lower limit of the normal, N: Number of subjects, ULN: Upper limit of the normal. Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

adsl.xpt; variable(s): ALTSCT ASTSCT ALBSCT BILISCT; criteria: (POOLGR2 == "Phase 3a pool" & SAFFL == "Y")

7.5.42 Liver parameters by categories of highest (ALT, AST, total bilirubin) or lowest (albumin) post baseline value - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec		Daily basal insulin	
	N	(%)	N	(%)
Number of subjects	1880		1878	
Alanine aminotransferase (U/L)				
N	1815		1812	
Normal	1594	(87.8)	1552	(85.7)
High (>ULN)	221	(12.2)	260	(14.3)
>3x ULN	9	(0.5)	9	(0.5)
>5x ULN	0		1	(0.1)
>10x ULN	0		1	(0.1)
>20x ULN	0		1	(0.1)
Aspartate aminotransferase (U/L)				
N	1807		1802	
Normal	1663	(92.0)	1673	(92.8)
High (>ULN)	144	(8.0)	129	(7.2)
>3x ULN	6	(0.3)	6	(0.3)
>5x ULN	1	(0.1)	3	(0.2)
>10x ULN	0		1	(0.1)
>20x ULN	0		1	(0.1)
Albumin (g/dL)				
N	1822		1816	
<.8x LLN	1	(0.1)	0	
Low (<LLN)	9	(0.5)	9	(0.5)
Normal	1812	(99.5)	1806	(99.5)
High (>ULN)	1	(0.1)	1	(0.1)
Total bilirubin (umol/L)				
N	1813		1806	
Normal	1778	(98.1)	1771	(98.1)
High (>ULN)	35	(1.9)	35	(1.9)
>1.5x ULN	4	(0.2)	2	(0.1)
>2x ULN	1	(0.1)	1	(0.1)
>3x ULN	1	(0.1)	1	(0.1)
>10x ULN	1	(0.1)	0	

%: Percentage of subjects, ALT: Alanine aminotransferase, AST: Aspartate aminotransferase, LLN: Lower limit of the normal, N: Number of subjects, ULN: Upper limit of the normal, Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

インスリン イコデク（遺伝子組換え）

2.7.4.7. 付録
6. 身体所見、バイタルサイン、体重及び心電図

ノボ ノルディスク ファーマ株式会社

Table of contents

Page

7.6.1 Physical examination by treatment week - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool 2
7.6.2 Physical examination by treatment week - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool 9
7.6.3 Physical examination by treatment week - baseline to end of treatment - on-treatment/main-on-treatment - shift table - safety analysis set - phase 3a pool 16
7.6.4 Physical examination by treatment week - baseline to end of treatment - on-treatment/main-on-treatment - shift table - safety analysis set - T2D pool 19
7.6.5 Body weight by trial and treatment week - in-trial - summary - safety analysis set 22
7.6.6 Body weight at end of treatment by trial - change from baseline - in-trial - supportive statistical analysis - full analysis set 27
7.6.7 Body weight at end of treatment by trial - change from baseline - in-trial - plot of estimated treatment differences - full analysis set 31
7.6.8 Vital signs by treatment week - change from baseline - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool 32
7.6.9 Vital signs by treatment week - change from baseline - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool 35
7.6.10 Vital signs by trial - systolic blood pressure - baseline and end-of treatment - on-treatment/main-on-treatment - box plot - safety analysis set 38
7.6.11 Vital signs by trial - diastolic blood pressure - baseline and end-of treatment - on-treatment/main-on-treatment - box plot - safety analysis set 39
7.6.12 Vital signs by trial - pulse - baseline and end-of treatment - on-treatment/main-on-treatment - box plot - safety analysis set 40
7.6.13 Electrocardiogram by treatment week - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool 41
7.6.14 Electrocardiogram by treatment week - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool 42
7.6.15 Electrocardiogram by treatment week - baseline to end of treatment - on-treatment/main-on-treatment - shift table - safety analysis set - phase 3a pool 43
7.6.16 Electrocardiogram by treatment week - baseline to end of treatment - on-treatment/main-on-treatment - shift table - safety analysis set - T2D pool 43

7.6 Physical examination, body weight, vital signs and electrocardiogram

7.6.1 Physical examination by treatment week - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec	Daily basal insulin
	N (%)	N (%)
Number of subjects	2170	2170
Cardiovascular system		
Week -2 visit		
N	2170 (100.0)	2170 (100.0)
Normal	2004 (92.4)	1988 (91.6)
Abnormal, NCS	138 (6.4)	146 (6.7)
Abnormal, CS	25 (1.2)	35 (1.6)
Missing	3 (0.1)	1 (0.0)
Week 26 visit		
N	1136 (100.0)	1140 (100.0)
Normal	1016 (89.4)	1012 (88.8)
Abnormal, NCS	46 (4.0)	46 (4.0)
Abnormal, CS	12 (1.1)	17 (1.5)
Missing	62 (5.5)	65 (5.7)
Week 52 visit		
N	1034 (100.0)	1030 (100.0)
Normal	888 (85.9)	890 (86.4)
Abnormal, NCS	59 (5.7)	66 (6.4)
Abnormal, CS	7 (0.7)	11 (1.1)
Missing	80 (7.7)	63 (6.1)
End-of-treatment visit		
N	2170 (100.0)	2170 (100.0)
Normal	1904 (87.7)	1902 (87.6)
Abnormal, NCS	105 (4.8)	112 (5.2)
Abnormal, CS	19 (0.9)	28 (1.3)
Missing	142 (6.5)	128 (5.9)

%: Percentage of subjects, CS: Clinically significant, N: Number of subjects, NCS: Not clinically significant. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Physical examination by treatment week - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec	Daily basal insulin
	N (%)	N (%)
Central and peripheral nervous system		
Week -2 visit		
N	2170 (100.0)	2170 (100.0)
Normal	1923 (88.6)	1894 (87.3)
Abnormal, NCS	212 (9.8)	232 (10.7)
Abnormal, CS	28 (1.3)	37 (1.7)
Missing	7 (0.3)	7 (0.3)
Week 26 visit		
N	1136 (100.0)	1140 (100.0)
Normal	948 (83.5)	935 (82.0)
Abnormal, NCS	107 (9.4)	118 (10.4)
Abnormal, CS	15 (1.3)	20 (1.8)
Missing	66 (5.8)	67 (5.9)
Week 52 visit		
N	1034 (100.0)	1030 (100.0)
Normal	881 (85.2)	877 (85.1)
Abnormal, NCS	60 (5.8)	77 (7.5)
Abnormal, CS	11 (1.1)	10 (1.0)
Missing	82 (7.9)	66 (6.4)
End-of-treatment visit		
N	2170 (100.0)	2170 (100.0)
Normal	1829 (84.3)	1812 (83.5)
Abnormal, NCS	167 (7.7)	195 (9.0)
Abnormal, CS	26 (1.2)	30 (1.4)
Missing	148 (6.8)	133 (6.1)

%: Percentage of subjects, CS: Clinically significant, N: Number of subjects, NCS: Not clinically significant. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Physical examination by treatment week - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec	Daily basal insulin
	N (%)	N (%)
Gastrointestinal system incl. mouth		
Week -2 visit		
N	2170 (100.0)	2170 (100.0)
Normal	2029 (93.5)	2006 (92.4)
Abnormal, NCS	117 (5.4)	135 (6.2)
Abnormal, CS	17 (0.8)	25 (1.2)
Missing	7 (0.3)	4 (0.2)
Week 26 visit		
N	1136 (100.0)	1140 (100.0)
Normal	1038 (91.4)	1023 (89.7)
Abnormal, NCS	31 (2.7)	37 (3.2)
Abnormal, CS	6 (0.5)	13 (1.1)
Missing	61 (5.4)	67 (5.9)
Week 52 visit		
N	1034 (100.0)	1030 (100.0)
Normal	889 (86.0)	887 (86.1)
Abnormal, NCS	59 (5.7)	71 (6.9)
Abnormal, CS	5 (0.5)	8 (0.8)
Missing	81 (7.8)	64 (6.2)
End-of-treatment visit		
N	2170 (100.0)	2170 (100.0)
Normal	1927 (88.8)	1910 (88.0)
Abnormal, NCS	90 (4.1)	108 (5.0)
Abnormal, CS	11 (0.5)	21 (1.0)
Missing	142 (6.5)	131 (6.0)

%: Percentage of subjects, CS: Clinically significant, N: Number of subjects, NCS: Not clinically significant. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Physical examination by treatment week - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec	Daily basal insulin
	N (%)	N (%)
Head, ears, eyes, nose, throat, neck		
Week -2 visit		
N	2170 (100.0)	2170 (100.0)
Normal	2029 (93.5)	2017 (92.9)
Abnormal, NCS	116 (5.3)	110 (5.1)
Abnormal, CS	21 (1.0)	40 (1.8)
Missing	4 (0.2)	3 (0.1)
Week 26 visit		
N	1136 (100.0)	1140 (100.0)
Normal	1026 (90.3)	1016 (89.1)
Abnormal, NCS	35 (3.1)	40 (3.5)
Abnormal, CS	14 (1.2)	18 (1.6)
Missing	61 (5.4)	66 (5.8)
Week 52 visit		
N	1034 (100.0)	1030 (100.0)
Normal	904 (87.4)	911 (88.4)
Abnormal, NCS	44 (4.3)	39 (3.8)
Abnormal, CS	7 (0.7)	15 (1.5)
Missing	79 (7.6)	65 (6.3)
End-of-treatment visit		
N	2170 (100.0)	2170 (100.0)
Normal	1930 (88.9)	1927 (88.8)
Abnormal, NCS	79 (3.6)	79 (3.6)
Abnormal, CS	21 (1.0)	33 (1.5)
Missing	140 (6.5)	131 (6.0)

%: Percentage of subjects, CS: Clinically significant, N: Number of subjects, NCS: Not clinically significant. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Physical examination by treatment week - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec	Daily basal insulin
	N (%)	N (%)
Musculoskeletal system		
Week -2 visit		
N	2170 (100.0)	2170 (100.0)
Normal	2040 (94.0)	2016 (92.9)
Abnormal, NCS	102 (4.7)	123 (5.7)
Abnormal, CS	15 (0.7)	26 (1.2)
Missing	13 (0.6)	5 (0.2)
Week 26 visit		
N	1136 (100.0)	1140 (100.0)
Normal	1027 (90.4)	1010 (88.6)
Abnormal, NCS	38 (3.3)	50 (4.4)
Abnormal, CS	10 (0.9)	11 (1.0)
Missing	61 (5.4)	69 (6.1)
Week 52 visit		
N	1034 (100.0)	1030 (100.0)
Normal	902 (87.2)	906 (88.0)
Abnormal, NCS	44 (4.3)	51 (5.0)
Abnormal, CS	7 (0.7)	8 (0.8)
Missing	81 (7.8)	65 (6.3)
End-of-treatment visit		
N	2170 (100.0)	2170 (100.0)
Normal	1929 (88.9)	1916 (88.3)
Abnormal, NCS	82 (3.8)	101 (4.7)
Abnormal, CS	17 (0.8)	19 (0.9)
Missing	142 (6.5)	134 (6.2)

%: Percentage of subjects, CS: Clinically significant, N: Number of subjects, NCS: Not clinically significant. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Physical examination by treatment week - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec	Daily basal insulin
	N (%)	N (%)
Respiratory System		
Week -2 visit		
N	2170 (100.0)	2170 (100.0)
Normal	2139 (98.6)	2133 (98.3)
Abnormal, NCS	27 (1.2)	31 (1.4)
Abnormal, CS	2 (0.1)	5 (0.2)
Missing	2 (0.1)	1 (0.0)
Week 26 visit		
N	1136 (100.0)	1140 (100.0)
Normal	1071 (94.3)	1070 (93.9)
Abnormal, NCS	8 (0.7)	6 (0.5)
Abnormal, CS	1 (0.1)	3 (0.3)
Missing	56 (4.9)	61 (5.4)
Week 52 visit		
N	1034 (100.0)	1030 (100.0)
Normal	941 (91.0)	950 (92.2)
Abnormal, NCS	13 (1.3)	14 (1.4)
Abnormal, CS	0	3 (0.3)
Missing	80 (7.7)	63 (6.1)
End-of-treatment visit		
N	2170 (100.0)	2170 (100.0)
Normal	2012 (92.7)	2020 (93.1)
Abnormal, NCS	21 (1.0)	20 (0.9)
Abnormal, CS	1 (0.0)	6 (0.3)
Missing	136 (6.3)	124 (5.7)

%: Percentage of subjects, CS: Clinically significant, N: Number of subjects, NCS: Not clinically significant. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Physical examination by treatment week - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec	Daily basal insulin
	N (%)	N (%)
Skin		
Week -2 visit		
N	2170 (100.0)	2170 (100.0)
Normal	1889 (87.1)	1902 (87.6)
Abnormal, NCS	249 (11.5)	243 (11.2)
Abnormal, CS	21 (1.0)	19 (0.9)
Missing	11 (0.5)	6 (0.3)
Week 26 visit		
N	1136 (100.0)	1140 (100.0)
Normal	970 (85.4)	961 (84.3)
Abnormal, NCS	90 (7.9)	99 (8.7)
Abnormal, CS	14 (1.2)	16 (1.4)
Missing	62 (5.5)	64 (5.6)
Week 52 visit		
N	1034 (100.0)	1030 (100.0)
Normal	855 (82.7)	865 (84.0)
Abnormal, NCS	93 (9.0)	91 (8.8)
Abnormal, CS	5 (0.5)	9 (0.9)
Missing	81 (7.8)	65 (6.3)
End-of-treatment visit		
N	2170 (100.0)	2170 (100.0)
Normal	1825 (84.1)	1826 (84.1)
Abnormal, NCS	183 (8.4)	190 (8.8)
Abnormal, CS	19 (0.9)	25 (1.2)
Missing	143 (6.6)	129 (5.9)

%: Percentage of subjects, CS: Clinically significant, N: Number of subjects, NCS: Not clinically significant. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

7.6.2 Physical examination by treatment week - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec	Daily basal insulin
	N (%)	N (%)
Number of subjects	1880	1878
Cardiovascular system		
Week -2 visit		
N	1880 (100.0)	1878 (100.0)
Normal	1726 (91.8)	1708 (90.9)
Abnormal, NCS	128 (6.8)	134 (7.1)
Abnormal, CS	25 (1.3)	35 (1.9)
Missing	1 (0.1)	1 (0.1)
Week 26 visit		
N	846 (100.0)	848 (100.0)
Normal	752 (88.9)	743 (87.6)
Abnormal, NCS	41 (4.8)	39 (4.6)
Abnormal, CS	11 (1.3)	15 (1.8)
Missing	42 (5.0)	51 (6.0)
Week 52 visit		
N	1034 (100.0)	1030 (100.0)
Normal	888 (85.9)	890 (86.4)
Abnormal, NCS	59 (5.7)	66 (6.4)
Abnormal, CS	7 (0.7)	11 (1.1)
Missing	80 (7.7)	63 (6.1)
End-of-treatment visit		
N	1880 (100.0)	1878 (100.0)
Normal	1640 (87.2)	1633 (87.0)
Abnormal, NCS	100 (5.3)	105 (5.6)
Abnormal, CS	18 (1.0)	26 (1.4)
Missing	122 (6.5)	114 (6.1)

%: Percentage of subjects, CS: Clinically significant, N: Number of subjects, NCS: Not clinically significant, Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4: Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Physical examination by treatment week - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec	Daily basal insulin
	N (%)	N (%)
Central and peripheral nervous system		
Week -2 visit		
N	1880 (100.0)	1878 (100.0)
Normal	1665 (88.6)	1630 (86.8)
Abnormal, NCS	185 (9.8)	205 (10.9)
Abnormal, CS	25 (1.3)	36 (1.9)
Missing	5 (0.3)	7 (0.4)
Week 26 visit		
N	846 (100.0)	848 (100.0)
Normal	702 (83.0)	681 (80.3)
Abnormal, NCS	87 (10.3)	94 (11.1)
Abnormal, CS	12 (1.4)	18 (2.1)
Missing	45 (5.3)	55 (6.5)
Week 52 visit		
N	1034 (100.0)	1030 (100.0)
Normal	881 (85.2)	877 (85.1)
Abnormal, NCS	60 (5.8)	77 (7.5)
Abnormal, CS	11 (1.1)	10 (1.0)
Missing	82 (7.9)	66 (6.4)
End-of-treatment visit		
N	1880 (100.0)	1878 (100.0)
Normal	1583 (84.2)	1558 (83.0)
Abnormal, NCS	147 (7.8)	171 (9.1)
Abnormal, CS	23 (1.2)	28 (1.5)
Missing	127 (6.8)	121 (6.4)

%: Percentage of subjects, CS: Clinically significant, N: Number of subjects, NCS: Not clinically significant, Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4: Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Physical examination by treatment week - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec	Daily basal insulin
	N (%)	N (%)
Gastrointestinal system incl. mouth		
Week -2 visit		
N	1880 (100.0)	1878 (100.0)
Normal	1749 (93.0)	1717 (91.4)
Abnormal, NCS	107 (5.7)	132 (7.0)
Abnormal, CS	17 (0.9)	25 (1.3)
Missing	7 (0.4)	4 (0.2)
Week 26 visit		
N	846 (100.0)	848 (100.0)
Normal	774 (91.5)	749 (88.3)
Abnormal, NCS	24 (2.8)	34 (4.0)
Abnormal, CS	6 (0.7)	13 (1.5)
Missing	42 (5.0)	52 (6.1)
Week 52 visit		
N	1034 (100.0)	1030 (100.0)
Normal	889 (86.0)	887 (86.1)
Abnormal, NCS	59 (5.7)	71 (6.9)
Abnormal, CS	5 (0.5)	8 (0.8)
Missing	81 (7.8)	64 (6.2)
End-of-treatment visit		
N	1880 (100.0)	1878 (100.0)
Normal	1663 (88.5)	1636 (87.1)
Abnormal, NCS	83 (4.4)	105 (5.6)
Abnormal, CS	11 (0.6)	21 (1.1)
Missing	123 (6.5)	116 (6.2)

%: Percentage of subjects, CS: Clinically significant, N: Number of subjects, NCS: Not clinically significant, Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4: Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Physical examination by treatment week - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec	Daily basal insulin
	N (%)	N (%)
Head, ears, eyes, nose, throat, neck		
Week -2 visit		
N	1880 (100.0)	1878 (100.0)
Normal	1757 (93.5)	1740 (92.7)
Abnormal, NCS	102 (5.4)	97 (5.2)
Abnormal, CS	18 (1.0)	39 (2.1)
Missing	3 (0.2)	2 (0.1)
Week 26 visit		
N	846 (100.0)	848 (100.0)
Normal	764 (90.3)	744 (87.7)
Abnormal, NCS	30 (3.5)	32 (3.8)
Abnormal, CS	10 (1.2)	17 (2.0)
Missing	42 (5.0)	55 (6.5)
Week 52 visit		
N	1034 (100.0)	1030 (100.0)
Normal	904 (87.4)	911 (88.4)
Abnormal, NCS	44 (4.3)	39 (3.8)
Abnormal, CS	7 (0.7)	15 (1.5)
Missing	79 (7.6)	65 (6.3)
End-of-treatment visit		
N	1880 (100.0)	1878 (100.0)
Normal	1668 (88.7)	1655 (88.1)
Abnormal, NCS	74 (3.9)	71 (3.8)
Abnormal, CS	17 (0.9)	32 (1.7)
Missing	121 (6.4)	120 (6.4)

%: Percentage of subjects, CS: Clinically significant, N: Number of subjects, NCS: Not clinically significant, Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4: Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Physical examination by treatment week - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec	Daily basal insulin
	N (%)	N (%)
Musculoskeletal system		
Week -2 visit		
N	1880 (100.0)	1878 (100.0)
Normal	1763 (93.8)	1745 (92.9)
Abnormal, NCS	93 (4.9)	105 (5.6)
Abnormal, CS	15 (0.8)	24 (1.3)
Missing	9 (0.5)	4 (0.2)
Week 26 visit		
N	846 (100.0)	848 (100.0)
Normal	763 (90.2)	746 (88.0)
Abnormal, NCS	33 (3.9)	36 (4.2)
Abnormal, CS	10 (1.2)	9 (1.1)
Missing	40 (4.7)	57 (6.7)
Week 52 visit		
N	1034 (100.0)	1030 (100.0)
Normal	902 (87.2)	906 (88.0)
Abnormal, NCS	44 (4.3)	51 (5.0)
Abnormal, CS	7 (0.7)	8 (0.8)
Missing	81 (7.8)	65 (6.3)
End-of-treatment visit		
N	1880 (100.0)	1878 (100.0)
Normal	1665 (88.6)	1652 (88.0)
Abnormal, NCS	77 (4.1)	87 (4.6)
Abnormal, CS	17 (0.9)	17 (0.9)
Missing	121 (6.4)	122 (6.5)

%: Percentage of subjects, CS: Clinically significant, N: Number of subjects, NCS: Not clinically significant, Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4: Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Physical examination by treatment week - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec	Daily basal insulin
	N (%)	N (%)
Respiratory System		
Week -2 visit		
N	1880 (100.0)	1878 (100.0)
Normal	1852 (98.5)	1846 (98.3)
Abnormal, NCS	25 (1.3)	27 (1.4)
Abnormal, CS	2 (0.1)	4 (0.2)
Missing	1 (0.1)	1 (0.1)
Week 26 visit		
N	846 (100.0)	848 (100.0)
Normal	802 (94.8)	790 (93.2)
Abnormal, NCS	6 (0.7)	4 (0.5)
Abnormal, CS	1 (0.1)	3 (0.4)
Missing	37 (4.4)	51 (6.0)
Week 52 visit		
N	1034 (100.0)	1030 (100.0)
Normal	941 (91.0)	950 (92.2)
Abnormal, NCS	13 (1.3)	14 (1.4)
Abnormal, CS	0	3 (0.3)
Missing	80 (7.7)	63 (6.1)
End-of-treatment visit		
N	1880 (100.0)	1878 (100.0)
Normal	1743 (92.7)	1740 (92.7)
Abnormal, NCS	19 (1.0)	18 (1.0)
Abnormal, CS	1 (0.1)	6 (0.3)
Missing	117 (6.2)	114 (6.1)

%: Percentage of subjects, CS: Clinically significant, N: Number of subjects, NCS: Not clinically significant, Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4: Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Physical examination by treatment week - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec	Daily basal insulin
	N (%)	N (%)
Skin		
Week -2 visit		
N	1880 (100.0)	1878 (100.0)
Normal	1642 (87.3)	1646 (87.6)
Abnormal, NCS	216 (11.5)	210 (11.2)
Abnormal, CS	13 (0.7)	16 (0.9)
Missing	9 (0.5)	6 (0.3)
Week 26 visit		
N	846 (100.0)	848 (100.0)
Normal	727 (85.9)	708 (83.5)
Abnormal, NCS	69 (8.2)	75 (8.8)
Abnormal, CS	8 (0.9)	13 (1.5)
Missing	42 (5.0)	52 (6.1)
Week 52 visit		
N	1034 (100.0)	1030 (100.0)
Normal	855 (82.7)	865 (84.0)
Abnormal, NCS	93 (9.0)	91 (8.8)
Abnormal, CS	5 (0.5)	9 (0.9)
Missing	81 (7.8)	65 (6.3)
End-of-treatment visit		
N	1880 (100.0)	1878 (100.0)
Normal	1582 (84.1)	1573 (83.8)
Abnormal, NCS	162 (8.6)	166 (8.8)
Abnormal, CS	13 (0.7)	22 (1.2)
Missing	123 (6.5)	117 (6.2)

%: Percentage of subjects, CS: Clinically significant, N: Number of subjects, NCS: Not clinically significant, Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4: Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

7.6.3 Physical examination by treatment week - baseline to end of treatment - on-treatment/main-on-treatment - shift table - safety analysis set - phase 3a pool

Parameter / Group / Baseline	End-of-treatment visit: Normal N	(%)	Abnormal, NCS N	(%)	Abnormal, CS N	(%)	Missing N	(%)
Cardiovascular system								
Insulin icodec, N = 2170								
Normal	1847	(85.1)	20	(0.9)	3	(0.1)	134	(6.2)
Abnormal, NCS	43	(2.0)	83	(3.8)	4	(0.2)	8	(0.4)
Abnormal, CS	11	(0.5)	2	(0.1)	12	(0.6)	0	
Missing	3	(0.1)	0		0		0	
Daily basal insulin, N = 2170								
Normal	1848	(85.2)	12	(0.6)	5	(0.2)	123	(5.7)
Abnormal, NCS	41	(1.9)	100	(4.6)	0		5	(0.2)
Abnormal, CS	12	(0.6)	0		23	(1.1)	0	
Missing	1	(0.0)	0		0		0	
Central and peripheral nervous system								
Insulin icodec, N = 2170								
Normal	1766	(81.4)	20	(0.9)	5	(0.2)	132	(6.1)
Abnormal, NCS	51	(2.4)	144	(6.6)	2	(0.1)	15	(0.7)
Abnormal, CS	5	(0.2)	3	(0.1)	19	(0.9)	1	(0.0)
Missing	7	(0.3)	0		0		0	
Daily basal insulin, N = 2170								
Normal	1759	(81.1)	14	(0.6)	3	(0.1)	118	(5.4)
Abnormal, NCS	41	(1.9)	178	(8.2)	1	(0.0)	12	(0.6)
Abnormal, CS	7	(0.3)	3	(0.1)	26	(1.2)	1	(0.0)
Missing	5	(0.2)	0		0		2	(0.1)
Gastrointestinal system incl. mouth								
Insulin icodec, N = 2170								
Normal	1878	(86.5)	21	(1.0)	0		130	(6.0)
Abnormal, NCS	36	(1.7)	69	(3.2)	0		12	(0.6)
Abnormal, CS	6	(0.3)	0		11	(0.5)	0	
Missing	7	(0.3)	0		0		0	
Daily basal insulin, N = 2170								
Normal	1867	(86.0)	17	(0.8)	1	(0.0)	121	(5.6)
Abnormal, NCS	37	(1.7)	90	(4.1)	0		8	(0.4)
Abnormal, CS	2	(0.1)	1	(0.0)	20	(0.9)	2	(0.1)
Missing	4	(0.2)	0		0		0	

%: Percentage of subjects, CS: Clinically significant, N: Number of subjects, NCS: Not clinically significant. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Physical examination by treatment week - baseline to end of treatment - on-treatment/main-on-treatment - shift table - safety analysis set - phase 3a pool

Parameter	End-of-treatment visit							
Group	Normal		Abnormal, NCS		Abnormal, CS		Missing	
Baseline	N	(%)	N	(%)	N	(%)	N	(%)
Head, ears, eyes, nose, throat, neck								
Insulin icodec, N = 2170								
Normal	1872	(86.3)	20	(0.9)	3	(0.1)	134	(6.2)
Abnormal, NCS	50	(2.3)	59	(2.7)	1	(0.0)	6	(0.3)
Abnormal, CS	4	(0.2)	0		17	(0.8)	0	
Missing	4	(0.2)	0		0		0	
Daily basal insulin, N = 2170								
Normal	1875	(86.4)	18	(0.8)	3	(0.1)	121	(5.6)
Abnormal, NCS	41	(1.9)	60	(2.8)	2	(0.1)	7	(0.3)
Abnormal, CS	9	(0.4)	1	(0.0)	28	(1.3)	2	(0.1)
Missing	2	(0.1)	0		0		1	(0.0)
Musculoskeletal system								
Insulin icodec, N = 2170								
Normal	1880	(86.6)	23	(1.1)	6	(0.3)	131	(6.0)
Abnormal, NCS	33	(1.5)	57	(2.6)	2	(0.1)	10	(0.5)
Abnormal, CS	5	(0.2)	1	(0.0)	9	(0.4)	0	
Missing	11	(0.5)	1	(0.0)	0		1	(0.0)
Daily basal insulin, N = 2170								
Normal	1861	(85.8)	27	(1.2)	3	(0.1)	125	(5.8)
Abnormal, NCS	45	(2.1)	71	(3.3)	0		7	(0.3)
Abnormal, CS	5	(0.2)	3	(0.1)	16	(0.7)	2	(0.1)
Missing	5	(0.2)	0		0		0	
Respiratory System								
Insulin icodec, N = 2170								
Normal	1998	(92.1)	8	(0.4)	0		133	(6.1)
Abnormal, NCS	12	(0.6)	13	(0.6)	0		2	(0.1)
Abnormal, CS	1	(0.0)	0		1	(0.0)	0	
Missing	1	(0.0)	0		0		1	(0.0)
Daily basal insulin, N = 2170								
Normal	2002	(92.3)	7	(0.3)	2	(0.1)	122	(5.6)
Abnormal, NCS	16	(0.7)	13	(0.6)	0		2	(0.1)
Abnormal, CS	1	(0.0)	0		4	(0.2)	0	
Missing	1	(0.0)	0		0		0	

%: Percentage of subjects, CS: Clinically significant, N: Number of subjects, NCS: Not clinically significant. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Physical examination by treatment week - baseline to end of treatment - on-treatment/main-on-treatment - shift table - safety analysis set - phase 3a pool

Parameter / Group / Baseline	End-of-treatment visit: Normal N	(%)	Abnormal, NCS N	(%)	Abnormal, CS N	(%)	Missing N	(%)
Skin								
Insulin icodec, N = 2170								
Normal	1721	(79.3)	37	(1.7)	7	(0.3)	124	(5.7)
Abnormal, NCS	88	(4.1)	144	(6.6)	0		17	(0.8)
Abnormal, CS	5	(0.2)	2	(0.1)	12	(0.6)	2	(0.1)
Missing	11	(0.5)	0		0		0	
Daily basal insulin, N = 2170								
Normal	1739	(80.1)	44	(2.0)	8	(0.4)	111	(5.1)
Abnormal, NCS	79	(3.6)	145	(6.7)	2	(0.1)	17	(0.8)
Abnormal, CS	3	(0.1)	0		15	(0.7)	1	(0.0)
Missing	5	(0.2)	1	(0.0)	0		0	

%: Percentage of subjects, CS: Clinically significant, N: Number of subjects, NCS: Not clinically significant. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

adsl.xpt; variable(s): NA; criteria: SAFFL == "Y" & POOLGR2 == "Phase 3a pool"
adpe.xpt; variable(s): AVALC; criteria: SAFFL == "Y" & POOLGR2 == "Phase 3a pool" & PARAMCD %in% c("CARDIO", "CNSPER", "GASTMOU", "HEENTN", "MUSCULO", "RESPSYS", "SKIN") & ANL06FL == "Y" & ANELFL == "Y" & AVISIT3N %in% c(-2, 10000)
nn1436/nn1436-iss/submission_20221024_er
05DEC2022:12:58:41 - tshift/tpecheotshiftontp3asas.txt

7.6.4 Physical examination by treatment week - baseline to end of treatment - on-treatment/main-on-treatment - shift table - safety analysis set - T2D pool

Parameter / Group / Baseline	End-of-treatment visit: Normal N	(%)	Abnormal, NCS N	(%)	Abnormal, CS N	(%)	Missing N	(%)
Cardiovascular system								
Insulin icodec, N = 1880								
Normal	1590	(84.6)	20	(1.1)	2	(0.1)	114	(6.1)
Abnormal, NCS	38	(2.0)	78	(4.1)	4	(0.2)	8	(0.4)
Abnormal, CS	11	(0.6)	2	(0.1)	12	(0.6)	0	
Missing	1	(0.1)	0		0		0	
Daily basal insulin, N = 1878								
Normal	1584	(84.3)	12	(0.6)	3	(0.2)	109	(5.8)
Abnormal, NCS	36	(1.9)	93	(5.0)	0		5	(0.3)
Abnormal, CS	12	(0.6)	0		23	(1.2)	0	
Missing	1	(0.1)	0		0		0	
Central and peripheral nervous system								
Insulin icodec, N = 1880								
Normal	1529	(81.3)	18	(1.0)	5	(0.3)	113	(6.0)
Abnormal, NCS	44	(2.3)	126	(6.7)	2	(0.1)	13	(0.7)
Abnormal, CS	5	(0.3)	3	(0.2)	16	(0.9)	1	(0.1)
Missing	5	(0.3)	0		0		0	
Daily basal insulin, N = 1878								
Normal	1510	(80.4)	12	(0.6)	2	(0.1)	106	(5.6)
Abnormal, NCS	36	(1.9)	156	(8.3)	1	(0.1)	12	(0.6)
Abnormal, CS	7	(0.4)	3	(0.2)	25	(1.3)	1	(0.1)
Missing	5	(0.3)	0		0		2	(0.1)
Gastrointestinal system incl. mouth								
Insulin icodec, N = 1880								
Normal	1617	(86.0)	20	(1.1)	0		112	(6.0)
Abnormal, NCS	33	(1.8)	63	(3.4)	0		11	(0.6)
Abnormal, CS	6	(0.3)	0		11	(0.6)	0	
Missing	7	(0.4)	0		0		0	
Daily basal insulin, N = 1878								
Normal	1595	(84.9)	15	(0.8)	1	(0.1)	106	(5.6)
Abnormal, NCS	35	(1.9)	89	(4.7)	0		8	(0.4)
Abnormal, CS	2	(0.1)	1	(0.1)	20	(1.1)	2	(0.1)
Missing	4	(0.2)	0		0		0	

%: Percentage of subjects, CS: Clinically significant, N: Number of subjects, NCS: Not clinically significant, End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4: Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Physical examination by treatment week - baseline to end of treatment - on-treatment/main-on-treatment - shift table - safety analysis set - T2D pool

Parameter / Group / Baseline	End-of-treatment visit: Normal N	(%)	Abnormal, NCS N	(%)	Abnormal, CS N	(%)	Missing N	(%)
Head, ears, eyes, nose, throat, neck								
Insulin icodec, N = 1880								
Normal	1622	(86.3)	18	(1.0)	2	(0.1)	115	(6.1)
Abnormal, NCS	39	(2.1)	56	(3.0)	1	(0.1)	6	(0.3)
Abnormal, CS	4	(0.2)	0		14	(0.7)	0	
Missing	3	(0.2)	0		0		0	
Daily basal insulin, N = 1878								
Normal	1607	(85.6)	18	(1.0)	3	(0.2)	112	(6.0)
Abnormal, NCS	37	(2.0)	52	(2.8)	2	(0.1)	6	(0.3)
Abnormal, CS	9	(0.5)	1	(0.1)	27	(1.4)	2	(0.1)
Missing	2	(0.1)	0		0		0	
Musculoskeletal system								
Insulin icodec, N = 1880								
Normal	1623	(86.3)	22	(1.2)	6	(0.3)	112	(6.0)
Abnormal, NCS	29	(1.5)	53	(2.8)	2	(0.1)	9	(0.5)
Abnormal, CS	5	(0.3)	1	(0.1)	9	(0.5)	0	
Missing	8	(0.4)	1	(0.1)	0		0	
Daily basal insulin, N = 1878								
Normal	1606	(85.5)	23	(1.2)	3	(0.2)	113	(6.0)
Abnormal, NCS	37	(2.0)	61	(3.2)	0		7	(0.4)
Abnormal, CS	5	(0.3)	3	(0.2)	14	(0.7)	2	(0.1)
Missing	4	(0.2)	0		0		0	
Respiratory System								
Insulin icodec, N = 1880								
Normal	1730	(92.0)	7	(0.4)	0		115	(6.1)
Abnormal, NCS	11	(0.6)	12	(0.6)	0		2	(0.1)
Abnormal, CS	1	(0.1)	0		1	(0.1)	0	
Missing	1	(0.1)	0		0		0	
Daily basal insulin, N = 1878								
Normal	1725	(91.9)	7	(0.4)	2	(0.1)	112	(6.0)
Abnormal, NCS	14	(0.7)	11	(0.6)	0		2	(0.1)
Abnormal, CS	0		0		4	(0.2)	0	
Missing	1	(0.1)	0		0		0	

%: Percentage of subjects, CS: Clinically significant, N: Number of subjects, NCS: Not clinically significant, End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4: Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Physical examination by treatment week - baseline to end of treatment - on-treatment/main-on-treatment - shift table - safety analysis set - T2D pool

Parameter / Group / Baseline	End-of-treatment visit: Normal N	(%)	Abnormal, NCS N	(%)	Abnormal, CS N	(%)	Missing N	(%)
Skin								
Insulin icodec, N = 1880								
Normal	1496	(79.6)	31	(1.6)	6	(0.3)	109	(5.8)
Abnormal, NCS	74	(3.9)	130	(6.9)	0		12	(0.6)
Abnormal, CS	3	(0.2)	1	(0.1)	7	(0.4)	2	(0.1)
Missing	9	(0.5)	0		0		0	
Daily basal insulin, N = 1878								
Normal	1505	(80.1)	35	(1.9)	7	(0.4)	99	(5.3)
Abnormal, NCS	61	(3.2)	130	(6.9)	2	(0.1)	17	(0.9)
Abnormal, CS	2	(0.1)	0		13	(0.7)	1	(0.1)
Missing	5	(0.3)	1	(0.1)	0		0	

%: Percentage of subjects, CS: Clinically significant, N: Number of subjects, NCS: Not clinically significant, End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4: Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

adsl.xpt; variable(s): NA; criteria: SAFFL == "Y" & POOLGR1 == "T2D pool"
adpe.xpt; variable(s): AVALC; criteria: SAFFL == "Y" & POOLGR1 == "T2D pool" & PARAMCD %in% c("CARDIO", "CNSPER", "GASTMOU", "HEENTN", "MUSCULO", "RESPSYS", "SKIN") & ANL06FL == "Y" & ANELFL == "Y" & AVISIT3N %in% c(-2, 10000)
nn1436/nn1436-iss/submission_20221024_er
05DEC2022:12:58:46 - tshift/tpecheotshiftontt2dsas.txt

7.6.5 Body weight by trial and treatment week - in-trial - summary - safety analysis set

	Insulin icodec	Daily basal insulin
Body weight (kg)		
ONWARDS 1		
Number of subjects	492	492
Week 0 visit		
N	492	492
Mean (SD)	85.17 (17.74)	84.31 (17.63)
Median	83.70	83.45
Min ; Max	44.50 ; 140.00	43.30 ; 142.00
Week 14 visit		
N	480	478
Mean (SD)	85.98 (17.53)	84.54 (17.18)
Median	84.10	83.50
Min ; Max	45.60 ; 142.00	44.90 ; 152.00
Week 26 visit		
N	480	480
Mean (SD)	86.62 (18.07)	84.87 (17.37)
Median	85.20	84.17
Min ; Max	45.90 ; 144.20	43.80 ; 153.00
Week 52 visit		
N	478	478
Mean (SD)	87.56 (18.04)	86.28 (17.88)
Median	86.25	85.15
Min ; Max	44.00 ; 144.00	43.60 ; 156.00
ONWARDS 2		
Number of subjects	262	263
Week 0 visit		
N	262	263
Mean (SD)	83.72 (18.47)	81.54 (17.14)
Median	83.90	81.30
Min ; Max	43.90 ; 136.80	40.80 ; 133.70
Week 14 visit		
N	257	253
Mean (SD)	84.76 (18.68)	81.89 (17.07)
Median	85.30	82.10
Min ; Max	44.00 ; 138.40	41.40 ; 132.20
Week 26 visit		
N	258	253
Mean (SD)	85.19 (19.23)	81.66 (17.14)
Median	84.85	81.90
Min ; Max	45.10 ; 136.70	42.00 ; 131.40

N: Number of subjects, SD: Standard deviation. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Body weight by trial and treatment week - in-trial - summary - safety analysis set

	Insulin icodec	Daily basal insulin
ONWARDS 3		
Number of subjects	293	294
Week 0 visit		
N	293	294
Mean (SD)	85.78 (20.13)	83.24 (18.22)
Median	84.90	81.45
Min ; Max	43.50 ; 151.40	45.80 ; 130.50
Week 14 visit		
N	280	282
Mean (SD)	87.67 (19.91)	84.88 (18.02)
Median	85.95	82.50
Min ; Max	49.40 ; 154.90	47.60 ; 131.90
Week 26 visit		
N	285	281
Mean (SD)	88.76 (20.23)	85.89 (18.45)
Median	87.50	84.50
Min ; Max	49.30 ; 157.60	48.80 ; 146.20
ONWARDS 4		
Number of subjects	291	291
Week 0 visit		
N	291	291
Mean (SD)	85.51 (17.63)	83.08 (17.29)
Median	84.60	81.60
Min ; Max	49.00 ; 136.70	41.30 ; 143.10
Week 14 visit		
N	272	275
Mean (SD)	87.30 (18.16)	84.55 (18.24)
Median	86.23	83.10
Min ; Max	50.90 ; 142.70	42.80 ; 149.20
Week 26 visit		
N	277	270
Mean (SD)	88.16 (18.27)	85.15 (18.23)
Median	87.40	83.45
Min ; Max	46.72 ; 146.80	47.10 ; 156.30
ONWARDS 5		
Number of subjects	542	538
Week -2 visit		
N	542	537
Mean (SD)	93.21 (22.52)	94.37 (21.59)
Median	90.80	92.26
Min ; Max	43.09 ; 208.43	49.50 ; 195.95
Week 52 visit		
N	497	496
Mean (SD)	95.87 (21.89)	96.05 (21.57)
Median	94.00	94.06
Min ; Max	46.08 ; 181.35	54.80 ; 186.79

N: Number of subjects, SD: Standard deviation. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Body weight by trial and treatment week - in-trial - summary - safety analysis set

	Insulin icodec	Daily basal insulin
ONWARDS 6		
Number of subjects	290	292
Week 0 visit		
N	290	292
Mean (SD)	78.65 (17.62)	77.10 (16.78)
Median	77.25	75.80
Min ; Max	39.60 ; 160.30	41.00 ; 131.60
Week 14 visit		
N	280	284
Mean (SD)	79.76 (18.02)	77.63 (17.09)
Median	78.06	76.10
Min ; Max	40.00 ; 160.50	41.00 ; 135.50
Week 26 visit		
N	277	284
Mean (SD)	79.97 (18.11)	78.13 (17.12)
Median	78.30	76.35
Min ; Max	39.80 ; 164.80	41.00 ; 139.20
Body weight (lb)		
ONWARDS 1		
Number of subjects	492	492
Week 0 visit		
N	492	492
Mean (SD)	187.76 (39.12)	185.87 (38.87)
Median	184.53	183.98
Min ; Max	98.11 ; 308.65	95.46 ; 313.06
Week 14 visit		
N	480	478
Mean (SD)	189.56 (38.65)	186.38 (37.88)
Median	185.41	184.09
Min ; Max	100.53 ; 313.06	98.99 ; 335.10
Week 26 visit		
N	480	480
Mean (SD)	190.97 (39.84)	187.11 (38.28)
Median	187.83	185.56
Min ; Max	101.19 ; 317.91	96.56 ; 337.31
Week 52 visit		
N	478	478
Mean (SD)	193.05 (39.76)	190.22 (39.43)
Median	190.15	187.72
Min ; Max	97.00 ; 317.47	96.12 ; 343.92

N: Number of subjects, SD: Standard deviation. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Body weight by trial and treatment week - in-trial - summary - safety analysis set

	Insulin icodec	Daily basal insulin
ONWARDS 2		
Number of subjects	262	263
Week 0 visit		
N	262	263
Mean (SD)	184.58 (40.73)	179.77 (37.78)
Median	184.97	179.24
Min ; Max	96.78 ; 301.59	89.95 ; 294.76
Week 14 visit		
N	257	253
Mean (SD)	186.86 (41.19)	180.54 (37.62)
Median	188.05	181.00
Min ; Max	97.00 ; 305.12	91.27 ; 291.45
Week 26 visit		
N	258	253
Mean (SD)	187.82 (42.40)	180.02 (37.80)
Median	187.06	180.56
Min ; Max	99.43 ; 301.37	92.59 ; 289.69
ONWARDS 3		
Number of subjects	293	294
Week 0 visit		
N	293	294
Mean (SD)	189.11 (44.39)	183.50 (40.16)
Median	187.17	179.57
Min ; Max	95.90 ; 333.78	100.97 ; 287.70
Week 14 visit		
N	280	282
Mean (SD)	193.27 (43.90)	187.12 (39.72)
Median	189.49	181.88
Min ; Max	108.91 ; 341.50	104.94 ; 290.79
Week 26 visit		
N	285	281
Mean (SD)	195.67 (44.60)	189.37 (40.67)
Median	192.90	186.29
Min ; Max	108.69 ; 347.45	107.59 ; 322.32
ONWARDS 4		
Number of subjects	291	291
Week 0 visit		
N	291	291
Mean (SD)	188.52 (38.87)	183.16 (38.11)
Median	186.51	179.90
Min ; Max	108.03 ; 301.37	91.05 ; 315.48
Week 14 visit		
N	272	275
Mean (SD)	192.46 (40.03)	186.41 (40.21)
Median	190.10	183.20
Min ; Max	112.22 ; 314.60	94.36 ; 328.93
Week 26 visit		
N	277	270
Mean (SD)	194.37 (40.28)	187.72 (40.18)
Median	192.68	183.98
Min ; Max	103.00 ; 323.64	103.84 ; 344.58

N: Number of subjects, SD: Standard deviation. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Body weight by trial and treatment week - in-trial - summary - safety analysis set

	Insulin icodec	Daily basal insulin
ONWARDS 5		
Number of subjects	542	538
Week -2 visit		
N	542	537
Mean (SD)	205.48 (49.64)	208.05 (47.60)
Median	200.18	203.40
Min ; Max	95.00 ; 459.50	109.13 ; 432.00
Week 52 visit		
N	497	496
Mean (SD)	211.37 (48.26)	211.75 (47.56)
Median	207.23	207.38
Min ; Max	101.60 ; 399.80	120.81 ; 411.80
ONWARDS 6		
Number of subjects	290	292
Week 0 visit		
N	290	292
Mean (SD)	173.39 (38.85)	169.97 (37.00)
Median	170.31	167.11
Min ; Max	87.30 ; 353.40	90.39 ; 290.13
Week 14 visit		
N	280	284
Mean (SD)	175.83 (39.72)	171.15 (37.67)
Median	172.09	167.77
Min ; Max	88.18 ; 353.84	90.39 ; 298.73
Week 26 visit		
N	277	284
Mean (SD)	176.29 (39.94)	172.25 (37.75)
Median	172.62	168.32
Min ; Max	87.74 ; 363.32	90.39 ; 306.88

N: Number of subjects, SD: Standard deviation. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

7.6.6 Body weight at end of treatment by trial - change from baseline - in-trial - supportive statistical analysis - full analysis set

	FAS	N	Estimate	SE	95% CI	P-value
Body weight (kg)						
ONWARDS 1						
LSMeans						
Insulin icodec	492	492	87.03	0.21		
Daily basal insulin	492	492	86.57	0.21		
Change from baseline						
LSMeans						
Insulin icodec	492	492	2.29	0.21		
Daily basal insulin	492	492	1.83	0.21		
Treatment difference						
Insulin icodec - Daily basal insulin			0.46		[-0.12 ; 1.04]	0.1187
ONWARDS 2						
LSMeans						
Insulin icodec	263	263	84.03	0.32		
Daily basal insulin	263	263	82.33	0.36		
Change from baseline						
LSMeans						
Insulin icodec	263	263	1.40	0.32		
Daily basal insulin	263	263	-0.30	0.36		
Treatment difference						
Insulin icodec - Daily basal insulin			1.70		[0.76 ; 2.63]	0.0004
ONWARDS 3						
LSMeans						
Insulin icodec	294	294	87.27	0.22		
Daily basal insulin	294	294	86.82	0.24		
Change from baseline						
LSMeans						
Insulin icodec	294	294	2.77	0.22		
Daily basal insulin	294	294	2.32	0.24		
Treatment difference						
Insulin icodec - Daily basal insulin			0.46		[-0.19 ; 1.10]	0.1657

ANCOVA: Analysis of covariance, CI: Confidence interval, FAS: Number of subjects in full analysis set, N: Number of subjects contributing to the analysis, SE: Standard error of the mean. P-value: Two-sided p-value for test of no treatment difference. No correction for multiplicity. ANCOVA with treatment, region and, if applicable, additional relevant factors as fixed factors, and baseline response as covariate. Missing data are imputed using multiple imputation. End of treatment: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Body weight at end of treatment by trial - change from baseline - in-trial - supportive statistical analysis - full analysis set

	FAS	N	Estimate	SE	95% CI	P-value
ONWARDS 4						
LSMeans						
Insulin icodec	291	291	87.03	0.29		
Daily basal insulin	291	291	86.45	0.40		
Change from baseline						
LSMeans						
Insulin icodec	291	291	2.73	0.29		
Daily basal insulin	291	291	2.16	0.40		
Treatment difference						
Insulin icodec - Daily basal insulin			0.57		[-0.39 ; 1.54]	0.2444
ONWARDS 5						
LSMeans						
Insulin icodec	542	542	96.05	0.37		
Daily basal insulin	543	542	95.22	0.50		
Change from baseline						
LSMeans						
Insulin icodec	542	542	2.28	0.37		
Daily basal insulin	543	542	1.45	0.50		
Treatment difference						
Insulin icodec - Daily basal insulin			0.83		[-0.37 ; 2.02]	0.1747
ONWARDS 6						
LSMeans						
Insulin icodec	290	290	79.16	0.23		
Daily basal insulin	292	292	78.88	0.23		
Change from baseline						
LSMeans						
Insulin icodec	290	290	1.29	0.23		
Daily basal insulin	292	292	1.01	0.23		
Treatment difference						
Insulin icodec - Daily basal insulin			0.28		[-0.37 ; 0.92]	0.4060

Body weight (lb)

ANCOVA: Analysis of covariance, CI: Confidence interval, FAS: Number of subjects in full analysis set, N: Number of subjects contributing to the analysis, SE: Standard error of the mean. P-value: Two-sided p-value for test of no treatment difference. No correction for multiplicity. ANCOVA with treatment, region and, if applicable, additional relevant factors as fixed factors, and baseline response as covariate. Missing data are imputed using multiple imputation. End of treatment: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Body weight at end of treatment by trial - change from baseline - in-trial - supportive statistical analysis - full analysis set

	FAS	N	Estimate	SE	95% CI	P-value
ONWARDS 1						
LSMeans						
Insulin icodec	492	492	191.87	0.46		
Daily basal insulin	492	492	190.86	0.46		
Change from baseline						
LSMeans						
Insulin icodec	492	492	5.06	0.46		
Daily basal insulin	492	492	4.04	0.46		
Treatment difference						
Insulin icodec - Daily basal insulin			1.02		[-0.26 ; 2.29]	0.1187
ONWARDS 2						
LSMeans						
Insulin icodec	263	263	185.26	0.70		
Daily basal insulin	263	263	181.51	0.79		
Change from baseline						
LSMeans						
Insulin icodec	263	263	3.08	0.70		
Daily basal insulin	263	263	-0.66	0.79		
Treatment difference						
Insulin icodec - Daily basal insulin			3.75		[1.68 ; 5.81]	0.0004
ONWARDS 3						
LSMeans						
Insulin icodec	294	294	192.40	0.49		
Daily basal insulin	294	294	191.40	0.54		
Change from baseline						
LSMeans						
Insulin icodec	294	294	6.12	0.49		
Daily basal insulin	294	294	5.11	0.54		
Treatment difference						
Insulin icodec - Daily basal insulin			1.01		[-0.42 ; 2.43]	0.1657
ONWARDS 4						
LSMeans						
Insulin icodec	291	291	191.86	0.63		
Daily basal insulin	291	291	190.60	0.87		
Change from baseline						
LSMeans						
Insulin icodec	291	291	6.02	0.63		
Daily basal insulin	291	291	4.76	0.87		
Treatment difference						
Insulin icodec - Daily basal insulin			1.26		[-0.86 ; 3.39]	0.2444


ANCOVA: Analysis of covariance, CI: Confidence interval, FAS: Number of subjects in full analysis set, N: Number of subjects contributing to the analysis, SE: Standard error of the mean. P-value: Two-sided p-value for test of no treatment difference. No correction for multiplicity. ANCOVA with treatment, region and, if applicable, additional relevant factors as fixed factors, and baseline response as covariate. Missing data are imputed using multiple imputation. End of treatment: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Body weight at end of treatment by trial - change from baseline - in-trial - supportive statistical analysis - full analysis set

	FAS	N	Estimate	SE	95% CI	P-value
ONWARDS 5						
LSMeans						
Insulin icodec	542	542	211.74	0.82		
Daily basal insulin	543	542	209.92	1.10		
Change from baseline						
LSMeans						
Insulin icodec	542	542	5.02	0.82		
Daily basal insulin	543	542	3.19	1.10		
Treatment difference						
Insulin icodec - Daily basal insulin			1.83		[-0.81 ; 4.46]	0.1747
ONWARDS 6						
LSMeans						
Insulin icodec	290	290	174.52	0.51		
Daily basal insulin	292	292	173.91	0.50		
Change from baseline						
LSMeans						
Insulin icodec	290	290	2.84	0.51		
Daily basal insulin	292	292	2.24	0.50		
Treatment difference						
Insulin icodec - Daily basal insulin			0.61		[-0.83 ; 2.04]	0.4060

ANCOVA: Analysis of covariance, CI: Confidence interval, FAS: Number of subjects in full analysis set, N: Number of subjects contributing to the analysis, SE: Standard error of the mean. P-value: Two-sided p-value for test of no treatment difference. No correction for multiplicity. ANCOVA with treatment, region and, if applicable, additional relevant factors as fixed factors, and baseline response as covariate. Missing data are imputed using multiple imputation. End of treatment: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

7.6.7 Body weight at end of treatment by trial - change from baseline - in-trial - plot of estimated treatment differences - full analysis set



ANCOVA: Analysis of covariance. ANCOVA with treatment, region and, if applicable, additional relevant factors as fixed factors, and baseline response as covariate. Missing data are imputed using multiple imputation. Estimates with 95% confidence interval. End of treatment: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. Daily basal insulin: IDeg (ONWARDS 2, ONWARDS 3, ONWARDS 6), IGlar U100 (ONWARDS 1, ONWARDS 4), and once-daily analogues (IDeg, IGlar U100, IGlar U300) (ONWARDS 5). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

axe.xpt; variable(s): STDNM AVAL TRTLBL2 STATISCD ESTTYPE; criteria: ANALYSID == "apechbbodywstatsuppintfas" & PARAMCD == "WEIGHT" & STATISCD %in% c("Estimate", "Lower", "Upper") & ESTTYPE %in% c("LSMECHBL_CONTRAST")

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:13:08:59 - fbwforest/fvsbodywforestintfas.png

7.6.8 Vital signs by treatment week - change from baseline - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec	Daily basal insulin
Number of subjects	2170	2170
Change from Baseline, Systolic Blood Pressure (mmHg)		
Week 14 visit		
N	1570	1569
Mean (SD)	-1.96 (12.84)	-2.61 (12.83)
Median	-1.50	-2.00
Min ; Max	-77.00 ; 48.00	-60.00 ; 77.00
Week 26 visit		
N	1562	1560
Mean (SD)	-1.32 (13.17)	-2.16 (13.17)
Median	-1.00	-1.50
Min ; Max	-50.50 ; 56.50	-63.50 ; 68.50
Week 52 visit		
N	956	966
Mean (SD)	-1.24 (13.86)	-1.63 (14.24)
Median	-1.00	-1.00
Min ; Max	-54.50 ; 66.50	-59.00 ; 69.50
End-of-treatment visit		
N	2038	2047
Mean (SD)	-0.63 (13.51)	-1.59 (13.72)
Median	-0.50	-1.00
Min ; Max	-54.50 ; 66.50	-59.00 ; 69.50
Lowest post baseline value		
N	2109	2107
Mean (SD)	-7.24 (13.07)	-8.14 (13.36)
Median	-6.50	-7.00
Min ; Max	-78.00 ; 65.00	-67.50 ; 68.00
Highest post baseline value		
N	2109	2107
Mean (SD)	4.85 (13.30)	4.16 (13.40)
Median	4.00	3.50
Min ; Max	-61.00 ; 68.00	-58.50 ; 83.00

N: Number of subjects, SD: Standard deviation. Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Vital signs by treatment week - change from baseline - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec	Daily basal insulin
Change from Baseline, Diastolic Blood Pressure (mmHg)		
Week 14 visit		
N	1570	1569
Mean (SD)	-1.02 (7.90)	-1.49 (7.96)
Median	-1.00	-1.00
Min ; Max	-27.50 ; 46.50	-33.50 ; 29.00
Week 26 visit		
N	1562	1560
Mean (SD)	-0.51 (8.04)	-0.80 (8.14)
Median	-0.50	-1.00
Min ; Max	-29.50 ; 34.00	-35.50 ; 30.50
Week 52 visit		
N	955	966
Mean (SD)	-1.77 (8.67)	-1.42 (8.85)
Median	-1.50	-1.50
Min ; Max	-32.00 ; 33.00	-36.50 ; 39.50
End-of-treatment visit		
N	2037	2047
Mean (SD)	-0.81 (8.31)	-0.82 (8.49)
Median	-0.50	-1.00
Min ; Max	-32.00 ; 34.00	-36.50 ; 39.50
Lowest post baseline value		
N	2108	2107
Mean (SD)	-4.98 (8.07)	-5.35 (8.16)
Median	-5.00	-5.00
Min ; Max	-33.00 ; 32.50	-38.00 ; 36.50
Highest post baseline value		
N	2108	2107
Mean (SD)	2.98 (8.36)	2.85 (8.32)
Median	3.00	2.50
Min ; Max	-32.00 ; 54.50	-36.00 ; 56.50

N: Number of subjects, SD: Standard deviation. Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Vital signs by treatment week - change from baseline - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec	Daily basal insulin
Change from Baseline, Pulse (beats/min)		
Week 14 visit		
N	1568	1564
Mean (SD)	-0.42 (9.11)	0.50 (9.06)
Median	-0.50	0.50
Min ; Max	-31.00 ; 42.50	-35.50 ; 39.50
Week 26 visit		
N	1561	1557
Mean (SD)	-1.85 (9.18)	-1.31 (9.13)
Median	-1.50	-1.00
Min ; Max	-40.50 ; 31.50	-37.00 ; 32.00
Week 52 visit		
N	956	965
Mean (SD)	-2.09 (9.43)	-1.60 (9.87)
Median	-2.00	-1.50
Min ; Max	-35.50 ; 33.50	-57.00 ; 48.00
End-of-treatment visit		
N	2037	2044
Mean (SD)	-1.80 (9.29)	-1.32 (9.40)
Median	-2.00	-1.00
Min ; Max	-40.50 ; 33.50	-57.00 ; 48.00
Lowest post baseline value		
N	2108	2104
Mean (SD)	-5.15 (8.87)	-4.46 (9.02)
Median	-5.00	-4.00
Min ; Max	-51.50 ; 36.00	-57.00 ; 45.50
Highest post baseline value		
N	2108	2104
Mean (SD)	2.67 (9.54)	3.32 (9.25)
Median	2.25	3.00
Min ; Max	-33.00 ; 50.00	-39.50 ; 50.50

N: Number of subjects, SD: Standard deviation. Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

7.6.9 Vital signs by treatment week - change from baseline - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec	Daily basal insulin
Number of subjects	1880	1878
Change from Baseline, Systolic Blood Pressure (mmHg)		
Week 14 visit		
N	1290	1286
Mean (SD)	-2.02 (13.00)	-3.05 (12.91)
Median	-1.50	-2.25
Min ; Max	-77.00 ; 48.00	-60.00 ; 43.00
Week 26 visit		
N	1290	1277
Mean (SD)	-1.26 (13.26)	-2.38 (13.18)
Median	-1.50	-2.00
Min ; Max	-50.50 ; 43.00	-63.50 ; 68.50
Week 52 visit		
N	956	966
Mean (SD)	-1.24 (13.86)	-1.63 (14.24)
Median	-1.00	-1.00
Min ; Max	-54.50 ; 66.50	-59.00 ; 69.50
End-of-treatment visit		
N	1766	1764
Mean (SD)	-0.48 (13.61)	-1.65 (13.83)
Median	-0.50	-1.00
Min ; Max	-54.50 ; 66.50	-59.00 ; 69.50
Lowest post baseline value		
N	1823	1818
Mean (SD)	-7.07 (13.32)	-8.22 (13.61)
Median	-6.50	-7.00
Min ; Max	-78.00 ; 65.00	-67.50 ; 68.00
Highest post baseline value		
N	1823	1818
Mean (SD)	4.84 (13.46)	3.85 (13.51)
Median	4.50	3.50
Min ; Max	-61.00 ; 68.00	-58.50 ; 71.00

N: Number of subjects, SD: Standard deviation, Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4: Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Vital signs by treatment week - change from baseline - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec	Daily basal insulin
Change from Baseline, Diastolic Blood Pressure (mmHg)		
Week 14 visit		
N	1290	1286
Mean (SD)	-1.08 (7.76)	-1.78 (8.05)
Median	-1.00	-1.50
Min ; Max	-27.50 ; 26.50	-33.50 ; 29.00
Week 26 visit		
N	1290	1277
Mean (SD)	-0.44 (8.08)	-0.97 (8.17)
Median	0.00	-1.00
Min ; Max	-29.50 ; 34.00	-35.50 ; 30.50
Week 52 visit		
N	955	966
Mean (SD)	-1.77 (8.67)	-1.42 (8.85)
Median	-1.50	-1.50
Min ; Max	-32.00 ; 33.00	-36.50 ; 39.50
End-of-treatment visit		
N	1765	1764
Mean (SD)	-0.81 (8.39)	-0.95 (8.57)
Median	-0.50	-1.00
Min ; Max	-32.00 ; 34.00	-36.50 ; 39.50
Lowest post baseline value		
N	1822	1818
Mean (SD)	-4.86 (8.13)	-5.43 (8.33)
Median	-4.50	-5.00
Min ; Max	-33.00 ; 32.50	-38.00 ; 36.50
Highest post baseline value		
N	1822	1818
Mean (SD)	2.83 (8.41)	2.60 (8.46)
Median	3.00	2.50
Min ; Max	-32.00 ; 35.00	-36.00 ; 56.50


N: Number of subjects, SD: Standard deviation, Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4: Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Vital signs by treatment week - change from baseline - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec	Daily basal insulin
Change from Baseline, Pulse (beats/min)		
Week 14 visit		
N	1289	1284
Mean (SD)	-0.67 (9.04)	0.31 (8.88)
Median	-0.50	0.50
Min ; Max	-31.00 ; 42.50	-35.50 ; 39.50
Week 26 visit		
N	1289	1275
Mean (SD)	-2.02 (9.15)	-1.34 (9.11)
Median	-2.00	-1.00
Min ; Max	-40.50 ; 31.50	-37.00 ; 32.00
Week 52 visit		
N	956	965
Mean (SD)	-2.09 (9.43)	-1.60 (9.87)
Median	-2.00	-1.50
Min ; Max	-35.50 ; 33.50	-57.00 ; 48.00
End-of-treatment visit		
N	1765	1762
Mean (SD)	-1.92 (9.29)	-1.34 (9.42)
Median	-2.00	-1.00
Min ; Max	-40.50 ; 33.50	-57.00 ; 48.00
Lowest post baseline value		
N	1822	1816
Mean (SD)	-5.14 (8.97)	-4.41 (9.11)
Median	-5.00	-4.00
Min ; Max	-51.50 ; 36.00	-57.00 ; 45.50
Highest post baseline value		
N	1822	1816
Mean (SD)	2.28 (9.53)	3.08 (9.15)
Median	2.00	3.00
Min ; Max	-33.00 ; 50.00	-39.50 ; 50.50

N: Number of subjects, SD: Standard deviation, Highest/Lowest post baseline value: Subject wise highest/lowest value across all post baseline values including values captured at unscheduled visits and retest. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4: Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

7.6.10 Vital signs by trial - systolic blood pressure - baseline and end-of treatment - on-treatment/main-on-treatment - box plot - safety analysis set




Safety analysis set. Observed data. Legend: Mean (symbol), median (centre line), 25th and 75th percentiles (box), and extremes (circles). Whiskers are from 2.5% - 97.5%. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. OD analogues: Once-daily basal insulin analogues (IDeg, IGlar U100, IGlar U300). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

advs.xpt; variable(s): STDNM PARAM AVISIT3 AVISIT3N AVAL; criteria: SAFFL == "Y" & ANELFL == "Y" & PARAMCD == "SYSBP" & ANL06FL == "Y"

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:13:08:20 - fbox/fvssystolicboxontsas.png

7.6.11 Vital signs by trial - diastolic blood pressure - baseline and end-of treatment - on-treatment/main-on-treatment - box plot - safety analysis set




Safety analysis set. Observed data. Legend: Mean (symbol), median (centre line), 25th and 75th percentiles (box), and extremes (circles). Whiskers are from 2.5% - 97.5%. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. OD analogues: Once-daily basal insulin analogues (IDeg, IGlar U100, IGlar U300). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

advs.xpt; variable(s): STDNM PARAM AVISIT3 AVISIT3N AVAL; criteria: SAFFL == "Y" & ANELFL == "Y" & PARAMCD == "DIABP" & ANL06FL == "Y"

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:13:08:29 - fbox/fvsdiastolicboxontsas.png

7.6.12 Vital signs by trial - pulse - baseline and end-of treatment - on-treatment/main-on-treatment - box plot - safety analysis set



Safety analysis set. Observed data. Legend: Mean (symbol), median (centre line), 25th and 75th percentiles (box), and extremes (circles). Whiskers are from 2.5% - 97.5%. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. OD analogues: Once-daily basal insulin analogues (IDeg, IGlar U100, IGlar U300). Data from ONWARDS 1-6, only main part of ONWARDS 1 and 6.

advs.xpt; variable(s): STDNM PARAM AVISIT3 AVISIT3N AVAL; criteria: SAFFL == "Y" & ANELFL == "Y" & PARAMCD == "PULSE" & ANL06FL == "Y"

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:13:08:36 - fbox/fvspulseboxontsas.png

7.6.13 Electrocardiogram by treatment week - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec	Daily basal insulin
	N (%)	N (%)
Number of subjects	2170	2170
Electrocardiogram		
Week -2 visit		
N	2170 (100.0)	2170 (100.0)
Normal	1389 (64.0)	1392 (64.1)
Abnormal, NCS	722 (33.3)	717 (33.0)
Abnormal, CS	58 (2.7)	59 (2.7)
Missing	1 (0.0)	2 (0.1)
Week 26 visit		
N	2170 (100.0)	2170 (100.0)
Normal	1388 (64.0)	1405 (64.7)
Abnormal, NCS	624 (28.8)	614 (28.3)
Abnormal, CS	43 (2.0)	47 (2.2)
Missing	115 (5.3)	104 (4.8)
Week 52 visit		
N	1034 (100.0)	1030 (100.0)
Normal	619 (59.9)	622 (60.4)
Abnormal, NCS	312 (30.2)	322 (31.3)
Abnormal, CS	19 (1.8)	18 (1.7)
Missing	84 (8.1)	68 (6.6)
End-of-treatment visit		
N	2170 (100.0)	2170 (100.0)
Normal	1347 (62.1)	1371 (63.2)
Abnormal, NCS	636 (29.3)	622 (28.7)
Abnormal, CS	35 (1.6)	48 (2.2)
Missing	152 (7.0)	129 (5.9)

%: Percentage of subjects, CS: Clinically significant, N: Number of subjects, NCS: Not clinically significant. Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

7.6.14 Electrocardiogram by treatment week - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec	Daily basal insulin
	N (%)	N (%)
Number of subjects	1880	1878
Electrocardiogram		
Week -2 visit		
N	1880 (100.0)	1878 (100.0)
Normal	1166 (62.0)	1174 (62.5)
Abnormal, NCS	657 (34.9)	647 (34.5)
Abnormal, CS	56 (3.0)	55 (2.9)
Missing	1 (0.1)	2 (0.1)
Week 26 visit		
N	1880 (100.0)	1878 (100.0)
Normal	1186 (63.1)	1181 (62.9)
Abnormal, NCS	569 (30.3)	559 (29.8)
Abnormal, CS	41 (2.2)	46 (2.4)
Missing	84 (4.5)	92 (4.9)
Week 52 visit		
N	1034 (100.0)	1030 (100.0)
Normal	619 (59.9)	622 (60.4)
Abnormal, NCS	312 (30.2)	322 (31.3)
Abnormal, CS	19 (1.8)	18 (1.7)
Missing	84 (8.1)	68 (6.6)
End-of-treatment visit		
N	1880 (100.0)	1878 (100.0)
Normal	1145 (60.9)	1147 (61.1)
Abnormal, NCS	581 (30.9)	567 (30.2)
Abnormal, CS	33 (1.8)	47 (2.5)
Missing	121 (6.4)	117 (6.2)

%: Percentage of subjects, CS: Clinically significant, N: Number of subjects, NCS: Not clinically significant, Not all trials contribute with data for all timepoints. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4: Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

7.6.15 Electrocardiogram by treatment week - baseline to end of treatment - on-treatment/main-on-treatment - shift table - safety analysis set - phase 3a pool

Parameter	End-of-treatment visit							
Group	Normal		Abnormal, NCS		Abnormal, CS		Missing	
Baseline	N	(%)	N	(%)	N	(%)	N	(%)
Electrocardiogram								
Insulin icodec, N = 2170								
Normal	1125	(51.8)	168	(7.7)	2	(0.1)	94	(4.3)
Abnormal, NCS	208	(9.6)	454	(20.9)	7	(0.3)	53	(2.4)
Abnormal, CS	13	(0.6)	14	(0.6)	26	(1.2)	5	(0.2)
Missing	1	(0.0)	0		0		0	
Daily basal insulin, N = 2170								
Normal	1134	(52.3)	155	(7.1)	13	(0.6)	90	(4.1)
Abnormal, NCS	225	(10.4)	452	(20.8)	4	(0.2)	36	(1.7)
Abnormal, CS	10	(0.5)	15	(0.7)	31	(1.4)	3	(0.1)
Missing	2	(0.1)	0		0		0	

%: Percentage of subjects, CS: Clinically significant, N: Number of subjects, NCS: Not clinically significant. End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4 and 6 (main part): Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

adsl.xpt; variable(s): NA; criteria: SAFFL == "Y" & POOLGR2 == "Phase 3a pool"
adeg.xpt; variable(s): AVALC; criteria: SAFFL == "Y" & POOLGR2 == "Phase 3a pool" & PARAMCD == "EGINTP" & ANL06FL == "Y" & ANELFL == "Y" & AVISIT3N %in% c(-2, 10000)
nn1436/nn1436-iss/submission_20221024_er
05DEC2022:12:58:31 - tshift/tegecgcheotshiftontp3asas.txt

7.6.16 Electrocardiogram by treatment week - baseline to end of treatment - on-treatment/main-on-treatment - shift table - safety analysis set - T2D pool

Parameter	End-of-treatment visit							
Group	Normal		Abnormal, NCS		Abnormal, CS		Missing	
Baseline	N	(%)	N	(%)	N	(%)	N	(%)
Electrocardiogram								
Insulin icodec, N = 1880								
Normal	954	(50.7)	142	(7.6)	2	(0.1)	68	(3.6)
Abnormal, NCS	178	(9.5)	425	(22.6)	6	(0.3)	48	(2.6)
Abnormal, CS	12	(0.6)	14	(0.7)	25	(1.3)	5	(0.3)
Missing	1	(0.1)	0		0		0	
Daily basal insulin, N = 1878								
Normal	947	(50.4)	132	(7.0)	13	(0.7)	82	(4.4)
Abnormal, NCS	191	(10.2)	421	(22.4)	3	(0.2)	32	(1.7)
Abnormal, CS	7	(0.4)	14	(0.7)	31	(1.7)	3	(0.2)
Missing	2	(0.1)	0		0		0	

%: Percentage of subjects, CS: Clinically significant, N: Number of subjects, NCS: Not clinically significant, End-of-treatment visit: Planned end-of-treatment visit for the trials or last planned visit in the main part of the trials, as applicable; ONWARDS 1 (main part) and 5: Week 52, ONWARDS 2-4: Week 26. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

adsl.xpt; variable(s): NA; criteria: SAFFL == "Y" & POOLGR1 == "T2D pool"
adeg.xpt; variable(s): AVALC; criteria: SAFFL == "Y" & POOLGR1 == "T2D pool" & PARAMCD == "EGINTP" & ANL06FL == "Y" & ANELFL == "Y" & AVISIT3N %in% c(-2, 10000)
nn1436/nn1436-iss/submission_20221024_er
05DEC2022:12:58:33 - tshift/tegecgcheotshiftontt2dsas.txt